{"PMC7182166": [["Introduction and backgroundThe coronaviruses (CoVs) belong to the genus Coronavirus, the family Coronaviridae, and the order Nidovirales [1].", [["coronaviruses", "ORGANISM", 31, 44], ["CoVs", "GENE_OR_GENE_PRODUCT", 46, 50], ["Coronavirus", "GENE_OR_GENE_PRODUCT", 72, 83], ["The coronaviruses (CoVs)", "PROBLEM", 27, 51], ["coronaviruses", "OBSERVATION", 31, 44], ["genus Coronavirus", "ANATOMY", 66, 83]]], ["They are enveloped and have a non-segmented, single-stranded, positive-sense ribonucleic acid (ssRNA+) as their nuclear material.", [["nuclear material", "ANATOMY", 112, 128], ["ribonucleic acid", "CHEMICAL", 77, 93], ["non-segmented, single-stranded", "DNA", 30, 60]]], ["On electron microscopy, these viruses show a characteristic appearance that resembles a crown (corona in Latin means crown) due to the presence of club-shaped surface protein projections [2-3].", [["surface", "ANATOMY", 159, 166], ["electron microscopy", "TEST", 3, 22], ["these viruses", "PROBLEM", 24, 37], ["a crown (corona", "PROBLEM", 86, 101], ["viruses", "OBSERVATION", 30, 37], ["crown", "OBSERVATION_MODIFIER", 88, 93], ["corona", "OBSERVATION_MODIFIER", 95, 101], ["shaped", "OBSERVATION_MODIFIER", 152, 158], ["surface", "OBSERVATION_MODIFIER", 159, 166]]], ["The CoVs are pleomorphic, measure between 80 and 160 nm in length, and have a small genome measuring 27-32 Kilobytes (KB) with a unique replication strategy [4].Introduction and backgroundThe RNA group of viruses is classified into three orders that include the order Nidovirales, which is further classified into four families: the Coronaviridae, Arteriviridae, Mesoniviridae, and Roniviridae.", [["CoVs", "ANATOMY", 4, 8], ["CoVs", "GENE_OR_GENE_PRODUCT", 4, 8], ["KB", "CANCER", 118, 120], ["Nidovirales", "GENE_OR_GENE_PRODUCT", 268, 279], ["Arteriviridae", "GENE_OR_GENE_PRODUCT", 348, 361], ["Roniviridae", "GENE_OR_GENE_PRODUCT", 382, 393], ["CoVs", "PROTEIN", 4, 8], ["length", "TEST", 59, 65], ["a small genome", "TEST", 76, 90], ["a unique replication strategy", "TREATMENT", 127, 156], ["viruses", "PROBLEM", 205, 212], ["Nidovirales", "TREATMENT", 268, 279], ["the Coronaviridae", "TREATMENT", 329, 346], ["Arteriviridae", "TREATMENT", 348, 361], ["Mesoniviridae", "TREATMENT", 363, 376], ["Roniviridae", "TREATMENT", 382, 393], ["CoVs", "OBSERVATION_MODIFIER", 4, 8], ["pleomorphic", "OBSERVATION", 13, 24], ["160 nm", "OBSERVATION_MODIFIER", 49, 55], ["small", "OBSERVATION_MODIFIER", 78, 83], ["genome", "OBSERVATION", 84, 90], ["viruses", "OBSERVATION", 205, 212]]], ["The family Coronaviridae is further divided into two subfamilies: Coronavirinae and Torovirinae.", [["Coronavirinae", "GENE_OR_GENE_PRODUCT", 66, 79], ["Torovirinae", "GENE_OR_GENE_PRODUCT", 84, 95], ["Coronavirinae", "TREATMENT", 66, 79], ["Torovirinae", "TREATMENT", 84, 95]]], ["The Coronavirinae subfamily includes four genera of viruses (Alphacoronaviruses, Betacoronaviruses, Gammacoronaviruses, and Deltacoronaviruses), which have been grouped primarily based on serology and phylogenetic clustering (divisions based on the habitat/genetic relatedness) [5].", [["Alphacoronaviruses", "GENE_OR_GENE_PRODUCT", 61, 79], ["Betacoronaviruses", "GENE_OR_GENE_PRODUCT", 81, 98], ["Gammacoronaviruses", "GENE_OR_GENE_PRODUCT", 100, 118], ["Deltacoronaviruses", "GENE_OR_GENE_PRODUCT", 124, 142], ["Coronavirinae subfamily", "PROTEIN", 4, 27], ["viruses", "PROBLEM", 52, 59], ["Alphacoronaviruses", "TREATMENT", 61, 79], ["Betacoronaviruses", "TREATMENT", 81, 98], ["Gammacoronaviruses", "TREATMENT", 100, 118], ["Deltacoronaviruses", "TREATMENT", 124, 142], ["serology", "TEST", 188, 196], ["viruses", "OBSERVATION", 52, 59]]], ["The detailed classification along with the origin of severe acute respiratory syndrome associated coronavirus 2 (SARS-CoV-2) is depicted in Figure 1.Introduction and backgroundA novel member of CoV capable of infecting humans was recently identified in Wuhan, China.", [["acute respiratory syndrome", "DISEASE", 60, 86], ["CoV", "ORGANISM", 194, 197], ["humans", "ORGANISM", 219, 225], ["humans", "SPECIES", 219, 225], ["humans", "SPECIES", 219, 225], ["severe acute respiratory syndrome", "PROBLEM", 53, 86], ["coronavirus", "PROBLEM", 98, 109], ["CoV", "TEST", 118, 121], ["infecting humans", "PROBLEM", 209, 225], ["severe", "OBSERVATION_MODIFIER", 53, 59], ["acute", "OBSERVATION_MODIFIER", 60, 65], ["respiratory syndrome", "OBSERVATION", 66, 86]]], ["This virus is now formally named as SARS-CoV-2.", [["SARS-CoV-2", "ORGANISM", 36, 46], ["SARS-CoV", "SPECIES", 36, 44], ["This virus", "PROBLEM", 0, 10]]], ["This new virus is noted to be a unique strain of RNA viruses that have not been previously observed to infect humans according to the International Committee on Taxonomy of Viruses.", [["humans", "ORGANISM", 110, 116], ["humans", "SPECIES", 110, 116], ["humans", "SPECIES", 110, 116], ["This new virus", "PROBLEM", 0, 14], ["a unique strain of RNA viruses", "PROBLEM", 30, 60], ["virus", "OBSERVATION", 9, 14], ["RNA viruses", "OBSERVATION", 49, 60], ["Viruses", "OBSERVATION", 173, 180]]], ["According to the World Health Organization (WHO), and preliminary research results, the infection with SARS-CoV-2, which was initially called as novel coronavirus disease 2019 (nCOVID-19), could result in a human infection that presents with signs and symptoms that include fever, dry cough, dyspnea, fatigue, and lymphopenia.", [["infection", "DISEASE", 88, 97], ["SARS", "DISEASE", 103, 107], ["coronavirus disease", "DISEASE", 151, 170], ["nCOVID-19", "CHEMICAL", 177, 186], ["infection", "DISEASE", 213, 222], ["fever", "DISEASE", 274, 279], ["dry cough", "DISEASE", 281, 290], ["dyspnea", "DISEASE", 292, 299], ["fatigue", "DISEASE", 301, 308], ["lymphopenia", "DISEASE", 314, 325], ["SARS-CoV-2", "ORGANISM", 103, 113], ["human", "ORGANISM", 207, 212], ["human", "SPECIES", 207, 212], ["SARS-CoV-2", "SPECIES", 103, 113], ["human", "SPECIES", 207, 212], ["the infection", "PROBLEM", 84, 97], ["SARS", "PROBLEM", 103, 107], ["CoV", "TEST", 108, 111], ["novel coronavirus disease", "PROBLEM", 145, 170], ["nCOVID", "TEST", 177, 183], ["a human infection", "PROBLEM", 205, 222], ["signs and symptoms", "PROBLEM", 242, 260], ["fever", "PROBLEM", 274, 279], ["dry cough", "PROBLEM", 281, 290], ["dyspnea", "PROBLEM", 292, 299], ["fatigue", "PROBLEM", 301, 308], ["lymphopenia", "PROBLEM", 314, 325], ["infection", "OBSERVATION", 88, 97], ["infection", "OBSERVATION", 213, 222], ["cough", "OBSERVATION", 285, 290], ["fatigue", "OBSERVATION", 301, 308], ["lymphopenia", "OBSERVATION", 314, 325]]], ["Occasionally, human infections may lead to complications such as pneumonia, severe acute respiratory syndrome (SARS), and even death [6-7].Introduction and backgroundIn this review, we attempt to update the history, genetics, epidemiology, modes of transmission, pathogenicity, clinical features, laboratory diagnosis, public health implications, economic impact, treatment, control, and prevention of SARS-CoV-2.ReviewHistoryReviewCoVs have been described as novel respiratory tract viruses, which were observed in the samples collected from the people who presented with signs and symptoms of respiratory tract infection in 1962 [4].", [["respiratory tract", "ANATOMY", 466, 483], ["samples", "ANATOMY", 520, 527], ["respiratory tract", "ANATOMY", 595, 612], ["infections", "DISEASE", 20, 30], ["pneumonia", "DISEASE", 65, 74], ["acute respiratory syndrome", "DISEASE", 83, 109], ["SARS", "DISEASE", 111, 115], ["death", "DISEASE", 127, 132], ["SARS", "DISEASE", 402, 406], ["respiratory tract viruses", "DISEASE", 466, 491], ["respiratory tract infection", "DISEASE", 595, 622], ["human", "ORGANISM", 14, 19], ["SARS-CoV-2", "ORGANISM", 402, 412], ["people", "ORGANISM", 547, 553], ["tract", "ORGANISM_SUBDIVISION", 607, 612], ["human", "SPECIES", 14, 19], ["people", "SPECIES", 547, 553], ["human", "SPECIES", 14, 19], ["SARS-CoV", "SPECIES", 402, 410], ["human infections", "PROBLEM", 14, 30], ["complications", "PROBLEM", 43, 56], ["pneumonia", "PROBLEM", 65, 74], ["severe acute respiratory syndrome", "PROBLEM", 76, 109], ["pathogenicity", "PROBLEM", 263, 276], ["economic impact", "TREATMENT", 347, 362], ["treatment", "TREATMENT", 364, 373], ["SARS", "PROBLEM", 402, 406], ["CoV", "TEST", 407, 410], ["novel respiratory tract viruses", "PROBLEM", 460, 491], ["signs and symptoms", "PROBLEM", 573, 591], ["respiratory tract infection", "PROBLEM", 595, 622], ["infections", "OBSERVATION", 20, 30], ["pneumonia", "OBSERVATION", 65, 74], ["severe", "OBSERVATION_MODIFIER", 76, 82], ["acute", "OBSERVATION_MODIFIER", 83, 88], ["respiratory syndrome", "OBSERVATION", 89, 109], ["respiratory tract", "ANATOMY", 466, 483], ["respiratory tract", "ANATOMY", 595, 612], ["infection", "OBSERVATION", 613, 622]]], ["The first cases of SARS were recognized to have emerged in mid-November, in the year 2002 in Guangdong Province of China.", [["SARS", "DISEASE", 19, 23], ["SARS", "PROBLEM", 19, 23]]], ["According to a 2003 WHO report, the first official report of an outbreak of peculiar pneumonia within the province had affected 305 people and caused five deaths.", [["pneumonia", "DISEASE", 85, 94], ["deaths", "DISEASE", 155, 161], ["people", "ORGANISM", 132, 138], ["people", "SPECIES", 132, 138], ["peculiar pneumonia", "PROBLEM", 76, 94], ["peculiar", "OBSERVATION_MODIFIER", 76, 84], ["pneumonia", "OBSERVATION", 85, 94]]], ["Around 30% of cases have been suggested to occur among health care employees who were involved in patient care.", [["patient", "ORGANISM", 98, 105], ["patient", "SPECIES", 98, 105]]], ["The previous incidence of the SARS-CoV outbreak, which started in China in the year 2002 and lasted until July 2003, had spread across the world, affecting 24 countries that included Cambodia, Hong Kong, Singapore, Hanoi, Canada, and others, recording 8,437 SARS cases and 813 deaths [8-10].ReviewIn December 2019, a group of patients with pneumonia have been confirmed to be infected with a novel CoV (nCoV), which was not previously observed in humans in Wuhan, the capital city of Hubei province of China [11-13].", [["SARS-CoV outbreak", "DISEASE", 30, 47], ["SARS", "DISEASE", 258, 262], ["deaths", "DISEASE", 277, 283], ["pneumonia", "DISEASE", 340, 349], ["patients", "ORGANISM", 326, 334], ["CoV", "ORGANISM", 398, 401], ["nCoV", "GENE_OR_GENE_PRODUCT", 403, 407], ["humans", "ORGANISM", 447, 453], ["patients", "SPECIES", 326, 334], ["humans", "SPECIES", 447, 453], ["SARS-CoV", "SPECIES", 30, 38], ["humans", "SPECIES", 447, 453], ["the SARS-CoV outbreak", "PROBLEM", 26, 47], ["pneumonia", "PROBLEM", 340, 349], ["a novel CoV (nCoV)", "TREATMENT", 390, 408], ["pneumonia", "OBSERVATION", 340, 349], ["infected", "OBSERVATION", 376, 384]]], ["The newly discovered virus, causing a similar infection (SARS-CoV), was initially named as nCoV 2019 (January 2020) and was later called COVID-19 in February 2020.", [["infection", "DISEASE", 46, 55], ["SARS", "DISEASE", 57, 61], ["SARS-CoV", "SPECIES", 57, 65], ["The newly discovered virus", "PROBLEM", 0, 26], ["a similar infection", "PROBLEM", 36, 55], ["virus", "OBSERVATION", 21, 26], ["similar", "OBSERVATION_MODIFIER", 38, 45], ["infection", "OBSERVATION", 46, 55]]], ["The WHO and the China Bureau had announced the discovery of a new coronavirus (SARS-CoV-2), which has been isolated from the patients suffering from pneumonia.", [["coronavirus", "DISEASE", 66, 77], ["pneumonia", "DISEASE", 149, 158], ["coronavirus", "ORGANISM", 66, 77], ["SARS-CoV-2", "ORGANISM", 79, 89], ["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 125, 133], ["SARS-CoV-2", "SPECIES", 79, 89], ["a new coronavirus (SARS-CoV", "PROBLEM", 60, 87], ["pneumonia", "PROBLEM", 149, 158], ["new", "OBSERVATION_MODIFIER", 62, 65], ["coronavirus", "OBSERVATION", 66, 77], ["pneumonia", "OBSERVATION", 149, 158]]], ["As of February 12, 2020, a total of 43,103 cases of infection and 1,018 deaths have been recorded [14].", [["infection", "DISEASE", 52, 61], ["deaths", "DISEASE", 72, 78], ["infection", "PROBLEM", 52, 61], ["infection", "OBSERVATION", 52, 61]]], ["Thousands of human infections have been confirmed in China, along with many exported cases throughout the globe [15].ReviewSARS-CoV-2 was found to infect more human beings than either of its predecessors that include the SARS-CoV and the Middle East respiratory syndrome virus (MERS) [16].", [["human infections", "DISEASE", 13, 29], ["SARS", "DISEASE", 221, 225], ["respiratory syndrome", "DISEASE", 250, 270], ["human", "ORGANISM", 13, 18], ["ReviewSARS-CoV-2", "GENE_OR_GENE_PRODUCT", 117, 133], ["human", "ORGANISM", 159, 164], ["SARS-CoV", "ORGANISM", 221, 229], ["Middle East respiratory syndrome virus", "ORGANISM", 238, 276], ["human", "SPECIES", 13, 18], ["human", "SPECIES", 159, 164], ["human", "SPECIES", 13, 18], ["human", "SPECIES", 159, 164], ["SARS-CoV", "SPECIES", 221, 229], ["Middle East respiratory syndrome virus", "SPECIES", 238, 276], ["human infections", "PROBLEM", 13, 29], ["the SARS-CoV", "PROBLEM", 217, 229], ["the Middle East respiratory syndrome virus", "PROBLEM", 234, 276], ["infections", "OBSERVATION", 19, 29], ["cases", "OBSERVATION", 85, 90], ["globe", "ANATOMY", 106, 111], ["Middle", "ANATOMY_MODIFIER", 238, 244], ["respiratory syndrome", "OBSERVATION", 250, 270]]], ["Numerous factors have contributed to the fast spread of this virus, with the main reason being the densely populated Wuhan, which is the capital city of China\u2019s Hubei province, with more than 11,000,000 population.", [["Numerous factors", "PROBLEM", 0, 16], ["this virus", "PROBLEM", 56, 66], ["densely", "OBSERVATION_MODIFIER", 99, 106], ["populated", "OBSERVATION", 107, 116], ["capital", "OBSERVATION_MODIFIER", 137, 144]]], ["Because Wuhan is a transportation hub, there was an increased chance of person-to-person transmission and the possibility of exporting cases to other places [14].ReviewGenetic characteristics and virion structureReviewThe CoVs belong to the order Nidovirales, family Coronaviridae, and the subfamily Coronavirinae.", [["CoVs", "GENE_OR_GENE_PRODUCT", 222, 226], ["Nidovirales", "GENE_OR_GENE_PRODUCT", 247, 258], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 267, 280], ["Coronavirinae", "GENE_OR_GENE_PRODUCT", 300, 313], ["CoVs", "PROTEIN", 222, 226], ["person", "SPECIES", 72, 78], ["person", "SPECIES", 82, 88], ["Coronaviridae", "TREATMENT", 267, 280], ["increased", "OBSERVATION_MODIFIER", 52, 61], ["virion structure", "OBSERVATION", 196, 212]]], ["They are genetically categorized into four important genera: the Alphacoronavirus, Betacoronavirus, Gammacoronavirus, and Deltacoronavirus.", [["Alphacoronavirus", "GENE_OR_GENE_PRODUCT", 65, 81], ["Betacoronavirus", "GENE_OR_GENE_PRODUCT", 83, 98], ["Gammacoronavirus", "GENE_OR_GENE_PRODUCT", 100, 116], ["Deltacoronavirus", "GENE_OR_GENE_PRODUCT", 122, 138], ["the Alphacoronavirus", "TREATMENT", 61, 81], ["Betacoronavirus", "TREATMENT", 83, 98], ["Gammacoronavirus", "TREATMENT", 100, 116], ["Deltacoronavirus", "TREATMENT", 122, 138]]], ["The former two genera typically infect mammals, whereas the latter two predominantly infect birds [9,17-18].ReviewThe whole-genome sequencing and the genetic analysis studies had revealed that SARS-CoV-2 is genetically related to SARS-CoV of the 2003 outbreak [14].", [["SARS", "DISEASE", 193, 197], ["SARS", "DISEASE", 230, 234], ["birds", "ORGANISM", 92, 97], ["SARS-CoV-2", "ORGANISM", 193, 203], ["SARS-CoV", "ORGANISM", 230, 238], ["SARS-CoV", "SPECIES", 193, 201], ["SARS-CoV", "SPECIES", 230, 238], ["the genetic analysis studies", "TEST", 146, 174], ["SARS", "PROBLEM", 193, 197], ["CoV", "TEST", 198, 201], ["SARS", "PROBLEM", 230, 234], ["genera typically", "OBSERVATION_MODIFIER", 15, 31], ["infect mammals", "OBSERVATION", 32, 46], ["predominantly", "OBSERVATION_MODIFIER", 71, 84], ["infect", "OBSERVATION", 85, 91]]], ["SARS-CoV-2 was also found to be closely related to the genus Betacoronavirus and was noted to be a distinct clade in lineage B of the subgenus Sarbecovirus, collectively with two other bat-derived SARS-CoV-like strains [12,19].", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "ORGANISM", 0, 10], ["Betacoronavirus", "GENE_OR_GENE_PRODUCT", 61, 76], ["lineage B", "CELL", 117, 126], ["Sarbecovirus", "GENE_OR_GENE_PRODUCT", 143, 155], ["SARS-CoV-like strains", "ORGANISM", 197, 218], ["SARS-CoV", "SPECIES", 0, 8], ["SARS-CoV", "SPECIES", 197, 205], ["SARS-CoV", "TEST", 0, 8], ["the genus Betacoronavirus", "PROBLEM", 51, 76], ["a distinct clade", "PROBLEM", 97, 113], ["like strains", "PROBLEM", 206, 218], ["distinct", "OBSERVATION_MODIFIER", 99, 107], ["clade", "OBSERVATION", 108, 113], ["subgenus Sarbecovirus", "OBSERVATION", 134, 155]]], ["The origin of the virus is not yet clearly understood.", [["origin", "ANATOMY_MODIFIER", 4, 10], ["virus", "OBSERVATION", 18, 23]]], ["The latest study showed that angiotensin-converting enzyme 2 (ACE 2), a membrane exopeptidase, is the receptor used by SARS-CoV-2 to enter into the human cells, much like its predecessor (SARS-CoV) [20].ReviewAll CoV genomes are organized further with the replicase locus encoded in the 5' end and the structural proteins encoded inside the 3' end of the genome.", [["membrane", "ANATOMY", 72, 80], ["cells", "ANATOMY", 154, 159], ["angiotensin", "CHEMICAL", 29, 40], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 29, 60], ["ACE 2", "GENE_OR_GENE_PRODUCT", 62, 67], ["membrane", "CELLULAR_COMPONENT", 72, 80], ["SARS-CoV-2", "ORGANISM", 119, 129], ["human", "ORGANISM", 148, 153], ["cells", "CELL", 154, 159], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 188, 196], ["3' end", "CELLULAR_COMPONENT", 341, 347], ["genome", "CELLULAR_COMPONENT", 355, 361], ["angiotensin-converting enzyme 2", "PROTEIN", 29, 60], ["ACE 2", "PROTEIN", 62, 67], ["membrane exopeptidase", "PROTEIN", 72, 93], ["human cells", "CELL_TYPE", 148, 159], ["CoV genomes", "DNA", 213, 224], ["replicase locus", "DNA", 256, 271], ["5' end", "DNA", 287, 293], ["structural proteins", "PROTEIN", 302, 321], ["3' end", "DNA", 341, 347], ["human", "SPECIES", 148, 153], ["human", "SPECIES", 148, 153], ["SARS-CoV", "SPECIES", 188, 196], ["The latest study", "TEST", 0, 16], ["angiotensin", "TEST", 29, 40], ["converting enzyme", "TEST", 41, 58], ["ACE", "TEST", 62, 65], ["a membrane exopeptidase", "PROBLEM", 70, 93], ["CoV", "TEST", 124, 127], ["the replicase locus", "PROBLEM", 252, 271], ["human cells", "ANATOMY", 148, 159], ["genome", "OBSERVATION", 355, 361]]], ["The structural proteins include the hemagglutinin esterase (HE) (only found in some beta-CoVs), spike (S), small membrane (E), membrane (M), nucleocapsid (N) and internal (I) protein, encoded inside the 'N' gene.", [["membrane", "ANATOMY", 113, 121], ["membrane", "ANATOMY", 127, 135], ["hemagglutinin esterase", "GENE_OR_GENE_PRODUCT", 36, 58], ["HE", "GENE_OR_GENE_PRODUCT", 60, 62], ["beta-CoVs", "GENE_OR_GENE_PRODUCT", 84, 93], ["spike (S)", "GENE_OR_GENE_PRODUCT", 96, 105], ["small membrane", "CELLULAR_COMPONENT", 107, 121], ["membrane", "CELLULAR_COMPONENT", 127, 135], ["nucleocapsid (N)", "GENE_OR_GENE_PRODUCT", 141, 157], ["structural proteins", "PROTEIN", 4, 23], ["hemagglutinin esterase", "PROTEIN", 36, 58], ["HE", "PROTEIN", 60, 62], ["beta", "PROTEIN", 84, 88], ["CoVs", "PROTEIN", 89, 93], ["spike (S)", "PROTEIN", 96, 105], ["small membrane (E), membrane (M)", "PROTEIN", 107, 139], ["nucleocapsid (N) and internal (I) protein", "PROTEIN", 141, 182], ["N' gene", "DNA", 204, 211], ["the hemagglutinin esterase", "TEST", 32, 58], ["spike (S), small membrane (E), membrane (M), nucleocapsid (N) and internal (I) protein", "PROBLEM", 96, 182], ["hemagglutinin esterase", "OBSERVATION", 36, 58], ["small membrane", "OBSERVATION_MODIFIER", 107, 121]]], ["The nucleocapsid protein complexes with the genome RNA to form a helical capsid structure observed in the viral envelope.", [["nucleocapsid protein complexes", "PROTEIN", 4, 34], ["genome RNA", "RNA", 44, 54], ["helical capsid structure", "PROTEIN", 65, 89], ["The nucleocapsid protein complexes", "PROBLEM", 0, 34], ["the genome RNA", "PROBLEM", 40, 54], ["a helical capsid structure", "PROBLEM", 63, 89], ["the viral envelope", "PROBLEM", 102, 120], ["protein complexes", "OBSERVATION", 17, 34], ["genome RNA", "OBSERVATION", 44, 54], ["helical", "OBSERVATION_MODIFIER", 65, 72], ["capsid structure", "OBSERVATION", 73, 89], ["viral envelope", "OBSERVATION", 106, 120]]], ["Trimers of the spike proteins form the peplomers embedded in the envelope, giving the virion its corona or crown-like morphology.", [["spike proteins", "PROTEIN", 15, 29], ["peplomers", "PROTEIN", 39, 48], ["the spike proteins", "TEST", 11, 29], ["envelope", "OBSERVATION_MODIFIER", 65, 73], ["corona", "OBSERVATION_MODIFIER", 97, 103], ["crown", "OBSERVATION_MODIFIER", 107, 112], ["morphology", "OBSERVATION_MODIFIER", 118, 128]]], ["In some CoV virions, the HE protein forms smaller spikes at the membrane.", [["membrane", "ANATOMY", 64, 72], ["CoV", "ORGANISM", 8, 11], ["HE protein", "GENE_OR_GENE_PRODUCT", 25, 35], ["membrane", "CELLULAR_COMPONENT", 64, 72], ["HE protein", "PROTEIN", 25, 35], ["some CoV virions", "TREATMENT", 3, 19], ["smaller spikes at the membrane", "PROBLEM", 42, 72], ["CoV virions", "OBSERVATION", 8, 19], ["smaller", "OBSERVATION_MODIFIER", 42, 49], ["spikes", "OBSERVATION_MODIFIER", 50, 56]]], ["The \u201cM\u201d and \u201cE\u201d also are transmembrane proteins involved in virus assembly [9].ReviewAll viruses within the Nidovirales order have a very large genome, an uncommon feature for RNA viruses, with Coronavirinae having the largest recognized RNA genomes, containing about 30 KB of genomes.", [["transmembrane", "ANATOMY", 25, 38], ["Coronavirinae", "GENE_OR_GENE_PRODUCT", 194, 207], ["transmembrane proteins", "PROTEIN", 25, 47], ["RNA genomes", "DNA", 238, 249], ["transmembrane proteins", "PROBLEM", 25, 47], ["a very large genome", "PROBLEM", 131, 150], ["RNA viruses", "PROBLEM", 176, 187], ["Coronavirinae", "TREATMENT", 194, 207], ["viruses", "OBSERVATION", 89, 96], ["very", "OBSERVATION_MODIFIER", 133, 137], ["large", "OBSERVATION_MODIFIER", 138, 143], ["genome", "OBSERVATION", 144, 150], ["RNA viruses", "OBSERVATION", 176, 187], ["largest", "OBSERVATION_MODIFIER", 219, 226], ["RNA genomes", "OBSERVATION", 238, 249]]], ["Other common capabilities within the Nidovirales order encompass: (1) a notably conserved genomic organization, with a huge replicase gene preceding structural and accent genes; (2) expression of many nonstructural genes through ribosomal frameshifting; (3) several unique or uncommon enzymatic activities encoded in the large replicase-transcriptase polyprotein; and (4) expression of downstream genes with the aid of synthesis of 3\u2032 nested sub-genomic mRNAs.", [["ribosomal", "ANATOMY", 229, 238], ["ribosomal", "CELLULAR_COMPONENT", 229, 238], ["replicase gene", "DNA", 124, 138], ["structural and accent genes", "DNA", 149, 176], ["nonstructural genes", "DNA", 201, 220], ["large replicase-transcriptase polyprotein", "DNA", 321, 362], ["downstream genes", "DNA", 386, 402], ["3\u2032 nested sub-genomic mRNAs", "RNA", 432, 459], ["a notably conserved genomic organization", "PROBLEM", 70, 110], ["a huge replicase gene preceding structural and accent genes", "PROBLEM", 117, 176], ["many nonstructural genes through ribosomal frameshifting", "PROBLEM", 196, 252], ["several unique or uncommon enzymatic activities", "PROBLEM", 258, 305], ["the large replicase-transcriptase polyprotein", "TREATMENT", 317, 362], ["downstream genes", "PROBLEM", 386, 402], ["synthesis", "TREATMENT", 419, 428], ["genomic organization", "OBSERVATION", 90, 110], ["nonstructural genes", "OBSERVATION", 201, 220], ["ribosomal frameshifting", "OBSERVATION", 229, 252]]], ["In reality, the Nidovirales order was derived from these nested 3\u2032 mRNAs as Nido is Latin means \u201cnest\u201d.", [["nested 3\u2032 mRNAs", "RNA", 57, 72]]], ["The principal variations in the members of the Nidovirales are within the variety, kind, and sizes of the structural proteins.", [["Nidovirales", "GENE_OR_GENE_PRODUCT", 47, 58], ["structural proteins", "PROTEIN", 106, 125], ["principal", "OBSERVATION_MODIFIER", 4, 13], ["variations", "OBSERVATION_MODIFIER", 14, 24], ["variety", "OBSERVATION_MODIFIER", 74, 81], ["sizes", "OBSERVATION_MODIFIER", 93, 98], ["structural proteins", "OBSERVATION", 106, 125]]], ["These variations cause considerable changes within the structure and morphology of the nucleocapsids and virions [5].ReviewThe genome consists of a 5\u2032 cap structure together with a 3\u2032 poly (A) tail, permitting it to behave as an mRNA, which is ready for translation of the replicase polyproteins.", [["nucleocapsids", "ANATOMY", 87, 100], ["nucleocapsids", "CELLULAR_COMPONENT", 87, 100], ["mRNA", "RNA", 229, 233], ["replicase polyproteins", "PROTEIN", 273, 295], ["considerable changes within the structure", "PROBLEM", 23, 64], ["a 5\u2032 cap structure", "TREATMENT", 146, 164], ["a 3\u2032 poly (A) tail", "TREATMENT", 179, 197], ["the replicase polyproteins", "PROBLEM", 269, 295], ["considerable", "OBSERVATION_MODIFIER", 23, 35], ["changes", "OBSERVATION", 36, 43], ["morphology", "OBSERVATION_MODIFIER", 69, 79], ["nucleocapsids", "OBSERVATION", 87, 100], ["tail", "ANATOMY", 193, 197], ["replicase polyproteins", "OBSERVATION", 273, 295]]], ["The replicase gene encoding the nonstructural proteins occupy two-thirds of the genome, approximately 20 kb, instead of the structural and accent proteins, which make up only approximately 10 kb of the viral genome.", [["replicase gene", "DNA", 4, 18], ["nonstructural proteins", "PROTEIN", 32, 54], ["structural and accent proteins", "PROTEIN", 124, 154], ["viral genome", "DNA", 202, 214], ["viral genome", "OBSERVATION", 202, 214]]], ["The 5\u2032 end of the genome includes a leader series and untranslated region (UTR) that consists of multiple stem-loop systems required for RNA replication and transcription.", [["5\u2032 end", "DNA", 4, 10], ["untranslated region", "DNA", 54, 73], ["UTR", "DNA", 75, 78], ["a leader series and untranslated region", "TREATMENT", 34, 73], ["multiple stem-loop systems", "TREATMENT", 97, 123], ["RNA replication", "TREATMENT", 137, 152], ["genome", "OBSERVATION", 18, 24], ["multiple", "OBSERVATION_MODIFIER", 97, 105], ["stem", "OBSERVATION", 106, 110]]], ["Moreover, at the start of every structural or accent gene, there are transcriptional regulatory sequences (TRSs) that might be required for the expression of each of those genes.", [["TRSs", "GENE_OR_GENE_PRODUCT", 107, 111], ["structural or accent gene", "DNA", 32, 57], ["transcriptional regulatory sequences", "DNA", 69, 105], ["TRSs", "DNA", 107, 111], ["transcriptional regulatory sequences", "TEST", 69, 105]]], ["The 3\u2032 UTR additionally consists of RNA structures required for replication and synthesis of viral RNA.", [["3\u2032 UTR", "DNA", 4, 10], ["viral RNA", "RNA", 93, 102], ["RNA structures", "PROBLEM", 36, 50], ["replication", "TREATMENT", 64, 75], ["viral RNA", "PROBLEM", 93, 102], ["viral RNA", "OBSERVATION", 93, 102]]], ["The organization of the CoV genome is 5\u2032-leader-UTR-replicase-S (Spike)-E (Envelope)-M (Membrane)-N (Nucleocapsid)-3\u2032 UTR-poly (A) tail with accessory genes interspersed in the structural genes on the 3\u2032 end of the genome.", [["CoV", "GENE_OR_GENE_PRODUCT", 24, 27], ["5\u2032", "GENE_OR_GENE_PRODUCT", 38, 40], ["poly (A) tail", "GENE_OR_GENE_PRODUCT", 122, 135], ["genome", "CELLULAR_COMPONENT", 215, 221], ["CoV genome", "DNA", 24, 34], ["5\u2032-leader-UTR-replicase-S (Spike)-E (Envelope)-M (Membrane)-N (Nucleocapsid)-3\u2032 UTR", "DNA", 38, 121], ["poly (A) tail", "DNA", 122, 135], ["accessory genes", "DNA", 141, 156], ["structural genes", "DNA", 177, 193], ["3\u2032 end", "DNA", 201, 207], ["the CoV genome", "TEST", 20, 34], ["replicase", "TEST", 52, 61], ["Nucleocapsid", "TEST", 101, 113], ["accessory genes", "PROBLEM", 141, 156], ["CoV genome", "OBSERVATION", 24, 34], ["accessory genes", "OBSERVATION", 141, 156], ["structural genes", "OBSERVATION", 177, 193], ["genome", "OBSERVATION", 215, 221]]], ["The accent proteins are nearly completely non-essential for the replication in tissue cultures, but some have been proven to play a crucial role in viral pathogenesis [5,21].ReviewCoV virions are spherical, with diameters of about 125 nm, as depicted from the available research by employing cryo-electron tomography and cryo-electron microscopy.", [["tissue cultures", "ANATOMY", 79, 94], ["tissue cultures", "CELL", 79, 94], ["accent proteins", "PROTEIN", 4, 19], ["tissue cultures", "TEST", 79, 94], ["viral pathogenesis", "PROBLEM", 148, 166], ["cryo-electron tomography", "TEST", 292, 316], ["cryo-electron microscopy", "TEST", 321, 345], ["spherical", "OBSERVATION_MODIFIER", 196, 205], ["diameters", "OBSERVATION_MODIFIER", 212, 221], ["125 nm", "OBSERVATION_MODIFIER", 231, 237]]], ["The maximum distinguished characteristic features of CoVs are the club-shaped spike projections emanating from the surface of the virion.", [["surface", "ANATOMY", 115, 122], ["virion", "ANATOMY", 130, 136], ["CoVs", "GENE_OR_GENE_PRODUCT", 53, 57], ["surface", "CELLULAR_COMPONENT", 115, 122], ["virion", "CELLULAR_COMPONENT", 130, 136], ["CoVs", "PROTEIN", 53, 57], ["CoVs", "PROBLEM", 53, 57], ["maximum", "OBSERVATION_MODIFIER", 4, 11], ["CoVs", "OBSERVATION", 53, 57], ["club", "OBSERVATION_MODIFIER", 66, 70], ["shaped", "OBSERVATION_MODIFIER", 71, 77], ["spike", "OBSERVATION_MODIFIER", 78, 83], ["surface", "ANATOMY_MODIFIER", 115, 122], ["virion", "ANATOMY", 130, 136]]], ["Those spikes are a defining characteristic of the virion and deliver them the appearance of a solar corona, prompting the name coronaviruses.", [["virion", "CELLULAR_COMPONENT", 50, 56], ["coronaviruses", "ORGANISM", 127, 140], ["Those spikes", "PROBLEM", 0, 12], ["the virion", "PROBLEM", 46, 56], ["a solar corona", "PROBLEM", 92, 106], ["virion", "OBSERVATION", 50, 56], ["solar corona", "OBSERVATION", 94, 106]]], ["In the envelope of the virion is the nucleocapsid.", [["virion", "CELLULAR_COMPONENT", 23, 29], ["nucleocapsid", "CELLULAR_COMPONENT", 37, 49], ["envelope", "OBSERVATION_MODIFIER", 7, 15], ["virion", "OBSERVATION", 23, 29], ["nucleocapsid", "OBSERVATION", 37, 49]]], ["CoVs have helically symmetrical nucleocapsids, which are unusual among positive-sense RNA viruses, however, a way more common for negative-sense RNA viruses [5,22-23].ReviewEpidemiologyReviewThere are seven CoV species recognized to infect human beings [12].", [["nucleocapsids", "ANATOMY", 32, 45], ["CoVs", "GENE_OR_GENE_PRODUCT", 0, 4], ["nucleocapsids", "CELLULAR_COMPONENT", 32, 45], ["CoV", "ORGANISM", 207, 210], ["human", "ORGANISM", 240, 245], ["CoVs", "PROTEIN", 0, 4], ["human", "SPECIES", 240, 245], ["human", "SPECIES", 240, 245], ["CoVs", "PROBLEM", 0, 4], ["helically symmetrical nucleocapsids", "PROBLEM", 10, 45], ["sense RNA viruses", "PROBLEM", 80, 97], ["sense RNA viruses", "PROBLEM", 139, 156], ["seven CoV species", "PROBLEM", 201, 218], ["helically symmetrical", "OBSERVATION_MODIFIER", 10, 31], ["nucleocapsids", "OBSERVATION", 32, 45], ["seven", "OBSERVATION_MODIFIER", 201, 206], ["CoV species", "OBSERVATION", 207, 218]]], ["Among these, only MERS-CoV and SARS-CoV have been able to cause severe human disease.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 18, 26], ["SARS-CoV", "ORGANISM", 31, 39], ["human", "ORGANISM", 71, 76], ["human", "SPECIES", 71, 76], ["MERS-CoV", "SPECIES", 18, 26], ["SARS-CoV", "SPECIES", 31, 39], ["human", "SPECIES", 71, 76], ["SARS", "PROBLEM", 31, 35], ["severe human disease", "PROBLEM", 64, 84], ["disease", "OBSERVATION", 77, 84]]], ["The rest are associated with mild respiratory ailments such as the common cold.", [["respiratory", "ANATOMY", 34, 45], ["respiratory ailments", "DISEASE", 34, 54], ["mild respiratory ailments", "PROBLEM", 29, 54], ["the common cold", "PROBLEM", 63, 78], ["mild", "OBSERVATION_MODIFIER", 29, 33], ["respiratory ailments", "OBSERVATION", 34, 54]]], ["However, they may cause serious consequences in immunocompromised individuals.", [["immunocompromised individuals", "PROBLEM", 48, 77], ["may cause", "UNCERTAINTY", 14, 23], ["immunocompromised", "OBSERVATION", 48, 65]]], ["At present, the medical severity of the nCoV-2019 (nCoV-19) is precisely unknown but life-threatening, and deaths have been associated with the infections [24].ReviewThey have wide host adaptability and can cause severe infections in humans, birds, livestock, masked palm civets, mice, dogs, cats, camels, pigs, chickens, and bats, wherein they typically cause respiratory and gastrointestinal sickness [5,11,14,18].", [["respiratory", "ANATOMY", 361, 372], ["gastrointestinal", "ANATOMY", 377, 393], ["deaths", "DISEASE", 107, 113], ["infections", "DISEASE", 144, 154], ["infections", "DISEASE", 220, 230], ["respiratory and gastrointestinal sickness", "DISEASE", 361, 402], ["humans", "ORGANISM", 234, 240], ["mice", "ORGANISM", 280, 284], ["dogs", "ORGANISM", 286, 290], ["cats", "ORGANISM", 292, 296], ["camels", "ORGANISM_SUBDIVISION", 298, 304], ["pigs", "ORGANISM", 306, 310], ["chickens", "ORGANISM", 312, 320], ["gastrointestinal", "ORGANISM_SUBDIVISION", 377, 393], ["humans", "SPECIES", 234, 240], ["mice", "SPECIES", 280, 284], ["dogs", "SPECIES", 286, 290], ["cats", "SPECIES", 292, 296], ["pigs", "SPECIES", 306, 310], ["chickens", "SPECIES", 312, 320], ["humans", "SPECIES", 234, 240], ["mice", "SPECIES", 280, 284], ["pigs", "SPECIES", 306, 310], ["chickens", "SPECIES", 312, 320], ["nCoV", "TEST", 51, 55], ["the infections", "PROBLEM", 140, 154], ["severe infections in humans", "PROBLEM", 213, 240], ["respiratory and gastrointestinal sickness", "PROBLEM", 361, 402], ["severe", "OBSERVATION_MODIFIER", 213, 219], ["infections", "OBSERVATION", 220, 230], ["gastrointestinal", "ANATOMY", 377, 393]]], ["Four human CoVs (HCoVs) (HCoV 229E, NL63, OC43, and HKU1) are endemic globally and account for 10% to 30% of upper respiratory tract infections in adults.", [["upper respiratory tract", "ANATOMY", 109, 132], ["respiratory tract infections", "DISEASE", 115, 143], ["human", "ORGANISM", 5, 10], ["CoVs", "GENE_OR_GENE_PRODUCT", 11, 15], ["HCoVs", "GENE_OR_GENE_PRODUCT", 17, 22], ["HCoV 229E", "ORGANISM", 25, 34], ["NL63", "GENE_OR_GENE_PRODUCT", 36, 40], ["OC43", "GENE_OR_GENE_PRODUCT", 42, 46], ["HKU1", "GENE_OR_GENE_PRODUCT", 52, 56], ["upper", "ORGANISM_SUBDIVISION", 109, 114], ["respiratory tract", "ORGANISM_SUBDIVISION", 115, 132], ["human", "SPECIES", 5, 10], ["human", "SPECIES", 5, 10], ["HCoVs", "SPECIES", 17, 22], ["HCoV", "SPECIES", 25, 29], ["Four human CoVs", "TEST", 0, 15], ["HCoVs", "TEST", 17, 22], ["HCoV", "TEST", 25, 29], ["NL63", "TEST", 36, 40], ["OC43", "TEST", 42, 46], ["upper respiratory tract infections", "PROBLEM", 109, 143], ["upper", "ANATOMY_MODIFIER", 109, 114], ["respiratory tract", "ANATOMY", 115, 132], ["infections", "OBSERVATION", 133, 143]]], ["Ecologically, there are several types of CoVs, and the greatest variety was noted in bats, suggesting that bats may be natural reservoirs for a lot of these viruses.", [["CoVs", "GENE_OR_GENE_PRODUCT", 41, 45], ["CoVs", "PROBLEM", 41, 45], ["natural reservoirs", "TREATMENT", 119, 137], ["several", "OBSERVATION_MODIFIER", 24, 31], ["types", "OBSERVATION_MODIFIER", 32, 37], ["CoVs", "OBSERVATION", 41, 45], ["greatest", "OBSERVATION_MODIFIER", 55, 63], ["variety", "OBSERVATION_MODIFIER", 64, 71], ["viruses", "OBSERVATION", 157, 164]]], ["Peri-domestic mammals can also serve as intermediate hosts, facilitating recombination, mutation, and genetic variations [1,25].", [["1,25", "CHEMICAL", 122, 126]]], ["SARS-CoV-2 is currently spreading to different countries throughout the world including European, American, Asian, and some African countries.ReviewTransmissionReviewEven though the exact mechanisms of transmission are presently uncertain, human-to-human transmission can arise, and the risk of airborne spread appears imminent [3,26].", [["SARS", "DISEASE", 0, 4], ["human", "ORGANISM", 240, 245], ["human", "ORGANISM", 249, 254], ["human", "SPECIES", 240, 245], ["human", "SPECIES", 249, 254], ["SARS-CoV", "SPECIES", 0, 8], ["human", "SPECIES", 240, 245], ["human", "SPECIES", 249, 254], ["airborne spread", "PROBLEM", 295, 310], ["airborne spread", "OBSERVATION", 295, 310]]], ["Moreover, SARS-CoV may be transmitted from bats to palm civets or dromedary camels and thereby spill over into human beings [27-28].", [["SARS", "DISEASE", 10, 14], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 10, 18], ["palm", "ORGANISM_SUBDIVISION", 51, 55], ["camels", "ORGANISM_SUBDIVISION", 76, 82], ["human", "ORGANISM", 111, 116], ["human", "SPECIES", 111, 116], ["SARS-CoV", "SPECIES", 10, 18], ["human", "SPECIES", 111, 116], ["SARS", "PROBLEM", 10, 14]]], ["Reintroduction into human beings from an animal reservoir, persistent infection in previously sick people, or the laboratory strains may cause human infections and human-to-human transmission [29].ReviewSARS is generally transmitted through direct or indirect contact of mucous membranes (eyes, nose, or mouth) with infectious respiratory droplets or fomites.", [["mucous membranes", "ANATOMY", 271, 287], ["eyes", "ANATOMY", 289, 293], ["nose", "ANATOMY", 295, 299], ["mouth", "ANATOMY", 304, 309], ["respiratory", "ANATOMY", 327, 338], ["infection", "DISEASE", 70, 79], ["infections", "DISEASE", 149, 159], ["human-to-human transmission", "DISEASE", 164, 191], ["human", "ORGANISM", 20, 25], ["people", "ORGANISM", 99, 105], ["human", "ORGANISM", 143, 148], ["human", "ORGANISM", 164, 169], ["human", "ORGANISM", 173, 178], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 271, 287], ["eyes", "ORGAN", 289, 293], ["nose", "ORGAN", 295, 299], ["mouth", "ORGANISM_SUBDIVISION", 304, 309], ["human", "SPECIES", 20, 25], ["people", "SPECIES", 99, 105], ["human", "SPECIES", 143, 148], ["human", "SPECIES", 164, 169], ["human", "SPECIES", 173, 178], ["human", "SPECIES", 20, 25], ["human", "SPECIES", 143, 148], ["human", "SPECIES", 164, 169], ["human", "SPECIES", 173, 178], ["an animal reservoir", "TREATMENT", 38, 57], ["persistent infection", "PROBLEM", 59, 79], ["the laboratory strains", "PROBLEM", 110, 132], ["human infections", "PROBLEM", 143, 159], ["mucous membranes (eyes, nose, or mouth)", "PROBLEM", 271, 310], ["infectious respiratory droplets", "PROBLEM", 316, 347], ["persistent", "OBSERVATION_MODIFIER", 59, 69], ["infection", "OBSERVATION", 70, 79], ["mucous membranes", "ANATOMY", 271, 287], ["nose", "ANATOMY", 295, 299], ["mouth", "ANATOMY", 304, 309]]], ["Transmission risks increase with period and proximity with the contacts/infected persons [30].", [["persons", "SPECIES", 81, 88]]], ["The time of survival of SARS-CoV-2 within the environment is presently unknown.", [["SARS", "DISEASE", 24, 28], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 24, 34], ["SARS-CoV", "SPECIES", 24, 32], ["SARS", "PROBLEM", 24, 28]]], ["Recent research showed that SARS-CoV can live up to two weeks after drying and five days at temperatures of 22-25\u00b0C and 40-50% relative humidity, with a gradual decline in the viability of the virus thereafter.", [["SARS", "DISEASE", 28, 32], ["SARS-CoV", "ORGANISM", 28, 36], ["SARS-CoV", "SPECIES", 28, 36], ["Recent research", "TEST", 0, 15], ["SARS", "PROBLEM", 28, 32], ["a gradual decline", "PROBLEM", 151, 168], ["gradual", "OBSERVATION_MODIFIER", 153, 160], ["decline", "OBSERVATION_MODIFIER", 161, 168]]], ["The viability of SARS-CoV was found to decrease after 24 hours at 38\u00b0C and 80-90% relative humidity [31].", [["SARS", "DISEASE", 17, 21], ["SARS-CoV", "ORGANISM", 17, 25], ["SARS-CoV", "SPECIES", 17, 25], ["viability", "OBSERVATION_MODIFIER", 4, 13], ["decrease", "OBSERVATION_MODIFIER", 39, 47]]], ["The virus may remain viable on distinct surfaces for 48 hours at 20\u00b0C and 40% relative humidity, even though viability reduced to 8 hours at 30\u00b0C and 80% relative humidity conditions [3,32].", [["The virus", "PROBLEM", 0, 9], ["40% relative humidity", "TREATMENT", 74, 95], ["virus", "OBSERVATION", 4, 9]]], ["This confirms the fact that at low temperature, low humidity conditions favor the virus survival in the environment.ReviewBased on the evidence of a rapidly increasing incidence of infections and the possibility of transmission by asymptomatic carriers, SARS-CoV-2 can be transmitted effectively among humans and exhibits high potential for a pandemic [6,33-36].", [["infections", "DISEASE", 181, 191], ["SARS", "DISEASE", 254, 258], ["SARS-CoV-2", "ORGANISM", 254, 264], ["humans", "ORGANISM", 302, 308], ["humans", "SPECIES", 302, 308], ["SARS-CoV", "SPECIES", 254, 262], ["humans", "SPECIES", 302, 308], ["low temperature", "PROBLEM", 31, 46], ["low humidity conditions", "PROBLEM", 48, 71], ["the virus survival", "TREATMENT", 78, 96], ["infections", "PROBLEM", 181, 191], ["asymptomatic carriers", "PROBLEM", 231, 252], ["rapidly", "OBSERVATION_MODIFIER", 149, 156], ["increasing", "OBSERVATION_MODIFIER", 157, 167], ["infections", "OBSERVATION", 181, 191]]], ["Additionally, the advancement and convenience of global travel could further facilitate the worldwide spread of SARS-CoV-2 [34,37].", [["SARS", "DISEASE", 112, 116], ["SARS-CoV", "SPECIES", 112, 120], ["SARS", "TEST", 112, 116], ["CoV", "TEST", 117, 120]]], ["The possibility of feco-oral transmission of SARS-CoV-2 has public health implications, especially in areas with poor sanitation [38].ReviewPathogenesisReviewCoVs demonstrate versatile host ranges and tissue tropism [14].", [["tissue", "ANATOMY", 201, 207], ["feco", "CHEMICAL", 19, 23], ["SARS", "DISEASE", 45, 49], ["feco-oral", "ORGANISM", 19, 28], ["SARS-CoV-2", "ORGANISM", 45, 55], ["ReviewPathogenesisReviewCoVs", "SIMPLE_CHEMICAL", 134, 162], ["tissue", "TISSUE", 201, 207], ["SARS-CoV", "SPECIES", 45, 53], ["SARS", "PROBLEM", 45, 49], ["versatile host ranges", "OBSERVATION", 175, 196]]], ["The preliminary attachment of the virion to the host cell is initiated by interactions between the \u201cS\u201d protein and its receptor [9].", [["cell", "ANATOMY", 53, 57], ["virion", "CELLULAR_COMPONENT", 34, 40], ["host cell", "CELL", 48, 57], ["\u201cS\u201d", "GENE_OR_GENE_PRODUCT", 99, 102], ["\u201cS\u201d protein", "PROTEIN", 99, 110], ["host cell", "OBSERVATION", 48, 57]]], ["The sites of the receptor-binding domain (RBD) in the S1 vicinity of a CoV\u2019s \u201cS\u201d protein vary with the virus strain.", [["CoV", "GENE_OR_GENE_PRODUCT", 71, 74], ["\u201cS\u201d", "GENE_OR_GENE_PRODUCT", 77, 80], ["receptor-binding domain", "PROTEIN", 17, 40], ["RBD", "PROTEIN", 42, 45], ["CoV\u2019s \u201cS\u201d protein", "PROTEIN", 71, 88], ["a CoV\u2019s", "TEST", 69, 76], ["the virus strain", "PROBLEM", 99, 115], ["S1", "ANATOMY", 54, 56], ["virus strain", "OBSERVATION", 103, 115]]], ["Some have the RBD at the N-terminus of S1 (MHV) and the others (SARS-CoV) have the RBD at the C-terminus of S1, as noted by the results of the recent research studies [5,39-40].ReviewCoV proteins, structural, enzymatic, and accent proteins play key roles in the pathogenesis of the CoV disease (COVID).", [["RBD", "DISEASE", 14, 17], ["CoV disease", "DISEASE", 282, 293], ["COVID", "DISEASE", 295, 300], ["N", "CHEMICAL", 25, 26], ["C", "CHEMICAL", 94, 95], ["S1", "GENE_OR_GENE_PRODUCT", 39, 41], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 64, 72], ["ReviewCoV", "GENE_OR_GENE_PRODUCT", 177, 186], ["RBD", "PROTEIN", 14, 17], ["N-terminus", "PROTEIN", 25, 35], ["S1", "PROTEIN", 39, 41], ["MHV", "PROTEIN", 43, 46], ["CoV", "PROTEIN", 69, 72], ["RBD", "PROTEIN", 83, 86], ["C-terminus", "PROTEIN", 94, 104], ["S1", "PROTEIN", 108, 110], ["ReviewCoV proteins", "PROTEIN", 177, 195], ["structural, enzymatic, and accent proteins", "PROTEIN", 197, 239], ["MHV", "SPECIES", 43, 46], ["SARS-CoV", "SPECIES", 64, 72], ["the RBD", "PROBLEM", 10, 17], ["the RBD", "PROBLEM", 79, 86], ["the recent research studies", "TEST", 139, 166], ["ReviewCoV proteins", "TEST", 177, 195], ["the CoV disease", "PROBLEM", 278, 293], ["RBD", "OBSERVATION", 14, 17], ["S1", "ANATOMY", 39, 41], ["RBD", "OBSERVATION", 83, 86], ["S1", "ANATOMY", 108, 110], ["CoV disease", "OBSERVATION", 282, 293]]], ["Structural proteins, in addition to their role in the maintenance of virion shape and morphogenesis, also contribute to the viral spread in vivo and antagonizing host cellular and immune responses.", [["virion", "ANATOMY", 69, 75], ["cellular", "ANATOMY", 167, 175], ["cellular", "CELL", 167, 175], ["Structural proteins", "PROBLEM", 0, 19], ["the viral spread", "PROBLEM", 120, 136], ["proteins", "OBSERVATION", 11, 19], ["virion shape", "OBSERVATION", 69, 81], ["viral spread", "OBSERVATION", 124, 136]]], ["Nonstructural proteins include the small accent proteins that are not at all conserved among mouse hepatitis virus (MHV) and SARS-CoVs and the 16 conserved proteins encoded in the replicase locus, a lot of which have an enzymatic role in RNA metabolism or protein processing, which further assists the viruses in antagonizing hosts immune responses during infections [9,14].ReviewClinical signsReviewCoVs naturally cause illnesses in mammals and birds that include enteritis in cows and pigs and respiratory diseases in chickens.", [["respiratory", "ANATOMY", 496, 507], ["hepatitis virus", "DISEASE", 99, 114], ["infections", "DISEASE", 356, 366], ["enteritis", "DISEASE", 465, 474], ["respiratory diseases", "DISEASE", 496, 516], ["mouse hepatitis virus (MHV)", "ORGANISM", 93, 120], ["SARS-CoVs", "GENE_OR_GENE_PRODUCT", 125, 134], ["birds", "ORGANISM", 446, 451], ["cows", "ORGANISM_SUBDIVISION", 478, 482], ["pigs", "ORGANISM", 487, 491], ["chickens", "ORGANISM", 520, 528], ["Nonstructural proteins", "PROTEIN", 0, 22], ["small accent proteins", "PROTEIN", 35, 56], ["replicase locus", "DNA", 180, 195], ["mouse", "SPECIES", 93, 98], ["hepatitis virus", "SPECIES", 99, 114], ["cows", "SPECIES", 478, 482], ["pigs", "SPECIES", 487, 491], ["chickens", "SPECIES", 520, 528], ["mouse hepatitis virus", "SPECIES", 93, 114], ["MHV", "SPECIES", 116, 119], ["pigs", "SPECIES", 487, 491], ["chickens", "SPECIES", 520, 528], ["Nonstructural proteins", "PROBLEM", 0, 22], ["the small accent proteins", "PROBLEM", 31, 56], ["mouse hepatitis virus", "PROBLEM", 93, 114], ["SARS", "PROBLEM", 125, 129], ["CoVs", "PROBLEM", 130, 134], ["an enzymatic role in RNA metabolism", "PROBLEM", 217, 252], ["protein processing", "PROBLEM", 256, 274], ["the viruses", "PROBLEM", 298, 309], ["illnesses", "PROBLEM", 421, 430], ["enteritis", "PROBLEM", 465, 474], ["respiratory diseases in chickens", "PROBLEM", 496, 528], ["small", "OBSERVATION_MODIFIER", 35, 40], ["accent proteins", "OBSERVATION", 41, 56], ["replicase locus", "OBSERVATION", 180, 195], ["enteritis", "OBSERVATION", 465, 474], ["respiratory diseases", "OBSERVATION", 496, 516]]], ["They may also be responsible for potentially lethal respiratory tract infections (acute and chronic) in humans [5,9].", [["respiratory tract", "ANATOMY", 52, 69], ["respiratory tract infections", "DISEASE", 52, 80], ["respiratory tract", "ORGANISM_SUBDIVISION", 52, 69], ["humans", "ORGANISM", 104, 110], ["humans", "SPECIES", 104, 110], ["humans", "SPECIES", 104, 110], ["potentially lethal respiratory tract infections", "PROBLEM", 33, 80], ["acute and chronic) in humans", "PROBLEM", 82, 110], ["may also be responsible for", "UNCERTAINTY", 5, 32], ["respiratory tract", "ANATOMY", 52, 69], ["infections", "OBSERVATION", 70, 80], ["acute", "OBSERVATION_MODIFIER", 82, 87], ["chronic", "OBSERVATION_MODIFIER", 92, 99]]], ["From the available preliminary clinical data, SARS can develop in COVID in stages, consisting of acute constitutional signs and symptoms, acute viral pneumonitis, acute lung damage, or even acute respiratory distress syndrome, evolving over one to two weeks.", [["lung", "ANATOMY", 169, 173], ["respiratory", "ANATOMY", 196, 207], ["SARS", "DISEASE", 46, 50], ["pneumonitis", "DISEASE", 150, 161], ["acute lung damage", "DISEASE", 163, 180], ["acute respiratory distress syndrome", "DISEASE", 190, 225], ["lung", "ORGAN", 169, 173], ["SARS", "PROBLEM", 46, 50], ["acute constitutional signs", "PROBLEM", 97, 123], ["symptoms", "PROBLEM", 128, 136], ["acute viral pneumonitis", "PROBLEM", 138, 161], ["acute lung damage", "PROBLEM", 163, 180], ["acute respiratory distress syndrome", "PROBLEM", 190, 225], ["acute", "OBSERVATION_MODIFIER", 97, 102], ["acute", "OBSERVATION_MODIFIER", 138, 143], ["viral", "OBSERVATION_MODIFIER", 144, 149], ["pneumonitis", "OBSERVATION", 150, 161], ["acute", "OBSERVATION_MODIFIER", 163, 168], ["lung", "ANATOMY", 169, 173], ["damage", "OBSERVATION", 174, 180], ["acute", "OBSERVATION_MODIFIER", 190, 195], ["respiratory distress syndrome", "OBSERVATION", 196, 225]]], ["The preliminary infection could be followed by a hyperactive immune reaction, which seems to underlie the severe manifestations of SARS [41].ReviewThe incubation period of COVID may average between two to seven days (range of one to two weeks).", [["infection", "DISEASE", 16, 25], ["hyperactive immune reaction", "DISEASE", 49, 76], ["SARS", "DISEASE", 131, 135], ["The preliminary infection", "PROBLEM", 0, 25], ["a hyperactive immune reaction", "PROBLEM", 47, 76], ["the severe manifestations of SARS", "PROBLEM", 102, 135], ["COVID", "TREATMENT", 172, 177], ["infection", "OBSERVATION", 16, 25], ["severe", "OBSERVATION_MODIFIER", 106, 112]]], ["Clinical manifestation is characterized by systemic symptoms such as high fever, chills, cough, shortness of breath or difficulty in breathing, diarrhea, myalgia or fatigue, expectoration, and hemoptysis.", [["fever", "DISEASE", 74, 79], ["chills", "DISEASE", 81, 87], ["cough", "DISEASE", 89, 94], ["shortness of breath", "DISEASE", 96, 115], ["difficulty in breathing", "DISEASE", 119, 142], ["diarrhea", "DISEASE", 144, 152], ["myalgia", "DISEASE", 154, 161], ["fatigue", "DISEASE", 165, 172], ["expectoration", "DISEASE", 174, 187], ["hemoptysis", "DISEASE", 193, 203], ["Clinical manifestation", "PROBLEM", 0, 22], ["systemic symptoms", "PROBLEM", 43, 60], ["high fever", "PROBLEM", 69, 79], ["chills", "PROBLEM", 81, 87], ["cough", "PROBLEM", 89, 94], ["shortness of breath", "PROBLEM", 96, 115], ["difficulty in breathing", "PROBLEM", 119, 142], ["diarrhea", "PROBLEM", 144, 152], ["myalgia", "PROBLEM", 154, 161], ["fatigue", "PROBLEM", 165, 172], ["expectoration", "PROBLEM", 174, 187], ["hemoptysis", "PROBLEM", 193, 203], ["hemoptysis", "OBSERVATION", 193, 203]]], ["In severe forms, the patients may develop pneumonia, and the case fatality rates may vary considerably.", [["pneumonia", "DISEASE", 42, 51], ["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["pneumonia", "PROBLEM", 42, 51], ["severe", "OBSERVATION_MODIFIER", 3, 9], ["pneumonia", "OBSERVATION", 42, 51]]], ["Serious complications such as heart failure, respiratory failure, and liver failure most likely occur in elderly patients [8,10,13].ReviewRespiratory failure is the most important problem of COVID; at least half of the patients (mostly the elderly people) require supplemental oxygen during the intense phase, whereas around 20% of patients progress to acute respiratory distress syndrome requiring invasive mechanical ventilator support.", [["heart", "ANATOMY", 30, 35], ["respiratory", "ANATOMY", 45, 56], ["liver", "ANATOMY", 70, 75], ["respiratory", "ANATOMY", 359, 370], ["heart failure", "DISEASE", 30, 43], ["respiratory failure", "DISEASE", 45, 64], ["liver failure", "DISEASE", 70, 83], ["ReviewRespiratory failure", "DISEASE", 132, 157], ["COVID", "DISEASE", 191, 196], ["oxygen", "CHEMICAL", 277, 283], ["respiratory distress syndrome", "DISEASE", 359, 388], ["oxygen", "CHEMICAL", 277, 283], ["heart", "ORGAN", 30, 35], ["liver", "ORGAN", 70, 75], ["patients", "ORGANISM", 113, 121], ["patients", "ORGANISM", 219, 227], ["people", "ORGANISM", 248, 254], ["oxygen", "SIMPLE_CHEMICAL", 277, 283], ["patients", "ORGANISM", 332, 340], ["patients", "SPECIES", 113, 121], ["patients", "SPECIES", 219, 227], ["people", "SPECIES", 248, 254], ["patients", "SPECIES", 332, 340], ["Serious complications", "PROBLEM", 0, 21], ["heart failure", "PROBLEM", 30, 43], ["respiratory failure", "PROBLEM", 45, 64], ["liver failure", "PROBLEM", 70, 83], ["ReviewRespiratory failure", "PROBLEM", 132, 157], ["supplemental oxygen", "TREATMENT", 264, 283], ["acute respiratory distress syndrome", "PROBLEM", 353, 388], ["invasive mechanical ventilator support", "TREATMENT", 399, 437], ["heart", "ANATOMY", 30, 35], ["failure", "OBSERVATION", 36, 43], ["respiratory failure", "OBSERVATION", 45, 64], ["liver", "ANATOMY", 70, 75], ["failure", "OBSERVATION", 76, 83], ["failure", "OBSERVATION", 150, 157], ["most important", "OBSERVATION_MODIFIER", 165, 179], ["acute", "OBSERVATION_MODIFIER", 353, 358], ["respiratory distress", "OBSERVATION", 359, 379], ["mechanical ventilator", "OBSERVATION", 408, 429]]], ["In contrast, the severity is usually mild in infected young children [42].", [["children", "ORGANISM", 60, 68], ["children", "SPECIES", 60, 68], ["mild", "OBSERVATION_MODIFIER", 37, 41], ["infected", "OBSERVATION_MODIFIER", 45, 53]]], ["Deaths may take place as early as day 4 and as overdue as 108 days after the onset of symptoms.", [["symptoms", "PROBLEM", 86, 94]]], ["Virus shedding from the respiratory tract was found to peak around day 10 and later declined.", [["respiratory tract", "ANATOMY", 24, 41], ["Virus", "ORGANISM", 0, 5], ["respiratory tract", "ORGANISM_SUBDIVISION", 24, 41], ["Virus shedding", "PROBLEM", 0, 14], ["the respiratory tract", "PROBLEM", 20, 41], ["respiratory tract", "ANATOMY", 24, 41]]], ["Virus excretion from the gastrointestinal tract was also noted.", [["gastrointestinal tract", "ANATOMY", 25, 47], ["Virus", "ORGANISM", 0, 5], ["gastrointestinal tract", "ORGAN", 25, 47], ["Virus excretion from the gastrointestinal tract", "PROBLEM", 0, 47], ["gastrointestinal tract", "ANATOMY", 25, 47]]], ["Immunoglobulin G (IgG) antibodies had been detected 10-15 days after the onset of symptoms, and the patient\u2019s improvement correlated with the decrease in virus load.", [["Immunoglobulin G", "GENE_OR_GENE_PRODUCT", 0, 16], ["IgG", "GENE_OR_GENE_PRODUCT", 18, 21], ["patient", "ORGANISM", 100, 107], ["Immunoglobulin G (IgG) antibodies", "PROTEIN", 0, 33], ["patient", "SPECIES", 100, 107], ["Immunoglobulin G (IgG) antibodies", "TEST", 0, 33], ["symptoms", "PROBLEM", 82, 90], ["the decrease in virus load", "PROBLEM", 138, 164]]], ["The severity of the disease was found to correlate with increasing age, with increased mortality (up to 50%) in patients over 60 years of age [9].ReviewGenerally, early clinical signs of COVID can be similar to other seasonal viral respiratory illnesses, thereby limiting the ability of the physicians to suspect the disease at its early stages.", [["respiratory", "ANATOMY", 232, 243], ["COVID", "DISEASE", 187, 192], ["viral respiratory illnesses", "DISEASE", 226, 253], ["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 112, 120], ["the disease", "PROBLEM", 16, 27], ["increased mortality", "PROBLEM", 77, 96], ["COVID", "PROBLEM", 187, 192], ["seasonal viral respiratory illnesses", "PROBLEM", 217, 253], ["the disease", "PROBLEM", 313, 324], ["severity", "OBSERVATION_MODIFIER", 4, 12], ["disease", "OBSERVATION", 20, 27], ["increased", "OBSERVATION_MODIFIER", 77, 86], ["respiratory illnesses", "OBSERVATION", 232, 253], ["disease", "OBSERVATION", 317, 324]]], ["Respiratory symptoms frequently increase from two to seven days after the onset of infection and usually include a non-productive cough and dyspnea.", [["Respiratory", "ANATOMY", 0, 11], ["Respiratory symptoms", "DISEASE", 0, 20], ["infection", "DISEASE", 83, 92], ["cough", "DISEASE", 130, 135], ["dyspnea", "DISEASE", 140, 147], ["Respiratory symptoms", "PROBLEM", 0, 20], ["infection", "PROBLEM", 83, 92], ["a non-productive cough", "PROBLEM", 113, 135], ["dyspnea", "PROBLEM", 140, 147], ["increase", "OBSERVATION_MODIFIER", 32, 40], ["infection", "OBSERVATION", 83, 92], ["non-productive", "OBSERVATION_MODIFIER", 115, 129], ["cough", "OBSERVATION", 130, 135]]], ["More severe respiratory symptoms along with rhinorrhea and sore throat may arise, which are unusual.", [["respiratory", "ANATOMY", 12, 23], ["sore throat", "ANATOMY", 59, 70], ["respiratory symptoms", "DISEASE", 12, 32], ["rhinorrhea", "DISEASE", 44, 54], ["sore throat", "DISEASE", 59, 70], ["More severe respiratory symptoms", "PROBLEM", 0, 32], ["rhinorrhea", "PROBLEM", 44, 54], ["sore throat", "PROBLEM", 59, 70], ["severe", "OBSERVATION_MODIFIER", 5, 11], ["respiratory symptoms", "OBSERVATION", 12, 32], ["rhinorrhea", "OBSERVATION", 44, 54], ["sore throat", "ANATOMY", 59, 70]]], ["Patients with positive laboratory tests for SARS-CoV may show advanced radiographic changes of lung indicating pneumonia after 7-10 days of infection.", [["lung", "ANATOMY", 95, 99], ["SARS", "DISEASE", 44, 48], ["pneumonia", "DISEASE", 111, 120], ["infection", "DISEASE", 140, 149], ["Patients", "ORGANISM", 0, 8], ["SARS-CoV", "ORGANISM", 44, 52], ["lung", "ORGAN", 95, 99], ["Patients", "SPECIES", 0, 8], ["SARS-CoV", "SPECIES", 44, 52], ["positive laboratory tests", "TEST", 14, 39], ["SARS", "PROBLEM", 44, 48], ["CoV", "PROBLEM", 49, 52], ["advanced radiographic changes of lung", "PROBLEM", 62, 99], ["pneumonia", "PROBLEM", 111, 120], ["infection", "PROBLEM", 140, 149], ["lung", "ANATOMY", 95, 99], ["pneumonia", "OBSERVATION", 111, 120], ["infection", "OBSERVATION", 140, 149]]], ["Many CoV infected patients (70-90%) were noted to develop lymphopenia [6].ReviewLaboratory diagnosisReviewLaboratory tests, which are currently available for the diagnosis of SARS-CoV-2 in various human clinical specimens (Sputum, throat swab, nasal secretions, feces, blood/serum/plasma), include real-time polymerase chain reaction (RT-PCR), viral cultural techniques for the isolation of virus from clinical specimens, immunological tests for the detection of antibodies and antigens such as enzyme-linked immunosorbent assay, indirect fluorescent antibody technique, rapid immunochromatographic tests, and immunofluorescence techniques [7].", [["specimens", "ANATOMY", 212, 221], ["Sputum", "ANATOMY", 223, 229], ["throat swab", "ANATOMY", 231, 242], ["nasal secretions", "ANATOMY", 244, 260], ["feces", "ANATOMY", 262, 267], ["blood", "ANATOMY", 269, 274], ["serum", "ANATOMY", 275, 280], ["plasma", "ANATOMY", 281, 287], ["specimens", "ANATOMY", 411, 420], ["CoV infected", "DISEASE", 5, 17], ["lymphopenia", "DISEASE", 58, 69], ["SARS", "DISEASE", 175, 179], ["CoV", "ORGANISM", 5, 8], ["patients", "ORGANISM", 18, 26], ["SARS-CoV-2", "ORGANISM", 175, 185], ["human", "ORGANISM", 197, 202], ["throat", "ORGANISM_SUBDIVISION", 231, 237], ["swab", "ORGANISM_SUBSTANCE", 238, 242], ["nasal secretions", "ORGANISM_SUBSTANCE", 244, 260], ["feces", "ORGANISM_SUBSTANCE", 262, 267], ["blood", "ORGANISM_SUBSTANCE", 269, 274], ["serum", "ORGANISM_SUBSTANCE", 275, 280], ["plasma", "ORGANISM_SUBSTANCE", 281, 287], ["antibodies", "PROTEIN", 463, 473], ["antigens", "PROTEIN", 478, 486], ["patients", "SPECIES", 18, 26], ["human", "SPECIES", 197, 202], ["SARS-CoV", "SPECIES", 175, 183], ["human", "SPECIES", 197, 202], ["Many CoV infected patients", "PROBLEM", 0, 26], ["lymphopenia", "PROBLEM", 58, 69], ["ReviewLaboratory diagnosisReviewLaboratory tests", "TEST", 74, 122], ["SARS", "PROBLEM", 175, 179], ["CoV", "TEST", 180, 183], ["various human clinical specimens", "TEST", 189, 221], ["Sputum", "TEST", 223, 229], ["throat swab", "TEST", 231, 242], ["nasal secretions", "TEST", 244, 260], ["feces", "TEST", 262, 267], ["blood/serum/plasma", "TEST", 269, 287], ["real-time polymerase chain reaction", "PROBLEM", 298, 333], ["RT-PCR", "TEST", 335, 341], ["viral cultural techniques", "TEST", 344, 369], ["the isolation of virus", "PROBLEM", 374, 396], ["clinical specimens", "TEST", 402, 420], ["immunological tests", "TEST", 422, 441], ["the detection", "TEST", 446, 459], ["antibodies", "PROBLEM", 463, 473], ["antigens", "TEST", 478, 486], ["enzyme", "TEST", 495, 501], ["immunosorbent assay", "TEST", 509, 528], ["indirect fluorescent antibody technique", "TEST", 530, 569], ["rapid immunochromatographic tests", "TEST", 571, 604], ["immunofluorescence techniques", "TEST", 610, 639], ["CoV", "OBSERVATION_MODIFIER", 5, 8], ["infected", "OBSERVATION", 9, 17], ["lymphopenia", "OBSERVATION", 58, 69]]], ["Other tests that may assist in the diagnosis may include the flow-cytometry analysis for CD4+ and CD8+ T cell counts, chest radiography (pneumonia), complete blood picture (to demonstrate lymphopenia), and serum biochemistry (serum protein and others) [9-10,13-14,41,43-44].ReviewThe 10 genome sequences of SARS-CoV-2 obtained from the nine patients have been noted to be extremely identical and exhibiting more than 99.98% sequence similarity.", [["CD4+", "ANATOMY", 89, 93], ["CD8+ T cell", "ANATOMY", 98, 109], ["chest", "ANATOMY", 118, 123], ["blood", "ANATOMY", 158, 163], ["serum", "ANATOMY", 206, 211], ["serum", "ANATOMY", 226, 231], ["pneumonia", "DISEASE", 137, 146], ["lymphopenia", "DISEASE", 188, 199], ["CD4", "GENE_OR_GENE_PRODUCT", 89, 92], ["CD8", "GENE_OR_GENE_PRODUCT", 98, 101], ["blood", "ORGANISM_SUBSTANCE", 158, 163], ["serum", "ORGANISM_SUBSTANCE", 206, 211], ["serum", "ORGANISM_SUBSTANCE", 226, 231], ["SARS-CoV-2", "ORGANISM", 307, 317], ["patients", "ORGANISM", 341, 349], ["CD4", "PROTEIN", 89, 92], ["CD8", "PROTEIN", 98, 101], ["serum protein", "PROTEIN", 226, 239], ["SARS-CoV-2", "DNA", 307, 317], ["patients", "SPECIES", 341, 349], ["SARS-CoV", "SPECIES", 307, 315], ["Other tests", "TEST", 0, 11], ["the flow-cytometry analysis", "TEST", 57, 84], ["CD4", "TEST", 89, 92], ["CD8", "TEST", 98, 101], ["T cell counts", "TEST", 103, 116], ["chest radiography", "TEST", 118, 135], ["pneumonia", "PROBLEM", 137, 146], ["complete blood picture", "TEST", 149, 171], ["lymphopenia", "PROBLEM", 188, 199], ["serum biochemistry", "TEST", 206, 224], ["serum protein", "TEST", 226, 239], ["SARS-CoV", "TEST", 307, 315], ["chest", "ANATOMY", 118, 123], ["pneumonia", "OBSERVATION", 137, 146], ["lymphopenia", "OBSERVATION", 188, 199]]], ["Notably, SARS-CoV-2 was closely related (with 88% similarity) to two bat-origin SARS-like CoVs (Bat-SL-CoV), Bat-SL-CoVZC45 and Bat-SL-CoVZXC21, which were collected in 2018 from Zhoushan, eastern China.", [["SARS", "DISEASE", 80, 84], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 9, 19], ["Bat-SL-CoV", "GENE_OR_GENE_PRODUCT", 96, 106], ["Bat-SL-CoVZC45", "GENE_OR_GENE_PRODUCT", 109, 123], ["Bat-SL-CoVZXC21", "CELL", 128, 143], ["bat-origin SARS-like CoVs", "DNA", 69, 94], ["CoV", "DNA", 103, 106], ["Bat-SL-CoVZC45", "DNA", 109, 123], ["Bat-SL-CoVZXC21", "DNA", 128, 143], ["SARS-CoV", "SPECIES", 9, 17], ["Bat-SL-CoV", "SPECIES", 96, 106], ["SARS", "TEST", 9, 13], ["CoV", "TEST", 14, 17], ["two bat-origin SARS", "PROBLEM", 65, 84], ["CoVs", "TEST", 90, 94], ["Bat", "TEST", 96, 99], ["Bat-SL-CoVZC45", "TREATMENT", 109, 123], ["Bat-SL-CoVZXC21", "TREATMENT", 128, 143]]], ["Interestingly, SARS-CoV-2 was found to be non-identical with SARS-CoV (about 79% similarity) and MERS-CoV (about 50% similarity).", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 15, 25], ["SARS-CoV", "ORGANISM", 61, 69], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 97, 105], ["MERS-CoV", "DNA", 97, 105], ["SARS-CoV", "SPECIES", 15, 23], ["SARS-CoV", "SPECIES", 61, 69], ["MERS-CoV", "SPECIES", 97, 105], ["SARS-CoV", "TEST", 15, 23], ["SARS", "PROBLEM", 61, 65], ["CoV", "TEST", 66, 69], ["MERS", "TEST", 97, 101], ["CoV", "TEST", 102, 105]]], ["Phylogenetic analysis revealed that the nCoV-19 fell within the subgenus Sarbecovirus of the genus Betacoronavirus, with a relatively long branch length to its closest relatives (Bat-SL-CoVZC45 and Bat-SL-CoVZXC21) and was genetically distinct from SARS-CoV and MERS-CoV.", [["nCoV-19", "ORGANISM", 40, 47], ["Betacoronavirus", "GENE_OR_GENE_PRODUCT", 99, 114], ["Bat-SL-CoVZXC21", "GENE_OR_GENE_PRODUCT", 198, 213], ["SARS-CoV", "ORGANISM", 249, 257], ["MERS-CoV", "ORGANISM", 262, 270], ["nCoV-19", "DNA", 40, 47], ["CoVZC45", "DNA", 186, 193], ["Bat-SL", "DNA", 198, 204], ["CoVZXC21", "DNA", 205, 213], ["nCoV-19", "SPECIES", 40, 47], ["SARS-CoV", "SPECIES", 249, 257], ["MERS-CoV", "SPECIES", 262, 270], ["Phylogenetic analysis", "TEST", 0, 21], ["the nCoV", "TEST", 36, 44], ["Bat-SL", "TEST", 198, 204], ["subgenus Sarbecovirus", "OBSERVATION", 64, 85], ["genus Betacoronavirus", "OBSERVATION", 93, 114]]], ["Notably, homology modeling revealed that SARS-CoV-19 had a similar RBD structure to that of SARS-CoV despite amino acid variations at some key residues [11].ReviewElectron microscopy, virus isolation, cloning, and sequencing studies have demonstrated that an nCoV was the etiologic agent of SARS [9].", [["SARS", "DISEASE", 92, 96], ["amino acid", "CHEMICAL", 109, 119], ["SARS", "DISEASE", 291, 295], ["amino acid", "CHEMICAL", 109, 119], ["SARS-CoV-19", "ORGANISM", 41, 52], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 92, 100], ["amino acid", "AMINO_ACID", 109, 119], ["nCoV", "GENE_OR_GENE_PRODUCT", 259, 263], ["SARS-CoV-19", "DNA", 41, 52], ["RBD structure", "PROTEIN", 67, 80], ["nCoV", "DNA", 259, 263], ["SARS-CoV-19", "SPECIES", 41, 52], ["SARS-CoV", "SPECIES", 92, 100], ["homology modeling", "TEST", 9, 26], ["SARS", "TEST", 41, 45], ["CoV", "TEST", 46, 49], ["a similar RBD structure", "PROBLEM", 57, 80], ["SARS", "PROBLEM", 92, 96], ["CoV", "PROBLEM", 97, 100], ["amino acid variations", "TREATMENT", 109, 130], ["ReviewElectron microscopy", "TEST", 157, 182], ["virus isolation", "TREATMENT", 184, 199], ["sequencing studies", "TEST", 214, 232], ["SARS", "PROBLEM", 291, 295], ["RBD", "OBSERVATION", 67, 70]]], ["An in-depth annotation of the newly discovered CoV (SARS-CoV-2) genome has revealed differences with SARS or SARS-like CoVs.", [["SARS", "DISEASE", 101, 105], ["SARS", "DISEASE", 109, 113], ["CoV", "ORGANISM", 47, 50], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 52, 62], ["SARS-like CoVs", "GENE_OR_GENE_PRODUCT", 109, 123], ["CoV (SARS-CoV-2) genome", "DNA", 47, 70], ["SARS-like CoVs", "DNA", 109, 123], ["CoV (SARS", "TEST", 47, 56], ["CoV", "TEST", 57, 60], ["SARS", "PROBLEM", 101, 105], ["SARS", "PROBLEM", 109, 113], ["CoVs", "PROBLEM", 119, 123]]], ["A systematic comparison study identified 380 amino acid substitutions between these CoVs, which may have caused functional and pathogenic divergences of SARS-CoV-2 [28].ReviewPublic health importanceReviewWhile most CoVs cause a mild common cold-like condition in human beings (children and adults), the emergence of the agents such as SARS and SARS-associated CoVs under the subgenus Betacoronavirus highlight the nature of adaptability and genetic variations of CoVs and their potential to cause significant/serious human illnesses.", [["amino acid", "CHEMICAL", 45, 55], ["SARS", "DISEASE", 153, 157], ["SARS", "DISEASE", 336, 340], ["SARS", "DISEASE", 345, 349], ["amino acid", "CHEMICAL", 45, 55], ["amino acid", "AMINO_ACID", 45, 55], ["CoVs", "GENE_OR_GENE_PRODUCT", 84, 88], ["CoVs", "GENE_OR_GENE_PRODUCT", 216, 220], ["human", "ORGANISM", 264, 269], ["children", "ORGANISM", 278, 286], ["CoVs", "GENE_OR_GENE_PRODUCT", 361, 365], ["CoVs", "GENE_OR_GENE_PRODUCT", 464, 468], ["human", "ORGANISM", 518, 523], ["human", "SPECIES", 264, 269], ["children", "SPECIES", 278, 286], ["human", "SPECIES", 518, 523], ["SARS-CoV", "SPECIES", 153, 161], ["human", "SPECIES", 264, 269], ["human", "SPECIES", 518, 523], ["A systematic comparison study", "TEST", 0, 29], ["amino acid substitutions", "PROBLEM", 45, 69], ["these CoVs", "PROBLEM", 78, 88], ["functional and pathogenic divergences of SARS", "PROBLEM", 112, 157], ["CoV", "TEST", 158, 161], ["a mild common cold-like condition", "PROBLEM", 227, 260], ["the agents", "TREATMENT", 317, 327], ["SARS", "PROBLEM", 336, 340], ["SARS", "PROBLEM", 345, 349], ["CoVs", "PROBLEM", 464, 468], ["significant/serious human illnesses", "PROBLEM", 498, 533], ["acid substitutions", "OBSERVATION", 51, 69], ["mild", "OBSERVATION_MODIFIER", 229, 233]]], ["Because of their novel nature and the unavailability of specific anti-viral agents and a vaccine, isolation and quarantine of exposed/infected persons appear to be of increased significance to control and prevent the spread of the virus among the general population [9,45].ReviewSARS-CoVs have the necessary potential to cause community and nosocomial transmission and result in severe morbidity and mortality [18].", [["persons", "ORGANISM", 143, 150], ["ReviewSARS-CoVs", "GENE_OR_GENE_PRODUCT", 273, 288], ["persons", "SPECIES", 143, 150], ["specific anti-viral agents", "TREATMENT", 56, 82], ["a vaccine", "TREATMENT", 87, 96], ["isolation", "TREATMENT", 98, 107], ["quarantine", "TREATMENT", 112, 122], ["increased significance", "PROBLEM", 167, 189], ["the virus", "PROBLEM", 227, 236], ["nosocomial transmission", "TEST", 341, 364], ["severe morbidity", "PROBLEM", 379, 395], ["severe", "OBSERVATION_MODIFIER", 379, 385], ["morbidity", "OBSERVATION", 386, 395]]], ["They also contribute to zoonotic infections, which may result in epidemics and represent a huge threat to public health.", [["zoonotic infections", "DISEASE", 24, 43], ["zoonotic infections", "PROBLEM", 24, 43], ["epidemics", "PROBLEM", 65, 74], ["zoonotic", "OBSERVATION_MODIFIER", 24, 32], ["infections", "OBSERVATION", 33, 43]]], ["Previous research had suggested that CoV infection in pregnant women may result in poor obstetric consequences, which include maternal morbidity and mortality [46-48].", [["CoV infection", "DISEASE", 37, 50], ["CoV", "ORGANISM", 37, 40], ["women", "ORGANISM", 63, 68], ["women", "SPECIES", 63, 68], ["CoV infection", "PROBLEM", 37, 50], ["poor obstetric consequences", "PROBLEM", 83, 110], ["maternal morbidity", "PROBLEM", 126, 144], ["CoV", "OBSERVATION_MODIFIER", 37, 40], ["infection", "OBSERVATION", 41, 50]]], ["As noted earlier in this review, people older than 60 years of age and those with co-morbid conditions may suffer from serious/life-threatening COVID.ReviewEconomic impactReviewThe outbreak of SARS-CoV-2 substantially affects the economic system of an individual, society, and the country as a whole.", [["COVID", "DISEASE", 144, 149], ["SARS", "DISEASE", 193, 197], ["people", "ORGANISM", 33, 39], ["SARS-CoV-2", "ORGANISM", 193, 203], ["people", "SPECIES", 33, 39], ["SARS-CoV", "SPECIES", 193, 201], ["co-morbid conditions", "PROBLEM", 82, 102]]], ["It affects transportation within the country and throughout the globe.", [["globe", "ANATOMY", 64, 69]]], ["Outbreaks result in financial losses associated with tourism, trade, and recreational activities [42].", [["financial losses", "PROBLEM", 20, 36]]], ["They may also result in gross domestic product increase.", [["gross domestic product increase", "PROBLEM", 24, 55], ["domestic product", "OBSERVATION", 30, 46], ["increase", "OBSERVATION_MODIFIER", 47, 55]]], ["The economic loss with SARS-CoV-2 may also be attributed to the loss of life of animals from the sickness and cost of treatment for both animals and humans during the outbreak [14].", [["SARS", "DISEASE", 23, 27], ["sickness", "DISEASE", 97, 105], ["humans", "ORGANISM", 149, 155], ["humans", "SPECIES", 149, 155], ["SARS-CoV", "SPECIES", 23, 31], ["humans", "SPECIES", 149, 155], ["The economic loss", "PROBLEM", 0, 17], ["SARS", "PROBLEM", 23, 27], ["the loss of life of animals", "PROBLEM", 60, 87], ["the sickness", "PROBLEM", 93, 105], ["treatment", "TREATMENT", 118, 127], ["economic loss", "OBSERVATION", 4, 17]]], ["Additionally, the disease has moral or psychological, legal, and political impacts throughout the world.", [["the disease", "PROBLEM", 14, 25], ["disease", "OBSERVATION", 18, 25]]], ["Such hindrances greatly affect the economic development of the country due to no foreign exchange.ReviewTreatmentReviewAt present, there is no single specific anti-viral therapy available against COVID, and the treatment is mostly supportive.", [["foreign exchange", "PROBLEM", 81, 97], ["single specific anti-viral therapy", "TREATMENT", 143, 177], ["foreign exchange", "OBSERVATION", 81, 97], ["no", "UNCERTAINTY", 140, 142], ["anti-viral therapy", "OBSERVATION", 159, 177]]], ["The cases of 2019 nCoV (SARS-CoV-2) infection have been continuously increasing throughout the world ever since its outbreak in China.", [["SARS-CoV-2) infection", "DISEASE", 24, 45], ["SARS-CoV-2", "ORGANISM", 24, 34], ["SARS-CoV-2", "SPECIES", 24, 34], ["SARS", "TEST", 24, 28], ["CoV", "TEST", 29, 32], ["infection", "PROBLEM", 36, 45], ["infection", "OBSERVATION", 36, 45], ["continuously", "OBSERVATION_MODIFIER", 56, 68], ["increasing", "OBSERVATION_MODIFIER", 69, 79]]], ["Currently, SARS-CoV-2 M protein has been used as a target, which may be inhibited by the already available and approved drugs.", [["SARS-CoV-2 M", "GENE_OR_GENE_PRODUCT", 11, 23], ["SARS-CoV-2 M protein", "PROTEIN", 11, 31], ["SARS", "TEST", 11, 15]]], ["For this reason, the safety profile of these FDA-approved drugs is carefully documented and the efficacy of the selected few can be quickly examined against the novel virus (drug repurposing).", [["drugs", "TREATMENT", 58, 63], ["the novel virus", "PROBLEM", 157, 172]]], ["Previous studies have demonstrated the efficacy of the available drugs against SARS-CoV-2 \u201cP\u201d and \u201cL\u201d proteins and their potential to inhibit the catalytic area and inactivate the virus [11,14].ReviewAnti-viral treatment with interferon-alpha inhalation (50 \u03bcg two times daily), lopinavir and ritonavir (anti-retroviral drugs) (400 mg twice each day and 100 mg twice every day, respectively), and arbidol (200 mg two times every day) is recommended.", [["SARS", "DISEASE", 79, 83], ["interferon-alpha", "CHEMICAL", 226, 242], ["lopinavir", "CHEMICAL", 279, 288], ["ritonavir", "CHEMICAL", 293, 302], ["arbidol", "CHEMICAL", 397, 404], ["lopinavir", "CHEMICAL", 279, 288], ["ritonavir", "CHEMICAL", 293, 302], ["arbidol", "CHEMICAL", 397, 404], ["SARS-CoV-2", "ORGANISM", 79, 89], ["interferon-alpha", "GENE_OR_GENE_PRODUCT", 226, 242], ["lopinavir", "SIMPLE_CHEMICAL", 279, 288], ["ritonavir", "SIMPLE_CHEMICAL", 293, 302], ["arbidol", "SIMPLE_CHEMICAL", 397, 404], ["interferon", "PROTEIN", 226, 236], ["SARS-CoV", "SPECIES", 79, 87], ["Previous studies", "TEST", 0, 16], ["the available drugs", "TREATMENT", 51, 70], ["SARS", "TEST", 79, 83], ["CoV", "TEST", 84, 87], ["P\u201d", "TEST", 91, 93], ["\u201cL\u201d proteins", "TREATMENT", 98, 110], ["the virus", "PROBLEM", 176, 185], ["ReviewAnti-viral treatment", "TREATMENT", 194, 220], ["interferon-alpha inhalation", "TREATMENT", 226, 253], ["lopinavir", "TREATMENT", 279, 288], ["ritonavir", "TREATMENT", 293, 302], ["anti-retroviral drugs", "TREATMENT", 304, 325], ["arbidol", "TREATMENT", 397, 404]]], ["Patients obtained treatment with a corticosteroid (40-80 mg/day) and gamma globulin (15-20 g/day) for three to five days while their resting respiratory rate became greater than 30 per minute, or oxygen saturation was under 93% without oxygen, or multiple pulmonary lobes showed more than 50% progression of sickness in 48 hours on imaging.", [["respiratory", "ANATOMY", 141, 152], ["pulmonary lobes", "ANATOMY", 256, 271], ["gamma globulin", "CHEMICAL", 69, 83], ["oxygen", "CHEMICAL", 196, 202], ["oxygen", "CHEMICAL", 236, 242], ["sickness", "DISEASE", 308, 316], ["oxygen", "CHEMICAL", 196, 202], ["oxygen", "CHEMICAL", 236, 242], ["Patients", "ORGANISM", 0, 8], ["corticosteroid", "SIMPLE_CHEMICAL", 35, 49], ["gamma globulin", "GENE_OR_GENE_PRODUCT", 69, 83], ["oxygen", "SIMPLE_CHEMICAL", 196, 202], ["oxygen", "SIMPLE_CHEMICAL", 236, 242], ["pulmonary lobes", "MULTI-TISSUE_STRUCTURE", 256, 271], ["Patients", "SPECIES", 0, 8], ["a corticosteroid", "TREATMENT", 33, 49], ["gamma globulin", "TREATMENT", 69, 83], ["their resting respiratory rate", "TEST", 127, 157], ["oxygen saturation", "TEST", 196, 213], ["multiple pulmonary lobes", "PROBLEM", 247, 271], ["sickness", "PROBLEM", 308, 316], ["imaging", "TEST", 332, 339], ["pulmonary lobes", "ANATOMY", 256, 271]]], ["Patients additionally may be treated with probiotics to relieve gastrointestinal illness.", [["gastrointestinal", "ANATOMY", 64, 80], ["gastrointestinal illness", "DISEASE", 64, 88], ["Patients", "ORGANISM", 0, 8], ["gastrointestinal", "ORGAN", 64, 80], ["Patients", "SPECIES", 0, 8], ["probiotics", "TREATMENT", 42, 52], ["gastrointestinal illness", "PROBLEM", 64, 88], ["gastrointestinal", "ANATOMY", 64, 80], ["illness", "OBSERVATION", 81, 88]]], ["Quinolones and higher generation cephalosporins (oral and intravenous) can be administered if fever lasted for more than seven days or C-reactive protein levels were 30 mg/L or more (normal range: 0-8 mg/L).", [["oral", "ANATOMY", 49, 53], ["intravenous", "ANATOMY", 58, 69], ["Quinolones", "CHEMICAL", 0, 10], ["cephalosporins", "CHEMICAL", 33, 47], ["fever", "DISEASE", 94, 99], ["Quinolones", "CHEMICAL", 0, 10], ["cephalosporins", "CHEMICAL", 33, 47], ["Quinolones", "SIMPLE_CHEMICAL", 0, 10], ["cephalosporins", "SIMPLE_CHEMICAL", 33, 47], ["oral", "ORGANISM_SUBDIVISION", 49, 53], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 58, 69], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 135, 153], ["Quinolones", "TREATMENT", 0, 10], ["higher generation cephalosporins", "TREATMENT", 15, 47], ["oral and intravenous)", "TREATMENT", 49, 70], ["fever", "PROBLEM", 94, 99], ["C-reactive protein levels", "TEST", 135, 160]]], ["After the course of treatment, the patients infected with SARS-CoV-2 can be discharged from the hospital only after two negative results of the samples collected with 24-hour interval using an RT-PCR [13].", [["samples", "ANATOMY", 144, 151], ["SARS", "DISEASE", 58, 62], ["patients", "ORGANISM", 35, 43], ["SARS-CoV-2", "ORGANISM", 58, 68], ["patients", "SPECIES", 35, 43], ["SARS-CoV", "SPECIES", 58, 66], ["treatment", "TREATMENT", 20, 29], ["SARS", "PROBLEM", 58, 62], ["the samples", "TEST", 140, 151], ["an RT-PCR", "TREATMENT", 190, 199]]], ["Other drugs like chloroquine (anti-malaria drug), hydroxychloroquine (used to treat rheumatoid arthritis, Lupus), azithromycin (anti-bacterial drug), and favipiravir are all either drugs recommended for other causes (repurposed) or drugs that are under clinical trials to treat serious infections caused by SARS-CoV-2.Protease inhibitors (lopinavir/ritonavir) in combination with ribavirin may be used for anti-viral therapy in the early phase, and nelfinavir was found to be a promising alternative.", [["chloroquine", "CHEMICAL", 17, 28], ["hydroxychloroquine", "CHEMICAL", 50, 68], ["rheumatoid arthritis", "DISEASE", 84, 104], ["Lupus", "DISEASE", 106, 111], ["azithromycin", "CHEMICAL", 114, 126], ["favipiravir", "CHEMICAL", 154, 165], ["infections", "DISEASE", 286, 296], ["SARS", "DISEASE", 307, 311], ["lopinavir/ritonavir", "CHEMICAL", 339, 358], ["ribavirin", "CHEMICAL", 380, 389], ["nelfinavir", "CHEMICAL", 449, 459], ["chloroquine", "CHEMICAL", 17, 28], ["hydroxychloroquine", "CHEMICAL", 50, 68], ["azithromycin", "CHEMICAL", 114, 126], ["favipiravir", "CHEMICAL", 154, 165], ["lopinavir", "CHEMICAL", 339, 348], ["ritonavir", "CHEMICAL", 349, 358], ["ribavirin", "CHEMICAL", 380, 389], ["nelfinavir", "CHEMICAL", 449, 459], ["chloroquine", "SIMPLE_CHEMICAL", 17, 28], ["anti-malaria", "SIMPLE_CHEMICAL", 30, 42], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 50, 68], ["azithromycin", "SIMPLE_CHEMICAL", 114, 126], ["favipiravir", "SIMPLE_CHEMICAL", 154, 165], ["SARS-CoV-2", "ORGANISM", 307, 317], ["Protease", "GENE_OR_GENE_PRODUCT", 318, 326], ["lopinavir", "SIMPLE_CHEMICAL", 339, 348], ["ritonavir", "SIMPLE_CHEMICAL", 349, 358], ["ribavirin", "SIMPLE_CHEMICAL", 380, 389], ["nelfinavir", "SIMPLE_CHEMICAL", 449, 459], ["SARS-CoV", "SPECIES", 307, 315], ["Other drugs", "TREATMENT", 0, 11], ["chloroquine (anti-malaria drug)", "TREATMENT", 17, 48], ["hydroxychloroquine", "TREATMENT", 50, 68], ["rheumatoid arthritis", "PROBLEM", 84, 104], ["Lupus)", "TREATMENT", 106, 112], ["azithromycin", "TREATMENT", 114, 126], ["anti-bacterial drug)", "TREATMENT", 128, 148], ["favipiravir", "TREATMENT", 154, 165], ["drugs", "TREATMENT", 181, 186], ["drugs", "TREATMENT", 232, 237], ["serious infections", "PROBLEM", 278, 296], ["Protease inhibitors", "TREATMENT", 318, 337], ["lopinavir/ritonavir)", "TREATMENT", 339, 359], ["ribavirin", "TREATMENT", 380, 389], ["anti-viral therapy", "TREATMENT", 406, 424], ["nelfinavir", "TREATMENT", 449, 459], ["rheumatoid arthritis", "OBSERVATION", 84, 104]]], ["The role of interferon and systemic corticosteroid therapy in preventing immune-mediated lung injury requires further investigation.", [["lung", "ANATOMY", 89, 93], ["lung injury", "DISEASE", 89, 100], ["interferon", "GENE_OR_GENE_PRODUCT", 12, 22], ["lung", "ORGAN", 89, 93], ["interferon", "PROTEIN", 12, 22], ["interferon", "TREATMENT", 12, 22], ["systemic corticosteroid therapy", "TREATMENT", 27, 58], ["immune-mediated lung injury", "PROBLEM", 73, 100], ["further investigation", "TEST", 110, 131], ["lung", "ANATOMY", 89, 93], ["injury", "OBSERVATION", 94, 100]]], ["Besides, other anti-viral treatments, RNA interference, monoclonal antibody, synthetic peptides, and vaccines are being developed [42].", [["monoclonal antibody", "PROTEIN", 56, 75], ["other anti-viral treatments", "TREATMENT", 9, 36], ["RNA interference", "TREATMENT", 38, 54], ["monoclonal antibody", "TREATMENT", 56, 75], ["synthetic peptides", "TREATMENT", 77, 95], ["vaccines", "TREATMENT", 101, 109]]], ["Corticosteroids can be used to limit excessive lung damage due to an inflammatory response, and a high flow of oxygen supplementation and mechanical ventilation can be used in cases of respiratory failure [41].", [["lung", "ANATOMY", 47, 51], ["respiratory", "ANATOMY", 185, 196], ["lung damage", "DISEASE", 47, 58], ["oxygen", "CHEMICAL", 111, 117], ["respiratory failure", "DISEASE", 185, 204], ["oxygen", "CHEMICAL", 111, 117], ["lung", "ORGAN", 47, 51], ["oxygen", "SIMPLE_CHEMICAL", 111, 117], ["Corticosteroids", "TREATMENT", 0, 15], ["excessive lung damage", "PROBLEM", 37, 58], ["an inflammatory response", "PROBLEM", 66, 90], ["a high flow of oxygen supplementation", "TREATMENT", 96, 133], ["mechanical ventilation", "TREATMENT", 138, 160], ["respiratory failure", "PROBLEM", 185, 204], ["lung", "ANATOMY", 47, 51], ["damage", "OBSERVATION", 52, 58], ["inflammatory", "OBSERVATION", 69, 81], ["respiratory failure", "OBSERVATION", 185, 204]]], ["Tracheostomy may be performed in patients who require prolonged mechanical ventilation and longer intensive care unit (ICU) stay.", [["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41], ["Tracheostomy", "TREATMENT", 0, 12], ["prolonged mechanical ventilation", "TREATMENT", 54, 86]]], ["Strict adherence to infection control guidelines is mandatory while performing tracheostomy in the ICU or operating rooms, as well as during subsequent changes of the tracheostomy tube.", [["infection", "DISEASE", 20, 29], ["tube", "TISSUE", 180, 184], ["infection control guidelines", "TREATMENT", 20, 48], ["tracheostomy", "TREATMENT", 79, 91], ["the tracheostomy tube", "TREATMENT", 163, 184], ["infection", "OBSERVATION", 20, 29], ["tracheostomy tube", "OBSERVATION", 167, 184]]], ["Care should be taken during the treatment procedures to reduce complications and the chances of transmission [30].", [["the treatment procedures", "TREATMENT", 28, 52], ["complications", "PROBLEM", 63, 76]]], ["The use of high-dose pulse methylprednisolone during the clinical course of a SARS outbreak was associated with clinical improvement, but randomized controlled trials are needed to ascertain its efficacy [49].ReviewControl and preventive measuresReviewThe SARS-CoV disease may precipitate nosocomial transmission, and, therefore, it is important to enhance ordinary infection control measures in healthcare settings.", [["methylprednisolone", "CHEMICAL", 27, 45], ["SARS", "DISEASE", 78, 82], ["SARS-CoV disease", "DISEASE", 256, 272], ["infection", "DISEASE", 366, 375], ["methylprednisolone", "CHEMICAL", 27, 45], ["methylprednisolone", "SIMPLE_CHEMICAL", 27, 45], ["SARS-CoV", "ORGANISM", 256, 264], ["SARS-CoV", "SPECIES", 256, 264], ["high-dose pulse methylprednisolone", "TREATMENT", 11, 45], ["a SARS outbreak", "PROBLEM", 76, 91], ["randomized controlled trials", "TREATMENT", 138, 166], ["ReviewControl", "TREATMENT", 209, 222], ["preventive measures", "TREATMENT", 227, 246], ["The SARS-CoV disease", "PROBLEM", 252, 272], ["nosocomial transmission", "PROBLEM", 289, 312], ["ordinary infection control measures", "TREATMENT", 357, 392], ["CoV disease", "OBSERVATION", 261, 272], ["nosocomial", "OBSERVATION_MODIFIER", 289, 299], ["infection", "OBSERVATION", 366, 375]]], ["Healthcare facilities must additionally ensure \u201crespiratory hygiene/cough etiquette\u201d strategy to restrict the nosocomial transmission of respiratory pathogens including SARS-CoV-2.", [["respiratory", "ANATOMY", 48, 59], ["respiratory", "ANATOMY", 137, 148], ["respiratory pathogens", "DISEASE", 137, 158], ["SARS", "DISEASE", 169, 173], ["SARS-CoV-2", "ORGANISM", 169, 179], ["SARS-CoV", "SPECIES", 169, 177], ["respiratory hygiene", "TREATMENT", 48, 67], ["cough", "PROBLEM", 68, 73], ["respiratory pathogens", "PROBLEM", 137, 158], ["respiratory", "ANATOMY", 137, 148]]], ["To contain the spread of respiratory secretions, all people with signs and symptoms of respiratory infection, irrespective of presumed cause, have to be advised to cover the nose and mouth while coughing or sneezing.", [["respiratory secretions", "ANATOMY", 25, 47], ["respiratory", "ANATOMY", 87, 98], ["nose", "ANATOMY", 174, 178], ["mouth", "ANATOMY", 183, 188], ["respiratory secretions", "DISEASE", 25, 47], ["respiratory infection", "DISEASE", 87, 108], ["coughing", "DISEASE", 195, 203], ["sneezing", "DISEASE", 207, 215], ["people", "ORGANISM", 53, 59], ["nose", "ORGANISM_SUBDIVISION", 174, 178], ["mouth", "ORGANISM_SUBDIVISION", 183, 188], ["people", "SPECIES", 53, 59], ["respiratory secretions", "PROBLEM", 25, 47], ["signs and symptoms", "PROBLEM", 65, 83], ["respiratory infection", "PROBLEM", 87, 108], ["coughing", "PROBLEM", 195, 203], ["sneezing", "PROBLEM", 207, 215], ["spread", "OBSERVATION_MODIFIER", 15, 21], ["respiratory", "ANATOMY", 25, 36], ["secretions", "OBSERVATION", 37, 47], ["respiratory", "ANATOMY", 87, 98], ["infection", "OBSERVATION", 99, 108], ["nose", "ANATOMY", 174, 178], ["mouth", "ANATOMY", 183, 188]]], ["People must be advised to use tissues to contain respiratory secretions and get rid of them within the nearest waste disposal container.", [["tissues", "ANATOMY", 30, 37], ["respiratory secretions", "ANATOMY", 49, 71], ["People", "ORGANISM", 0, 6], ["tissues", "TISSUE", 30, 37], ["People", "SPECIES", 0, 6], ["respiratory secretions", "PROBLEM", 49, 71], ["respiratory", "ANATOMY", 49, 60], ["secretions", "OBSERVATION", 61, 71]]], ["They have to also be sensitized about hand hygiene after contact with respiratory secretions and contaminated items and substances.", [["hand", "ANATOMY", 38, 42], ["respiratory secretions", "ANATOMY", 70, 92], ["hand", "ORGANISM_SUBDIVISION", 38, 42], ["respiratory secretions", "PROBLEM", 70, 92]]], ["Healthcare centers have to ensure the availability of materials (tissues and no-contact receptacles for used tissue disposal, provide conveniently placed dispensers for alcohol-based hand sanitizer, and provide cleaning soap and disposable towels for handwashing) for adhering to respiratory hygiene/cough etiquette in waiting areas for patients and site visitors [44].ReviewBecause of the potential survival of the virus in the environment for several days, the premises and areas doubtlessly contaminated with SARS-CoV-2 need to be wiped clean earlier than their re-use, with disinfectants containing antimicrobial agents recognized to be effective against CoVs.", [["tissues", "ANATOMY", 65, 72], ["tissue", "ANATOMY", 109, 115], ["hand", "ANATOMY", 183, 187], ["respiratory", "ANATOMY", 280, 291], ["alcohol", "CHEMICAL", 169, 176], ["SARS", "DISEASE", 512, 516], ["alcohol", "CHEMICAL", 169, 176], ["tissues", "TISSUE", 65, 72], ["tissue", "TISSUE", 109, 115], ["alcohol", "SIMPLE_CHEMICAL", 169, 176], ["hand", "ORGANISM_SUBDIVISION", 183, 187], ["patients", "ORGANISM", 337, 345], ["CoV-2", "ORGANISM", 517, 522], ["CoVs", "SIMPLE_CHEMICAL", 659, 663], ["patients", "SPECIES", 337, 345], ["SARS-CoV", "SPECIES", 512, 520], ["materials (tissues and no-contact receptacles", "TREATMENT", 54, 99], ["tissue disposal", "TREATMENT", 109, 124], ["alcohol", "TREATMENT", 169, 176], ["hand sanitizer", "TREATMENT", 183, 197], ["soap and disposable towels", "TREATMENT", 220, 246], ["cough", "PROBLEM", 300, 305], ["the virus", "PROBLEM", 412, 421], ["SARS", "PROBLEM", 512, 516], ["disinfectants", "TREATMENT", 578, 591], ["antimicrobial agents", "TREATMENT", 603, 623], ["CoVs", "PROBLEM", 659, 663], ["virus", "OBSERVATION", 416, 421]]], ["Even though there is a lack of particular evidence for their effectiveness against SARS-CoV-2, cleansing with water and household detergents and the use of common disinfectant products ought to be sufficient for general precautionary cleaning.", [["SARS", "DISEASE", 83, 87], ["SARS-CoV", "SPECIES", 83, 91], ["SARS", "PROBLEM", 83, 87], ["cleansing with water and household detergents", "TREATMENT", 95, 140], ["common disinfectant products", "TREATMENT", 156, 184], ["general precautionary cleaning", "TREATMENT", 212, 242]]], ["Many antimicrobial agents have been examined against different CoVs.", [["CoVs", "GENE_OR_GENE_PRODUCT", 63, 67], ["Many antimicrobial agents", "TREATMENT", 0, 25]]], ["Several active substances, e.g., sodium hypochlorite (the household bleach) and ethanol, are extensively available in non-healthcare and non-laboratory settings [3].ReviewA previous research study had proposed three prevention strategies for SARS [44].", [["sodium hypochlorite", "CHEMICAL", 33, 52], ["ethanol", "CHEMICAL", 80, 87], ["SARS", "DISEASE", 242, 246], ["sodium hypochlorite", "CHEMICAL", 33, 52], ["ethanol", "CHEMICAL", 80, 87], ["sodium hypochlorite", "SIMPLE_CHEMICAL", 33, 52], ["ethanol", "SIMPLE_CHEMICAL", 80, 87], ["sodium hypochlorite", "TREATMENT", 33, 52], ["previous research study", "TEST", 173, 196], ["SARS", "PROBLEM", 242, 246], ["active", "OBSERVATION_MODIFIER", 8, 14], ["substances", "OBSERVATION", 15, 25]]], ["These include the primary prevention strategies that deal with stopping transmission of infection to increase personal protection for individuals; secondary prevention focused on detecting the SARS infection as early as possible and referring suspected individuals to the quarantine or emergency room in the nearby medical center if needed; and tertiary prevention is focused on restoration and rehabilitation.", [["infection", "DISEASE", 88, 97], ["SARS infection", "DISEASE", 193, 207], ["the primary prevention strategies", "TREATMENT", 14, 47], ["infection", "PROBLEM", 88, 97], ["personal protection", "TREATMENT", 110, 129], ["the SARS infection", "PROBLEM", 189, 207], ["tertiary prevention", "TREATMENT", 345, 364], ["restoration", "TREATMENT", 379, 390], ["rehabilitation", "TREATMENT", 395, 409], ["infection", "OBSERVATION", 88, 97]]], ["The major strategies at the tertiary level of prevention include providing training and education in hospital and community facilities to maximize the use of preventive strategies.ReviewEarly recognition of the disease, rapid diagnosis, isolation, and stringent infection control measures are the keys to control this highly contagious disease.", [["infection", "DISEASE", 262, 271], ["preventive strategies", "TREATMENT", 158, 179], ["the disease", "PROBLEM", 207, 218], ["isolation", "TREATMENT", 237, 246], ["stringent infection control measures", "TREATMENT", 252, 288], ["this highly contagious disease", "PROBLEM", 313, 343], ["disease", "OBSERVATION", 211, 218], ["infection", "OBSERVATION", 262, 271], ["highly", "OBSERVATION_MODIFIER", 318, 324], ["contagious", "OBSERVATION", 325, 335]]], ["Isolation facilities, strict droplet and contact precautions (hand hygiene, gown, gloves, masks, eye protection), contact tracing, and quarantine/isolation of close contacts are all important measures in controlling the spread of the infection in the hospital and the community [42].ReviewEffective staff education in infection control, personal protection equipment (PPE), disinfecting the environment, controlling patient transport, the accuracy and timeliness of the reporting and dissemination of data relating to SARS are important issues affecting public perception, thereby removing the fear and limiting the spread of disease [30].", [["hand", "ANATOMY", 62, 66], ["eye", "ANATOMY", 97, 100], ["infection", "DISEASE", 234, 243], ["infection", "DISEASE", 318, 327], ["SARS", "DISEASE", 518, 522], ["hand", "ORGANISM_SUBDIVISION", 62, 66], ["eye", "ORGANISM_SUBDIVISION", 97, 100], ["patient", "ORGANISM", 416, 423], ["patient", "SPECIES", 416, 423], ["Isolation facilities", "TREATMENT", 0, 20], ["strict droplet", "TREATMENT", 22, 36], ["contact precautions", "TREATMENT", 41, 60], ["hand hygiene", "TREATMENT", 62, 74], ["gown", "TREATMENT", 76, 80], ["gloves", "TREATMENT", 82, 88], ["masks", "TREATMENT", 90, 95], ["eye protection", "TREATMENT", 97, 111], ["contact tracing", "TEST", 114, 129], ["quarantine/isolation", "TREATMENT", 135, 155], ["the infection", "PROBLEM", 230, 243], ["infection control", "TREATMENT", 318, 335], ["SARS", "PROBLEM", 518, 522], ["infection", "OBSERVATION", 234, 243]]], ["Since SARS and any other novel infectious disease poses a great challenge to the healthcare community with medical, social, political, legal, and economic implications, all countries have to be prepared at different levels of the pandemic to deal with the threat [50].", [["SARS", "DISEASE", 6, 10], ["infectious disease", "DISEASE", 31, 49], ["SARS", "PROBLEM", 6, 10], ["any other novel infectious disease", "PROBLEM", 15, 49], ["infectious", "OBSERVATION", 31, 41]]], ["Because there is no effective therapy or vaccine, the best measures to control is identification of the source of infection, early diagnosis, reporting, isolation, supportive treatments, and timely publishing epidemic information to avoid unnecessary panic.ConclusionsSARS-CoV-2 is a viral disease that is caused by an nCoV.", [["infection", "DISEASE", 114, 123], ["panic", "DISEASE", 251, 256], ["viral disease", "DISEASE", 284, 297], ["ConclusionsSARS-CoV-2", "GENE_OR_GENE_PRODUCT", 257, 278], ["nCoV", "DNA", 319, 323], ["effective therapy", "TREATMENT", 20, 37], ["vaccine", "TREATMENT", 41, 48], ["infection", "PROBLEM", 114, 123], ["supportive treatments", "TREATMENT", 164, 185], ["panic", "PROBLEM", 251, 256], ["ConclusionsSARS", "TEST", 257, 272], ["a viral disease", "PROBLEM", 282, 297], ["no", "UNCERTAINTY", 17, 19], ["effective", "OBSERVATION_MODIFIER", 20, 29], ["therapy", "OBSERVATION", 30, 37], ["infection", "OBSERVATION", 114, 123], ["viral disease", "OBSERVATION", 284, 297]]], ["Currently, it is one of the global issues ever since it had first emerged and caused the outbreak in China.", [["global", "OBSERVATION_MODIFIER", 28, 34], ["issues", "OBSERVATION", 35, 41]]], ["The disease can be transmitted from person to person through aerosol droplets, direct and indirect contact, and handling clinical cases by the medical practitioner, as well as in the laboratory setting.", [["person", "SPECIES", 36, 42], ["person", "SPECIES", 46, 52], ["The disease", "PROBLEM", 0, 11], ["aerosol droplets", "TREATMENT", 61, 77], ["disease", "OBSERVATION", 4, 11]]], ["Also, it can be transmitted from bats to humans, which confirms its zoonotic importance.", [["humans", "ORGANISM", 41, 47], ["humans", "SPECIES", 41, 47], ["humans", "SPECIES", 41, 47]]], ["COVID can present various clinical signs that include high fever, chills, cough, shortness of breath or difficulty in breathing, diarrhea, myalgia or fatigue, expectoration, and hemoptysis.", [["fever", "DISEASE", 59, 64], ["chills", "DISEASE", 66, 72], ["cough", "DISEASE", 74, 79], ["shortness of breath", "DISEASE", 81, 100], ["difficulty in breathing", "DISEASE", 104, 127], ["diarrhea", "DISEASE", 129, 137], ["myalgia", "DISEASE", 139, 146], ["fatigue", "DISEASE", 150, 157], ["expectoration", "DISEASE", 159, 172], ["hemoptysis", "DISEASE", 178, 188], ["high fever", "PROBLEM", 54, 64], ["chills", "PROBLEM", 66, 72], ["cough", "PROBLEM", 74, 79], ["shortness of breath", "PROBLEM", 81, 100], ["difficulty in breathing", "PROBLEM", 104, 127], ["diarrhea", "PROBLEM", 129, 137], ["myalgia", "PROBLEM", 139, 146], ["fatigue", "PROBLEM", 150, 157], ["expectoration", "PROBLEM", 159, 172], ["hemoptysis", "PROBLEM", 178, 188], ["hemoptysis", "OBSERVATION", 178, 188]]], ["It can be diagnosed by clinical findings and laboratory tests including serology, viral isolation, and molecular techniques.", [["laboratory tests", "TEST", 45, 61], ["serology", "TEST", 72, 80], ["viral isolation", "TEST", 82, 97]]], ["COVID has great public health and economic impact.", [["COVID", "CHEMICAL", 0, 5], ["great", "OBSERVATION_MODIFIER", 10, 15], ["public health", "OBSERVATION", 16, 29]]], ["Since the disease has no specific treatment, proper measures should be taken to control and prevent the spread.ConclusionsAs a future recommendation for the prevention of SARS-CoV-2, each country of the world should give attention to the diagnosis and prevention of the disease and have quarantine facilities where the suspected persons can be kept in isolation until the confirmation of the disease or otherwise, and all healthcare centers should have personal protective equipment during the diagnosis and identification of the disease.", [["SARS", "DISEASE", 171, 175], ["SARS-CoV-2", "ORGANISM", 171, 181], ["persons", "ORGANISM", 329, 336], ["persons", "SPECIES", 329, 336], ["SARS-CoV", "SPECIES", 171, 179], ["the disease", "PROBLEM", 6, 17], ["specific treatment", "TREATMENT", 25, 43], ["proper measures", "TREATMENT", 45, 60], ["SARS", "PROBLEM", 171, 175], ["CoV", "TEST", 176, 179], ["the disease", "PROBLEM", 266, 277], ["quarantine facilities", "TREATMENT", 287, 308], ["the disease", "PROBLEM", 388, 399], ["personal protective equipment", "TREATMENT", 453, 482], ["the disease", "PROBLEM", 526, 537], ["disease", "OBSERVATION", 10, 17], ["no", "UNCERTAINTY", 22, 24], ["specific", "OBSERVATION_MODIFIER", 25, 33], ["treatment", "OBSERVATION", 34, 43], ["disease", "OBSERVATION", 530, 537]]], ["The governments of the respective countries of the world should give attention to the prevention of the disease by promoting or amending the laws concerning prevention strategies to combat the disease.", [["the disease", "PROBLEM", 100, 111], ["prevention strategies", "TREATMENT", 157, 178], ["the disease", "PROBLEM", 189, 200], ["disease", "OBSERVATION", 104, 111]]], ["The scientists, medical workers, and pharmaceutical organizations should work hard to prepare a vaccine for prevention and control and to discover a specific drug for the treatment of the disease.", [["a vaccine", "TREATMENT", 94, 103], ["prevention and control", "TREATMENT", 108, 130], ["the disease", "PROBLEM", 184, 195], ["disease", "OBSERVATION", 188, 195]]], ["Most importantly, timely disease surveillance and preventive measures should be implemented all over the world to fight the disease globally.", [["timely disease surveillance", "PROBLEM", 18, 45], ["preventive measures", "TREATMENT", 50, 69], ["the disease globally", "PROBLEM", 120, 140], ["disease", "OBSERVATION", 124, 131]]]], "PMC7201112": [["Transmission of viruses from one species to another is not unusual in nature.", [["viruses", "PROBLEM", 16, 23], ["viruses", "OBSERVATION", 16, 23], ["not unusual", "UNCERTAINTY", 55, 66]]], ["Focusing on humans, many people all over the world are in close proximity to animals due to local customs or due to their way of life.", [["humans", "ORGANISM", 12, 18], ["people", "ORGANISM", 25, 31], ["humans", "SPECIES", 12, 18], ["people", "SPECIES", 25, 31], ["humans", "SPECIES", 12, 18]]], ["One can suppose that single transmission events of animal viruses to humans (viral exposure in human bodies/cells by direct contact) are happening daily, on the order of millions of times.", [["bodies", "ANATOMY", 101, 107], ["cells", "ANATOMY", 108, 113], ["humans", "ORGANISM", 69, 75], ["human", "ORGANISM", 95, 100], ["cells", "CELL", 108, 113], ["humans", "SPECIES", 69, 75], ["human", "SPECIES", 95, 100], ["humans", "SPECIES", 69, 75], ["human", "SPECIES", 95, 100], ["animal viruses", "PROBLEM", 51, 65], ["viruses", "OBSERVATION", 58, 65]]], ["The vast majority of those events are not successful in causing infection.", [["infection", "DISEASE", 64, 73], ["infection", "PROBLEM", 64, 73], ["infection", "OBSERVATION", 64, 73]]], ["It takes 100s or 1000s of years for a virus to \u201cgain\u201d the right combination of mutations in order to insert in human cells and survive further through spreading in multiple individuals (Longdon et al. 2014).", [["cells", "ANATOMY", 117, 122], ["human", "ORGANISM", 111, 116], ["cells", "CELL", 117, 122], ["human cells", "CELL_TYPE", 111, 122], ["human", "SPECIES", 111, 116], ["human", "SPECIES", 111, 116], ["a virus", "PROBLEM", 36, 43], ["mutations", "PROBLEM", 79, 88], ["human cells", "TREATMENT", 111, 122], ["right", "ANATOMY_MODIFIER", 58, 63]]], ["Alternatively, it is just a matter of poor lack, the right virus at the right time to transit to a new host.", [["poor lack, the right virus", "PROBLEM", 38, 64], ["right", "ANATOMY_MODIFIER", 53, 58], ["right", "ANATOMY_MODIFIER", 72, 77]]], ["Newly emerged viruses need an appropriate host cell receptor, ability to proliferate in the cytoplasm, and a way to escape host immunity (Llorente Garc\u00eda and Marsh 2020).", [["cell", "ANATOMY", 47, 51], ["cytoplasm", "ANATOMY", 92, 101], ["host cell", "CELL", 42, 51], ["cytoplasm", "ORGANISM_SUBSTANCE", 92, 101], ["Newly emerged viruses", "PROBLEM", 0, 21], ["an appropriate host cell receptor", "TREATMENT", 27, 60], ["viruses", "OBSERVATION", 14, 21]]], ["Thinking evolutionarily, natural selection favors: viruses that successfully infect host\u2019s cells, viruses that are minimally lethal, viruses that are highly contagious (Plauzolles et al. 2015).", [["\u2019s cells", "ANATOMY", 88, 96], ["host\u2019s cells", "CELL", 84, 96], ["host\u2019s cells", "CELL_TYPE", 84, 96], ["viruses", "PROBLEM", 51, 58], ["viruses", "PROBLEM", 98, 105], ["minimally lethal, viruses", "PROBLEM", 115, 140], ["viruses", "OBSERVATION", 51, 58]]], ["Maybe the most known examples of such cases in humans are the viruses causing the seasonal common colds (Greenberg 2016).", [["colds", "DISEASE", 98, 103], ["humans", "ORGANISM", 47, 53], ["humans", "SPECIES", 47, 53], ["humans", "SPECIES", 47, 53], ["such cases in humans", "PROBLEM", 33, 53], ["the viruses", "PROBLEM", 58, 69], ["the seasonal common colds", "PROBLEM", 78, 103], ["viruses", "OBSERVATION", 62, 69]]], ["On the other hand, emergence of successful viruses is a rare event.", [["viruses", "OBSERVATION", 43, 50]]], ["Rare but it happens, since millions of mutations and infections (or transmissions) are happening every day.", [["infections", "DISEASE", 53, 63], ["mutations", "PROBLEM", 39, 48], ["infections", "PROBLEM", 53, 63]]], ["Pandemic phenomena could be the first presentation of trans-species infections.", [["infections", "DISEASE", 68, 78], ["Pandemic phenomena", "PROBLEM", 0, 18], ["trans-species infections", "PROBLEM", 54, 78], ["species", "OBSERVATION_MODIFIER", 60, 67], ["infections", "OBSERVATION", 68, 78]]], ["Through pandemic events, viruses can increase their fitness and become minimally harmful (see below for explanation).", [["pandemic events", "PROBLEM", 8, 23], ["viruses", "PROBLEM", 25, 32], ["minimally harmful", "PROBLEM", 71, 88]]], ["SARS-CoV-2 (Huang et al. 2020) may be an example of an evolutionary successful transition.", [["SARS", "DISEASE", 0, 4]]], ["Perhaps, we are all now witnesses of the first manifestations of this virus\u2013host coevolution.", [["this virus\u2013host coevolution", "PROBLEM", 65, 92]]]], "PMC7195089": [["Introduction ::: Introduction ::: Executive SummarySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has exhibited a pattern of pandemic spread in a few short months, as countries and communities struggle to rapidly design effective strategies to prevent spread of the novel coronavirus.", [["acute respiratory syndrome coronavirus", "DISEASE", 58, 96], ["coronavirus", "DISEASE", 286, 297], ["SummarySevere acute respiratory syndrome coronavirus 2", "ORGANISM", 44, 98], ["SARS-CoV-2", "ORGANISM", 100, 110], ["coronavirus", "ORGANISM", 286, 297], ["SummarySevere acute respiratory syndrome coronavirus", "SPECIES", 44, 96], ["SARS-CoV-2", "SPECIES", 100, 110], ["Executive SummarySevere acute respiratory syndrome coronavirus", "PROBLEM", 34, 96], ["SARS-CoV", "TEST", 100, 108], ["pandemic spread", "PROBLEM", 139, 154], ["the novel coronavirus", "PROBLEM", 276, 297], ["acute", "OBSERVATION_MODIFIER", 58, 63], ["respiratory syndrome", "OBSERVATION", 64, 84], ["pandemic", "OBSERVATION", 139, 147]]], ["The virus has been named SARS-CoV-2 and the disease it causes \u201ccoronavirus disease 2019\u201d (COVID-19).1,2 Community transmission is now evident, and it is clear that SARS-CoV-2 is a highly contagious virus.3,4 The spectrum of disease ranges from severe respiratory illness and fatality from these complications (particularly in the elderly and those with comorbidities) to asymptomatic spread,1,5,6 with the proclivity of SARS-CoV-2 for person-to-person transmission in asymptomatic individuals presenting one of the most vexing problems from a public health standpoint.1 Given the rapid and pervasive spread, the World Health Organization declared SARS-CoV-2 a pandemic on March 11, 2020, and on March 13, 2020, the president of the United States declared a national emergency in the United States, consistent with similar actions taken in several other countries7,8 (Figure 1).Prevention and control ::: Introduction ::: Executive SummaryAlthough vaccine development is underway, it is unlikely that a vaccine will be available in 2020.1 The Centers for Disease Control and Prevention has recommended use of personal protective equipment by health care workers including standard, contact, and airborne precautions and with the use of eye protection.", [["respiratory", "ANATOMY", 251, 262], ["eye", "ANATOMY", 1235, 1238], ["coronavirus disease", "DISEASE", 63, 82], ["SARS", "DISEASE", 164, 168], ["respiratory illness", "DISEASE", 251, 270], ["fatality", "DISEASE", 275, 283], ["SARS", "DISEASE", 420, 424], ["SARS-CoV-2", "ORGANISM", 25, 35], ["SARS-CoV-2", "ORGANISM", 164, 174], ["SARS-CoV-2", "ORGANISM", 420, 430], ["eye", "ORGAN", 1235, 1238], ["person", "SPECIES", 435, 441], ["SARS-CoV", "SPECIES", 25, 33], ["SARS-CoV-2", "SPECIES", 164, 174], ["SARS-CoV", "SPECIES", 420, 428], ["SARS-CoV", "SPECIES", 647, 655], ["The virus", "PROBLEM", 0, 9], ["the disease", "PROBLEM", 40, 51], ["\u201ccoronavirus disease", "PROBLEM", 62, 82], ["COVID", "TEST", 90, 95], ["SARS", "PROBLEM", 164, 168], ["a highly contagious virus", "PROBLEM", 178, 203], ["disease ranges", "PROBLEM", 224, 238], ["severe respiratory illness", "PROBLEM", 244, 270], ["these complications", "PROBLEM", 289, 308], ["asymptomatic spread", "PROBLEM", 371, 390], ["the rapid and pervasive spread", "PROBLEM", 576, 606], ["vaccine", "TREATMENT", 947, 954], ["a vaccine", "TREATMENT", 1000, 1009], ["Disease Control", "TREATMENT", 1054, 1069], ["personal protective equipment", "TREATMENT", 1108, 1137], ["airborne precautions", "TREATMENT", 1194, 1214], ["eye protection", "TREATMENT", 1235, 1249], ["virus", "OBSERVATION", 4, 9], ["disease", "OBSERVATION", 44, 51], ["coronavirus disease", "OBSERVATION", 63, 82], ["contagious virus", "OBSERVATION", 187, 203], ["spectrum", "OBSERVATION_MODIFIER", 212, 220], ["disease", "OBSERVATION", 224, 231], ["severe", "OBSERVATION_MODIFIER", 244, 250], ["respiratory illness", "OBSERVATION", 251, 270], ["pervasive", "OBSERVATION_MODIFIER", 590, 599], ["spread", "OBSERVATION_MODIFIER", 600, 606]]], ["This means health care workers caring for a patient with suspected COVID-19 should wear a gown, gloves, and either an N95 respirator plus face shield and goggles or a powered air-purifying respirator; however, the Centers for Disease Control and Prevention also notes that a face mask may be substituted for an N95 respirator if one is not available, and a negative pressure room may be reserved for patients undergoing aerosol-generating procedures.1,2 However, this information is fluid and may continue to change.", [["patient", "ORGANISM", 44, 51], ["patients", "ORGANISM", 400, 408], ["patient", "SPECIES", 44, 51], ["patients", "SPECIES", 400, 408], ["a gown, gloves", "TREATMENT", 88, 102], ["an N95 respirator plus face shield", "TREATMENT", 115, 149], ["a powered air-purifying respirator", "TREATMENT", 165, 199], ["Disease Control", "TREATMENT", 226, 241], ["a face mask", "TREATMENT", 273, 284], ["an N95 respirator", "TREATMENT", 308, 325], ["a negative pressure room", "TREATMENT", 355, 379], ["aerosol-generating procedures", "TREATMENT", 420, 449], ["fluid", "OBSERVATION", 483, 488]]], ["Commonsense strategies to control the spread of SARS-CoV-2 are detailed in Table E1 and frequently asked questions in Table E2 in this article's Online Repository at www.jaci-inpractice.org.2,9 During the COVID-19 pandemic the concept of social distancing has also been incorporated into prevention strategies, with the Centers for Disease Control and Prevention recommending avoiding close contact (<6 ft).2,9", [["SARS", "DISEASE", 48, 52], ["E2", "CHEMICAL", 124, 126], ["jaci-inpractice.org.2,9", "CHEMICAL", 170, 193], ["2,9", "CHEMICAL", 407, 410], ["SARS-CoV", "SPECIES", 48, 56], ["Commonsense strategies", "TREATMENT", 0, 22], ["Disease Control", "TREATMENT", 332, 347]]]], "13bc396fab607d24e0dfd5b38704463d13a85c08": [["DiSCOveRiNG A GReAT TOOL AGAiNST MiCROBeSAntibiotics are an important example of how man can learn from nature to improve his own living conditions.", [["man", "ORGANISM", 85, 88], ["man", "SPECIES", 85, 88]]], ["The first observation that microbes are able to produces substances capable of killing pathogens came from the Italian scientist Vincenzio Tiberio in 1895, who showed the antibacterial activity of a natural substance produced by molds (5) .", [["killing pathogens", "PROBLEM", 79, 96], ["antibacterial activity", "OBSERVATION", 171, 193]]], ["Then Ernest Duchesne in France published in his doctorate thesis presented in 1897 (6) that the mold Penicillium glaucum possesses antibacterial properties.", [["mold", "ORGANISM", 96, 100], ["Penicillium glaucum", "ORGANISM", 101, 120], ["Penicillium glaucum", "SPECIES", 101, 120], ["Penicillium glaucum", "SPECIES", 101, 120], ["the mold Penicillium glaucum possesses antibacterial properties", "TREATMENT", 92, 155], ["Penicillium glaucum", "OBSERVATION", 101, 120], ["antibacterial properties", "OBSERVATION", 131, 155]]], ["It was Alexander Flaming in 1928 that succeeded in definitely identifying the world's first antibiotic.", [["first antibiotic", "TREATMENT", 86, 102]]], ["It was a substance isolated from the mold Penicillium notatum, defined as benzylpenicillin (penicillin G) (7) .", [["benzylpenicillin", "CHEMICAL", 74, 90], ["penicillin", "CHEMICAL", 92, 102], ["benzylpenicillin", "CHEMICAL", 74, 90], ["penicillin G", "CHEMICAL", 92, 104], ["Penicillium notatum", "ORGANISM", 42, 61], ["benzylpenicillin", "SIMPLE_CHEMICAL", 74, 90], ["penicillin G)", "SIMPLE_CHEMICAL", 92, 105], ["Penicillium notatum", "SPECIES", 42, 61], ["Penicillium notatum", "SPECIES", 42, 61], ["the mold Penicillium notatum", "TREATMENT", 33, 61], ["benzylpenicillin (penicillin G)", "TREATMENT", 74, 105]]], ["Thus, after the Pearl Harbor attack in 1941 a mass production could be initiated.", [["a mass production", "PROBLEM", 44, 61], ["mass", "OBSERVATION", 46, 50]]], ["By 1944, enough penicillin was produced to treat the wounded soldiers in the Allied forces.", [["penicillin", "CHEMICAL", 16, 26], ["penicillin", "CHEMICAL", 16, 26], ["penicillin", "SIMPLE_CHEMICAL", 16, 26], ["penicillin", "TREATMENT", 16, 26]]], ["The era of antibiotics had begun, and several other molecules produced by microbes followed penicillin.", [["penicillin", "CHEMICAL", 92, 102], ["penicillin", "CHEMICAL", 92, 102], ["penicillin", "SIMPLE_CHEMICAL", 92, 102], ["antibiotics", "TREATMENT", 11, 22], ["penicillin", "TREATMENT", 92, 102]]], ["With antibiotics, mankind could claim an historical success in the eternal war against pathogens.", [["antibiotics", "TREATMENT", 5, 16], ["pathogens", "PROBLEM", 87, 96]]], ["However, it was soon clear that antibiotics were not the definitive weapon.DiSCOveRiNG A GReAT TOOL AGAiNST MiCROBeSIn a book published in 1975, Stanley Falkow wrote that \"we owe to chemotherapy (antibiotics) the debt of reducing the high mortal ity rate of many bacterial infections\" and to hygiene and vaccines the debt of preventing them, however \"in helping to solve some of the problems of infectious diseases, chemotherapy has created some problems of its own\" (8) .", [["bacterial infections", "DISEASE", 263, 283], ["infectious diseases", "DISEASE", 395, 414], ["antibiotics", "TREATMENT", 32, 43], ["chemotherapy (antibiotics", "TREATMENT", 182, 207], ["many bacterial infections", "PROBLEM", 258, 283], ["vaccines", "TREATMENT", 304, 312], ["infectious diseases", "PROBLEM", 395, 414], ["chemotherapy", "TREATMENT", 416, 428], ["bacterial", "OBSERVATION_MODIFIER", 263, 272], ["infections", "OBSERVATION", 273, 283], ["infectious", "OBSERVATION", 395, 405]]], ["The problem created by antibiotics was the generation of bacterial strains resistant to multiple antibiotics, an event reported for the first time in 1956, with the isolation in Japan of a strain of Shigella flexneri resistant to streptomycin, tetracycline, chloramphenicol, and sulfonamides.DiSCOveRiNG A GReAT TOOL AGAiNST MiCROBeSToday, antimicrobial resistance (AMR) has grown out of proportion, and many pathogenic bacteria are resistant to multiple antibiotics, including Neisseria gonorrhoeae, Staphylococcus aureus, Pseudomonas aeruginosa, Salmonella typhi, Shigella, Escherichia coli, Acinetobacter, Proteus, Klebsiella, Serratia, Strep tococcus pneumoniae, Mycobacterium tuberculosis, Vibrio cholerae, Helicobacter pylori, and others.", [["streptomycin", "CHEMICAL", 230, 242], ["tetracycline", "CHEMICAL", 244, 256], ["chloramphenicol", "CHEMICAL", 258, 273], ["sulfonamides", "CHEMICAL", 279, 291], ["Neisseria gonorrhoeae", "DISEASE", 478, 499], ["Staphylococcus aureus", "DISEASE", 501, 522], ["Mycobacterium tuberculosis", "DISEASE", 667, 693], ["Vibrio cholerae", "DISEASE", 695, 710], ["Helicobacter pylori", "DISEASE", 712, 731], ["streptomycin", "CHEMICAL", 230, 242], ["tetracycline", "CHEMICAL", 244, 256], ["chloramphenicol", "CHEMICAL", 258, 273], ["sulfonamides", "CHEMICAL", 279, 291], ["Shigella flexneri", "ORGANISM", 199, 216], ["streptomycin", "SIMPLE_CHEMICAL", 230, 242], ["tetracycline", "SIMPLE_CHEMICAL", 244, 256], ["chloramphenicol", "SIMPLE_CHEMICAL", 258, 273], ["sulfonamides", "SIMPLE_CHEMICAL", 279, 291], ["Neisseria gonorrhoeae", "ORGANISM", 478, 499], ["Staphylococcus aureus", "ORGANISM", 501, 522], ["Pseudomonas aeruginosa", "ORGANISM", 524, 546], ["Salmonella typhi", "ORGANISM", 548, 564], ["Shigella,", "ORGANISM", 566, 575], ["Escherichia coli", "ORGANISM", 576, 592], ["Acinetobacter,", "ORGANISM", 594, 608], ["Proteus, Klebsiella", "ORGANISM", 609, 628], ["Serratia,", "ORGANISM", 630, 639], ["Strep tococcus pneumoniae", "ORGANISM", 640, 665], ["Mycobacterium tuberculosis", "ORGANISM", 667, 693], ["Vibrio cholerae", "ORGANISM", 695, 710], ["Helicobacter pylori", "ORGANISM", 712, 731], ["Shigella flexneri", "SPECIES", 199, 216], ["Neisseria gonorrhoeae", "SPECIES", 478, 499], ["Staphylococcus aureus", "SPECIES", 501, 522], ["Pseudomonas aeruginosa", "SPECIES", 524, 546], ["Salmonella typhi", "SPECIES", 548, 564], ["Shigella", "SPECIES", 566, 574], ["Escherichia coli", "SPECIES", 576, 592], ["Strep tococcus pneumoniae", "SPECIES", 640, 665], ["Mycobacterium tuberculosis", "SPECIES", 667, 693], ["Vibrio cholerae", "SPECIES", 695, 710], ["Helicobacter pylori", "SPECIES", 712, 731], ["Shigella flexneri", "SPECIES", 199, 216], ["Neisseria gonorrhoeae", "SPECIES", 478, 499], ["Staphylococcus aureus", "SPECIES", 501, 522], ["Pseudomonas aeruginosa", "SPECIES", 524, 546], ["Salmonella typhi", "SPECIES", 548, 564], ["Escherichia coli", "SPECIES", 576, 592], ["Strep tococcus pneumoniae", "SPECIES", 640, 665], ["Mycobacterium tuberculosis", "SPECIES", 667, 693], ["Vibrio cholerae", "SPECIES", 695, 710], ["Helicobacter pylori", "SPECIES", 712, 731], ["antibiotics", "TREATMENT", 23, 34], ["bacterial strains", "PROBLEM", 57, 74], ["multiple antibiotics", "TREATMENT", 88, 108], ["Shigella flexneri", "PROBLEM", 199, 216], ["streptomycin", "TREATMENT", 230, 242], ["tetracycline", "TREATMENT", 244, 256], ["chloramphenicol", "TREATMENT", 258, 273], ["sulfonamides", "TREATMENT", 279, 291], ["antimicrobial resistance (AMR", "PROBLEM", 340, 369], ["many pathogenic bacteria", "PROBLEM", 404, 428], ["multiple antibiotics", "TREATMENT", 446, 466], ["Neisseria gonorrhoeae", "TEST", 478, 499], ["Staphylococcus aureus", "PROBLEM", 501, 522], ["Pseudomonas aeruginosa", "PROBLEM", 524, 546], ["Salmonella typhi", "PROBLEM", 548, 564], ["Shigella", "PROBLEM", 566, 574], ["Escherichia coli", "PROBLEM", 576, 592], ["Acinetobacter", "PROBLEM", 594, 607], ["Proteus", "PROBLEM", 609, 616], ["Klebsiella", "PROBLEM", 618, 628], ["Serratia", "PROBLEM", 630, 638], ["Strep tococcus pneumoniae", "PROBLEM", 640, 665], ["Mycobacterium tuberculosis", "PROBLEM", 667, 693], ["Vibrio cholerae", "PROBLEM", 695, 710], ["Helicobacter pylori", "PROBLEM", 712, 731], ["bacterial strains", "OBSERVATION", 57, 74], ["many", "OBSERVATION_MODIFIER", 404, 408], ["pathogenic", "OBSERVATION_MODIFIER", 409, 419], ["bacteria", "OBSERVATION", 420, 428], ["Escherichia coli", "OBSERVATION", 576, 592], ["Klebsiella", "OBSERVATION_MODIFIER", 618, 628], ["Mycobacterium tuberculosis", "OBSERVATION", 667, 693], ["Helicobacter pylori", "OBSERVATION", 712, 731]]], ["In a few cases, bacteria became resistant to most of the available antibiotics and are on the verge of becoming untreatable.", [["bacteria", "PROBLEM", 16, 24], ["the available antibiotics", "TREATMENT", 53, 78]]], ["As a consequence, AMR is perhaps the most alarming emerging problem of infectious diseases.", [["AMR", "DISEASE", 18, 21], ["infectious diseases", "DISEASE", 71, 90], ["AMR", "PROBLEM", 18, 21], ["infectious diseases", "PROBLEM", 71, 90], ["infectious", "OBSERVATION", 71, 81]]], ["Globally, AMR already causes 700,000 deaths/year, and the forecast is that in 2050 it will cause 10 million deaths/year, higher than the 8.2 million deaths caused by cancer today.", [["cancer", "ANATOMY", 166, 172], ["AMR", "DISEASE", 10, 13], ["deaths", "DISEASE", 37, 43], ["deaths", "DISEASE", 108, 114], ["deaths", "DISEASE", 149, 155], ["cancer", "DISEASE", 166, 172], ["cancer", "CANCER", 166, 172], ["cancer", "PROBLEM", 166, 172], ["cancer", "OBSERVATION", 166, 172]]], ["As an example we can look at S. pneumoniae, also known as pneumococcus, a human pathogen that is the major cause of community-acquired pneumonia, bacterial meningitis, bacteremia, and otitis media (9, 10) .", [["pneumonia", "DISEASE", 135, 144], ["bacterial meningitis", "DISEASE", 146, 166], ["bacteremia", "DISEASE", 168, 178], ["otitis", "DISEASE", 184, 190], ["S. pneumoniae", "ORGANISM", 29, 42], ["human", "ORGANISM", 74, 79], ["S. pneumoniae", "SPECIES", 29, 42], ["human", "SPECIES", 74, 79], ["S. pneumoniae", "SPECIES", 29, 42], ["human", "SPECIES", 74, 79], ["S. pneumoniae", "PROBLEM", 29, 42], ["pneumococcus", "PROBLEM", 58, 70], ["a human pathogen", "PROBLEM", 72, 88], ["community-acquired pneumonia", "PROBLEM", 116, 144], ["bacterial meningitis", "PROBLEM", 146, 166], ["bacteremia", "PROBLEM", 168, 178], ["otitis media", "PROBLEM", 184, 196], ["pneumoniae", "OBSERVATION", 32, 42], ["pneumococcus", "OBSERVATION", 58, 70], ["pneumonia", "OBSERVATION", 135, 144], ["bacterial", "OBSERVATION_MODIFIER", 146, 155], ["meningitis", "OBSERVATION", 156, 166], ["bacteremia", "OBSERVATION", 168, 178], ["otitis", "OBSERVATION", 184, 190]]], ["In the past, most strains of S. pneumoniae were sensitive to penicillin, whereas today penicillin resistance goes from 5 up to 60% in various parts of the world.", [["penicillin", "CHEMICAL", 61, 71], ["penicillin", "CHEMICAL", 87, 97], ["penicillin", "CHEMICAL", 61, 71], ["penicillin", "CHEMICAL", 87, 97], ["S. pneumoniae", "ORGANISM", 29, 42], ["penicillin", "SIMPLE_CHEMICAL", 61, 71], ["penicillin", "SIMPLE_CHEMICAL", 87, 97], ["S. pneumoniae", "SPECIES", 29, 42], ["S. pneumoniae", "SPECIES", 29, 42], ["S. pneumoniae", "PROBLEM", 29, 42], ["penicillin", "TREATMENT", 61, 71], ["penicillin resistance", "TREATMENT", 87, 108], ["pneumoniae", "OBSERVATION", 32, 42]]], ["Thus, with time old antibiotics become less effective or lose efficacy, making the search for new molecules with different mechanisms of action a priority (11) .DiSCOveRiNG A GReAT TOOL AGAiNST MiCROBeSAlarming documents, calling for action and asking for new antibiotics, have been issued by governments such as those of the UK and USA, by the European Union (EU), and by international organizations such as the World Health Organization (WHO), the United Nations General Assembly, and the World Bank and the G20.", [["time old antibiotics", "TREATMENT", 11, 31], ["new molecules", "PROBLEM", 94, 107], ["new antibiotics", "TREATMENT", 256, 271]]], ["The interest in fighting the increase in AMR has intensified, and new incentives for research and development of new drugs have been deployed.", [["AMR", "DISEASE", 41, 44], ["new drugs", "TREATMENT", 113, 122], ["increase", "OBSERVATION_MODIFIER", 29, 37], ["new", "OBSERVATION_MODIFIER", 113, 116], ["drugs", "OBSERVATION", 117, 122]]], ["In 2016, about 500 million US$ have been allocated to new and existing initiatives aiming to accelerate the develop ment of new antibiotics 1 .", [["new antibiotics", "TREATMENT", 124, 139]]], ["Other initiatives include CARB-X, a collaboration between US and UK partners 3 , and the Global Antibiotic Research and Development Partnership, a collaboration between the Drugs for Neglected Diseases initiative and the WHO 4 .", [["Neglected Diseases", "DISEASE", 183, 201], ["the Drugs", "TREATMENT", 169, 178], ["Neglected Diseases", "PROBLEM", 183, 201]]], ["It is also interesting a German proposal for a Global Union for Antibiotics Research and Development (GUARD), aimed at funding and coordinating a facility for antibiotics research and development.DiSCOveRiNG A GReAT TOOL AGAiNST MiCROBeSOn February 27th 2017, the WHO published a document 5 , which we partially report hereafter: \"This is the first ever list of antibioticresistant \"priority pathogens\", a catalog of 12 The WHO document strongly underlines the need for new treatments.", [["Antibiotics Research", "TREATMENT", 64, 84], ["antibiotics research", "TREATMENT", 159, 179], ["new treatments", "TREATMENT", 470, 484]]], ["Thus, the search for new antimicrobial drugs is and must remain a great priority.", [["new antimicrobial drugs", "TREATMENT", 21, 44]]], ["However, it is important to realize that the pipeline for new antibiotics is not very promising, thereby making unlikely that the problem will be solved along this line (12) .", [["new antibiotics", "TREATMENT", 58, 73]]], ["On the other hand, another tool that, together with antibiotics, contributed to conquer and eliminate many infectious diseases, i.e., vaccines, have a very promising pipeline thanks to the new technologies (3).", [["infectious diseases", "DISEASE", 107, 126], ["antibiotics", "TREATMENT", 52, 63], ["many infectious diseases", "PROBLEM", 102, 126], ["vaccines", "TREATMENT", 134, 142], ["infectious", "OBSERVATION", 107, 117]]], ["Thus, vaccines have the possibility to make a big contribution to the control of AMR.ReSiSTANCe TO ANTiBiOTiCS AND vACCiNeSThe analysis of how vaccines and antibiotics contributed to conquering infectious diseases during the last century was originally published by the group of one of the authors of this paper (13) , and more recently re-analyzed in depth by Kennedy and Read [(14) , Figure 1 ].", [["AMR", "DISEASE", 81, 84], ["vACCiNe", "CHEMICAL", 115, 122], ["infectious diseases", "DISEASE", 194, 213], ["vACCiNe", "CHEMICAL", 115, 122], ["vaccines", "TREATMENT", 6, 14], ["AMR", "PROBLEM", 81, 84], ["ANTiBiOTiCS", "TREATMENT", 99, 110], ["vACCiNe", "TREATMENT", 115, 122], ["SThe analysis", "TEST", 122, 135], ["how vaccines", "TREATMENT", 139, 151], ["antibiotics", "TREATMENT", 156, 167], ["conquering infectious diseases", "PROBLEM", 183, 213]]], ["This analysis shows that resistance to antibiotics inevitably emerges every time that a new antibiotic is introduced, starting a process of selection in the target bacteria that will eventually make that antibiotic useless.", [["This analysis", "TEST", 0, 13], ["antibiotics", "TREATMENT", 39, 50], ["a new antibiotic", "TREATMENT", 86, 102], ["the target bacteria", "PROBLEM", 153, 172], ["antibiotic useless", "TREATMENT", 204, 222]]], ["The consequence is that there is a continuous need of a fresh supply of novel antibiotics, to maintaining effectiveness of the therapeutic treatment.", [["novel antibiotics", "TREATMENT", 72, 89], ["the therapeutic treatment", "TREATMENT", 123, 148]]], ["This strategy worked very well up to 1970s, when the identification of new antibiotics was abundant.", [["new antibiotics", "TREATMENT", 71, 86]]], ["However, since then the pipeline for new antibiotics has been drying out, and we have not been able to discover new classes of antibiotics (11) .", [["new antibiotics", "TREATMENT", 37, 52], ["antibiotics", "TREATMENT", 127, 138]]], ["In marked contrast, Kennedy and Read show that we can use vaccines for a long time, generating no or very little resistance (14) .", [["vaccines", "TREATMENT", 58, 66], ["marked", "OBSERVATION_MODIFIER", 3, 9]]], ["Thus, vaccines can control infections over a long period of time without becoming obsolete.", [["infections", "DISEASE", 27, 37], ["vaccines", "TREATMENT", 6, 14], ["infections", "PROBLEM", 27, 37], ["obsolete", "OBSERVATION", 82, 90]]], ["This occurs because vaccines work prophylactically and prevent the start of infections, while drugs work therapeutically on an ongoing infection in which bacteria proliferate and mutate, allowing the drug to select the resistant variants.ReSiSTANCe TO ANTiBiOTiCS AND vACCiNeSFurthermore, drugs are targeting few metabolic pathways on the pathogens, whereas vaccines induce a protective immune response against multiple antigenic targets.", [["infections", "DISEASE", 76, 86], ["infection", "DISEASE", 135, 144], ["vaccines", "TREATMENT", 20, 28], ["infections", "PROBLEM", 76, 86], ["an ongoing infection", "PROBLEM", 124, 144], ["bacteria proliferate", "PROBLEM", 154, 174], ["the resistant variants", "PROBLEM", 215, 237], ["ANTiBiOTiCS", "TREATMENT", 252, 263], ["vACCiNeSFurthermore", "TREATMENT", 268, 287], ["drugs", "TREATMENT", 289, 294], ["the pathogens", "PROBLEM", 335, 348], ["vaccines", "TREATMENT", 358, 366], ["multiple antigenic targets", "TREATMENT", 411, 437], ["infections", "OBSERVATION", 76, 86], ["infection", "OBSERVATION", 135, 144]]], ["It can be concluded that selection has fewer opportunities to act upon vaccination than with antibiotic treatment.", [["vaccination", "TREATMENT", 71, 82], ["antibiotic treatment", "TREATMENT", 93, 113]]], ["Still, both vaccines and antibiotics are very important in the control of infections.", [["infections", "DISEASE", 74, 84], ["both vaccines", "TREATMENT", 7, 20], ["antibiotics", "TREATMENT", 25, 36], ["infections", "PROBLEM", 74, 84], ["infections", "OBSERVATION", 74, 84]]], ["Table 1 reports the major differences in the mode of action of vaccines and antibiotics and provides information that can guide us to take advantage of their strengths and to minimize their weaknesses.", [["vaccines", "TREATMENT", 63, 71], ["antibiotics", "TREATMENT", 76, 87], ["their weaknesses", "PROBLEM", 184, 200]]], ["From this comparison, it is evident that antibiotics are the only life-saving tool FiGuRe 1 | Time to detection of resistance of human pathogens to antimicrobials (in red) and to vaccines (in green).", [["human", "ORGANISM", 129, 134], ["human", "SPECIES", 129, 134], ["human", "SPECIES", 129, 134], ["antibiotics", "TREATMENT", 41, 52], ["resistance of human pathogens", "PROBLEM", 115, 144], ["antimicrobials", "TREATMENT", 148, 162]]], ["Black X symbols indicate insurgence of resistance, with lines starting at product introduction (yellow stars; except for smallpox vaccination that began much earlier; with modifications from Ref.", [["resistance", "PROBLEM", 39, 49], ["lines", "TREATMENT", 56, 61], ["yellow stars", "PROBLEM", 96, 108], ["smallpox vaccination", "TREATMENT", 121, 141]]], ["(14) with the permission of the publisher). that we can use during acute bacterial infections, although their often improper or excessive use is causing bacterial resistance in a continuously increasing fashion.", [["bacterial infections", "DISEASE", 73, 93], ["acute bacterial infections", "PROBLEM", 67, 93], ["bacterial resistance", "PROBLEM", 153, 173], ["acute", "OBSERVATION_MODIFIER", 67, 72], ["bacterial", "OBSERVATION_MODIFIER", 73, 82], ["infections", "OBSERVATION", 83, 93], ["bacterial resistance", "OBSERVATION", 153, 173]]], ["The availability of vaccines to control infections may allow us to decrease the use of antibiotics and to generate less AMR.", [["infections", "DISEASE", 40, 50], ["AMR", "DISEASE", 120, 123], ["vaccines", "TREATMENT", 20, 28], ["infections", "PROBLEM", 40, 50], ["antibiotics", "TREATMENT", 87, 98]]], ["This will permit a more efficient use of existing and new antibiotics during acute infections.", [["infections", "DISEASE", 83, 93], ["new antibiotics", "TREATMENT", 54, 69], ["acute infections", "PROBLEM", 77, 93], ["acute", "OBSERVATION_MODIFIER", 77, 82], ["infections", "OBSERVATION", 83, 93]]], ["As shown in Figure 1 , there are, however, some cases in which resistance evolved after vaccination.", [["vaccination", "TREATMENT", 88, 99]]], ["This can be due to several causes, such as the fact that vaccines can protect from disease but may not have the capability to completely prevent pathogen colonization and transmission, as in the case of the acellular pertussis vaccine, or it can be caused by serotype replacement after vaccination with vaccines not including all serotypes, as in the case of the vaccines against S. pneumoniae.", [["S. pneumoniae", "DISEASE", 380, 393], ["acellular pertussis", "ORGANISM", 207, 226], ["S. pneumoniae", "ORGANISM", 380, 393], ["S. pneumoniae", "SPECIES", 380, 393], ["S. pneumoniae", "SPECIES", 380, 393], ["vaccines", "TREATMENT", 57, 65], ["disease", "PROBLEM", 83, 90], ["the capability", "PROBLEM", 108, 122], ["pathogen colonization", "PROBLEM", 145, 166], ["the acellular pertussis vaccine", "TREATMENT", 203, 234], ["serotype replacement", "TREATMENT", 259, 279], ["vaccination", "TREATMENT", 286, 297], ["vaccines", "TREATMENT", 303, 311], ["all serotypes", "TREATMENT", 326, 339], ["the vaccines", "TREATMENT", 359, 371], ["S. pneumoniae", "PROBLEM", 380, 393], ["pneumoniae", "OBSERVATION", 383, 393]]], ["Thus, even for vaccines the search for better protective antigens (Ag) is very important, particularly for antibiotic-resistant infections.ReSiSTANCe TO ANTiBiOTiCS AND vACCiNeSIn May 2016, a group of experts coordinated by the economist Jim O'Neill published a comprehensive report entitled \"Tackling drugresistant infections globally\" (11) .", [["Ag", "CHEMICAL", 67, 69], ["infections", "DISEASE", 128, 138], ["infections", "DISEASE", 316, 326], ["Ag", "CHEMICAL", 67, 69], ["protective antigens", "PROTEIN", 46, 65], ["Ag", "PROTEIN", 67, 69], ["vaccines", "TREATMENT", 15, 23], ["antibiotic", "TREATMENT", 107, 117], ["resistant infections", "PROBLEM", 118, 138], ["ANTiBiOTiCS", "TREATMENT", 153, 164], ["vACCiNeSIn", "TREATMENT", 169, 179], ["infections", "OBSERVATION", 128, 138]]], ["Among many indications to prevent the increasing global problem of AMR, an entire section was devoted to vaccines.", [["AMR", "DISEASE", 67, 70], ["the increasing global problem", "PROBLEM", 34, 63], ["AMR", "PROBLEM", 67, 70], ["an entire section", "TREATMENT", 72, 89], ["vaccines", "TREATMENT", 105, 113], ["increasing", "OBSERVATION_MODIFIER", 38, 48], ["global", "OBSERVATION_MODIFIER", 49, 55]]], ["Hereafter we report part of the section \"We must reduce the demand for antimicrobial so the Similarly, the WHO document on priority pathogens stresses that the role of vaccines in the global AMR crisis remains of great importance.PROMOTiNG THe DiSCuSSiON ABOuT vACCiNeS AS A ReMeDY TO AMRSince 2004, the year of 100th anniversary of the foundation of the Serology and Vaccinology Institute Achille Sclavo, a forum for the discussion of the most important issues of the vaccine world takes place every year in Siena, Italy.", [["AMR", "DISEASE", 191, 194], ["antimicrobial", "TREATMENT", 71, 84], ["vaccines", "TREATMENT", 168, 176], ["the Serology", "TEST", 351, 363]]], ["Each annual meeting aimed to analyze the state-of-the-art of important themes in the field of vaccines and expand the vision for the years to come.", [["vaccines", "TREATMENT", 94, 102]]], ["The participation of excellent speakers and expert discussants ensured the high quality of the meetings, whose conclusions were published in international journals (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) .", [["16) (17) (18) (19) (20) (21", "SIMPLE_CHEMICAL", 170, 197]]], ["The meetings were organized close to a popular event, the horse race named \"Palio di Siena, \" for which the town is worldwide famous.", [["horse", "ORGANISM", 58, 63], ["horse", "SPECIES", 58, 63]]], ["The topic of the meetings can vary but the mission is always based on one or more of the following pillars: (1) must define the state-of-the-art of cutting edge topics related to infectious diseases; (2) must advocate science policies to promote progress and improvement in human health; and (3) must be a strategic forum aimed to build new initiatives.", [["infectious diseases", "DISEASE", 179, 198], ["human", "ORGANISM", 274, 279], ["human", "SPECIES", 274, 279], ["human", "SPECIES", 274, 279], ["infectious diseases", "PROBLEM", 179, 198]]], ["It was therefore almost mandatory that the subject of the 2017 Palio Meeting should be on the growing emergency caused by antibiotics failure, with the title \"Prioritizing vaccines to fight antimicrobial resistance. \"", [["antibiotics failure", "PROBLEM", 122, 141], ["Prioritizing vaccines", "TREATMENT", 159, 180], ["fight antimicrobial resistance", "TREATMENT", 184, 214]]], ["The London meeting provided a clear consensus that vaccines complement the actions of antibiotics and can contribute to control, reduce, and sometimes eliminate diseases caused by AMR pathogens, more than any other intervention.", [["AMR", "DISEASE", 180, 183], ["vaccines", "TREATMENT", 51, 59], ["antibiotics", "TREATMENT", 86, 97], ["diseases", "PROBLEM", 161, 169], ["AMR pathogens", "PROBLEM", 180, 193]]], ["Thus, the main scope of the 2017 Palio Meeting was to build on the conclusions of the London meeting, and posed the question of how can we make vaccines achieve their full potential and become one of the top tools to tackle AMR.", [["AMR", "DISEASE", 224, 227], ["vaccines", "TREATMENT", 144, 152]]], ["Indeed, the discussion led to conclude that there is a need to make stronger, more evidence-based cases supporting the importance of vaccines in AMR prevention (24) .PROMOTiNG THe DiSCuSSiON ABOuT vACCiNeS AS A ReMeDY TO AMROne example is represented by vaccines against the main strains of S. pneumoniae, vaccines that have reduced pneumonia cases in the first decade of this century and in parallel have decreased the number of infections resistant to front-line antibiotics (26) .", [["AMR", "DISEASE", 145, 148], ["pneumonia", "DISEASE", 333, 342], ["infections", "DISEASE", 430, 440], ["S. pneumoniae", "ORGANISM", 291, 304], ["S. pneumoniae", "SPECIES", 291, 304], ["S. pneumoniae", "SPECIES", 291, 304], ["vaccines", "TREATMENT", 133, 141], ["S. pneumoniae", "PROBLEM", 291, 304], ["vaccines", "TREATMENT", 306, 314], ["reduced pneumonia cases", "PROBLEM", 325, 348], ["infections", "PROBLEM", 430, 440], ["front-line antibiotics", "TREATMENT", 454, 476], ["pneumoniae", "OBSERVATION", 294, 304], ["reduced", "OBSERVATION_MODIFIER", 325, 332], ["pneumonia", "OBSERVATION", 333, 342], ["decreased", "OBSERVATION_MODIFIER", 406, 415], ["number", "OBSERVATION_MODIFIER", 420, 426], ["infections", "OBSERVATION", 430, 440]]], ["The introduction in 2009 in South Africa of a pneumococcal vaccine achieved an analogous result.", [["pneumococcal", "ORGANISM", 46, 58], ["pneumococcal", "SPECIES", 46, 58], ["a pneumococcal vaccine", "TREATMENT", 44, 66]]], ["Furthermore, it is interesting to note that the high use of antibiotics, prescribed to treat opportunistic bacterial infections in people weakened by flu, is prevented when flu vaccines are employed.", [["opportunistic bacterial infections", "DISEASE", 93, 127], ["flu", "DISEASE", 150, 153], ["people", "ORGANISM", 131, 137], ["people", "SPECIES", 131, 137], ["antibiotics", "TREATMENT", 60, 71], ["opportunistic bacterial infections", "PROBLEM", 93, 127], ["flu", "PROBLEM", 150, 153], ["flu vaccines", "TREATMENT", 173, 185], ["opportunistic", "OBSERVATION_MODIFIER", 93, 106], ["bacterial", "OBSERVATION_MODIFIER", 107, 116], ["infections", "OBSERVATION", 117, 127]]], ["There is a FiGuRe 2 | Interplay of B cell technology and structural biology in vaccine design, as shown with the Reverse Vaccinology 2.0 approach (from 35).", [["B cell", "ANATOMY", 35, 41], ["B cell", "CELL", 35, 41], ["B cell technology", "TREATMENT", 35, 52]]], ["Flow path representation of how the analysis of the human B cell repertoire leads to the identification of protective Abs from vaccinated or infected subjects.", [["B cell", "ANATOMY", 58, 64], ["human", "ORGANISM", 52, 57], ["B cell", "CELL", 58, 64], ["Abs", "GENE_OR_GENE_PRODUCT", 118, 121], ["protective Abs", "PROTEIN", 107, 121], ["human", "SPECIES", 52, 57], ["human", "SPECIES", 52, 57], ["the analysis", "TEST", 32, 44], ["the human B cell repertoire", "TREATMENT", 48, 75], ["protective Abs", "PROBLEM", 107, 121], ["vaccinated or infected subjects", "PROBLEM", 127, 158], ["infected", "OBSERVATION", 141, 149]]], ["From upper left: Single B cell sorting and culturing enables a direct screening and selection of naturally produced Abs with desired functionality, and the recovery of the corresponding Ig gene sequences.", [["B cell", "ANATOMY", 24, 30], ["B cell", "CELL", 24, 30], ["Ig", "GENE_OR_GENE_PRODUCT", 186, 188], ["Abs", "PROTEIN", 116, 119], ["Ig gene sequences", "DNA", 186, 203], ["Single B cell sorting", "TEST", 17, 38], ["culturing", "TEST", 43, 52], ["a direct screening", "TEST", 61, 79], ["the corresponding Ig gene sequences", "TEST", 168, 203], ["upper", "ANATOMY_MODIFIER", 5, 10], ["left", "ANATOMY_MODIFIER", 11, 15], ["cell", "OBSERVATION", 26, 30]]], ["This approach allows us to interrogate single-sorted B cells through direct screening of Ab functionality.", [["B cells", "ANATOMY", 53, 60], ["B cells", "CELL", 53, 60], ["Ab", "GENE_OR_GENE_PRODUCT", 89, 91], ["single-sorted B cells", "CELL_LINE", 39, 60], ["direct screening", "TEST", 69, 85]]], ["From the recovered Ig sequences, we can produce the Abs of interest as recombinant proteins, and fine-tune their properties.", [["Ig", "GENE_OR_GENE_PRODUCT", 19, 21], ["Ig sequences", "DNA", 19, 31], ["Abs", "PROTEIN", 52, 55], ["recombinant proteins", "PROTEIN", 71, 91]]], ["The structural characterization of recombinant monoclonal Abs bound to their target antigen (Ag) leads to a detailed definition of the protective epitope.", [["Ag", "CHEMICAL", 93, 95], ["Ag", "CHEMICAL", 93, 95], ["Ag", "GENE_OR_GENE_PRODUCT", 93, 95], ["recombinant monoclonal Abs", "PROTEIN", 35, 61], ["target antigen", "PROTEIN", 77, 91], ["Ag", "PROTEIN", 93, 95], ["The structural characterization", "TEST", 0, 31], ["recombinant monoclonal Abs bound", "PROBLEM", 35, 67], ["the protective epitope", "PROBLEM", 131, 153], ["protective", "OBSERVATION_MODIFIER", 135, 145], ["epitope", "OBSERVATION", 146, 153]]], ["The right inset shows the co-crystal structure of an Ag-Ab (Fab) complex, identifying a protective epitope (red).", [["Ag", "CHEMICAL", 53, 55], ["Ag", "CHEMICAL", 53, 55], ["Ag", "GENE_OR_GENE_PRODUCT", 53, 55], ["Ag", "PROTEIN", 53, 55], ["Ab (Fab) complex", "PROTEIN", 56, 72], ["an Ag", "TEST", 50, 55], ["right", "ANATOMY_MODIFIER", 4, 9], ["co-crystal structure", "OBSERVATION", 26, 46], ["protective", "OBSERVATION_MODIFIER", 88, 98], ["epitope", "OBSERVATION", 99, 106]]], ["Engineering of the protective epitope can lead to the design of a novel optimized immunogen.", [["the protective epitope", "TREATMENT", 15, 37], ["a novel optimized immunogen", "TREATMENT", 64, 91]]], ["For example, we can mount the epitope in an oriented multi-copy array on a nanoparticle that will act as carrier and increase an epitope-focused immune response (\"structure-based Ag design\").", [["Ag", "CHEMICAL", 179, 181], ["Ag", "PROTEIN", 179, 181], ["a nanoparticle", "TREATMENT", 73, 87], ["an epitope", "TREATMENT", 126, 136]]], ["The new Ag can be developed with the best formulation or delivery system to then be tested in humans (from Ref.", [["Ag", "CHEMICAL", 8, 10], ["Ag", "CHEMICAL", 8, 10], ["Ag", "GENE_OR_GENE_PRODUCT", 8, 10], ["humans", "ORGANISM", 94, 100], ["Ag", "PROTEIN", 8, 10], ["humans", "SPECIES", 94, 100], ["humans", "SPECIES", 94, 100], ["delivery system", "TREATMENT", 57, 72]]], ["(30) with permission of the publisher). need to make public the data generated by vaccine companies on vaccine effectiveness against AMR, and to continuously monitor the circulation of resistant bacterial strains.", [["AMR", "DISEASE", 133, 136], ["vaccine effectiveness", "TREATMENT", 103, 124], ["AMR", "PROBLEM", 133, 136], ["resistant bacterial strains", "PROBLEM", 185, 212], ["bacterial strains", "OBSERVATION", 195, 212]]], ["A global strategic effort to develop a portfolio of vaccines that target AMR is becoming mandatory.evOLuTiON iN vACCiNe ReSeARCHWhy vaccines are becoming an advantageous weapon to curb AMR?", [["AMR", "DISEASE", 73, 76], ["AMR", "DISEASE", 185, 188], ["A global strategic effort", "PROBLEM", 0, 25], ["a portfolio of vaccines", "TREATMENT", 37, 60], ["vACCiNe ReSeARCHWhy vaccines", "TREATMENT", 112, 140], ["global", "OBSERVATION_MODIFIER", 2, 8], ["strategic effort", "OBSERVATION", 9, 25]]], ["This is because their effectiveness in preventing infections has hugely improved, as a consequence of the enormous technological developments of the last two decades.", [["infections", "DISEASE", 50, 60], ["infections", "PROBLEM", 50, 60], ["infections", "OBSERVATION", 50, 60], ["hugely", "OBSERVATION_MODIFIER", 65, 71], ["improved", "OBSERVATION_MODIFIER", 72, 80], ["enormous", "OBSERVATION_MODIFIER", 106, 114]]], ["Since the introduction of Jenner's vaccine against smallpox in 1798, the field of vaccines has steadily progressed, but in the last years vaccine development has enormously benefited from the -omics approaches.", [["smallpox", "DISEASE", 51, 59], ["Jenner's vaccine", "TREATMENT", 26, 42], ["smallpox", "TREATMENT", 51, 59], ["vaccines", "TREATMENT", 82, 90]]], ["Thus, new potential vaccine candidates can be discovered in much shorter time than in the past, when vaccines have been developed more empirically (3) .evOLuTiON iN vACCiNe ReSeARCHThe new techniques of genome sequencing introduced in the late 1990 completely changed the process for discovering novel vaccine Ags.", [["vaccine Ags", "PROTEIN", 302, 313], ["new potential vaccine candidates", "TREATMENT", 6, 38], ["vaccines", "TREATMENT", 101, 109], ["vACCiNe ReSeARCHThe new techniques of genome sequencing", "TREATMENT", 165, 220]]], ["The \"reverse vaccinology\" approach showed that, starting from sequence information, it is possible to discover the protective Ags without handling the microbes (28) .", [["Ags", "PROTEIN", 126, 129]]], ["A recently licensed vaccine against meningococcus B is the first vaccine produced with reverse vaccinology (29) .", [["meningococcus B", "CHEMICAL", 36, 51], ["meningococcus B", "ORGANISM", 36, 51], ["meningococcus B", "SPECIES", 36, 51], ["A recently licensed vaccine", "TREATMENT", 0, 27], ["meningococcus", "PROBLEM", 36, 49]]], ["During the last decade, vaccine design was further potentiated by new technologies, leading to an approach that has been named \"reverse vaccinology 2.0\" (30) .", [["vaccine", "TREATMENT", 24, 31]]], ["As summarized in Figure 2 , this approach takes advantage of human immunology for designing optimal vaccine Ags.evOLuTiON iN vACCiNe ReSeARCHThanks to better knowledge in handling human B cells and by selecting the most favorable donors, it is now possible to produce highly specific recombinant monoclonal antibodies (mAbs) and also their Ag-binding fragments (Fabs) (31) .", [["B cells", "ANATOMY", 186, 193], ["Ag", "CHEMICAL", 340, 342], ["Ag", "CHEMICAL", 340, 342], ["human", "ORGANISM", 61, 66], ["human", "ORGANISM", 180, 185], ["B cells", "CELL", 186, 193], ["donors", "ORGANISM", 230, 236], ["human B cells", "CELL_TYPE", 180, 193], ["recombinant monoclonal antibodies", "PROTEIN", 284, 317], ["mAbs", "PROTEIN", 319, 323], ["Ag", "PROTEIN", 340, 342], ["binding fragments", "PROTEIN", 343, 360], ["Fabs", "PROTEIN", 362, 366], ["human", "SPECIES", 61, 66], ["human", "SPECIES", 180, 185], ["human", "SPECIES", 61, 66], ["human", "SPECIES", 180, 185], ["optimal vaccine Ags.evOLuTiON", "TREATMENT", 92, 121], ["vACCiNe ReSeARCHThanks", "TREATMENT", 125, 147], ["highly specific recombinant monoclonal antibodies (mAbs)", "PROBLEM", 268, 324], ["binding fragments", "OBSERVATION", 343, 360]]], ["Further analysis by structural biology approaches brings to 3D studies of the target Ags complexed with the Fabs.", [["Fabs", "GENE_OR_GENE_PRODUCT", 108, 112], ["Ags", "PROTEIN", 85, 88], ["Fabs", "PROTEIN", 108, 112], ["Further analysis", "TEST", 0, 16], ["3D studies", "TEST", 60, 70], ["the Fabs", "TREATMENT", 104, 112]]], ["It is also possible to discover the protective epitopes capable of inducing broadly neutralizing Abs (32) (33) (34) .", [["broadly neutralizing Abs", "TEST", 76, 100]]], ["Furthermore, new computational approaches have allowed to obtain completely novel immunogens capable of inducing protection (35) .evOLuTiON iN vACCiNe ReSeARCHIn viral infections, new structure-based powerful vaccine molecules have been already designed by screening human mAbs from convalescent people and obtaining the molecular structure of Ags and Ag-Ab complexes, as described earlier.evOLuTiON iN vACCiNe ReSeARCHExamples are the identification of the pentamer as key Ag for cytomegalovirus (CMV), and of the pre-fusion Ag of respiratory syncytial virus (RSV).evOLuTiON iN vACCiNe ReSeARCHUntil recently, the most promising CMV vaccine candidate was a recombinant form of the fusion protein gB.", [["viral infections", "DISEASE", 162, 178], ["Ag", "CHEMICAL", 526, 528], ["respiratory syncytial virus", "DISEASE", 532, 559], ["Ag", "CHEMICAL", 352, 354], ["Ag", "CHEMICAL", 474, 476], ["Ag", "CHEMICAL", 526, 528], ["human", "ORGANISM", 267, 272], ["mAbs", "GENE_OR_GENE_PRODUCT", 273, 277], ["people", "ORGANISM", 296, 302], ["Ags", "GENE_OR_GENE_PRODUCT", 344, 347], ["Ag-Ab", "GENE_OR_GENE_PRODUCT", 352, 357], ["Ag", "GENE_OR_GENE_PRODUCT", 474, 476], ["cytomegalovirus", "ORGANISM", 481, 496], ["CMV", "ORGANISM", 498, 501], ["Ag", "GENE_OR_GENE_PRODUCT", 526, 528], ["respiratory syncytial virus", "ORGANISM", 532, 559], ["RSV", "ORGANISM", 561, 564], ["CMV", "ORGANISM", 630, 633], ["gB", "GENE_OR_GENE_PRODUCT", 697, 699], ["human mAbs", "PROTEIN", 267, 277], ["Ags", "PROTEIN", 344, 347], ["Ag", "PROTEIN", 352, 354], ["Ab complexes", "PROTEIN", 355, 367], ["Ag", "PROTEIN", 474, 476], ["pre-fusion Ag", "PROTEIN", 515, 528], ["fusion protein gB", "PROTEIN", 682, 699], ["human", "SPECIES", 267, 272], ["people", "SPECIES", 296, 302], ["respiratory syncytial virus", "SPECIES", 532, 559], ["human", "SPECIES", 267, 272], ["CMV", "SPECIES", 498, 501], ["respiratory syncytial virus", "SPECIES", 532, 559], ["RSV", "SPECIES", 561, 564], ["CMV", "SPECIES", 630, 633], ["novel immunogens", "TREATMENT", 76, 92], ["vACCiNe", "TREATMENT", 143, 150], ["viral infections", "PROBLEM", 162, 178], ["new structure", "PROBLEM", 180, 193], ["vACCiNe ReSeARCHExamples", "TREATMENT", 403, 427], ["the pentamer", "TREATMENT", 454, 466], ["cytomegalovirus", "PROBLEM", 481, 496], ["the pre-fusion Ag", "TEST", 511, 528], ["respiratory syncytial virus", "PROBLEM", 532, 559], ["vACCiNe ReSeARCHUntil", "TREATMENT", 579, 600], ["CMV vaccine", "TREATMENT", 630, 641], ["the fusion protein gB", "PROBLEM", 678, 699], ["respiratory syncytial", "ANATOMY", 532, 553], ["fusion", "OBSERVATION", 682, 688]]], ["However, the human trial of gB combined with a potent adjuvant showed only moderate efficacy, and therefore the vaccine development was put on hold.", [["human", "ORGANISM", 13, 18], ["gB", "ORGANISM", 28, 30], ["gB", "PROTEIN", 28, 30], ["human", "SPECIES", 13, 18], ["human", "SPECIES", 13, 18], ["gB", "TREATMENT", 28, 30], ["a potent adjuvant", "TREATMENT", 45, 62], ["the vaccine development", "TREATMENT", 108, 131], ["moderate", "OBSERVATION_MODIFIER", 75, 83]]], ["Later, isolation of human mAbs from people previously exposed to CMV demonstrated that the most potent CMV neutralizing antibodies were not recognizing gB, but a complex Ag made by five proteins (pentamer).", [["Ag", "CHEMICAL", 170, 172], ["Ag", "CHEMICAL", 170, 172], ["human", "ORGANISM", 20, 25], ["mAbs", "GENE_OR_GENE_PRODUCT", 26, 30], ["people", "ORGANISM", 36, 42], ["CMV", "ORGANISM", 65, 68], ["CMV", "ORGANISM", 103, 106], ["gB", "GENE_OR_GENE_PRODUCT", 152, 154], ["Ag", "GENE_OR_GENE_PRODUCT", 170, 172], ["human mAbs", "PROTEIN", 20, 30], ["CMV neutralizing antibodies", "PROTEIN", 103, 130], ["gB", "PROTEIN", 152, 154], ["Ag", "PROTEIN", 170, 172], ["pentamer", "PROTEIN", 196, 204], ["human", "SPECIES", 20, 25], ["people", "SPECIES", 36, 42], ["human", "SPECIES", 20, 25], ["CMV", "SPECIES", 65, 68], ["CMV", "SPECIES", 103, 106], ["isolation of human mAbs", "TREATMENT", 7, 30], ["CMV", "PROBLEM", 65, 68], ["the most potent CMV neutralizing antibodies", "PROBLEM", 87, 130]]], ["A recombinant form of the pentamer induced neutralizing antibodies that are orders of magnitude more potent than those induced by gB.", [["neutralizing antibodies", "PROTEIN", 43, 66], ["the pentamer induced neutralizing antibodies", "TREATMENT", 22, 66], ["neutralizing antibodies", "OBSERVATION", 43, 66]]], ["The new Ag is a very promising candidate for a CMV vaccine and will soon undergo human trials (35) .evOLuTiON iN vACCiNe ReSeARCHIn the case of RSV, it was possible to obtain a humanized mAb, palivizumab, that binds to an epitope present in the F protein in both the pre-fusion (pre-F) and post-fusion (post-F) conformation.", [["Ag", "CHEMICAL", 8, 10], ["palivizumab", "CHEMICAL", 192, 203], ["Ag", "CHEMICAL", 8, 10], ["Ag", "GENE_OR_GENE_PRODUCT", 8, 10], ["CMV", "ORGANISM", 47, 50], ["human", "ORGANISM", 81, 86], ["RSV", "ORGANISM", 144, 147], ["palivizumab", "SIMPLE_CHEMICAL", 192, 203], ["Ag", "PROTEIN", 8, 10], ["humanized mAb", "PROTEIN", 177, 190], ["F protein", "PROTEIN", 245, 254], ["human", "SPECIES", 81, 86], ["CMV", "SPECIES", 47, 50], ["human", "SPECIES", 81, 86], ["RSV", "SPECIES", 144, 147], ["a CMV vaccine", "TREATMENT", 45, 58], ["human trials", "TREATMENT", 81, 93], ["RSV", "PROBLEM", 144, 147], ["a humanized mAb", "TREATMENT", 175, 190], ["palivizumab", "TREATMENT", 192, 203], ["an epitope", "PROBLEM", 219, 229], ["post-fusion (post-F) conformation", "TREATMENT", 290, 323], ["new", "OBSERVATION_MODIFIER", 4, 7], ["Ag", "OBSERVATION", 8, 10], ["RSV", "OBSERVATION", 144, 147]]], ["Initial studies to develop an RSV vaccine were mainly focused on the use of the post-F protein that, unlike pre-F, is highly stable both as soluble Ag and when displayed onto virus-like particles.", [["Ag", "CHEMICAL", 148, 150], ["Ag", "CHEMICAL", 148, 150], ["RSV", "ORGANISM", 30, 33], ["pre-F", "CELL", 108, 113], ["Ag", "GENE_OR_GENE_PRODUCT", 148, 150], ["post-F protein", "PROTEIN", 80, 94], ["Ag", "PROTEIN", 148, 150], ["RSV", "SPECIES", 30, 33], ["Initial studies", "TEST", 0, 15], ["an RSV vaccine", "TREATMENT", 27, 41], ["the post-F protein", "TREATMENT", 76, 94], ["virus", "PROBLEM", 175, 180], ["RSV", "OBSERVATION", 30, 33], ["stable", "OBSERVATION", 125, 131]]], ["However, experimental vaccines based on whole virus, live attenuated virus, or post-F protein have failed to yield appropriate levels safety or efficacy.", [["whole virus", "ORGANISM", 40, 51], ["live attenuated virus", "ORGANISM", 53, 74], ["post-F", "GENE_OR_GENE_PRODUCT", 79, 85], ["F protein", "PROTEIN", 84, 93], ["experimental vaccines", "TREATMENT", 9, 30], ["whole virus", "PROBLEM", 40, 51], ["live attenuated virus", "PROBLEM", 53, 74]]], ["The scenario changed when the isolation and characterization of human neutralizing mAbs elicited by natural infection showed that the majority of antibodies are specific for the pre-F form of the protein and failed to cross-react with the post-F conformation.", [["infection", "DISEASE", 108, 117], ["human", "ORGANISM", 64, 69], ["mAbs", "GENE_OR_GENE_PRODUCT", 83, 87], ["human neutralizing mAbs", "PROTEIN", 64, 87], ["antibodies", "PROTEIN", 146, 156], ["pre-F form", "PROTEIN", 178, 188], ["human", "SPECIES", 64, 69], ["human", "SPECIES", 64, 69], ["the isolation", "TREATMENT", 26, 39], ["human neutralizing mAbs", "TREATMENT", 64, 87], ["natural infection", "PROBLEM", 100, 117], ["the protein", "PROBLEM", 192, 203]]], ["A structure-based design of a stabilized RSV pre-F protein was eventually obtained by complementing the crystal structure of the pre-F protein complexed with a highly neutralizing antibody with the neutralizing studies.", [["RSV", "ORGANISM", 41, 44], ["pre-F", "GENE_OR_GENE_PRODUCT", 45, 50], ["pre-F", "GENE_OR_GENE_PRODUCT", 129, 134], ["RSV pre-F protein", "PROTEIN", 41, 58], ["pre-F protein", "PROTEIN", 129, 142], ["RSV", "SPECIES", 41, 44], ["a stabilized RSV pre-F protein", "TEST", 28, 58], ["the neutralizing studies", "TEST", 194, 218]]], ["The designed pre-F protein (DS-Cav1) could induce neutralizing antibodies 10-15 times more potent than those elicited by previous vaccines and is presently being tested in human trials (36, 37) .evOLuTiON iN vACCiNe ReSeARCHWe can conclude that interrogation of human antibody responses can allow us to identify pathogen epitopes that are more likely to be protective and that are difficult to discover by conventional technologies.", [["pre-F", "GENE_OR_GENE_PRODUCT", 13, 18], ["DS-Cav1", "GENE_OR_GENE_PRODUCT", 28, 35], ["human", "ORGANISM", 172, 177], ["human", "ORGANISM", 262, 267], ["pre-F protein", "PROTEIN", 13, 26], ["DS", "PROTEIN", 28, 30], ["Cav1", "PROTEIN", 31, 35], ["neutralizing antibodies", "PROTEIN", 50, 73], ["human", "SPECIES", 172, 177], ["human", "SPECIES", 262, 267], ["human", "SPECIES", 172, 177], ["human", "SPECIES", 262, 267], ["The designed pre-F protein", "TEST", 0, 26], ["neutralizing antibodies", "TEST", 50, 73], ["previous vaccines", "TREATMENT", 121, 138], ["human antibody responses", "TEST", 262, 286], ["pathogen epitopes", "PROBLEM", 312, 329]]], ["So far, isolation of human mAbs has been successfully used to identify viral Ags that could not be discovered by conventional technologies.", [["human", "ORGANISM", 21, 26], ["mAbs", "GENE_OR_GENE_PRODUCT", 27, 31], ["human mAbs", "PROTEIN", 21, 31], ["Ags", "PROTEIN", 77, 80], ["human", "SPECIES", 21, 26], ["human", "SPECIES", 21, 26], ["isolation of human mAbs", "TREATMENT", 8, 31], ["could not be", "UNCERTAINTY", 86, 98]]], ["On the other hand, there are no data yet regarding the identification of new Ags for antibacterial vaccines.", [["Ags", "PROTEIN", 77, 80], ["new Ags", "TREATMENT", 73, 80], ["antibacterial vaccines", "TREATMENT", 85, 107]]], ["After the proof-of-concept obtained with viral Ags, it would be very important to apply the same approach to the identification of novel bacterial Ags.", [["Ags", "GENE_OR_GENE_PRODUCT", 147, 150], ["viral Ags", "PROTEIN", 41, 50], ["bacterial Ags", "PROTEIN", 137, 150], ["viral Ags", "TREATMENT", 41, 50], ["novel bacterial Ags", "PROBLEM", 131, 150], ["bacterial Ags", "OBSERVATION", 137, 150]]], ["This will allow us to design innovative vaccines against antibiotic-resistant pathogens, thereby effectively tackling the most pressing global health emergency.CONCLuSiONIt is time to consider how to find an effective solution to fight antibiotic resistance, and win this battle in the never-ending war against pathogenic microorganisms.", [["innovative vaccines", "TREATMENT", 29, 48], ["antibiotic", "TREATMENT", 57, 67], ["resistant pathogens", "PROBLEM", 68, 87], ["an effective solution", "TREATMENT", 205, 226], ["antibiotic resistance", "TREATMENT", 236, 257], ["pathogenic microorganisms", "PROBLEM", 311, 336]]], ["As discussed, the human species has experienced an impressive prolongation of its life expectancy and improvement in life conditions, due to hygiene, antibiotics, and vaccines.", [["human", "ORGANISM", 18, 23], ["human", "SPECIES", 18, 23], ["human", "SPECIES", 18, 23], ["antibiotics", "TREATMENT", 150, 161], ["vaccines", "TREATMENT", 167, 175], ["impressive", "OBSERVATION_MODIFIER", 51, 61], ["prolongation", "OBSERVATION_MODIFIER", 62, 74]]], ["Now, one of these pillars has weakened to the point that it will affect some important medical methodologies, first of all important surgeries, but also immunosuppressive chemotherapy and consequently organ transplantation, a great success of the medicine of our era.", [["organ", "ANATOMY", 201, 206], ["organ", "ORGAN", 201, 206], ["all important surgeries", "TREATMENT", 119, 142], ["immunosuppressive chemotherapy", "TREATMENT", 153, 183], ["consequently organ transplantation", "TREATMENT", 188, 222], ["pillars", "OBSERVATION", 18, 25], ["weakened", "OBSERVATION", 30, 38]]], ["Again, infectious diseases could severely reduce our life span, as we will not be able to survive important medical treatments or even accidental wounds.", [["wounds", "ANATOMY", 146, 152], ["infectious diseases", "DISEASE", 7, 26], ["wounds", "PATHOLOGICAL_FORMATION", 146, 152], ["infectious diseases", "PROBLEM", 7, 26], ["medical treatments", "TREATMENT", 108, 126], ["accidental wounds", "PROBLEM", 135, 152], ["infectious", "OBSERVATION", 7, 17], ["wounds", "OBSERVATION", 146, 152]]], ["A possible solution in sight is that of developing a combined preventive-therapeutic approach, in which vaccines will be one of the two arms and chemotherapy the other one.", [["therapeutic approach", "TREATMENT", 73, 93], ["vaccines", "TREATMENT", 104, 112], ["chemotherapy", "TREATMENT", 145, 157], ["possible", "UNCERTAINTY", 2, 10]]], ["There are reasons to believe that the combination of the two approaches will result in an overall success.CONCLuSiONThe main reason is the difference in the mode of action between vaccines and antibiotics.", [["action between vaccines", "TREATMENT", 165, 188], ["antibiotics", "TREATMENT", 193, 204]]], ["First of all, vaccines on their own are rarely capable to generate resistance.", [["vaccines", "TREATMENT", 14, 22]]], ["Another critical difference between antibiotics and vaccines is the rate of discovery of new effective molecules.", [["antibiotics", "TREATMENT", 36, 47], ["vaccines", "TREATMENT", 52, 60], ["new effective molecules", "PROBLEM", 89, 112], ["difference", "OBSERVATION_MODIFIER", 17, 27], ["new", "OBSERVATION_MODIFIER", 89, 92], ["effective", "OBSERVATION_MODIFIER", 93, 102]]], ["In the past, new antibiotics were identified and regularly reached the clinic, particularly in the three decades after 1950.", [["new antibiotics", "TREATMENT", 13, 28]]], ["Since then, however, very few new molecules have been introduced in the clinical use.", [["very few new molecules", "PROBLEM", 21, 43], ["very", "OBSERVATION_MODIFIER", 21, 25], ["few", "OBSERVATION_MODIFIER", 26, 29], ["new", "OBSERVATION_MODIFIER", 30, 33], ["molecules", "OBSERVATION", 34, 43]]], ["An opposite situation occurred in the case of vaccines, which have been developed at an increasing speed.", [["An opposite situation", "PROBLEM", 0, 21], ["vaccines", "TREATMENT", 46, 54], ["opposite", "OBSERVATION_MODIFIER", 3, 11], ["situation", "OBSERVATION", 12, 21]]], ["As for today, 22 new vaccines became available since 1980.", [["new vaccines", "TREATMENT", 17, 29]]], ["This is a consequence of the introduction of new technologies, such as recombinant DNA, that led to the generation of new synthetic sequences.", [["DNA", "CELLULAR_COMPONENT", 83, 86], ["recombinant DNA", "DNA", 71, 86], ["new technologies", "TREATMENT", 45, 61], ["recombinant DNA", "PROBLEM", 71, 86], ["new synthetic sequences", "TEST", 118, 141]]], ["Therefore, we have obtained a great reduction of the incidence of bacterial meningitis (caused by Haemophilus influenzae, S. pneumoniae, and Neisseria meningitidis) thanks to a new generation of very effective conjugated vaccines, generated by chemical technologies for covalently linking bacterial polysaccharides to proteins.", [["bacterial meningitis", "DISEASE", 66, 86], ["Haemophilus influenzae, S. pneumoniae", "DISEASE", 98, 135], ["Neisseria meningitidis", "DISEASE", 141, 163], ["Haemophilus influenzae", "ORGANISM", 98, 120], ["S. pneumoniae", "ORGANISM", 122, 135], ["Neisseria meningitidis", "ORGANISM", 141, 163], ["Haemophilus influenzae", "SPECIES", 98, 120], ["S. pneumoniae", "SPECIES", 122, 135], ["Neisseria meningitidis", "SPECIES", 141, 163], ["Haemophilus influenzae", "SPECIES", 98, 120], ["S. pneumoniae", "SPECIES", 122, 135], ["Neisseria meningitidis", "SPECIES", 141, 163], ["bacterial meningitis", "PROBLEM", 66, 86], ["Haemophilus influenzae", "PROBLEM", 98, 120], ["S. pneumoniae", "PROBLEM", 122, 135], ["Neisseria meningitidis", "PROBLEM", 141, 163], ["very effective conjugated vaccines", "TREATMENT", 195, 229], ["covalently linking bacterial polysaccharides", "PROBLEM", 270, 314], ["great", "OBSERVATION_MODIFIER", 30, 35], ["reduction", "OBSERVATION_MODIFIER", 36, 45], ["bacterial", "OBSERVATION_MODIFIER", 66, 75], ["meningitis", "OBSERVATION", 76, 86]]], ["More recently, genomic sequencing opened the access to a higher level in vaccine design, since it made possible to predict the thousands of proteins encoded by bacterial genes, and to identify those likely exposed on the cell surface, in search of new vaccine candidates.", [["cell surface", "ANATOMY", 221, 233], ["cell surface", "CELLULAR_COMPONENT", 221, 233], ["bacterial genes", "DNA", 160, 175], ["new vaccine candidates", "TREATMENT", 248, 270], ["bacterial genes", "OBSERVATION", 160, 175], ["cell surface", "OBSERVATION", 221, 233]]], ["This approach, defined as \"reverse vaccinology\" has resulted in a first important protein vaccine against meningococcus B that is now in use worldwide (29) .", [["meningococcus B", "CHEMICAL", 106, 121], ["meningococcus B", "ORGANISM", 106, 121], ["a first important protein vaccine", "TREATMENT", 64, 97], ["meningococcus B", "PROBLEM", 106, 121]]], ["Finally, a better understanding of the mechanisms regulating the induction of a protective immune response has opened the possibility to introduce, in vaccine formulations, new moieties that can make them more effective.", [["a protective immune response", "TREATMENT", 78, 106], ["vaccine formulations", "TREATMENT", 151, 171]]], ["These substances are defined with the general name of adjuvants.CONCLuSiONThe difference in the mechanisms of action of vaccines and antibiotics is enormous.", [["action of vaccines", "TREATMENT", 110, 128], ["antibiotics", "TREATMENT", 133, 144], ["substances", "OBSERVATION", 6, 16]]], ["Antibiotics are families of molecules pro duced by microorganisms to kill microorganisms.", [["Antibiotics", "TREATMENT", 0, 11]]], ["What makes them effective is their capability to reach and poison targets across the strong barrier of the bacterial cell wall and avoid being ejected by potent efflux pumps.", [["cell wall", "ANATOMY", 117, 126], ["cell wall", "TISSUE", 117, 126], ["potent efflux pumps", "TREATMENT", 154, 173], ["bacterial cell wall", "OBSERVATION", 107, 126], ["efflux pumps", "OBSERVATION", 161, 173]]], ["Any biochemical modification of the target microorganism can make the antibiotic inefficient.", [["Any biochemical modification", "PROBLEM", 0, 28], ["the target microorganism", "PROBLEM", 32, 56], ["the antibiotic", "TREATMENT", 66, 80]]], ["Among billions of bacteria present during an infection, such modifications can stochastically arise frequently.", [["infection", "DISEASE", 45, 54], ["bacteria", "PROBLEM", 18, 26], ["an infection", "PROBLEM", 42, 54], ["bacteria", "OBSERVATION", 18, 26], ["infection", "OBSERVATION", 45, 54]]], ["Vaccines are molecules with the capacity to evoke in the host a protective activity against infections.", [["infections", "DISEASE", 92, 102], ["Vaccines", "TREATMENT", 0, 8], ["the capacity", "PROBLEM", 28, 40], ["infections", "PROBLEM", 92, 102], ["protective activity", "OBSERVATION_MODIFIER", 64, 83]]], ["They do so by interacting with the immune system of the host, a system that during evolution has developed sophisticated mechanisms to recognize and destroy any kind of \"danger\" agents, essentially by distinguishing molecules that are different from self.", [["immune system", "ANATOMY", 35, 48]]], ["The human immune system can potentially recognize any Ag in the universe, even those never encountered before, thanks to its complex gene rearrangement mechanisms.", [["immune system", "ANATOMY", 10, 23], ["Ag", "CHEMICAL", 54, 56], ["Ag", "CHEMICAL", 54, 56], ["human", "ORGANISM", 4, 9], ["Ag", "GENE_OR_GENE_PRODUCT", 54, 56], ["Ag", "PROTEIN", 54, 56], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 4, 9]]], ["Thus, it is quite obvious that the potential of vaccines to protect us is extraordinary.", [["vaccines", "TREATMENT", 48, 56]]], ["And the more we learn about our immune system, the better we can design strategies and develop tools to protect our health from infections.", [["infections", "DISEASE", 128, 138], ["infections", "PROBLEM", 128, 138], ["infections", "OBSERVATION", 128, 138]]], ["For instance, in some cases it is now possible to cure established infections by administering the patient with specific antibodies produced in the lab with new technologies.", [["infections", "DISEASE", 67, 77], ["patient", "ORGANISM", 99, 106], ["antibodies", "PROTEIN", 121, 131], ["patient", "SPECIES", 99, 106], ["specific antibodies", "TEST", 112, 131], ["infections", "OBSERVATION", 67, 77]]], ["In a way, these anti-infective antibodies could be considered as a new kind of antibiotic family, even though much more expensive.CONCLuSiONFor the time being, the strategy of combing antibiotics and vaccines remains the most sustainable option, which can allow us to avoid in an affordable way the AMR threat.", [["anti-infective antibodies", "PROTEIN", 16, 41], ["these anti-infective antibodies", "TREATMENT", 10, 41], ["combing antibiotics", "TREATMENT", 176, 195], ["vaccines", "TREATMENT", 200, 208]]], ["We wish to stress again how serious this threat is, as we expect AMR will cause 10 million deaths/year from 2050.CONCLuSiONBefore embarking in complex combination studies, it is important to further investigate the role that existing vaccines could have against resistant infections.", [["AMR", "DISEASE", 65, 68], ["deaths", "DISEASE", 91, 97], ["infections", "DISEASE", 272, 282], ["existing vaccines", "TREATMENT", 225, 242], ["resistant infections", "PROBLEM", 262, 282]]], ["Indeed, there are some indications that an unconventional use of existing vaccines could provide important advantages.", [["existing vaccines", "TREATMENT", 65, 82]]], ["For instance, in New Zealand a new vaccine against meningitis B was introduced few years after the meningitis B outbreak of the end of the 1990.", [["meningitis", "DISEASE", 51, 61], ["meningitis", "DISEASE", 99, 109], ["a new vaccine", "TREATMENT", 29, 42], ["meningitis", "PROBLEM", 51, 61], ["the meningitis", "PROBLEM", 95, 109]]], ["The vaccine was still produced with traditional techniques and was composed by bacterial outer membrane vesicles.", [["outer membrane vesicles", "ANATOMY", 89, 112], ["membrane vesicles", "CELLULAR_COMPONENT", 95, 112], ["The vaccine", "TREATMENT", 0, 11], ["traditional techniques", "TREATMENT", 36, 58], ["bacterial outer membrane vesicles", "PROBLEM", 79, 112], ["membrane vesicles", "OBSERVATION", 95, 112]]], ["Recent studies in the population vaccinated with this vaccine revealed protection against gonorrhea, a sexually transmitted infection induced by N. gonorrhoeae that is becoming resistant to antibiotics (38) .", [["gonorrhea", "DISEASE", 90, 99], ["sexually transmitted infection", "DISEASE", 103, 133], ["N. gonorrhoeae", "DISEASE", 145, 159], ["N. gonorrhoeae", "ORGANISM", 145, 159], ["N. gonorrhoeae", "SPECIES", 145, 159], ["N. gonorrhoeae", "SPECIES", 145, 159], ["Recent studies", "TEST", 0, 14], ["this vaccine", "TREATMENT", 49, 61], ["gonorrhea", "PROBLEM", 90, 99], ["a sexually transmitted infection", "PROBLEM", 101, 133], ["N. gonorrhoeae", "PROBLEM", 145, 159], ["antibiotics", "TREATMENT", 190, 201], ["infection", "OBSERVATION", 124, 133], ["gonorrhoeae", "OBSERVATION", 148, 159]]], ["The reason of this protection is likely due to the fact that bacteria causing meningitis and gonorrhea are genetically related.", [["meningitis", "DISEASE", 78, 88], ["gonorrhea", "DISEASE", 93, 102], ["this protection", "TREATMENT", 14, 29], ["bacteria", "PROBLEM", 61, 69], ["meningitis", "PROBLEM", 78, 88], ["gonorrhea", "PROBLEM", 93, 102], ["likely due to", "UNCERTAINTY", 33, 46], ["bacteria", "OBSERVATION", 61, 69], ["meningitis", "OBSERVATION", 78, 88], ["gonorrhea", "OBSERVATION", 93, 102]]], ["Furthermore, the current evidence shows that existing pneumococcal vaccines reduce AMR, due to the fact they prevent infection thereby reducing the carriage and transmission of antibiotic-resistant bacteria.", [["AMR", "DISEASE", 83, 86], ["infection", "DISEASE", 117, 126], ["pneumococcal", "ORGANISM", 54, 66], ["pneumococcal", "SPECIES", 54, 66], ["existing pneumococcal vaccines", "TREATMENT", 45, 75], ["AMR", "PROBLEM", 83, 86], ["infection", "PROBLEM", 117, 126], ["the carriage", "PROBLEM", 144, 156], ["antibiotic", "TREATMENT", 177, 187], ["resistant bacteria", "PROBLEM", 188, 206], ["pneumococcal", "OBSERVATION", 54, 66], ["infection", "OBSERVATION", 117, 126]]], ["Another example is the influenza vaccine that indirectly reduces the incidence of fever and sickness, thereby minimizing the use and, more often, the misuse of antibiotics.CONCLuSiONThe increasing AMR is one of the several alarming signals of the profound effects that human activities can have on our world and life on it.", [["fever", "DISEASE", 82, 87], ["sickness", "DISEASE", 92, 100], ["AMR", "DISEASE", 197, 200], ["human", "ORGANISM", 269, 274], ["human", "SPECIES", 269, 274], ["human", "SPECIES", 269, 274], ["the influenza vaccine", "TREATMENT", 19, 40], ["fever", "PROBLEM", 82, 87], ["sickness", "PROBLEM", 92, 100], ["antibiotics", "TREATMENT", 160, 171], ["fever", "OBSERVATION", 82, 87], ["increasing", "OBSERVATION_MODIFIER", 186, 196], ["AMR", "OBSERVATION", 197, 200], ["profound", "OBSERVATION_MODIFIER", 247, 255]]], ["How can we try to solve the problem of infections that are resistant to antibiotics?", [["infections", "DISEASE", 39, 49], ["infections", "PROBLEM", 39, 49], ["antibiotics", "TREATMENT", 72, 83], ["infections", "OBSERVATION", 39, 49]]], ["The most critical point is the difficulty in obtaining new antibiotics.", [["new antibiotics", "TREATMENT", 55, 70]]], ["As already discussed, the classical approach does not work anymore, thus we need to devise a completely novel approach.CONCLuSiONPassive immunization, i.e., the administration of immune antibodies, could perhaps be a solution, if we can solve the issue of sustainability.", [["immune antibodies", "PROTEIN", 179, 196], ["a completely novel approach", "TREATMENT", 91, 118], ["CONCLuSiONPassive immunization", "TREATMENT", 119, 149], ["immune antibodies", "TREATMENT", 179, 196], ["a solution", "TREATMENT", 215, 225]]], ["Nowadays, immune antibodies can be produced only in low amounts and with high costs.", [["immune antibodies", "PROTEIN", 10, 27], ["immune antibodies", "PROBLEM", 10, 27], ["low amounts", "OBSERVATION_MODIFIER", 52, 63], ["high costs", "OBSERVATION", 73, 83]]], ["At the beginning of the last century, immune antibodies able to neutralize bacterial toxins were produced in big animals and largely employed, and contributed to building an industrial sector (\"serum\" institutes) that evolved in today's vaccine industry.", [["serum", "ANATOMY", 194, 199], ["serum", "ORGANISM_SUBSTANCE", 194, 199], ["immune antibodies", "PROTEIN", 38, 55], ["immune antibodies", "TREATMENT", 38, 55], ["bacterial toxins", "PROBLEM", 75, 91]]], ["We hope that the new technologies will allow us to revive the serology concept and make it a new tool against infection.CONCLuSiONA revolutionary approach would be to make the bacteria living within or on us, our microbiota, to become our allies in fighting the infections.", [["infection", "DISEASE", 110, 119], ["infections", "DISEASE", 262, 272], ["the serology", "TEST", 58, 70], ["infection", "PROBLEM", 110, 119], ["CONCLuSiONA revolutionary approach", "TREATMENT", 120, 154], ["the bacteria", "PROBLEM", 172, 184], ["the infections", "PROBLEM", 258, 272], ["infection", "OBSERVATION", 110, 119], ["infections", "OBSERVATION", 262, 272]]], ["As already mentioned, a large component of our body is bacteria (over 50%).", [["body", "ANATOMY", 47, 51], ["body", "ORGANISM_SUBDIVISION", 47, 51], ["bacteria", "PROBLEM", 55, 63], ["large", "OBSERVATION_MODIFIER", 24, 29], ["component", "OBSERVATION_MODIFIER", 30, 39], ["bacteria", "OBSERVATION", 55, 63]]], ["An increasing number of studies indicate that gut microbiota is influencing our health and pathological conditions (39) .", [["gut microbiota", "ANATOMY", 46, 60], ["gut", "ORGANISM_SUBDIVISION", 46, 49], ["increasing", "OBSERVATION_MODIFIER", 3, 13]]], ["Intestinal microbes can influence host energy metabolism (40) , intestinal epithelial proliferation (41) , and immune responses (42) .", [["Intestinal", "ANATOMY", 0, 10], ["intestinal epithelial", "ANATOMY", 64, 85], ["Intestinal", "ORGAN", 0, 10], ["intestinal epithelial", "CELL", 64, 85], ["intestinal epithelial proliferation", "TEST", 64, 99], ["intestinal", "ANATOMY", 64, 74], ["epithelial proliferation", "OBSERVATION", 75, 99]]], ["It has been shown that the microbiota composition could influence vaginosis (43) , obesity (44) , inflammatory bowel disease (45) , functional bowel disorders (46) , allergies (47) , and other diseases.", [["bowel", "ANATOMY", 111, 116], ["bowel", "ANATOMY", 143, 148], ["vaginosis", "DISEASE", 66, 75], ["obesity", "DISEASE", 83, 90], ["inflammatory bowel disease", "DISEASE", 98, 124], ["functional bowel disorders", "DISEASE", 132, 158], ["allergies", "DISEASE", 166, 175], ["bowel", "ORGAN", 111, 116], ["bowel", "ORGAN", 143, 148], ["influence vaginosis", "PROBLEM", 56, 75], ["obesity", "PROBLEM", 83, 90], ["inflammatory bowel disease", "PROBLEM", 98, 124], ["functional bowel disorders", "PROBLEM", 132, 158], ["allergies", "PROBLEM", 166, 175], ["other diseases", "PROBLEM", 187, 201], ["inflammatory", "OBSERVATION_MODIFIER", 98, 110], ["bowel", "ANATOMY", 111, 116], ["disease", "OBSERVATION", 117, 124], ["bowel", "ANATOMY", 143, 148], ["diseases", "OBSERVATION", 193, 201]]], ["An increasing number of studies suggest we can educate our microbiota to combat metabolic and chronic diseases.", [["metabolic and chronic diseases", "DISEASE", 80, 110], ["metabolic and chronic diseases", "PROBLEM", 80, 110], ["increasing", "OBSERVATION_MODIFIER", 3, 13], ["chronic", "OBSERVATION_MODIFIER", 94, 101], ["diseases", "OBSERVATION", 102, 110]]], ["Could it be also the case in fighting infections?CONCLuSiONSeveral candidate vaccines are in development pipelines since the last few years.", [["infections", "DISEASE", 38, 48], ["fighting infections", "PROBLEM", 29, 48], ["CONCLuSiONSeveral candidate vaccines", "TREATMENT", 49, 85]]], ["For sure the emergency that we are facing will change the health priorities, and vaccines against antibioticresistant bacterial strains will move to the top.AuTHOR CONTRiBuTiONSAT wrote the manuscript.", [["vaccines", "TREATMENT", 81, 89], ["antibioticresistant bacterial strains", "PROBLEM", 98, 135]]]], "fcf9988e5e4d1c7f18b534e2702b272209711eb5": [["IntroductionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged from the epicentre in Wuhan, China, in December 2019 with rapid human to human transmission.", [["acute respiratory syndrome coronavirus", "DISEASE", 19, 57], ["IntroductionSevere acute respiratory syndrome coronavirus 2", "ORGANISM", 0, 59], ["SARS-CoV-2", "ORGANISM", 61, 71], ["human", "ORGANISM", 145, 150], ["human", "ORGANISM", 154, 159], ["human", "SPECIES", 145, 150], ["human", "SPECIES", 154, 159], ["IntroductionSevere acute respiratory syndrome coronavirus", "SPECIES", 0, 57], ["SARS-CoV-2", "SPECIES", 61, 71], ["human", "SPECIES", 145, 150], ["human", "SPECIES", 154, 159], ["acute respiratory syndrome coronavirus", "PROBLEM", 19, 57], ["acute", "OBSERVATION_MODIFIER", 19, 24], ["respiratory syndrome", "OBSERVATION", 25, 45]]], ["At the time of writing, there have been over eight million confirmed cases with over 450,000 deaths worldwide [1] .", [["deaths", "DISEASE", 93, 99]]], ["As the novel virus moves through the population, it is inevitable that people with concurrent severe illness also become infected.", [["people", "ORGANISM", 71, 77], ["people", "SPECIES", 71, 77], ["the novel virus", "PROBLEM", 3, 18], ["concurrent severe illness", "PROBLEM", 83, 108], ["infected", "PROBLEM", 121, 129], ["severe", "OBSERVATION_MODIFIER", 94, 100], ["illness", "OBSERVATION", 101, 108], ["infected", "OBSERVATION", 121, 129]]], ["We present a case of confirmed SARS-CoV-2 infection in a patient with newly diagnosed acute myeloid leukaemia (AML) and the progress of both illnesses through intensive induction chemotherapy.", [["acute myeloid leukaemia", "ANATOMY", 86, 109], ["AML", "ANATOMY", 111, 114], ["SARS-CoV-2 infection", "DISEASE", 31, 51], ["acute myeloid leukaemia", "DISEASE", 86, 109], ["AML", "DISEASE", 111, 114], ["SARS-CoV-2", "ORGANISM", 31, 41], ["patient", "ORGANISM", 57, 64], ["acute myeloid leukaemia", "CANCER", 86, 109], ["AML", "CANCER", 111, 114], ["patient", "SPECIES", 57, 64], ["SARS-CoV-2", "SPECIES", 31, 41], ["SARS", "PROBLEM", 31, 35], ["CoV-2 infection", "PROBLEM", 36, 51], ["newly diagnosed acute myeloid leukaemia", "PROBLEM", 70, 109], ["AML", "PROBLEM", 111, 114], ["both illnesses", "PROBLEM", 136, 150], ["intensive induction chemotherapy", "TREATMENT", 159, 191], ["infection", "OBSERVATION", 42, 51], ["acute", "OBSERVATION_MODIFIER", 86, 91], ["myeloid leukaemia", "OBSERVATION", 92, 109]]], ["A review of the existing literature on SARS-CoV-2 infection in the immunocompromised patient is also presented.Case ReportA previously fit and healthy 54-year-old Maori woman presented to a secondary care hospital with a 10-day history of increasing fatigue and three days of progressive fevers, dyspnoea, headache, myalgias, and dry cough.", [["SARS-CoV-2 infection", "DISEASE", 39, 59], ["fatigue", "DISEASE", 250, 257], ["fevers", "DISEASE", 288, 294], ["dyspnoea", "DISEASE", 296, 304], ["headache", "DISEASE", 306, 314], ["myalgias", "DISEASE", 316, 324], ["dry cough", "DISEASE", 330, 339], ["SARS-CoV-2", "ORGANISM", 39, 49], ["patient", "ORGANISM", 85, 92], ["woman", "ORGANISM", 169, 174], ["patient", "SPECIES", 85, 92], ["woman", "SPECIES", 169, 174], ["SARS-CoV", "SPECIES", 39, 47], ["SARS", "PROBLEM", 39, 43], ["CoV-2 infection", "PROBLEM", 44, 59], ["increasing fatigue", "PROBLEM", 239, 257], ["progressive fevers", "PROBLEM", 276, 294], ["dyspnoea", "PROBLEM", 296, 304], ["headache", "PROBLEM", 306, 314], ["myalgias", "PROBLEM", 316, 324], ["dry cough", "PROBLEM", 330, 339], ["infection", "OBSERVATION", 50, 59], ["immunocompromised", "OBSERVATION", 67, 84], ["increasing", "OBSERVATION_MODIFIER", 239, 249], ["fatigue", "OBSERVATION", 250, 257], ["progressive", "OBSERVATION_MODIFIER", 276, 287], ["fevers", "OBSERVATION", 288, 294], ["dyspnoea", "OBSERVATION", 296, 304], ["headache", "OBSERVATION", 306, 314], ["myalgias", "OBSERVATION", 316, 324], ["dry", "OBSERVATION_MODIFIER", 330, 333], ["cough", "OBSERVATION", 334, 339]]], ["She denied anosmia.", [["anosmia", "DISEASE", 11, 18], ["anosmia", "PROBLEM", 11, 18]]], ["The only significant medical history was pT1c grade 2 breast cancer treated with surgery, adjuvant chemotherapy, and radiotherapy in 2013.", [["pT1c grade 2 breast cancer", "ANATOMY", 41, 67], ["breast cancer", "DISEASE", 54, 67], ["pT1c grade 2 breast cancer", "CANCER", 41, 67], ["grade 2 breast cancer", "PROBLEM", 46, 67], ["surgery", "TREATMENT", 81, 88], ["adjuvant chemotherapy", "TREATMENT", 90, 111], ["radiotherapy", "TREATMENT", 117, 129], ["significant", "OBSERVATION_MODIFIER", 9, 20], ["breast", "ANATOMY", 54, 60], ["cancer", "OBSERVATION", 61, 67]]], ["There was no family history of haematological malignancy.", [["haematological malignancy", "ANATOMY", 31, 56], ["haematological malignancy", "DISEASE", 31, 56], ["haematological malignancy", "CANCER", 31, 56], ["haematological malignancy", "PROBLEM", 31, 56], ["no", "UNCERTAINTY", 10, 12], ["haematological", "ANATOMY", 31, 45], ["malignancy", "OBSERVATION", 46, 56]]], ["She was an ex-smoker with a 15 pack-year history.Case ReportOn examination, the patient had pallor with mild tachycardia (115 bpm), low pulse oximetry [90% on Fraction of Inspired Oxygen (FiO 2 ) 21%], and tachypnoea (24/min).", [["pallor", "DISEASE", 92, 98], ["tachycardia", "DISEASE", 109, 120], ["tachypnoea", "DISEASE", 206, 216], ["Oxygen", "CHEMICAL", 180, 186], ["patient", "ORGANISM", 80, 87], ["Oxygen", "SIMPLE_CHEMICAL", 180, 186], ["patient", "SPECIES", 80, 87], ["Case ReportOn examination", "TEST", 49, 74], ["pallor", "PROBLEM", 92, 98], ["mild tachycardia", "PROBLEM", 104, 120], ["low pulse oximetry", "PROBLEM", 132, 150], ["Inspired Oxygen (FiO", "TREATMENT", 171, 191], ["tachypnoea", "PROBLEM", 206, 216], ["mild", "OBSERVATION_MODIFIER", 104, 108], ["tachycardia", "OBSERVATION", 109, 120]]], ["She required 1-2 L of O 2 via nasal prongs to maintain O 2 saturation > 92%.", [["nasal", "ANATOMY", 30, 35], ["O 2", "CHEMICAL", 22, 25], ["O 2", "CHEMICAL", 55, 58], ["O 2 via nasal prongs", "TREATMENT", 22, 42]]], ["Her complete blood count showed moderate macrocytic anaemia (haemoglobin: 77 g/L) with moderate thrombocytopenia (platelets: 80 \u00d7 10 9 /L).", [["blood", "ANATOMY", 13, 18], ["platelets", "ANATOMY", 114, 123], ["macrocytic anaemia", "DISEASE", 41, 59], ["thrombocytopenia", "DISEASE", 96, 112], ["blood", "ORGANISM_SUBSTANCE", 13, 18], ["platelets", "CELL", 114, 123], ["platelets", "CELL_TYPE", 114, 123], ["Her complete blood count", "TEST", 0, 24], ["moderate macrocytic anaemia", "PROBLEM", 32, 59], ["haemoglobin", "TEST", 61, 72], ["moderate thrombocytopenia", "PROBLEM", 87, 112], ["platelets", "TEST", 114, 123], ["moderate", "OBSERVATION_MODIFIER", 32, 40], ["macrocytic anaemia", "OBSERVATION", 41, 59], ["moderate", "OBSERVATION_MODIFIER", 87, 95], ["thrombocytopenia", "OBSERVATION", 96, 112]]], ["There was a marked leucocytosis (white cell count (WCC): 377.1 \u00d7 10 9 /L) comprised almost entirely of blasts.", [["white cell", "ANATOMY", 33, 43], ["blasts", "ANATOMY", 103, 109], ["leucocytosis", "DISEASE", 19, 31], ["white cell", "CELL", 33, 43], ["blasts", "CELL", 103, 109], ["blasts", "CELL_TYPE", 103, 109], ["a marked leucocytosis", "PROBLEM", 10, 31], ["white cell count", "TEST", 33, 49], ["WCC", "TEST", 51, 54], ["blasts", "PROBLEM", 103, 109], ["marked", "OBSERVATION_MODIFIER", 12, 18], ["leucocytosis", "OBSERVATION", 19, 31], ["white cell", "OBSERVATION_MODIFIER", 33, 43], ["blasts", "OBSERVATION", 103, 109]]], ["Flow cytometry of peripheral blood confirmed myeloid blasts with expression of myeloperoxidase (MPO), CD13, CD33, and with aberrant CD7.", [["peripheral blood", "ANATOMY", 18, 34], ["myeloid blasts", "ANATOMY", 45, 59], ["peripheral blood", "ORGANISM_SUBSTANCE", 18, 34], ["myeloid blasts", "CELL", 45, 59], ["myeloperoxidase", "GENE_OR_GENE_PRODUCT", 79, 94], ["MPO", "SIMPLE_CHEMICAL", 96, 99], ["CD13", "GENE_OR_GENE_PRODUCT", 102, 106], ["CD33", "GENE_OR_GENE_PRODUCT", 108, 112], ["CD7", "GENE_OR_GENE_PRODUCT", 132, 135], ["myeloid blasts", "CELL_TYPE", 45, 59], ["myeloperoxidase", "PROTEIN", 79, 94], ["MPO", "PROTEIN", 96, 99], ["CD13", "PROTEIN", 102, 106], ["CD33", "PROTEIN", 108, 112], ["CD7", "PROTEIN", 132, 135], ["Flow cytometry", "TEST", 0, 14], ["peripheral blood", "TEST", 18, 34], ["myeloid blasts", "PROBLEM", 45, 59], ["myeloperoxidase", "TEST", 79, 94], ["MPO", "TEST", 96, 99], ["CD13", "TEST", 102, 106], ["CD33", "TEST", 108, 112], ["aberrant CD7", "PROBLEM", 123, 135], ["peripheral", "ANATOMY_MODIFIER", 18, 28], ["blood", "ANATOMY", 29, 34], ["myeloid blasts", "OBSERVATION", 45, 59], ["myeloperoxidase", "OBSERVATION_MODIFIER", 79, 94], ["aberrant CD7", "OBSERVATION", 123, 135]]], ["Karyotyping showed 46,XX and molecular analysis showed a type D NPM1 mutation, an FLT3 internal tandem duplication (ITD) (high variant allele fraction), and a low-level FLT3 tyrosine kinase domain (TKD) mutation.Case ReportOther key laboratory findings included elevated Creactive protein of 130 mg/L, lactate dehydrogenase (LDH) of 2450 U/L, D-dimer of 16,300 \u03bcg/L, and N-terminal-pro Brain Natriuretic Peptide (NT-proBNP) of 263 pmol/L. Serial high-sensitivity troponins were normal.", [["tyrosine", "CHEMICAL", 174, 182], ["lactate", "CHEMICAL", 302, 309], ["tyrosine", "CHEMICAL", 174, 182], ["lactate", "CHEMICAL", 302, 309], ["NPM1", "GENE_OR_GENE_PRODUCT", 64, 68], ["FLT3", "GENE_OR_GENE_PRODUCT", 82, 86], ["FLT3 tyrosine kinase domain", "GENE_OR_GENE_PRODUCT", 169, 196], ["TKD", "GENE_OR_GENE_PRODUCT", 198, 201], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 302, 323], ["LDH", "SIMPLE_CHEMICAL", 325, 328], ["D-dimer", "GENE_OR_GENE_PRODUCT", 343, 350], ["NT-proBNP", "GENE_OR_GENE_PRODUCT", 413, 422], ["FLT3 internal tandem duplication", "DNA", 82, 114], ["ITD", "DNA", 116, 119], ["FLT3 tyrosine kinase domain", "PROTEIN", 169, 196], ["TKD", "PROTEIN", 198, 201], ["Creactive protein", "PROTEIN", 271, 288], ["lactate dehydrogenase", "PROTEIN", 302, 323], ["LDH", "PROTEIN", 325, 328], ["troponins", "PROTEIN", 463, 472], ["Karyotyping", "TEST", 0, 11], ["molecular analysis", "TEST", 29, 47], ["a type D NPM1 mutation", "PROBLEM", 55, 77], ["an FLT3 internal tandem duplication", "PROBLEM", 79, 114], ["high variant allele fraction", "PROBLEM", 122, 150], ["a low-level FLT3 tyrosine kinase domain (TKD) mutation", "PROBLEM", 157, 211], ["elevated Creactive protein", "PROBLEM", 262, 288], ["lactate dehydrogenase", "TEST", 302, 323], ["LDH", "TEST", 325, 328], ["U/L", "TEST", 338, 341], ["D-dimer", "TEST", 343, 350], ["N-terminal", "TEST", 371, 381], ["Brain Natriuretic Peptide", "TEST", 386, 411], ["NT", "TEST", 413, 415], ["proBNP", "TEST", 416, 422], ["Serial high-sensitivity troponins", "TEST", 439, 472], ["NPM1 mutation", "OBSERVATION", 64, 77], ["FLT3 internal", "OBSERVATION", 82, 95], ["tandem duplication", "OBSERVATION", 96, 114], ["FLT3", "OBSERVATION", 169, 173], ["tyrosine kinase", "OBSERVATION", 174, 189], ["normal", "OBSERVATION", 478, 484]]], ["A portable Anterior-Posterior (AP) chest radiograph showed no interstitial infiltrates, lobar consolidation, or effusion.Case ReportThe patient was diagnosed with therapy-related AML (t-AML) and admitted to the haematology ward.", [["interstitial infiltrates", "ANATOMY", 62, 86], ["lobar", "ANATOMY", 88, 93], ["AML", "ANATOMY", 179, 182], ["t-AML", "ANATOMY", 184, 189], ["effusion", "DISEASE", 112, 120], ["AML", "DISEASE", 179, 182], ["AML", "DISEASE", 186, 189], ["patient", "ORGANISM", 136, 143], ["AML", "CANCER", 179, 182], ["t-AML", "CANCER", 184, 189], ["patient", "SPECIES", 136, 143], ["A portable Anterior-Posterior (AP) chest radiograph", "TEST", 0, 51], ["interstitial infiltrates", "PROBLEM", 62, 86], ["lobar consolidation", "PROBLEM", 88, 107], ["effusion", "PROBLEM", 112, 120], ["therapy", "TREATMENT", 163, 170], ["AML", "PROBLEM", 179, 182], ["t-AML", "PROBLEM", 184, 189], ["Posterior", "ANATOMY_MODIFIER", 20, 29], ["chest", "ANATOMY", 35, 40], ["no", "UNCERTAINTY", 59, 61], ["interstitial", "ANATOMY_MODIFIER", 62, 74], ["infiltrates", "OBSERVATION", 75, 86], ["lobar", "OBSERVATION_MODIFIER", 88, 93], ["consolidation", "OBSERVATION", 94, 107], ["effusion", "OBSERVATION", 112, 120], ["AML", "OBSERVATION", 179, 182]]], ["Although it was felt highly probable that her presenting symptoms were explained by her AML, in line with the broad testing strategy in New Zealand at the time, a nasopharyngeal swab for reverse transcriptase-polymerase chain reaction (RT-PCR) for SARS-CoV-2 was taken and the patient was isolated until the RT-PCR results became available.", [["AML", "ANATOMY", 88, 91], ["nasopharyngeal swab", "ANATOMY", 163, 182], ["AML", "DISEASE", 88, 91], ["AML", "CANCER", 88, 91], ["SARS-CoV-2", "ORGANISM", 248, 258], ["patient", "ORGANISM", 277, 284], ["reverse transcriptase", "PROTEIN", 187, 208], ["patient", "SPECIES", 277, 284], ["SARS-CoV", "SPECIES", 248, 256], ["her presenting symptoms", "PROBLEM", 42, 65], ["her AML", "PROBLEM", 84, 91], ["a nasopharyngeal swab", "TEST", 161, 182], ["reverse transcriptase-polymerase chain reaction", "PROBLEM", 187, 234], ["RT-PCR", "TEST", 236, 242], ["SARS", "PROBLEM", 248, 252], ["CoV", "TEST", 253, 256], ["the RT-PCR", "TEST", 304, 314], ["nasopharyngeal", "ANATOMY", 163, 177]]], ["No other source of infection was identified and the patient was commenced on empiric amoxicillin/clavulanic acid.", [["infection", "DISEASE", 19, 28], ["amoxicillin/clavulanic acid", "CHEMICAL", 85, 112], ["amoxicillin", "CHEMICAL", 85, 96], ["clavulanic acid", "CHEMICAL", 97, 112], ["patient", "ORGANISM", 52, 59], ["amoxicillin", "SIMPLE_CHEMICAL", 85, 96], ["clavulanic acid", "SIMPLE_CHEMICAL", 97, 112], ["patient", "SPECIES", 52, 59], ["infection", "PROBLEM", 19, 28], ["empiric amoxicillin", "TREATMENT", 77, 96], ["clavulanic acid", "TREATMENT", 97, 112], ["infection", "OBSERVATION", 19, 28]]], ["She was then transferred to a tertiary hospital for specialized haematology care and a repeat nasopharyngeal swab for RT-PCR for SARS-CoV-2 was sent on arrival.", [["nasopharyngeal swab", "ANATOMY", 94, 113], ["SARS", "DISEASE", 129, 133], ["nasopharyngeal swab", "CANCER", 94, 113], ["SARS-CoV", "SPECIES", 129, 137], ["a repeat nasopharyngeal swab", "TEST", 85, 113], ["RT-PCR", "TEST", 118, 124], ["SARS", "PROBLEM", 129, 133], ["CoV", "TEST", 134, 137], ["nasopharyngeal", "ANATOMY", 94, 108]]], ["The swabs were taken 7 h apart.", [["swabs", "ANATOMY", 4, 9], ["The swabs", "TEST", 0, 9]]], ["The first swab became positive on day 2 at 35 cycles.", [["swab", "ANATOMY", 10, 14], ["The first swab", "TEST", 0, 14], ["positive", "PROBLEM", 22, 30], ["positive", "OBSERVATION", 22, 30]]], ["This was sent for confirmatory testing to the national reference laboratory and was confirmed positive.", [["confirmatory testing", "TEST", 18, 38], ["positive", "OBSERVATION", 94, 102]]], ["The second swab was processed locally at the tertiary centre and this was negative at 38 cycles (local testing protocol).", [["swab", "ANATOMY", 11, 15], ["The second swab", "TREATMENT", 0, 15], ["local testing protocol", "TEST", 97, 119]]], ["At this point, the tertiary centre laboratory requested and tested an aliquot from the first swab which again became positive at 35 cycles.", [["swab", "ANATOMY", 93, 97], ["the first swab", "TEST", 83, 97], ["positive", "PROBLEM", 117, 125]]], ["Following discussion involving a haematologist (H. Goodman), a respiratory physician (C. L. Chang), and a clinical microbiologist, it was deemed that a false-positive result was unlikely due to a very low false-positive rate with local RT-PCR methodology and multiple positive confirmatory tests at different laboratories.", [["C. L.", "SPECIES", 86, 91], ["a very low false-positive rate", "PROBLEM", 194, 224], ["local RT-PCR methodology", "TEST", 230, 254], ["multiple positive confirmatory tests", "PROBLEM", 259, 295]]], ["The conclusion was that the second sample was a false negative possibly due to suboptimal sampling of the nasopharynx resulting in a nasal or mid turbinate swab.", [["nasopharynx", "ANATOMY", 106, 117], ["nasal", "ANATOMY", 133, 138], ["turbinate swab", "ANATOMY", 146, 160], ["nasopharynx", "ORGAN", 106, 117], ["nasal", "ORGANISM_SUBDIVISION", 133, 138], ["turbinate swab", "MULTI-TISSUE_STRUCTURE", 146, 160], ["suboptimal sampling of the nasopharynx", "PROBLEM", 79, 117], ["a nasal or mid turbinate swab", "PROBLEM", 131, 160], ["possibly due to", "UNCERTAINTY", 63, 78], ["nasopharynx", "ANATOMY", 106, 117], ["nasal", "ANATOMY", 133, 138], ["mid turbinate", "ANATOMY", 142, 155], ["swab", "OBSERVATION", 156, 160]]], ["The patient also had a plausible epidemiological risk factor working in a hotel accommodating international guests.Case ReportChemotherapy was commenced despite the positive SARS-CoV-2 status due to unacceptable risk of disease progression and mortality without treatment.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["Case ReportChemotherapy", "TREATMENT", 115, 138], ["the positive SARS", "PROBLEM", 161, 178], ["disease progression", "PROBLEM", 220, 239], ["treatment", "TREATMENT", 262, 271], ["disease", "OBSERVATION", 220, 227]]], ["Cytoreduction was initially achieved with hydroxyurea then cytosine arabinoside.", [["hydroxyurea", "CHEMICAL", 42, 53], ["cytosine arabinoside", "CHEMICAL", 59, 79], ["hydroxyurea", "CHEMICAL", 42, 53], ["cytosine arabinoside", "CHEMICAL", 59, 79], ["hydroxyurea", "SIMPLE_CHEMICAL", 42, 53], ["cytosine arabinoside", "SIMPLE_CHEMICAL", 59, 79], ["Cytoreduction", "TREATMENT", 0, 13], ["hydroxyurea", "TREATMENT", 42, 53], ["cytosine arabinoside", "TREATMENT", 59, 79]]], ["Intravenous dexamethasone was commenced for possible hyperleucocytosis.", [["dexamethasone", "CHEMICAL", 12, 25], ["hyperleucocytosis", "DISEASE", 53, 70], ["dexamethasone", "CHEMICAL", 12, 25], ["dexamethasone", "SIMPLE_CHEMICAL", 12, 25], ["Intravenous dexamethasone", "TREATMENT", 0, 25], ["hyperleucocytosis", "PROBLEM", 53, 70]]], ["Rasburicase and intravenous fluid were given to prevent tumour lysis syndrome (TLS).", [["intravenous", "ANATOMY", 16, 27], ["tumour", "ANATOMY", 56, 62], ["Rasburicase", "CHEMICAL", 0, 11], ["tumour lysis syndrome", "DISEASE", 56, 77], ["TLS", "DISEASE", 79, 82], ["Rasburicase", "CHEMICAL", 0, 11], ["Rasburicase", "SIMPLE_CHEMICAL", 0, 11], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 16, 27], ["fluid", "ORGANISM_SUBSTANCE", 28, 33], ["tumour", "CANCER", 56, 62], ["Rasburicase", "TREATMENT", 0, 11], ["intravenous fluid", "TREATMENT", 16, 33], ["tumour lysis syndrome", "PROBLEM", 56, 77], ["tumour lysis", "OBSERVATION", 56, 68]]], ["Cytoreduction continued until WCC was <50 \u00d7 10 9 /L prior to intensifying to induction therapy with an anthracycline.Case ReportThe patient continued to express symptoms of only a mild coronavirus disease 2019 (COVID-19) phenotype.", [["anthracycline", "CHEMICAL", 103, 116], ["coronavirus disease", "DISEASE", 185, 204], ["anthracycline", "CHEMICAL", 103, 116], ["anthracycline", "SIMPLE_CHEMICAL", 103, 116], ["patient", "ORGANISM", 132, 139], ["WCC", "PROTEIN", 30, 33], ["patient", "SPECIES", 132, 139], ["Cytoreduction", "TREATMENT", 0, 13], ["WCC", "TEST", 30, 33], ["induction therapy", "TREATMENT", 77, 94], ["an anthracycline", "TREATMENT", 100, 116], ["symptoms", "PROBLEM", 161, 169], ["a mild coronavirus disease", "PROBLEM", 178, 204], ["COVID", "TEST", 211, 216], ["phenotype", "PROBLEM", 221, 230], ["mild", "OBSERVATION_MODIFIER", 180, 184], ["coronavirus", "OBSERVATION", 185, 196]]], ["Low-grade fevers continued until the third day of admission.", [["fevers", "DISEASE", 10, 16], ["Low-grade fevers", "PROBLEM", 0, 16], ["-grade", "OBSERVATION_MODIFIER", 3, 9], ["fevers", "OBSERVATION", 10, 16]]], ["The patient did not require supplemental oxygen after the initial presentation.", [["oxygen", "CHEMICAL", 41, 47], ["oxygen", "CHEMICAL", 41, 47], ["patient", "ORGANISM", 4, 11], ["oxygen", "SIMPLE_CHEMICAL", 41, 47], ["patient", "SPECIES", 4, 11], ["supplemental oxygen", "TREATMENT", 28, 47]]], ["Dyspnoea on minimal exertion and dry cough continued until the fifth day of admission where the respiratory rate normalized and no further respiratory symptoms were reported.", [["respiratory", "ANATOMY", 96, 107], ["respiratory", "ANATOMY", 139, 150], ["Dyspnoea", "DISEASE", 0, 8], ["dry cough", "DISEASE", 33, 42], ["Dyspnoea", "PROBLEM", 0, 8], ["minimal exertion", "PROBLEM", 12, 28], ["dry cough", "PROBLEM", 33, 42], ["the respiratory rate", "TEST", 92, 112], ["further respiratory symptoms", "PROBLEM", 131, 159], ["minimal", "OBSERVATION_MODIFIER", 12, 19], ["exertion", "OBSERVATION", 20, 28], ["dry", "OBSERVATION_MODIFIER", 33, 36], ["cough", "OBSERVATION", 37, 42], ["no", "UNCERTAINTY", 128, 130]]], ["At this time, cytoreduction had achieved a leucocyte count < 100 \u00d7 109/L. Three SARS-CoV-2 RT-PCRs between days 13 and 19 of admission were negative and the patient was successfully de-isolated to the haematology ward on day 20.", [["leucocyte", "ANATOMY", 43, 52], ["leucocyte", "CELL", 43, 52], ["patient", "ORGANISM", 157, 164], ["SARS-CoV-2 RT-PCRs", "DNA", 80, 98], ["patient", "SPECIES", 157, 164], ["cytoreduction", "TREATMENT", 14, 27], ["a leucocyte count", "TEST", 41, 58], ["Three SARS", "TEST", 74, 84], ["CoV", "TEST", 85, 88], ["negative", "OBSERVATION", 140, 148]]], ["During her 26th day of admission, she completed a cycle of induction chemotherapy, had a second course of antibiotics for neutropenic colitis, and was discharged on cell count recovery.", [["cell", "ANATOMY", 165, 169], ["neutropenic colitis", "DISEASE", 122, 141], ["colitis", "PATHOLOGICAL_FORMATION", 134, 141], ["cell", "CELL", 165, 169], ["induction chemotherapy", "TREATMENT", 59, 81], ["antibiotics", "TREATMENT", 106, 117], ["neutropenic colitis", "PROBLEM", 122, 141], ["cell count recovery", "TREATMENT", 165, 184], ["neutropenic colitis", "OBSERVATION", 122, 141]]], ["Her disease was refractory to daunorubicin, ara-C (DA) induction chemotherapy but she subsequently achieved morphological remission with fludarabine, ara-C, granulocyte colony stimulating factor, idarubincin (FLAG-IDA) salvage and has been referred for consideration of allogeneic stem cell transplant.DiscussionThis case highlights the potential of coexistence of COVID-19 and other acute severe diagnoses including acute haematological malignancies, where both the pathophysiology and treatment may render the patient highly immunovulnerable.DiscussionThere is limited existing literature on the clinical course and outcome of SARS-CoV-2 infections in immunosuppressed states, such as patients with active malignancy or due to immunosuppressants.", [["stem cell", "ANATOMY", 281, 290], ["haematological malignancies", "ANATOMY", 423, 450], ["daunorubicin", "CHEMICAL", 30, 42], ["ara-C", "CHEMICAL", 44, 49], ["DA", "CHEMICAL", 51, 53], ["fludarabine", "CHEMICAL", 137, 148], ["ara-C", "CHEMICAL", 150, 155], ["idarubincin", "CHEMICAL", 196, 207], ["FLAG-IDA", "CHEMICAL", 209, 217], ["acute haematological malignancies", "DISEASE", 417, 450], ["SARS", "DISEASE", 629, 633], ["infections", "DISEASE", 640, 650], ["malignancy", "DISEASE", 708, 718], ["daunorubicin", "CHEMICAL", 30, 42], ["ara-C", "CHEMICAL", 44, 49], ["fludarabine", "CHEMICAL", 137, 148], ["ara-C", "CHEMICAL", 150, 155], ["idarubincin", "CHEMICAL", 196, 207], ["daunorubicin", "SIMPLE_CHEMICAL", 30, 42], ["ara-C", "SIMPLE_CHEMICAL", 44, 49], ["DA", "SIMPLE_CHEMICAL", 51, 53], ["fludarabine", "SIMPLE_CHEMICAL", 137, 148], ["ara-C", "SIMPLE_CHEMICAL", 150, 155], ["granulocyte colony stimulating factor", "GENE_OR_GENE_PRODUCT", 157, 194], ["idarubincin", "SIMPLE_CHEMICAL", 196, 207], ["FLAG-IDA", "SIMPLE_CHEMICAL", 209, 217], ["stem cell", "CELL", 281, 290], ["malignancies", "CANCER", 438, 450], ["patient", "ORGANISM", 512, 519], ["SARS-CoV-2", "ORGANISM", 629, 639], ["patients", "ORGANISM", 687, 695], ["malignancy", "CANCER", 708, 718], ["granulocyte colony stimulating factor", "PROTEIN", 157, 194], ["FLAG", "PROTEIN", 209, 213], ["patient", "SPECIES", 512, 519], ["patients", "SPECIES", 687, 695], ["SARS-CoV-2", "SPECIES", 629, 639], ["Her disease", "PROBLEM", 0, 11], ["daunorubicin", "TREATMENT", 30, 42], ["ara-C (DA) induction chemotherapy", "TREATMENT", 44, 77], ["morphological remission", "TREATMENT", 108, 131], ["fludarabine", "TREATMENT", 137, 148], ["ara", "TREATMENT", 150, 153], ["granulocyte colony stimulating factor", "PROBLEM", 157, 194], ["idarubincin (FLAG-IDA) salvage", "TREATMENT", 196, 226], ["allogeneic stem cell transplant", "TREATMENT", 270, 301], ["COVID", "TEST", 365, 370], ["other acute severe diagnoses", "PROBLEM", 378, 406], ["acute haematological malignancies", "PROBLEM", 417, 450], ["treatment", "TREATMENT", 487, 496], ["SARS", "PROBLEM", 629, 633], ["CoV", "PROBLEM", 634, 637], ["2 infections in immunosuppressed states", "PROBLEM", 638, 677], ["active malignancy", "PROBLEM", 701, 718], ["immunosuppressants", "TREATMENT", 729, 747], ["disease", "OBSERVATION", 4, 11], ["granulocyte", "ANATOMY", 157, 168], ["allogeneic stem cell transplant", "OBSERVATION", 270, 301], ["acute", "OBSERVATION_MODIFIER", 384, 389], ["severe", "OBSERVATION_MODIFIER", 390, 396], ["acute", "OBSERVATION_MODIFIER", 417, 422], ["haematological malignancies", "OBSERVATION", 423, 450], ["active", "OBSERVATION_MODIFIER", 701, 707], ["malignancy", "OBSERVATION", 708, 718]]], ["Case reports have shown that the presentation and outcomes can vary from mild to severe disease [2] [3] [4] [5] [6] [7] [8] .", [["[2] [3] [4] [5] [6] [7]", "CHEMICAL", 96, 119], ["[2] [3] [4] [5] [6] [7] [8]", "SIMPLE_CHEMICAL", 96, 123], ["mild to severe disease", "PROBLEM", 73, 95], ["severe", "OBSERVATION_MODIFIER", 81, 87], ["disease", "OBSERVATION", 88, 95]]], ["As immunosuppressive therapy downregulates the production of interleukins (ILs) and the proliferation, survival, and maturation of T cells, it is possible that although the risk of acquiring the virus is higher, the anti-inflammatory effects of such therapy reduce the overall severity of COVID-19 [9] .", [["T cells", "ANATOMY", 131, 138], ["COVID-19", "CHEMICAL", 289, 297], ["interleukins", "GENE_OR_GENE_PRODUCT", 61, 73], ["ILs", "GENE_OR_GENE_PRODUCT", 75, 78], ["T cells", "CELL", 131, 138], ["interleukins", "PROTEIN", 61, 73], ["ILs", "PROTEIN", 75, 78], ["T cells", "CELL_TYPE", 131, 138], ["immunosuppressive therapy", "TREATMENT", 3, 28], ["interleukins (ILs", "TREATMENT", 61, 78], ["the proliferation", "PROBLEM", 84, 101], ["maturation of T cells", "PROBLEM", 117, 138], ["the virus", "PROBLEM", 191, 200], ["such therapy", "TREATMENT", 245, 257], ["COVID", "TEST", 289, 294]]], ["Furthermore, AML itself leads to impaired T-cell response [10] .", [["AML", "ANATOMY", 13, 16], ["T-cell", "ANATOMY", 42, 48], ["AML", "DISEASE", 13, 16], ["AML", "CANCER", 13, 16], ["T-cell", "CELL", 42, 48], ["AML", "PROBLEM", 13, 16], ["AML", "OBSERVATION", 13, 16]]], ["We note evidence supporting the link between overactivation of T cells and severe immune injury in patients with severe COVID-19 [11] .", [["T cells", "ANATOMY", 63, 70], ["immune injury", "DISEASE", 82, 95], ["COVID-19", "CHEMICAL", 120, 128], ["T cells", "CELL", 63, 70], ["patients", "ORGANISM", 99, 107], ["T cells", "CELL_TYPE", 63, 70], ["patients", "SPECIES", 99, 107], ["T cells", "PROBLEM", 63, 70], ["severe immune injury", "PROBLEM", 75, 95], ["severe COVID", "PROBLEM", 113, 125], ["severe", "OBSERVATION_MODIFIER", 75, 81], ["immune injury", "OBSERVATION", 82, 95]]], ["Systemic inflammatory response has also been shown to play a role in provoking viral-induced lung injury.", [["lung", "ANATOMY", 93, 97], ["lung injury", "DISEASE", 93, 104], ["lung", "ORGAN", 93, 97], ["Systemic inflammatory response", "PROBLEM", 0, 30], ["provoking viral-induced lung injury", "PROBLEM", 69, 104], ["inflammatory", "OBSERVATION", 9, 21], ["lung", "ANATOMY", 93, 97], ["injury", "OBSERVATION", 98, 104]]], ["Table 1 summarizes the case reports of COVID-19 infection in patients who are immunosuppressed as a result of solid organ transplant or Chronic Lymphocytic Leukaemia (CLL).", [["solid organ", "ANATOMY", 110, 121], ["Chronic Lymphocytic Leukaemia", "ANATOMY", 136, 165], ["CLL", "ANATOMY", 167, 170], ["infection", "DISEASE", 48, 57], ["Chronic Lymphocytic Leukaemia", "DISEASE", 136, 165], ["CLL", "DISEASE", 167, 170], ["COVID-19", "ORGANISM", 39, 47], ["patients", "ORGANISM", 61, 69], ["solid", "CANCER", 110, 115], ["organ", "ORGAN", 116, 121], ["Chronic Lymphocytic Leukaemia", "CANCER", 136, 165], ["CLL", "CANCER", 167, 170], ["patients", "SPECIES", 61, 69], ["COVID-19", "SPECIES", 39, 47], ["COVID-19 infection", "PROBLEM", 39, 57], ["immunosuppressed", "PROBLEM", 78, 94], ["solid organ transplant", "TREATMENT", 110, 132], ["Chronic Lymphocytic Leukaemia", "PROBLEM", 136, 165], ["CLL", "PROBLEM", 167, 170], ["infection", "OBSERVATION", 48, 57], ["organ", "ANATOMY", 116, 121], ["transplant", "OBSERVATION", 122, 132], ["Chronic", "OBSERVATION_MODIFIER", 136, 143], ["Lymphocytic Leukaemia", "OBSERVATION", 144, 165]]], ["Of the 19 patients described, four died.", [["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18]]], ["Of note, three of these four patients were on very low-dose immunosuppression therapy at the time.", [["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37], ["very low-dose immunosuppression therapy", "TREATMENT", 46, 85]]], ["The fourth death was unrelated to COVID-19.", [["death", "DISEASE", 11, 16], ["COVID-19", "CHEMICAL", 34, 42], ["COVID-19", "DNA", 34, 42], ["The fourth death", "PROBLEM", 0, 16], ["COVID", "TEST", 34, 39]]], ["In terms of severity of disease, five patients were managed as outpatients; seven were admitted, one of whom did not have an oxygen requirement, and four required intensive care unit (ICU) for ventilation, one of whom was successfully de-escalated to ward-based care.", [["oxygen", "CHEMICAL", 125, 131], ["oxygen", "CHEMICAL", 125, 131], ["patients", "ORGANISM", 38, 46], ["oxygen", "SIMPLE_CHEMICAL", 125, 131], ["patients", "SPECIES", 38, 46], ["disease", "PROBLEM", 24, 31], ["an oxygen requirement", "PROBLEM", 122, 143], ["ventilation", "TREATMENT", 193, 204], ["severity", "OBSERVATION_MODIFIER", 12, 20], ["disease", "OBSERVATION", 24, 31], ["oxygen requirement", "OBSERVATION", 125, 143]]], ["Of note, ours is the first reported case of a patient with COVID-19 actively undergoing cytoreduction chemotherapy rather than broad-spectrum immunosuppression following transplantation.", [["patient", "ORGANISM", 46, 53], ["patient", "SPECIES", 46, 53], ["COVID", "TEST", 59, 64], ["cytoreduction chemotherapy", "TREATMENT", 88, 114], ["broad-spectrum immunosuppression", "TREATMENT", 127, 159], ["transplantation", "TREATMENT", 170, 185], ["immunosuppression", "OBSERVATION", 142, 159]]], ["In this case, the patient was given dexamethasone for hyperleucocytosis.", [["dexamethasone", "CHEMICAL", 36, 49], ["hyperleucocytosis", "DISEASE", 54, 71], ["dexamethasone", "CHEMICAL", 36, 49], ["patient", "ORGANISM", 18, 25], ["dexamethasone", "SIMPLE_CHEMICAL", 36, 49], ["patient", "SPECIES", 18, 25], ["dexamethasone", "TREATMENT", 36, 49], ["hyperleucocytosis", "PROBLEM", 54, 71]]], ["At the time of treatment, steroids were not recommended for the management of COVID-19 as they have not demonstrated efficacy in prior SARS or Middle East respiratory syndrome (MERS) epidemics.", [["steroids", "CHEMICAL", 26, 34], ["SARS", "DISEASE", 135, 139], ["Middle East respiratory syndrome (MERS) epidemics", "DISEASE", 143, 192], ["steroids", "CHEMICAL", 26, 34], ["COVID-19", "CHEMICAL", 78, 86], ["steroids", "SIMPLE_CHEMICAL", 26, 34], ["treatment", "TREATMENT", 15, 24], ["steroids", "TREATMENT", 26, 34], ["COVID", "TEST", 78, 83], ["prior SARS", "PROBLEM", 129, 139], ["Middle East respiratory syndrome", "PROBLEM", 143, 175], ["epidemics", "PROBLEM", 183, 192], ["Middle", "OBSERVATION_MODIFIER", 143, 149], ["respiratory syndrome", "OBSERVATION", 155, 175]]], ["The early reports of steroid use from China suggest detrimental effects rather than benefits.", [["steroid", "CHEMICAL", 21, 28], ["steroid", "CHEMICAL", 21, 28], ["steroid", "SIMPLE_CHEMICAL", 21, 28], ["steroid use", "TREATMENT", 21, 32]]], ["However, the recent RECOVERY Trial conducted in the UK found that dexamethasone was associated with improved outcomes in patients hospitalized with COVID-19 [12] .", [["dexamethasone", "CHEMICAL", 66, 79], ["dexamethasone", "CHEMICAL", 66, 79], ["COVID-19", "CHEMICAL", 148, 156], ["dexamethasone", "SIMPLE_CHEMICAL", 66, 79], ["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 121, 129], ["dexamethasone", "TREATMENT", 66, 79], ["COVID", "TEST", 148, 153]]], ["It is possible that early administration of systemic steroids improved the overall clinical course of the coronavirus infection in our patient.", [["steroids", "CHEMICAL", 53, 61], ["coronavirus infection", "DISEASE", 106, 127], ["steroids", "CHEMICAL", 53, 61], ["coronavirus", "ORGANISM", 106, 117], ["patient", "ORGANISM", 135, 142], ["patient", "SPECIES", 135, 142], ["systemic steroids", "TREATMENT", 44, 61], ["the coronavirus infection", "PROBLEM", 102, 127], ["early", "OBSERVATION_MODIFIER", 20, 25], ["coronavirus", "OBSERVATION_MODIFIER", 106, 117], ["infection", "OBSERVATION", 118, 127]]], ["Elevated serum ferritin and IL-6 level have been associated with increased mortality from COVID-19 infection suggesting inflammation may contribute to poor outcomes.", [["serum", "ANATOMY", 9, 14], ["infection", "DISEASE", 99, 108], ["inflammation", "DISEASE", 120, 132], ["serum", "ORGANISM_SUBSTANCE", 9, 14], ["ferritin", "GENE_OR_GENE_PRODUCT", 15, 23], ["IL-6", "GENE_OR_GENE_PRODUCT", 28, 32], ["COVID-19", "GENE_OR_GENE_PRODUCT", 90, 98], ["serum ferritin", "PROTEIN", 9, 23], ["IL-6", "PROTEIN", 28, 32], ["Elevated serum ferritin", "PROBLEM", 0, 23], ["IL", "TEST", 28, 30], ["increased mortality", "PROBLEM", 65, 84], ["COVID-19 infection", "PROBLEM", 90, 108], ["inflammation", "PROBLEM", 120, 132], ["poor outcomes", "PROBLEM", 151, 164], ["serum ferritin", "OBSERVATION_MODIFIER", 9, 23], ["associated with", "UNCERTAINTY", 49, 64], ["increased", "OBSERVATION_MODIFIER", 65, 74], ["mortality", "OBSERVATION_MODIFIER", 75, 84], ["infection", "OBSERVATION", 99, 108], ["inflammation", "OBSERVATION", 120, 132]]], ["It has been suggested that a subset of patients with COVID-19 and high H-score (used in the diagnosis of haemophagocytic syndromes) may benefit from immunosuppression with biological agents such as tocilizumab [13] .", [["haemophagocytic syndromes", "DISEASE", 105, 130], ["tocilizumab", "CHEMICAL", 198, 209], ["patients", "ORGANISM", 39, 47], ["tocilizumab", "SIMPLE_CHEMICAL", 198, 209], ["patients", "SPECIES", 39, 47], ["COVID", "TEST", 53, 58], ["haemophagocytic syndromes", "PROBLEM", 105, 130], ["immunosuppression", "TREATMENT", 149, 166], ["biological agents", "TREATMENT", 172, 189], ["tocilizumab", "TREATMENT", 198, 209], ["haemophagocytic syndromes", "OBSERVATION", 105, 130]]], ["Thus, patients undergoing intensive induction chemotherapy are less likely to suffer from a cytokine storm, which is a proposed pathway leading to COVID-19-related mortality.", [["patients", "ORGANISM", 6, 14], ["cytokine", "PROTEIN", 92, 100], ["patients", "SPECIES", 6, 14], ["intensive induction chemotherapy", "TREATMENT", 26, 58], ["a cytokine storm", "PROBLEM", 90, 106], ["COVID", "TEST", 147, 152], ["cytokine storm", "OBSERVATION", 92, 106]]], ["Interestingly, despite severe immunosuppression, our patient only developed mild respiratory symptoms.", [["respiratory", "ANATOMY", 81, 92], ["respiratory symptoms", "DISEASE", 81, 101], ["patient", "ORGANISM", 53, 60], ["patient", "SPECIES", 53, 60], ["severe immunosuppression", "TREATMENT", 23, 47], ["mild respiratory symptoms", "PROBLEM", 76, 101], ["severe", "OBSERVATION_MODIFIER", 23, 29], ["immunosuppression", "OBSERVATION", 30, 47], ["mild", "OBSERVATION_MODIFIER", 76, 80], ["respiratory symptoms", "OBSERVATION", 81, 101]]], ["Furthermore, the pulmonary and neurological symptoms may also be secondary to AML-associated hyperleucocytosis-fever and medullary pain can also accompany acute leukaemia which may masquerade as the fever and myalgia of a viral respiratory illness.", [["pulmonary", "ANATOMY", 17, 26], ["neurological", "ANATOMY", 31, 43], ["AML", "ANATOMY", 78, 81], ["medullary", "ANATOMY", 121, 130], ["acute leukaemia", "ANATOMY", 155, 170], ["respiratory", "ANATOMY", 228, 239], ["pulmonary and neurological symptoms", "DISEASE", 17, 52], ["AML", "DISEASE", 78, 81], ["hyperleucocytosis", "DISEASE", 93, 110], ["fever", "DISEASE", 111, 116], ["medullary pain", "DISEASE", 121, 135], ["acute leukaemia", "DISEASE", 155, 170], ["fever", "DISEASE", 199, 204], ["myalgia", "DISEASE", 209, 216], ["viral respiratory illness", "DISEASE", 222, 247], ["pulmonary", "ORGAN", 17, 26], ["AML", "CANCER", 78, 81], ["medullary", "ORGAN", 121, 130], ["acute leukaemia", "CANCER", 155, 170], ["the pulmonary and neurological symptoms", "PROBLEM", 13, 52], ["AML", "PROBLEM", 78, 81], ["hyperleucocytosis", "PROBLEM", 93, 110], ["fever", "PROBLEM", 111, 116], ["medullary pain", "PROBLEM", 121, 135], ["acute leukaemia", "PROBLEM", 155, 170], ["the fever", "PROBLEM", 195, 204], ["myalgia", "PROBLEM", 209, 216], ["a viral respiratory illness", "PROBLEM", 220, 247], ["pulmonary", "ANATOMY", 17, 26], ["AML", "OBSERVATION", 78, 81], ["fever", "OBSERVATION", 111, 116], ["medullary", "ANATOMY", 121, 130], ["acute", "OBSERVATION_MODIFIER", 155, 160], ["leukaemia", "OBSERVATION", 161, 170], ["viral", "OBSERVATION_MODIFIER", 222, 227], ["respiratory illness", "OBSERVATION", 228, 247]]], ["Other elevated prognostic markers of COVID-19 such as D-dimer, LDH, and thrombocytopenia can all be attributed to acute leukaemia in this patient.", [["acute leukaemia", "ANATOMY", 114, 129], ["thrombocytopenia", "DISEASE", 72, 88], ["acute leukaemia", "DISEASE", 114, 129], ["COVID-19", "GENE_OR_GENE_PRODUCT", 37, 45], ["D-dimer", "GENE_OR_GENE_PRODUCT", 54, 61], ["LDH", "GENE_OR_GENE_PRODUCT", 63, 66], ["acute leukaemia", "CANCER", 114, 129], ["patient", "ORGANISM", 138, 145], ["COVID", "PROTEIN", 37, 42], ["D-dimer", "PROTEIN", 54, 61], ["LDH", "PROTEIN", 63, 66], ["patient", "SPECIES", 138, 145], ["Other elevated prognostic markers", "PROBLEM", 0, 33], ["COVID", "TEST", 37, 42], ["D-dimer", "TEST", 54, 61], ["LDH", "TEST", 63, 66], ["thrombocytopenia", "PROBLEM", 72, 88], ["acute leukaemia", "PROBLEM", 114, 129], ["elevated", "OBSERVATION_MODIFIER", 6, 14], ["LDH", "ANATOMY", 63, 66], ["thrombocytopenia", "OBSERVATION", 72, 88], ["acute", "OBSERVATION_MODIFIER", 114, 119], ["leukaemia", "OBSERVATION", 120, 129]]], ["It was unclear if the clinical symptoms in this case were secondary to hyperleucocytosis or COVID-19 infection.DiscussionThe coexistence of a highly communicable infectious disease also introduced significant practical complications in the management of this case.", [["hyperleucocytosis", "DISEASE", 71, 88], ["COVID-19", "CHEMICAL", 92, 100], ["infection", "DISEASE", 101, 110], ["infectious disease", "DISEASE", 162, 180], ["the clinical symptoms", "PROBLEM", 18, 39], ["hyperleucocytosis", "PROBLEM", 71, 88], ["COVID-19 infection", "PROBLEM", 92, 110], ["a highly communicable infectious disease", "PROBLEM", 140, 180], ["significant practical complications", "PROBLEM", 197, 232], ["the management", "TREATMENT", 236, 250], ["infection", "OBSERVATION", 101, 110], ["significant", "OBSERVATION_MODIFIER", 197, 208]]], ["Following careful consideration, the patient was placed in isolation in the respiratory ward rather than the haematology ward to reduce exposure to other vulnerable patients.", [["patient", "ORGANISM", 37, 44], ["patients", "ORGANISM", 165, 173], ["patient", "SPECIES", 37, 44], ["patients", "SPECIES", 165, 173]]], ["There is also concern that immunocompromised patients have prolonged viral shedding and may remain infective for longer.", [["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["immunocompromised", "PROBLEM", 27, 44], ["prolonged viral shedding", "PROBLEM", 59, 83], ["infective", "PROBLEM", 99, 108], ["immunocompromised", "OBSERVATION", 27, 44], ["prolonged", "OBSERVATION_MODIFIER", 59, 68], ["viral", "OBSERVATION", 69, 74], ["infective", "OBSERVATION", 99, 108]]], ["We were conservative in de-isolating our patient to the main haematology ward and only did so following complete resolution of respiratory symptoms and two consecutive negative PCR nasopharyngeal swabs were obtained.", [["respiratory", "ANATOMY", 127, 138], ["nasopharyngeal swabs", "ANATOMY", 181, 201], ["patient", "ORGANISM", 41, 48], ["patient", "SPECIES", 41, 48], ["respiratory symptoms", "PROBLEM", 127, 147], ["PCR nasopharyngeal swabs", "TEST", 177, 201], ["respiratory", "ANATOMY", 127, 138], ["nasopharyngeal", "ANATOMY", 181, 195]]], ["Furthermore, isolation for the first few weeks with minimized staff exposure and no family or friend visits coupled with the natural grief process of such a grave diagnosis may lead to an increased need for psychological health support.DiscussionRoutine monitoring and treatment options were also affected by the co-diagnoses.", [["isolation", "TREATMENT", 13, 22], ["psychological health support", "TREATMENT", 207, 235], ["DiscussionRoutine monitoring", "TEST", 236, 264], ["treatment options", "TREATMENT", 269, 286]]], ["For example, we were unable to obtain a pre-treatment echocardiogram prior to commencing anthracycline due to local infection control guidelines, although we note that myocarditis is a wellrecognized sequelae of COVID-19 infection [14] .", [["anthracycline", "CHEMICAL", 89, 102], ["infection", "DISEASE", 116, 125], ["myocarditis", "DISEASE", 168, 179], ["COVID-19", "CHEMICAL", 212, 220], ["infection", "DISEASE", 221, 230], ["anthracycline", "CHEMICAL", 89, 102], ["COVID-19", "CHEMICAL", 212, 220], ["anthracycline", "SIMPLE_CHEMICAL", 89, 102], ["a pre-treatment echocardiogram", "TEST", 38, 68], ["anthracycline", "TREATMENT", 89, 102], ["local infection control guidelines", "TREATMENT", 110, 144], ["myocarditis", "PROBLEM", 168, 179], ["COVID-19 infection", "PROBLEM", 212, 230], ["infection", "OBSERVATION", 116, 125], ["myocarditis", "OBSERVATION", 168, 179]]], ["Instead, the patient received the iron chelator dexrazoxane to decrease the risk of anthracycline-induced cardiotoxicity.DiscussionWe also elected to continue moderately aggressive fluid resuscitation despite an elevated NT-proBNP and the risk of cardiac complications following COVID-19, as the benefit of preventing TLS was deemed greater than the potential risks of fluid overload.DiscussionIn conclusion, this case report adds to the discussion of COVID-19 and whether immunosuppression alters the clinical course and outcome.", [["fluid", "ANATOMY", 181, 186], ["cardiac", "ANATOMY", 247, 254], ["fluid", "ANATOMY", 369, 374], ["iron", "CHEMICAL", 34, 38], ["dexrazoxane", "CHEMICAL", 48, 59], ["anthracycline", "CHEMICAL", 84, 97], ["cardiotoxicity", "DISEASE", 106, 120], ["NT-proBNP", "CHEMICAL", 221, 230], ["cardiac complications", "DISEASE", 247, 268], ["TLS", "DISEASE", 318, 321], ["fluid overload", "DISEASE", 369, 383], ["iron", "CHEMICAL", 34, 38], ["dexrazoxane", "CHEMICAL", 48, 59], ["anthracycline", "CHEMICAL", 84, 97], ["COVID-19", "CHEMICAL", 279, 287], ["patient", "ORGANISM", 13, 20], ["iron chelator", "SIMPLE_CHEMICAL", 34, 47], ["dexrazoxane", "SIMPLE_CHEMICAL", 48, 59], ["anthracycline", "SIMPLE_CHEMICAL", 84, 97], ["NT-proBNP", "GENE_OR_GENE_PRODUCT", 221, 230], ["cardiac", "ORGAN", 247, 254], ["fluid", "ORGANISM_SUBSTANCE", 369, 374], ["COVID-19", "CELL", 452, 460], ["patient", "SPECIES", 13, 20], ["the iron chelator dexrazoxane", "TREATMENT", 30, 59], ["anthracycline", "TREATMENT", 84, 97], ["induced cardiotoxicity", "PROBLEM", 98, 120], ["moderately aggressive fluid resuscitation", "TREATMENT", 159, 200], ["an elevated NT-proBNP", "PROBLEM", 209, 230], ["cardiac complications", "PROBLEM", 247, 268], ["COVID", "TEST", 279, 284], ["TLS", "TREATMENT", 318, 321], ["fluid overload", "PROBLEM", 369, 383], ["COVID", "TEST", 452, 457], ["immunosuppression", "TREATMENT", 473, 490], ["anthracycline", "OBSERVATION", 84, 97], ["elevated", "OBSERVATION", 212, 220], ["cardiac", "ANATOMY", 247, 254], ["complications", "OBSERVATION", 255, 268], ["fluid overload", "OBSERVATION", 369, 383]]], ["It highlights the difficulties of treating high-grade haematological neoplasia in the current pandemic.", [["high-grade haematological neoplasia", "ANATOMY", 43, 78], ["neoplasia", "DISEASE", 69, 78], ["high-grade haematological neoplasia", "CANCER", 43, 78], ["high-grade haematological neoplasia", "PROBLEM", 43, 78], ["haematological neoplasia", "OBSERVATION", 54, 78]]], ["To our knowledge, this is the first documented case of AML and COVID-19.Disclosure StatementAppropriate written informed consent was obtained for publication of this case report and accompanying images.", [["AML", "ANATOMY", 55, 58], ["AML", "DISEASE", 55, 58], ["AML", "CANCER", 55, 58], ["AML", "PROBLEM", 55, 58], ["COVID", "TEST", 63, 68], ["accompanying images", "TEST", 182, 201], ["AML", "OBSERVATION", 55, 58]]]], "42311b11c5256d17559b1bbda5acc951593e6406": [["Introduction exert their roles in regulating chromatin accessibility, mRNA stability and protein activity by 48 interacting with chromatin DNA, mRNAs or proteins (15-18).", [["chromatin", "ANATOMY", 45, 54], ["chromatin", "ANATOMY", 129, 138], ["chromatin", "CELLULAR_COMPONENT", 45, 54], ["chromatin", "CELLULAR_COMPONENT", 129, 138], ["DNA", "CELLULAR_COMPONENT", 139, 142], ["chromatin", "DNA", 45, 54], ["chromatin DNA", "DNA", 129, 142], ["mRNAs", "RNA", 144, 149], ["mRNA stability", "TEST", 70, 84], ["protein activity", "TEST", 89, 105], ["chromatin DNA", "TEST", 129, 142], ["mRNAs or proteins", "TEST", 144, 161]]], ["With the discovery and 49 characterization of an increasing number of lncRNAs, several mechanisms of these lncRNAs 50 in virus-host interactions have been elucidated (19) , however, many others remain 51 uncharacterized.", [["lncRNAs", "DNA", 70, 77], ["lncRNAs 50", "DNA", 107, 117], ["an increasing number of lncRNAs", "PROBLEM", 46, 77], ["these lncRNAs", "TEST", 101, 114], ["increasing", "OBSERVATION_MODIFIER", 49, 59], ["number", "OBSERVATION_MODIFIER", 60, 66], ["lncRNAs", "OBSERVATION", 70, 77]]], ["52 Influenza A virus (IAV) is a leading cause of respiratory-related morbidity and mortality, to the production of type I IFN and inflammatory cytokines (31).", [["respiratory", "ANATOMY", 49, 60], ["Influenza A virus", "DISEASE", 3, 20], ["52", "ORGANISM", 0, 2], ["Influenza A virus", "ORGANISM", 3, 20], ["IAV", "ORGANISM", 22, 25], ["type I IFN", "GENE_OR_GENE_PRODUCT", 115, 125], ["type I IFN", "PROTEIN", 115, 125], ["inflammatory cytokines", "PROTEIN", 130, 152], ["Influenza A virus", "SPECIES", 3, 20], ["Influenza A virus", "SPECIES", 3, 20], ["IAV", "SPECIES", 22, 25], ["Influenza A virus (IAV", "PROBLEM", 3, 25], ["respiratory-related morbidity", "PROBLEM", 49, 78], ["type I IFN and inflammatory cytokines", "PROBLEM", 115, 152], ["inflammatory", "OBSERVATION_MODIFIER", 130, 142]]], ["However, little is known 73 about the roles of lncRNAs in IAV-infected patients or the mechanisms of lncRNA activity 74 and host antiviral immune responses.", [["IAV-infected", "DISEASE", 58, 70], ["IAV", "ORGANISM", 58, 61], ["patients", "ORGANISM", 71, 79], ["lncRNAs", "DNA", 47, 54], ["patients", "SPECIES", 71, 79], ["lncRNA activity", "PROBLEM", 101, 116], ["infected", "OBSERVATION_MODIFIER", 62, 70]]], ["75 In this study, we profile the lncRNAs of IAV-infected patient neutrophils and identify a 76 human lncRNA, designated AVAN, which plays a critical role in anti-IAV infection.", [["neutrophils", "ANATOMY", 65, 76], ["anti-IAV", "ANATOMY", 157, 165], ["infection", "DISEASE", 166, 175], ["IAV", "ORGANISM", 44, 47], ["patient", "ORGANISM", 57, 64], ["neutrophils", "CELL", 65, 76], ["human", "ORGANISM", 95, 100], ["AVAN", "GENE_OR_GENE_PRODUCT", 120, 124], ["anti-IAV", "CANCER", 157, 165], ["lncRNAs", "DNA", 33, 40], ["IAV-infected patient neutrophils", "CELL_TYPE", 44, 76], ["76 human lncRNA", "DNA", 92, 107], ["AVAN", "DNA", 120, 124], ["patient", "SPECIES", 57, 64], ["human", "SPECIES", 95, 100], ["human", "SPECIES", 95, 100], ["anti-IAV", "SPECIES", 157, 165], ["this study", "TEST", 6, 16], ["IAV", "PROBLEM", 44, 47], ["a 76 human lncRNA", "PROBLEM", 90, 107], ["anti-IAV infection", "PROBLEM", 157, 175], ["infection", "OBSERVATION", 166, 175]]], ["77 Functional experiments demonstrate that AVAN up-regulates FOXO3a expression to promote 78 neutrophil chemotaxis and recruitment.", [["neutrophil", "ANATOMY", 93, 103], ["AVAN", "GENE_OR_GENE_PRODUCT", 43, 47], ["FOXO3a", "GENE_OR_GENE_PRODUCT", 61, 67], ["neutrophil", "CELL", 93, 103], ["AVAN", "PROTEIN", 43, 47], ["FOXO3a", "PROTEIN", 61, 67], ["AVAN", "TEST", 43, 47], ["neutrophil chemotaxis", "TEST", 93, 114], ["neutrophil chemotaxis", "OBSERVATION", 93, 114]]], ["In addition, AVAN enhances the activation of the 79 RIG-I-mediated antiviral response by directly binding to TRIM25.", [["AVAN", "CHEMICAL", 13, 17], ["AVAN", "CHEMICAL", 13, 17], ["AVAN", "SIMPLE_CHEMICAL", 13, 17], ["RIG-I", "GENE_OR_GENE_PRODUCT", 52, 57], ["TRIM25", "GENE_OR_GENE_PRODUCT", 109, 115], ["AVAN", "PROTEIN", 13, 17], ["79 RIG-I", "PROTEIN", 49, 57], ["TRIM25", "PROTEIN", 109, 115], ["antiviral response", "OBSERVATION", 67, 85]]], ["These results show that an 80 unannotated lncRNA, AVAN, functions to maintain innate immune homeostasis of antiviral 81 immunity during IAV infection.", [["IAV infection", "DISEASE", 136, 149], ["AVAN", "GENE_OR_GENE_PRODUCT", 50, 54], ["IAV", "ORGANISM", 136, 139], ["80 unannotated lncRNA", "DNA", 27, 48], ["AVAN", "DNA", 50, 54], ["IAV", "SPECIES", 136, 139], ["an 80 unannotated lncRNA", "PROBLEM", 24, 48], ["AVAN", "TREATMENT", 50, 54], ["innate immune homeostasis", "TREATMENT", 78, 103], ["antiviral", "TREATMENT", 107, 116], ["IAV infection", "PROBLEM", 136, 149], ["lncRNA", "OBSERVATION", 42, 48], ["IAV", "OBSERVATION_MODIFIER", 136, 139], ["infection", "OBSERVATION", 140, 149]]], ["82 LncRNA expression is regulated by the influenza A (H7N9) virus in human neutrophils.", [["neutrophils", "ANATOMY", 75, 86], ["LncRNA", "GENE_OR_GENE_PRODUCT", 3, 9], ["influenza A (H7N9) virus", "ORGANISM", 41, 65], ["human", "ORGANISM", 69, 74], ["neutrophils", "CELL", 75, 86], ["LncRNA", "PROTEIN", 3, 9], ["human neutrophils", "CELL_TYPE", 69, 86], ["human", "SPECIES", 69, 74], ["influenza A (H7N9) virus", "SPECIES", 41, 65], ["human", "SPECIES", 69, 74], ["the influenza A (H7N9) virus in human neutrophils", "PROBLEM", 37, 86]]], ["84 Neutrophils, the prototypic cells of the innate immune system, are reported to play a 85 pivotal role in the innate immune response to IAV (21-23).", [["Neutrophils", "ANATOMY", 3, 14], ["cells", "ANATOMY", 31, 36], ["immune system", "ANATOMY", 51, 64], ["Neutrophils", "CELL", 3, 14], ["cells", "CELL", 31, 36], ["Neutrophils", "CELL_TYPE", 3, 14], ["Neutrophils", "TEST", 3, 14], ["IAV", "TEST", 138, 141]]], ["To explore the roles of host 86 lncRNAs during IAV infection, we profiled whole transcriptional alterations using RNA-Seq 87 in neutrophil samples from patients infected with IAV in the acute stage and their matched 88 recovery-stage samples (GSE108807).", [["neutrophil samples", "ANATOMY", 128, 146], ["samples", "ANATOMY", 234, 241], ["IAV infection", "DISEASE", 47, 60], ["GSE108807", "CHEMICAL", 243, 252], ["IAV", "ORGANISM", 47, 50], ["neutrophil samples", "CELL", 128, 146], ["patients", "ORGANISM", 152, 160], ["86 lncRNAs", "DNA", 29, 39], ["patients", "SPECIES", 152, 160], ["IAV", "SPECIES", 47, 50], ["IAV", "SPECIES", 175, 178], ["IAV infection", "PROBLEM", 47, 60], ["whole transcriptional alterations", "PROBLEM", 74, 107], ["RNA", "TEST", 114, 117], ["neutrophil samples", "TEST", 128, 146], ["IAV", "PROBLEM", 175, 178], ["IAV", "OBSERVATION_MODIFIER", 47, 50], ["infection", "OBSERVATION", 51, 60]]], ["We identified a total of 404 differentially expressed 89 protein-coding genes (FC>2, p<0.05), including 234 up-regulated and 170 down-regulated 90 genes, in each patient sample ( Fig S1) .", [["patient", "ORGANISM", 162, 169], ["89 protein-coding genes", "DNA", 54, 77], ["90 genes", "DNA", 144, 152], ["patient", "SPECIES", 162, 169], ["protein", "TEST", 57, 64], ["coding genes", "TEST", 65, 77], ["FC", "TEST", 79, 81]]], ["The differentially expressed genes were strongly 91 associated with the immune response, inflammatory response and innate immune response 92 according to Gene ontology (GO) analysis ( Fig 1A) .", [["the immune response", "PROBLEM", 68, 87], ["inflammatory response", "PROBLEM", 89, 110]]], ["We then mapped the detected lncRNAs 93 to the human genome (UCSC version hg19) and the NONCODE V3.0 database and found an 94 average of 240 up-regulated (range from 164 to 357) and 193 down-regulated (range from 95 158 to 257) novel lncRNAs in acute-stage influenza patients compared with their 96 recovery-stage counterparts (FC>2, p<0.05) and subjected them to a cluster analysis ( Fig 1B) .", [["acute-stage influenza", "DISEASE", 244, 265], ["human", "ORGANISM", 46, 51], ["influenza", "ORGANISM", 256, 265], ["patients", "ORGANISM", 266, 274], ["lncRNAs 93", "DNA", 28, 38], ["human genome", "DNA", 46, 58], ["UCSC version hg19", "DNA", 60, 77], ["NONCODE V3.0", "DNA", 87, 99], ["lncRNAs", "DNA", 233, 240], ["human", "SPECIES", 46, 51], ["patients", "SPECIES", 266, 274], ["human", "SPECIES", 46, 51], ["the NONCODE V3.0 database", "TEST", 83, 108], ["novel lncRNAs", "TEST", 227, 240], ["acute-stage influenza patients", "PROBLEM", 244, 274], ["FC", "TEST", 327, 329], ["a cluster analysis", "TEST", 363, 381], ["acute", "OBSERVATION_MODIFIER", 244, 249], ["-stage", "OBSERVATION_MODIFIER", 249, 255], ["influenza", "OBSERVATION", 256, 265]]], ["97 To investigate the association between lncRNAs and IAV infection, in silico analysis 98 identified 26 novel lncRNAs candidates with notably aberrant expression (Fig 1C) .", [["IAV infection", "DISEASE", 54, 67], ["lncRNAs", "DNA", 42, 49], ["lncRNAs candidates", "DNA", 111, 129], ["IAV", "SPECIES", 54, 57], ["IAV infection", "PROBLEM", 54, 67], ["silico analysis", "TEST", 72, 87], ["IAV", "OBSERVATION_MODIFIER", 54, 57], ["infection", "OBSERVATION", 58, 67]]], ["To 99 confirm the expression of these lncRNAs, we separated the neutrophils and monocytes from 100 healthy volunteers and infected the cells with IAV for 12 h and found that XLOC_040025 101 (AVAN) was most significantly up-regulated after IAV challenge (Fig 1D, E) .", [["neutrophils", "ANATOMY", 64, 75], ["monocytes", "ANATOMY", 80, 89], ["cells", "ANATOMY", 135, 140], ["neutrophils", "CELL", 64, 75], ["monocytes", "CELL", 80, 89], ["volunteers", "ORGANISM", 107, 117], ["cells", "CELL", 135, 140], ["IAV", "ORGANISM", 146, 149], ["XLOC_040025 101", "GENE_OR_GENE_PRODUCT", 174, 189], ["AVAN", "GENE_OR_GENE_PRODUCT", 191, 195], ["IAV", "ORGANISM", 239, 242], ["lncRNAs", "DNA", 38, 45], ["neutrophils", "CELL_TYPE", 64, 75], ["monocytes", "CELL_TYPE", 80, 89], ["IAV", "SPECIES", 146, 149], ["XLOC_040025 101", "SPECIES", 174, 189], ["IAV", "SPECIES", 239, 242], ["the neutrophils", "TEST", 60, 75], ["monocytes", "TEST", 80, 89], ["XLOC", "TEST", 174, 178], ["IAV challenge", "TREATMENT", 239, 252], ["neutrophils", "ANATOMY", 64, 75]]], ["We also infected 102 human alveolar epithelial cells (A549) with IAV and measured the expression of the 26 103 lncRNAs and found that AVAN was most strongly up-regulated after IAV infection (Fig 1F) .", [["alveolar epithelial cells", "ANATOMY", 27, 52], ["A549", "ANATOMY", 54, 58], ["IAV infection", "DISEASE", 176, 189], ["human", "ORGANISM", 21, 26], ["alveolar epithelial cells", "CELL", 27, 52], ["A549", "CELL", 54, 58], ["IAV", "ORGANISM", 65, 68], ["AVAN", "GENE_OR_GENE_PRODUCT", 134, 138], ["IAV", "ORGANISM", 176, 179], ["102 human alveolar epithelial cells", "CELL_LINE", 17, 52], ["A549", "CELL_LINE", 54, 58], ["26 103 lncRNAs", "DNA", 104, 118], ["AVAN", "PROTEIN", 134, 138], ["human", "SPECIES", 21, 26], ["human", "SPECIES", 21, 26], ["IAV", "SPECIES", 65, 68], ["IAV", "SPECIES", 176, 179], ["IAV", "PROBLEM", 65, 68], ["AVAN", "TEST", 134, 138], ["IAV infection", "PROBLEM", 176, 189], ["infected", "OBSERVATION_MODIFIER", 8, 16], ["102 human", "OBSERVATION_MODIFIER", 17, 26], ["alveolar", "ANATOMY_MODIFIER", 27, 35], ["epithelial cells", "OBSERVATION", 36, 52], ["IAV", "OBSERVATION_MODIFIER", 176, 179], ["infection", "OBSERVATION", 180, 189]]], ["106 We then performed qRT-PCR to quantify AVAN expression in the RNA-Seq samples and 107 found that the results were consistent with the RNA-Seq data ( Fig S2A) .", [["RNA-Seq samples", "ANATOMY", 65, 80], ["AVAN", "GENE_OR_GENE_PRODUCT", 42, 46], ["AVAN", "PROTEIN", 42, 46], ["qRT", "TEST", 22, 25], ["PCR", "TEST", 26, 29], ["the RNA", "TEST", 133, 140], ["consistent with", "UNCERTAINTY", 117, 132]]], ["Thus, AVAN was 108 chosen for subsequent investigation.", [["AVAN", "TEST", 6, 10], ["subsequent investigation", "TEST", 30, 54]]], ["To further confirm the expression of AVAN in 109 IAV-infected patients, we collected blood samples from 63 additional IAV-positive patients 110 and measured the expression of AVAN, which was significantly up-regulated in the neutrophils 111 of these patients (Fig 2A; Table S1 ).", [["blood samples", "ANATOMY", 85, 98], ["neutrophils", "ANATOMY", 225, 236], ["IAV-infected", "DISEASE", 49, 61], ["AVAN", "GENE_OR_GENE_PRODUCT", 37, 41], ["IAV", "ORGANISM", 49, 52], ["patients", "ORGANISM", 62, 70], ["blood samples", "ORGANISM_SUBSTANCE", 85, 98], ["IAV", "ORGANISM", 118, 121], ["patients", "ORGANISM", 131, 139], ["AVAN", "GENE_OR_GENE_PRODUCT", 175, 179], ["neutrophils", "CELL", 225, 236], ["patients", "ORGANISM", 250, 258], ["AVAN", "PROTEIN", 37, 41], ["AVAN", "PROTEIN", 175, 179], ["neutrophils", "CELL_TYPE", 225, 236], ["patients", "SPECIES", 62, 70], ["patients", "SPECIES", 131, 139], ["patients", "SPECIES", 250, 258], ["AVAN", "TEST", 37, 41], ["blood samples", "TEST", 85, 98], ["the neutrophils", "TEST", 221, 236], ["infected", "OBSERVATION_MODIFIER", 53, 61]]], ["Similarly, AVAN was up-regulated in A549 cells after 112 infection with multiple sub-strains of IAV and several other viruses, including Sendai virus 113 (SeV) and respiratory syncytial virus (RSV) (Fig 2B) .", [["A549 cells", "ANATOMY", 36, 46], ["infection", "DISEASE", 57, 66], ["respiratory syncytial virus", "DISEASE", 164, 191], ["AVAN", "GENE_OR_GENE_PRODUCT", 11, 15], ["A549 cells", "CELL", 36, 46], ["IAV", "ORGANISM", 96, 99], ["Sendai virus 113", "ORGANISM", 137, 153], ["SeV", "ORGANISM", 155, 158], ["respiratory syncytial virus", "ORGANISM", 164, 191], ["RSV", "ORGANISM", 193, 196], ["AVAN", "PROTEIN", 11, 15], ["A549 cells", "CELL_LINE", 36, 46], ["Sendai virus", "SPECIES", 137, 149], ["respiratory syncytial virus", "SPECIES", 164, 191], ["IAV", "SPECIES", 96, 99], ["Sendai virus 113", "SPECIES", 137, 153], ["SeV", "SPECIES", 155, 158], ["respiratory syncytial virus", "SPECIES", 164, 191], ["RSV", "SPECIES", 193, 196], ["AVAN", "TEST", 11, 15], ["112 infection", "PROBLEM", 53, 66], ["multiple sub-strains", "PROBLEM", 72, 92], ["IAV", "PROBLEM", 96, 99], ["several other viruses", "PROBLEM", 104, 125], ["Sendai virus", "PROBLEM", 137, 149], ["respiratory syncytial virus", "PROBLEM", 164, 191], ["A549 cells", "OBSERVATION", 36, 46], ["viruses", "OBSERVATION", 118, 125], ["respiratory syncytial", "ANATOMY", 164, 185]]], ["Moreover, AVAN expression was 114 significantly up-regulated upon IAV challenge in a time-and dose-dependent manner in A549 115 cells (Fig 2C, D) .", [["A549 115 cells", "ANATOMY", 119, 133], ["AVAN", "GENE_OR_GENE_PRODUCT", 10, 14], ["IAV", "ORGANISM", 66, 69], ["A549 115 cells", "CELL", 119, 133], ["AVAN", "PROTEIN", 10, 14], ["A549 115 cells", "CELL_LINE", 119, 133], ["IAV", "SPECIES", 66, 69], ["AVAN expression", "TEST", 10, 25], ["IAV challenge", "TREATMENT", 66, 79]]], ["Moreover, AVAN expression was also significantly up-regulated in a time- 116 and dose-dependent manner in the human promyelocytic leukemia cell line (HL60), which is 117 often a substitute for neutrophils, upon IAV challenge (Fig S2B, C) .", [["promyelocytic leukemia cell line", "ANATOMY", 116, 148], ["HL60", "ANATOMY", 150, 154], ["neutrophils", "ANATOMY", 193, 204], ["promyelocytic leukemia", "DISEASE", 116, 138], ["AVAN", "GENE_OR_GENE_PRODUCT", 10, 14], ["human", "ORGANISM", 110, 115], ["promyelocytic leukemia cell line", "CELL", 116, 148], ["HL60", "CELL", 150, 154], ["neutrophils", "CELL", 193, 204], ["AVAN", "PROTEIN", 10, 14], ["human promyelocytic leukemia cell line", "CELL_LINE", 110, 148], ["HL60", "CELL_LINE", 150, 154], ["neutrophils", "CELL_TYPE", 193, 204], ["human", "SPECIES", 110, 115], ["human", "SPECIES", 110, 115], ["IAV", "SPECIES", 211, 214], ["the human promyelocytic leukemia cell line", "TREATMENT", 106, 148], ["neutrophils", "TEST", 193, 204], ["IAV challenge", "TREATMENT", 211, 224], ["human", "ANATOMY", 110, 115], ["promyelocytic leukemia cell line", "OBSERVATION", 116, 148]]], ["Subcellular fractionation 118 followed by qRT-PCR in IAV-infected A549 cells revealed that the amount of AVAN localized 119 in the cytoplasm was nearly as same as the one in nucleus (Fig 2E, Fig S2D) .", [["Subcellular", "ANATOMY", 0, 11], ["A549 cells", "ANATOMY", 66, 76], ["cytoplasm", "ANATOMY", 131, 140], ["nucleus", "ANATOMY", 174, 181], ["IAV", "ORGANISM", 53, 56], ["A549 cells", "CELL", 66, 76], ["AVAN", "GENE_OR_GENE_PRODUCT", 105, 109], ["cytoplasm", "ORGANISM_SUBSTANCE", 131, 140], ["nucleus", "CELLULAR_COMPONENT", 174, 181], ["IAV-infected A549 cells", "CELL_LINE", 53, 76], ["AVAN", "PROTEIN", 105, 109], ["IAV", "SPECIES", 53, 56], ["Subcellular fractionation", "TEST", 0, 25], ["qRT", "TEST", 42, 45], ["PCR", "TEST", 46, 49], ["IAV", "PROBLEM", 53, 56], ["infected A549 cells", "PROBLEM", 57, 76], ["AVAN", "TEST", 105, 109], ["fractionation", "OBSERVATION", 12, 25], ["A549 cells", "OBSERVATION", 66, 76], ["amount", "OBSERVATION_MODIFIER", 95, 101], ["nucleus", "ANATOMY", 174, 181]]], ["Besides, we 120 performed RNA fluorescence in situ hybridization (RNA-FISH) with two specific probes in 121 IAV-uninfected and -infected A549 cells and found that AVAN localized in the cytoplasm and 122 nucleus were almost the same abundance ( Fig 2F) .", [["A549 cells", "ANATOMY", 137, 147], ["cytoplasm", "ANATOMY", 185, 194], ["nucleus", "ANATOMY", 203, 210], ["A549 cells", "CELL", 137, 147], ["AVAN", "GENE_OR_GENE_PRODUCT", 163, 167], ["cytoplasm", "ORGANISM_SUBSTANCE", 185, 194], ["nucleus", "CELLULAR_COMPONENT", 203, 210], ["A549 cells", "CELL_LINE", 137, 147], ["AVAN", "PROTEIN", 163, 167], ["RNA fluorescence", "TEST", 26, 42], ["IAV", "PROBLEM", 108, 111], ["infected A549 cells", "PROBLEM", 128, 147], ["AVAN", "PROBLEM", 163, 167], ["A549 cells", "OBSERVATION", 137, 147], ["cytoplasm", "ANATOMY_MODIFIER", 185, 194], ["122 nucleus", "OBSERVATION_MODIFIER", 199, 210]]], ["In addition, we constructed competitive 123 association FISH to display the specific distribution of AVAN.", [["AVAN", "GENE_OR_GENE_PRODUCT", 101, 105], ["AVAN", "PROTEIN", 101, 105]]], ["When adding free 124 labeling-probes, the fluorescent dye from biotin labeling-probes was weaken (Fig S2E) .", [["biotin", "CHEMICAL", 63, 69], ["biotin", "CHEMICAL", 63, 69], ["fluorescent dye", "SIMPLE_CHEMICAL", 42, 57], ["biotin", "SIMPLE_CHEMICAL", 63, 69], ["the fluorescent dye", "TREATMENT", 38, 57], ["biotin labeling", "TREATMENT", 63, 78]]], ["AVAN 125 exhibits no protein-coding potential according to ORF finder (32) and the coding potential calculator (33) (Fig S2F) .", [["AVAN 125", "CHEMICAL", 0, 8], ["AVAN 125", "PROTEIN", 0, 8], ["ORF", "DNA", 59, 62], ["ORF finder", "TEST", 59, 69]]], ["Only one transcript variant (approximately 500 nt) of AVAN was 127 found in A549 cells, and it was found to be up-regulated upon IAV infection using northern 128 blot analysis (Fig 2G) .", [["A549 cells", "ANATOMY", 76, 86], ["infection", "DISEASE", 133, 142], ["A549 cells", "CELL", 76, 86], ["IAV", "ORGANISM", 129, 132], ["A549 cells", "CELL_LINE", 76, 86], ["IAV", "SPECIES", 129, 132], ["AVAN", "TEST", 54, 58], ["A549 cells", "PROBLEM", 76, 86], ["IAV infection", "PROBLEM", 129, 142], ["blot analysis", "TEST", 162, 175], ["transcript variant", "OBSERVATION", 9, 27], ["A549 cells", "OBSERVATION", 76, 86], ["IAV", "OBSERVATION_MODIFIER", 129, 132], ["infection", "OBSERVATION", 133, 142]]], ["The exact transcript length (517 nt) of AVAN was confirmed by 5' and 129 3' RACE (Table S2) , which revealed that AVAN is polyadenylated (Fig S2G) .", [["AVAN", "GENE_OR_GENE_PRODUCT", 40, 44], ["AVAN", "GENE_OR_GENE_PRODUCT", 114, 118], ["AVAN", "DNA", 40, 44], ["5' and 129 3' RACE", "DNA", 62, 80], ["AVAN", "DNA", 114, 118], ["AVAN", "TEST", 40, 44], ["RACE (Table S2)", "TEST", 76, 91], ["AVAN", "PROBLEM", 114, 118]]], ["Taken Table S3 -S8), suggesting that AVAN participates in innate antiviral immunity.", [["AVAN", "CHEMICAL", 37, 41], ["S3 -S8", "GENE_OR_GENE_PRODUCT", 12, 18], ["AVAN", "GENE_OR_GENE_PRODUCT", 37, 41], ["S8", "PROTEIN", 16, 18], ["AVAN", "PROTEIN", 37, 41]]], ["To 140 identify the functions of AVAN, we generated AVAN-overexpressing A549 cells ( Fig 3A) and 141 found that viral replication was strongly inhibited (Fig 3B) .", [["A549 cells", "ANATOMY", 72, 82], ["AVAN", "GENE_OR_GENE_PRODUCT", 33, 37], ["AVAN", "GENE_OR_GENE_PRODUCT", 52, 56], ["A549 cells", "CELL", 72, 82], ["Fig 3A", "CELL", 85, 91], ["AVAN", "PROTEIN", 33, 37], ["AVAN-overexpressing A549 cells", "CELL_LINE", 52, 82], ["AVAN", "TEST", 52, 56], ["viral replication", "PROBLEM", 112, 129], ["A549 cells", "OBSERVATION", 72, 82], ["viral replication", "OBSERVATION", 112, 129]]], ["In contrast, virus titer was 142 up-regulated following AVAN knockdown with two specific siRNAs (Fig 3H, I IFN-\u03b2 transcript levels upon IAV infection compared with those of the control vector ( Fig 3C) .", [["IAV infection", "DISEASE", 136, 149], ["AVAN", "GENE_OR_GENE_PRODUCT", 56, 60], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 107, 112], ["IAV", "ORGANISM", 136, 139], ["IFN", "PROTEIN", 107, 110], ["IAV", "SPECIES", 136, 139], ["virus titer", "TEST", 13, 24], ["AVAN knockdown", "TREATMENT", 56, 70], ["I IFN", "TREATMENT", 105, 110], ["transcript levels", "TEST", 113, 130], ["IAV infection", "PROBLEM", 136, 149], ["IAV", "OBSERVATION_MODIFIER", 136, 139], ["infection", "OBSERVATION", 140, 149]]], ["150 To confirm this result, we performed ELISA to measure IFN-\u03b1 and IFN-\u03b2 protein expression 151 and found that IFN-\u03b1 and IFN-\u03b2 were strongly up-regulated in AVAN-overexpressing A549 152 cells during IAV infection ( Fig 3D) .", [["AVAN-overexpressing A549 152 cells", "ANATOMY", 158, 192], ["IAV infection", "DISEASE", 200, 213], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 58, 63], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 68, 73], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 112, 117], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 122, 127], ["AVAN", "CELL", 158, 162], ["A549 152 cells", "CELL", 178, 192], ["IAV", "ORGANISM", 200, 203], ["IFN", "PROTEIN", 58, 61], ["IFN", "PROTEIN", 68, 71], ["IFN", "PROTEIN", 112, 115], ["\u03b1", "PROTEIN", 116, 117], ["IFN", "PROTEIN", 122, 125], ["\u03b2", "PROTEIN", 126, 127], ["AVAN-overexpressing A549 152 cells", "CELL_LINE", 158, 192], ["IAV", "SPECIES", 200, 203], ["ELISA", "TEST", 41, 46], ["IFN", "TEST", 58, 61], ["\u03b1", "TEST", 62, 63], ["IFN", "TEST", 68, 71], ["protein expression", "TEST", 74, 92], ["IFN", "TEST", 112, 115], ["IFN", "TEST", 122, 125], ["AVAN", "TEST", 158, 162], ["overexpressing A549 152 cells", "PROBLEM", 163, 192], ["IAV infection", "PROBLEM", 200, 213], ["IAV", "OBSERVATION_MODIFIER", 200, 203], ["infection", "OBSERVATION", 204, 213]]], ["Conversely, these phenomena were abolished by 153 knocking down AVAN (Fig 3J, K) .", [["AVAN", "PROTEIN", 64, 68]]], ["154 The above GSEA data and GO analysis showed that the genes related to AVAN were also 155 significantly enriched in chemotaxis and immune cell activation ( Fig S4A, Table S9 , S10), the results from HL60 cells were consistent with those obtained in A549 cells (Fig S4D, F) .", [["immune cell", "ANATOMY", 133, 144], ["HL60 cells", "ANATOMY", 201, 211], ["A549 cells", "ANATOMY", 251, 261], ["AVAN", "GENE_OR_GENE_PRODUCT", 73, 77], ["immune cell", "CELL", 133, 144], ["S4A", "GENE_OR_GENE_PRODUCT", 162, 165], ["Table S9", "GENE_OR_GENE_PRODUCT", 167, 175], ["S10", "GENE_OR_GENE_PRODUCT", 178, 181], ["HL60 cells", "CELL", 201, 211], ["A549 cells", "CELL", 251, 261], ["Fig S4D, F", "CELL", 263, 273], ["GSEA", "DNA", 14, 18], ["AVAN", "DNA", 73, 77], ["S10", "PROTEIN", 178, 181], ["HL60 cells", "CELL_LINE", 201, 211], ["A549 cells", "CELL_LINE", 251, 261], ["The above GSEA data", "TEST", 4, 23], ["GO analysis", "TEST", 28, 39], ["AVAN", "TEST", 73, 77], ["chemotaxis", "TEST", 118, 128], ["immune cell activation", "TEST", 133, 155], ["Fig S4A", "TEST", 158, 165], ["Table S9", "TEST", 167, 175], ["HL60 cells", "TEST", 201, 211], ["immune cell", "OBSERVATION", 133, 144], ["HL60 cells", "OBSERVATION", 201, 211]]], ["174 Collectively, these data indicate that lncRNA-AVAN plays a vital role in antiviral responses by 175 positively regulating type I IFN induction and neutrophil chemotaxis.", [["neutrophil", "ANATOMY", 151, 161], ["lncRNA-AVAN", "GENE_OR_GENE_PRODUCT", 43, 54], ["type I IFN", "GENE_OR_GENE_PRODUCT", 126, 136], ["neutrophil", "CELL", 151, 161], ["lncRNA", "DNA", 43, 49], ["AVAN", "PROTEIN", 50, 54], ["IFN", "PROTEIN", 133, 136], ["neutrophil", "CELL_TYPE", 151, 161], ["these data", "TEST", 18, 28], ["type I IFN induction", "TREATMENT", 126, 146], ["neutrophil chemotaxis", "TEST", 151, 172], ["lncRNA", "OBSERVATION", 43, 49], ["neutrophil chemotaxis", "OBSERVATION", 151, 172]]], ["Most of these divergent 182 genes were associated with antiviral innate immune responses and inflammatory diseases 183 according to Reactome pathway analysis ( Fig 4B) and FunDO diseases analysis ( Fig S5) .", [["divergent 182 genes", "DNA", 14, 33], ["antiviral innate immune responses", "TREATMENT", 55, 88], ["inflammatory diseases", "PROBLEM", 93, 114], ["Reactome pathway analysis", "TEST", 132, 157], ["FunDO diseases analysis", "PROBLEM", 172, 195], ["inflammatory", "OBSERVATION_MODIFIER", 93, 105]]], ["184 Notably, genes associated with immune system IFN signaling and cytokine signaling were 185 markedly up-regulated in cells with ectopic AVAN expression compared with control cells, 186 including chemokines and ISGs (IFN stimulated genes) ( Fig 4C) .", [["cells", "ANATOMY", 120, 125], ["cells", "ANATOMY", 177, 182], ["immune system IFN", "GENE_OR_GENE_PRODUCT", 35, 52], ["cells", "CELL", 120, 125], ["AVAN", "GENE_OR_GENE_PRODUCT", 139, 143], ["cells", "CELL", 177, 182], ["ISGs", "GENE_OR_GENE_PRODUCT", 213, 217], ["IFN", "GENE_OR_GENE_PRODUCT", 219, 222], ["IFN", "PROTEIN", 49, 52], ["cytokine", "PROTEIN", 67, 75], ["AVAN", "PROTEIN", 139, 143], ["chemokines", "PROTEIN", 198, 208], ["ISGs", "DNA", 213, 217], ["IFN stimulated genes", "DNA", 219, 239], ["immune system IFN signaling", "TEST", 35, 62], ["cytokine signaling", "TEST", 67, 85], ["ectopic AVAN expression", "PROBLEM", 131, 154], ["chemokines", "TEST", 198, 208], ["ISGs (IFN stimulated genes", "TREATMENT", 213, 239]]], ["These significantly 187 up-regulated genes, including MX1, ISG15, IFIT2, OASL, IFIM3, TNFAIP3, CXCL2 and 188 CCL5, were confirmed by qRT-PCR ( Fig 4D) .", [["MX1", "GENE_OR_GENE_PRODUCT", 54, 57], ["ISG15", "GENE_OR_GENE_PRODUCT", 59, 64], ["IFIT2", "GENE_OR_GENE_PRODUCT", 66, 71], ["OASL", "GENE_OR_GENE_PRODUCT", 73, 77], ["IFIM3", "GENE_OR_GENE_PRODUCT", 79, 84], ["TNFAIP3", "GENE_OR_GENE_PRODUCT", 86, 93], ["CXCL2", "GENE_OR_GENE_PRODUCT", 95, 100], ["CCL5", "GENE_OR_GENE_PRODUCT", 109, 113], ["187 up-regulated genes", "DNA", 20, 42], ["MX1", "DNA", 54, 57], ["ISG15", "DNA", 59, 64], ["IFIT2", "DNA", 66, 71], ["OASL", "DNA", 73, 77], ["IFIM3", "DNA", 79, 84], ["TNFAIP3", "DNA", 86, 93], ["CXCL2", "DNA", 95, 100], ["188 CCL5", "DNA", 105, 113], ["MX1", "TEST", 54, 57], ["ISG15", "TEST", 59, 64], ["IFIT2", "TEST", 66, 71], ["OASL", "TEST", 73, 77], ["IFIM3", "TEST", 79, 84], ["TNFAIP3", "TEST", 86, 93], ["CXCL2", "TEST", 95, 100], ["CCL5", "TEST", 109, 113], ["qRT", "TEST", 133, 136], ["PCR", "TEST", 137, 140]]], ["These data again reveal that AVAN strongly 189 participates in antiviral innate immune processes and neutrophil chemotaxis.", [["neutrophil", "ANATOMY", 101, 111], ["AVAN", "GENE_OR_GENE_PRODUCT", 29, 33], ["neutrophil", "CELL", 101, 111], ["neutrophil", "CELL_TYPE", 101, 111], ["These data", "TEST", 0, 10], ["AVAN", "TEST", 29, 33], ["antiviral innate immune processes", "TREATMENT", 63, 96], ["neutrophil chemotaxis", "PROBLEM", 101, 122], ["neutrophil chemotaxis", "OBSERVATION", 101, 122]]], ["Previous experiments demonstrated that AVAN is located in the cytoplasm (Fig 2E, 2F ).", [["cytoplasm", "ANATOMY", 62, 71], ["AVAN", "GENE_OR_GENE_PRODUCT", 39, 43], ["cytoplasm", "ORGANISM_SUBSTANCE", 62, 71], ["AVAN", "PROTEIN", 39, 43], ["AVAN", "PROBLEM", 39, 43]]], ["232 To investigate the molecular mechanism of AVAN in the cytoplasm, RNA pull-down assays 233 using biotin-labeled AVAN or AVAN antisense control followed by mass spectrometry (MS) 234 analysis were performed.", [["cytoplasm", "ANATOMY", 58, 67], ["biotin", "CHEMICAL", 100, 106], ["biotin", "CHEMICAL", 100, 106], ["AVAN", "SIMPLE_CHEMICAL", 46, 50], ["cytoplasm", "ORGANISM_SUBSTANCE", 58, 67], ["biotin", "SIMPLE_CHEMICAL", 100, 106], ["AVAN", "SIMPLE_CHEMICAL", 115, 119], ["AVAN", "SIMPLE_CHEMICAL", 123, 127], ["AVAN", "PROTEIN", 46, 50], ["biotin-labeled AVAN", "PROTEIN", 100, 119], ["RNA pull", "TEST", 69, 77], ["assays", "TEST", 83, 89], ["biotin-labeled AVAN", "TREATMENT", 100, 119], ["AVAN antisense control", "TREATMENT", 123, 145], ["mass spectrometry (MS) 234 analysis", "TEST", 158, 193]]], ["The E3 ubiquitin ligase TRIM25, an RNA-binding protein, was 235 found to bind AVAN in IAV-infected A549 cells compared with the AVAN antisense control Previous study showed that a stabilization of TRIM25-RIG-I interaction is important for a 257 sustained antiviral IFN response (48).", [["A549 cells", "ANATOMY", 99, 109], ["E3", "GENE_OR_GENE_PRODUCT", 4, 6], ["TRIM25", "GENE_OR_GENE_PRODUCT", 24, 30], ["AVAN", "GENE_OR_GENE_PRODUCT", 78, 82], ["IAV", "ORGANISM", 86, 89], ["A549 cells", "CELL", 99, 109], ["TRIM25", "GENE_OR_GENE_PRODUCT", 197, 203], ["RIG-I", "GENE_OR_GENE_PRODUCT", 204, 209], ["E3 ubiquitin ligase", "PROTEIN", 4, 23], ["TRIM25", "PROTEIN", 24, 30], ["RNA-binding protein", "PROTEIN", 35, 54], ["AVAN", "PROTEIN", 78, 82], ["IAV-infected A549 cells", "CELL_LINE", 86, 109], ["TRIM25", "PROTEIN", 197, 203], ["RIG", "PROTEIN", 204, 207], ["IFN", "PROTEIN", 265, 268], ["an RNA-binding protein", "TEST", 32, 54], ["infected A549 cells", "PROBLEM", 90, 109], ["the AVAN antisense control", "TREATMENT", 124, 150], ["Previous study", "TEST", 151, 165], ["a stabilization of TRIM25", "TREATMENT", 178, 203], ["A549 cells", "OBSERVATION", 99, 109]]], ["We next examined the effect of AVAN on the interaction between TRIM25 and RIG-I.", [["AVAN", "CHEMICAL", 31, 35], ["AVAN", "SIMPLE_CHEMICAL", 31, 35], ["TRIM25", "GENE_OR_GENE_PRODUCT", 63, 69], ["RIG-I.", "GENE_OR_GENE_PRODUCT", 74, 80], ["TRIM25", "PROTEIN", 63, 69], ["RIG", "PROTEIN", 74, 77], ["AVAN", "TREATMENT", 31, 35]]], ["We found that ectopically expressing AVAN markedly enhanced 259 the association between TRIM25 and RIG-I upon IAV infection ( Fig 6H) .", [["infection", "DISEASE", 114, 123], ["AVAN", "GENE_OR_GENE_PRODUCT", 37, 41], ["TRIM25", "GENE_OR_GENE_PRODUCT", 88, 94], ["RIG-I", "GENE_OR_GENE_PRODUCT", 99, 104], ["IAV", "ORGANISM", 110, 113], ["AVAN", "PROTEIN", 37, 41], ["TRIM25", "PROTEIN", 88, 94], ["RIG-I", "PROTEIN", 99, 104], ["IAV infection", "PROBLEM", 110, 123], ["IAV", "OBSERVATION_MODIFIER", 110, 113], ["infection", "OBSERVATION", 114, 123]]], ["Additionally, 260 different fragments of AVAN were overexpressed in A549.", [["fragments", "ANATOMY", 28, 37], ["A549", "ANATOMY", 68, 72], ["AVAN", "GENE_OR_GENE_PRODUCT", 41, 45], ["A549", "CELL", 68, 72], ["AVAN", "PROTEIN", 41, 45], ["A549", "CELL_LINE", 68, 72], ["AVAN", "TREATMENT", 41, 45], ["260 different", "OBSERVATION_MODIFIER", 14, 27], ["fragments", "OBSERVATION_MODIFIER", 28, 37]]], ["We observed that P1(1-200nt) 261 could enhance the association between TRIM25 and RIG-I, as full-length AVAN, while 262 fragment P2+P3 (201-517nt) couldn't ( Fig S7B) .", [["TRIM25", "GENE_OR_GENE_PRODUCT", 71, 77], ["RIG-I", "GENE_OR_GENE_PRODUCT", 82, 87], ["AVAN", "GENE_OR_GENE_PRODUCT", 104, 108], ["TRIM25", "PROTEIN", 71, 77], ["RIG-I", "DNA", 82, 87], ["full-length AVAN", "DNA", 92, 108], ["262 fragment P2", "DNA", 116, 131], ["P3", "DNA", 132, 134], ["201-517nt", "DNA", 136, 145], ["P1", "TEST", 17, 19], ["fragment P2", "TEST", 120, 131], ["P3", "TEST", 132, 134]]], ["Moreover, endogenous or exogenous RIG-I 263 ubiquitylation was significantly increased in AVAN-overexpressing cells in the context of IAV 264 infection compared with the control vector (Fig 6I, J) .", [["AVAN-overexpressing cells", "ANATOMY", 90, 115], ["IAV 264", "CHEMICAL", 134, 141], ["infection", "DISEASE", 142, 151], ["RIG-I 263", "GENE_OR_GENE_PRODUCT", 34, 43], ["AVAN", "GENE_OR_GENE_PRODUCT", 90, 94], ["cells", "CELL", 110, 115], ["IAV 264", "ORGANISM", 134, 141], ["AVAN-overexpressing cells", "CELL_LINE", 90, 115], ["IAV 264", "SPECIES", 134, 141], ["overexpressing cells", "PROBLEM", 95, 115], ["IAV 264 infection", "PROBLEM", 134, 151], ["endogenous", "OBSERVATION_MODIFIER", 10, 20], ["exogenous", "OBSERVATION_MODIFIER", 24, 33], ["RIG", "OBSERVATION_MODIFIER", 34, 37], ["increased", "OBSERVATION_MODIFIER", 77, 86], ["overexpressing cells", "OBSERVATION", 95, 115], ["infection", "OBSERVATION", 142, 151]]], ["Furthermore, we explored the impact of 265 altered AVAN levels on RIG-I signaling.", [["AVAN", "GENE_OR_GENE_PRODUCT", 51, 55], ["RIG-I", "GENE_OR_GENE_PRODUCT", 66, 71], ["AVAN", "PROTEIN", 51, 55], ["altered AVAN levels", "PROBLEM", 43, 62]]], ["Total RIG-I protein levels did not differ significantly 266 between AVAN-overexpressing and control cells.", [["cells", "ANATOMY", 100, 105], ["RIG-I", "GENE_OR_GENE_PRODUCT", 6, 11], ["AVAN", "GENE_OR_GENE_PRODUCT", 68, 72], ["cells", "CELL", 100, 105], ["RIG", "PROTEIN", 6, 9], ["AVAN-overexpressing and control cells", "CELL_LINE", 68, 105], ["Total RIG-I protein levels", "TEST", 0, 26], ["AVAN", "TEST", 68, 72], ["overexpressing and control cells", "PROBLEM", 73, 105]]], ["However, AVAN overexpression increased 267 TBK1 and IRF3 phosphorylation upon IAV infection (Fig 6K, left) .", [["infection", "DISEASE", 82, 91], ["AVAN", "GENE_OR_GENE_PRODUCT", 9, 13], ["TBK1", "GENE_OR_GENE_PRODUCT", 43, 47], ["IRF3", "GENE_OR_GENE_PRODUCT", 52, 56], ["AVAN", "PROTEIN", 9, 13], ["TBK1", "PROTEIN", 43, 47], ["IRF3", "PROTEIN", 52, 56], ["IAV", "SPECIES", 78, 81], ["AVAN overexpression", "PROBLEM", 9, 28], ["TBK1", "PROBLEM", 43, 47], ["IRF3 phosphorylation", "PROBLEM", 52, 72], ["IAV infection", "PROBLEM", 78, 91], ["Fig", "TEST", 93, 96], ["IAV", "OBSERVATION_MODIFIER", 78, 81], ["infection", "OBSERVATION", 82, 91], ["left", "ANATOMY_MODIFIER", 101, 105]]], ["In contrast, AVAN 268 knockdown abolished these changes (Fig 6K, right) .", [["AVAN 268", "CHEMICAL", 13, 21], ["AVAN 268", "CHEMICAL", 13, 21], ["AVAN 268", "GENE_OR_GENE_PRODUCT", 13, 21], ["AVAN", "TREATMENT", 13, 17], ["these changes", "PROBLEM", 42, 55], ["Fig", "TEST", 57, 60], ["right", "ANATOMY_MODIFIER", 65, 70]]], ["To test whether AVAN enhances the 279 To further investigate the in vivo effect of AVAN on IAV pathogenesis, we constructed an AVAN-containing AAV2/9 vector and a control vector, which were then delivered into 281 4-week-old C57L/B6 mice via intranasal (i.n.) administration.", [["AVAN", "CHEMICAL", 83, 87], ["AVAN", "SIMPLE_CHEMICAL", 83, 87], ["IAV", "ORGANISM", 91, 94], ["AVAN", "GENE_OR_GENE_PRODUCT", 127, 131], ["AAV2/9", "GENE_OR_GENE_PRODUCT", 143, 149], ["C57L/B6 mice", "ORGANISM", 225, 237], ["AVAN-containing AAV2/9 vector", "DNA", 127, 156], ["mice", "SPECIES", 233, 237], ["IAV", "SPECIES", 91, 94], ["mice", "SPECIES", 233, 237], ["AVAN", "TREATMENT", 83, 87], ["IAV pathogenesis", "PROBLEM", 91, 107], ["an AVAN-containing AAV2/9 vector", "TREATMENT", 124, 156], ["a control vector", "TREATMENT", 161, 177], ["old C57L/B6 mice via intranasal", "TREATMENT", 221, 252]]], ["We found that AVAN was 282 ectopically expressed in the lung of AAV2/9-AVAN treated mice (Fig 7A) .", [["lung", "ANATOMY", 56, 60], ["AVAN", "GENE_OR_GENE_PRODUCT", 14, 18], ["lung", "ORGAN", 56, 60], ["AAV2/9-AVAN", "ORGANISM", 64, 75], ["mice", "ORGANISM", 84, 88], ["AVAN", "PROTEIN", 14, 18], ["mice", "SPECIES", 84, 88], ["mice", "SPECIES", 84, 88], ["AVAN", "TEST", 14, 18], ["AAV2", "TEST", 64, 68], ["lung", "ANATOMY", 56, 60], ["AAV2", "ANATOMY_MODIFIER", 64, 68]]], ["Strikingly, after 283 BJ501 infection, the groups pretreated with AAV2/9-AVAN exhibited significantly increased 284 survival rates and reduced body weight loss at 10 days post-infection compared with the 285 control group (Fig 7B, C) .", [["body", "ANATOMY", 143, 147], ["infection", "DISEASE", 28, 37], ["AAV2/9-AVAN", "CHEMICAL", 66, 77], ["weight loss", "DISEASE", 148, 159], ["AAV2", "ORGANISM", 66, 70], ["body", "ORGANISM_SUBDIVISION", 143, 147], ["AAV2", "SPECIES", 66, 70], ["BJ501 infection", "PROBLEM", 22, 37], ["AAV2", "TEST", 66, 70], ["significantly increased 284 survival rates", "PROBLEM", 88, 130], ["reduced body weight loss", "PROBLEM", 135, 159]]], ["Furthermore, lung edema, measured as the wet-to-dry ratio of 286 whole lung, was ameliorated (Fig 7D) , and improved lung histopathology was observed in 287 infected mice pretreated with AAV2/9-AVAN (Fig 7E, F) .", [["lung", "ANATOMY", 13, 17], ["lung", "ANATOMY", 71, 75], ["lung", "ANATOMY", 117, 121], ["lung edema", "DISEASE", 13, 23], ["lung", "ORGAN", 13, 17], ["lung", "ORGAN", 71, 75], ["lung", "ORGAN", 117, 121], ["mice", "ORGANISM", 166, 170], ["AAV2", "ORGANISM", 187, 191], ["mice", "SPECIES", 166, 170], ["mice", "SPECIES", 166, 170], ["AAV2", "SPECIES", 187, 191], ["lung edema", "PROBLEM", 13, 23], ["the wet", "TEST", 37, 44], ["AAV2", "TEST", 187, 191], ["lung", "ANATOMY", 13, 17], ["edema", "OBSERVATION", 18, 23], ["lung", "ANATOMY", 71, 75], ["improved", "OBSERVATION_MODIFIER", 108, 116], ["lung", "ANATOMY", 117, 121], ["histopathology", "OBSERVATION", 122, 136]]], ["Moreover, the virus titer from the 288 lungs of infected mice was also significantly reduced in AAV2/9-AVAN-treated mice 289 compared with that in control mice (Fig 7G, H) .", [["lungs", "ANATOMY", 39, 44], ["AVAN", "CHEMICAL", 103, 107], ["lungs", "ORGAN", 39, 44], ["mice", "ORGANISM", 57, 61], ["AAV2/9-AVAN", "ORGANISM", 96, 107], ["mice", "ORGANISM", 116, 120], ["mice", "ORGANISM", 155, 159], ["mice", "SPECIES", 57, 61], ["mice", "SPECIES", 116, 120], ["mice", "SPECIES", 155, 159], ["mice", "SPECIES", 57, 61], ["AAV2", "SPECIES", 96, 100], ["mice", "SPECIES", 116, 120], ["mice", "SPECIES", 155, 159], ["the virus titer", "TEST", 10, 25], ["AAV2", "TEST", 96, 100], ["lungs", "ANATOMY", 39, 44], ["infected", "OBSERVATION", 48, 56], ["significantly", "OBSERVATION_MODIFIER", 71, 84], ["reduced", "OBSERVATION_MODIFIER", 85, 92]]], ["Although AVAN triggers FOXO3a expression 290 in the nucleus to enhance neutrophil chemotaxis in vitro, we did not observe that AVAN 291 promotes FOXO3a expression in vivo (data not shown).", [["nucleus", "ANATOMY", 52, 59], ["neutrophil", "ANATOMY", 71, 81], ["AVAN 291", "CHEMICAL", 127, 135], ["AVAN 291", "CHEMICAL", 127, 135], ["AVAN", "GENE_OR_GENE_PRODUCT", 9, 13], ["FOXO3a", "GENE_OR_GENE_PRODUCT", 23, 29], ["nucleus", "CELLULAR_COMPONENT", 52, 59], ["neutrophil", "CELL", 71, 81], ["AVAN 291", "GENE_OR_GENE_PRODUCT", 127, 135], ["FOXO3a", "GENE_OR_GENE_PRODUCT", 145, 151], ["AVAN", "PROTEIN", 9, 13], ["FOXO3a", "PROTEIN", 23, 29], ["FOXO3a", "PROTEIN", 145, 151], ["FOXO3a expression", "TEST", 23, 40], ["neutrophil chemotaxis", "TEST", 71, 92], ["AVAN", "TEST", 127, 131], ["nucleus", "ANATOMY", 52, 59], ["neutrophil chemotaxis", "OBSERVATION", 71, 92], ["FOXO3a expression", "OBSERVATION", 145, 162]]], ["This finding may result from the low 292 conservation of AVAN between humans and mice.", [["AVAN", "GENE_OR_GENE_PRODUCT", 57, 61], ["humans", "ORGANISM", 70, 76], ["mice", "ORGANISM", 81, 85], ["humans", "SPECIES", 70, 76], ["mice", "SPECIES", 81, 85], ["humans", "SPECIES", 70, 76], ["mice", "SPECIES", 81, 85], ["AVAN between humans and mice", "TREATMENT", 57, 85]]], ["Consistent with the association in human, 293 we found that AVAN also bind to rodent Trim25 through RNA pull-down using mouse tissue 294 ( Fig 7I) .", [["293", "ANATOMY", 42, 45], ["tissue", "ANATOMY", 126, 132], ["human", "ORGANISM", 35, 40], ["AVAN", "GENE_OR_GENE_PRODUCT", 60, 64], ["Trim25", "GENE_OR_GENE_PRODUCT", 85, 91], ["mouse", "ORGANISM", 120, 125], ["tissue", "TISSUE", 126, 132], ["AVAN", "PROTEIN", 60, 64], ["Trim25", "DNA", 85, 91], ["human", "SPECIES", 35, 40], ["rodent", "SPECIES", 78, 84], ["mouse", "SPECIES", 120, 125], ["human", "SPECIES", 35, 40], ["mouse", "SPECIES", 120, 125], ["RNA pull", "TEST", 100, 108]]], ["In addition, AAV2/9-AVAN promote type I IFN expression in vivo (Fig 7J) .", [["AAV2", "ORGANISM", 13, 17], ["AVAN", "GENE_OR_GENE_PRODUCT", 20, 24], ["type I IFN", "GENE_OR_GENE_PRODUCT", 33, 43], ["AAV2/9-AVAN", "DNA", 13, 24], ["IFN", "PROTEIN", 40, 43], ["AAV2", "TEST", 13, 17], ["AVAN", "TREATMENT", 20, 24]]], ["Taken 295 together, these observations indicate that AVAN can ameliorate IAV-induced acute lung injury 296 in vivo and protect mice from IAV infection.", [["lung", "ANATOMY", 91, 95], ["AVAN", "CHEMICAL", 53, 57], ["acute lung injury", "DISEASE", 85, 102], ["IAV infection", "DISEASE", 137, 150], ["AVAN", "CHEMICAL", 53, 57], ["AVAN", "SIMPLE_CHEMICAL", 53, 57], ["IAV", "ORGANISM", 73, 76], ["lung", "ORGAN", 91, 95], ["mice", "ORGANISM", 127, 131], ["IAV", "ORGANISM", 137, 140], ["mice", "SPECIES", 127, 131], ["mice", "SPECIES", 127, 131], ["IAV", "SPECIES", 137, 140], ["AVAN", "TREATMENT", 53, 57], ["IAV", "PROBLEM", 73, 76], ["acute lung injury", "PROBLEM", 85, 102], ["IAV infection", "PROBLEM", 137, 150], ["acute", "OBSERVATION_MODIFIER", 85, 90], ["lung", "ANATOMY", 91, 95], ["injury", "OBSERVATION", 96, 102], ["IAV", "OBSERVATION_MODIFIER", 137, 140], ["infection", "OBSERVATION", 141, 150]]], ["(Fig 3) , speculated that lncRNA AVAN is critical in the IFN induction pathway.", [["AVAN", "GENE_OR_GENE_PRODUCT", 33, 37], ["IFN", "GENE_OR_GENE_PRODUCT", 57, 60], ["lncRNA AVAN", "DNA", 26, 37], ["IFN", "PROTEIN", 57, 60], ["the IFN induction pathway", "TREATMENT", 53, 78], ["lncRNA", "OBSERVATION", 26, 32]]], ["368 To the best of our knowledge, our work represents the first identification of lncRNA-AVAN as 369 a novel partner of TRIM25 and demonstrates that AVAN suppresses IAV replication via 370 TRIM25-RIG-I-dependent antiviral pathways.", [["lncRNA-AVAN", "GENE_OR_GENE_PRODUCT", 82, 93], ["TRIM25", "GENE_OR_GENE_PRODUCT", 120, 126], ["AVAN", "GENE_OR_GENE_PRODUCT", 149, 153], ["IAV", "ORGANISM", 165, 168], ["TRIM25", "GENE_OR_GENE_PRODUCT", 189, 195], ["RIG-I", "GENE_OR_GENE_PRODUCT", 196, 201], ["lncRNA-AVAN", "PROTEIN", 82, 93], ["TRIM25", "PROTEIN", 120, 126], ["AVAN", "PROTEIN", 149, 153], ["TRIM25", "PROTEIN", 189, 195], ["IAV", "SPECIES", 165, 168], ["AVAN suppresses IAV replication", "TREATMENT", 149, 180], ["TRIM25", "TEST", 189, 195]]], ["371 In conclusion, we provide the first lncRNA landscape of IAV-infected patient neutrophils 372 and identify the function of AVAN, a novel lncRNA, in the innate antiviral immune response.", [["neutrophils", "ANATOMY", 81, 92], ["IAV", "ORGANISM", 60, 63], ["patient", "ORGANISM", 73, 80], ["neutrophils 372", "CELL", 81, 96], ["AVAN", "GENE_OR_GENE_PRODUCT", 126, 130], ["AVAN", "PROTEIN", 126, 130], ["lncRNA", "DNA", 140, 146], ["patient", "SPECIES", 73, 80], ["AVAN", "TREATMENT", 126, 130], ["a novel lncRNA", "PROBLEM", 132, 146], ["lncRNA", "OBSERVATION", 140, 146], ["antiviral immune response", "OBSERVATION", 162, 187]]], ["373 AVAN can enhance the chemotaxis of neutrophils by promoting FOXO3a expression in cis.", [["neutrophils", "ANATOMY", 39, 50], ["neutrophils", "CELL", 39, 50], ["FOXO3a", "GENE_OR_GENE_PRODUCT", 64, 70], ["neutrophils", "CELL_TYPE", 39, 50], ["FOXO3a", "PROTEIN", 64, 70], ["FOXO3a expression", "OBSERVATION", 64, 81]]], ["374 On the one hand, AVAN can serve as a positive regulator of RIG-I signaling by directly 375 binding TRIM25 and enhancing the association between TRIM25 and RIG-I in trans.", [["AVAN", "GENE_OR_GENE_PRODUCT", 21, 25], ["RIG-I", "GENE_OR_GENE_PRODUCT", 63, 68], ["TRIM25", "GENE_OR_GENE_PRODUCT", 103, 109], ["TRIM25", "GENE_OR_GENE_PRODUCT", 148, 154], ["RIG-I", "GENE_OR_GENE_PRODUCT", 159, 164], ["AVAN", "PROTEIN", 21, 25], ["RIG-I", "PROTEIN", 63, 68], ["375 binding TRIM25", "PROTEIN", 91, 109], ["TRIM25", "PROTEIN", 148, 154], ["RIG-I", "PROTEIN", 159, 164]]], ["The samples were separated by SDS-PAGE and transferred onto nitrocellulose membranes.", [["samples", "ANATOMY", 4, 11], ["membranes", "ANATOMY", 75, 84], ["nitrocellulose", "CHEMICAL", 60, 74], ["membranes", "CELLULAR_COMPONENT", 75, 84], ["The samples", "TEST", 0, 11], ["nitrocellulose membranes", "TREATMENT", 60, 84]]], ["456 The membranes were then blocked with 5% nonfat milk (BD) in 1\u00d7 Tris-buffered saline and 457 0.1% Triton 100 for 1 h while shaking at room temperature.", [["membranes", "ANATOMY", 8, 17], ["nonfat milk", "ANATOMY", 44, 55], ["Triton 100", "CHEMICAL", 101, 111], ["Tris", "CHEMICAL", 67, 71], ["Triton 100", "CHEMICAL", 101, 111], ["membranes", "CELLULAR_COMPONENT", 8, 17], ["milk", "ORGANISM_SUBSTANCE", 51, 55], ["Tris-buffered saline", "SIMPLE_CHEMICAL", 67, 87], ["Triton 100", "SIMPLE_CHEMICAL", 101, 111], ["Tris-buffered saline", "TREATMENT", 67, 87]]], ["Next, the membranes were 458 incubated with primary antibodies and horseradish peroxidase-conjugated secondary 459 antibodies.", [["membranes", "ANATOMY", 10, 19], ["membranes", "CELLULAR_COMPONENT", 10, 19], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 67, 89], ["primary antibodies", "PROTEIN", 44, 62], ["horseradish peroxidase", "PROTEIN", 67, 89], ["conjugated secondary 459 antibodies", "PROTEIN", 90, 125], ["horseradish", "SPECIES", 67, 78], ["primary antibodies", "TEST", 44, 62], ["horseradish peroxidase", "TEST", 67, 89]]], ["Bands were visualized using the Kodak film exposure detection system.", [["Bands", "GENE_OR_GENE_PRODUCT", 0, 5], ["Bands", "PROBLEM", 0, 5], ["the Kodak film exposure", "TEST", 28, 51]]], ["The film 460 was scanned, and the band intensity was analyzed using Quantity One software.462Quantitative real-time PCR 463 Total RNA was extracted from cultured cells using TRIzol reagent (Invitrogen). cDNA was 464 generated by reverse transcription with commercial PrimeScript RT Master Mix (Takara).", [["cells", "ANATOMY", 162, 167], ["cells", "CELL", 162, 167], ["cultured cells", "CELL_LINE", 153, 167], ["cDNA", "DNA", 203, 207], ["The film", "TEST", 0, 8], ["the band intensity", "TREATMENT", 30, 48], ["PCR", "TEST", 116, 119], ["Total RNA", "TEST", 124, 133], ["TRIzol reagent", "TREATMENT", 174, 188], ["Invitrogen", "TREATMENT", 190, 200], ["cDNA", "TEST", 203, 207], ["commercial PrimeScript RT Master Mix (Takara)", "TREATMENT", 256, 301]]], ["465 Primer pairs (Table S12) Table 506 S12.", [["Primer pairs", "DNA", 4, 16]]], ["The ChIP-enriched FOXO3a promoter was 507 quantified by qPCR using the primer pairs listed in Table S12 .", [["FOXO3a", "GENE_OR_GENE_PRODUCT", 18, 24], ["ChIP-enriched FOXO3a promoter", "DNA", 4, 33], ["primer pairs", "DNA", 71, 83], ["The ChIP-enriched FOXO3a promoter", "TREATMENT", 0, 33], ["FOXO3a promoter", "OBSERVATION", 18, 33]]]], "94da4f9156cb16888357d3a4cfbc7db0d260f59e": [["IntroductionOnce confined to the battlefield and the occasional industrial accident, the sequela of explosive force has now become all too commonplace and continues to increase as industry expands and explosive weaponry proliferates.", [["explosive force", "PROBLEM", 100, 115]]], ["The ubiquitous threat of terrorism places responsibility for the care of victims not only upon the military surgeon, but upon civilian counterparts as well.", [["ubiquitous", "OBSERVATION_MODIFIER", 4, 14], ["threat", "OBSERVATION_MODIFIER", 15, 21], ["terrorism", "OBSERVATION", 25, 34]]], ["The medical system, military, and civilians must understand the pathophysiology of injury induced from explosive devices, be they letter bombs, shaped warheads from a rocket propelled grenade (RPG), antipersonnel land mines, aerial-delivered cluster bombs, or enhanced blast weapons.IntroductionUrban warfare is becoming more widespread, providing both a rich environment for the bomber to strike and the ideal medium for enhanced blast weapons.", [["injury", "PROBLEM", 83, 89], ["explosive devices", "TREATMENT", 103, 120], ["aerial-delivered cluster bombs", "PROBLEM", 225, 255], ["enhanced blast weapons", "PROBLEM", 260, 282], ["enhanced blast weapons", "PROBLEM", 422, 444], ["injury", "OBSERVATION", 83, 89], ["blast weapons", "OBSERVATION", 269, 282], ["more widespread", "OBSERVATION_MODIFIER", 321, 336], ["blast weapons", "OBSERVATION", 431, 444]]], ["The terrorist may employ pipe bombs, large high-energy car bombs, or the suicide bomber wearing several kilograms of explosive.IntroductionIn the United States alone from 1990 to 1995, the FBI reported 15 700 bombings, with 3176 injuries and 355 deaths, and these numbers only continue to increase.IntroductionPrimary blast injury, secondary to conventional high explosives, is uncommon in surviving casualties.", [["Primary blast", "ANATOMY", 310, 323], ["injuries", "DISEASE", 229, 237], ["deaths", "DISEASE", 246, 252], ["Primary blast injury", "DISEASE", 310, 330], ["Primary blast injury", "PROBLEM", 310, 330], ["conventional high explosives", "PROBLEM", 345, 373], ["large", "OBSERVATION_MODIFIER", 37, 42], ["high", "OBSERVATION_MODIFIER", 43, 47], ["blast injury", "OBSERVATION", 318, 330]]], ["This is because they would have been close to the epicenter of the explosion and are likely to have suffered lethal fragment and heat injury.", [["heat injury", "DISEASE", 129, 140], ["lethal fragment", "PROBLEM", 109, 124], ["heat injury", "PROBLEM", 129, 140], ["fragment", "OBSERVATION", 116, 124], ["heat", "OBSERVATION_MODIFIER", 129, 133], ["injury", "OBSERVATION", 134, 140]]], ["With the advent of enhanced blast weapons (already populating the arms market), primary blast injury will increase in frequency, placing extreme clinical and logistical stress on the medical system.IntroductionAlthough antipersonnel mines were banned by the Ottawa Convention in 1997, civilian mine injuries have become even more common than military mine injuries that occur during combat, with farmers, women, and children 10 times more likely to encounter these abandoned weapons of war.", [["primary blast injury", "DISEASE", 80, 100], ["injuries", "DISEASE", 299, 307], ["injuries", "DISEASE", 356, 364], ["women", "ORGANISM", 405, 410], ["children", "ORGANISM", 416, 424], ["women", "SPECIES", 405, 410], ["children", "SPECIES", 416, 424], ["enhanced blast weapons", "PROBLEM", 19, 41], ["primary blast injury", "PROBLEM", 80, 100], ["extreme clinical and logistical stress on the medical system", "PROBLEM", 137, 197], ["antipersonnel mines", "TREATMENT", 219, 238], ["civilian mine injuries", "PROBLEM", 285, 307], ["enhanced", "OBSERVATION_MODIFIER", 19, 27], ["blast weapons", "OBSERVATION", 28, 41], ["arms", "ANATOMY", 66, 70], ["blast injury", "OBSERVATION", 88, 100], ["increase", "OBSERVATION_MODIFIER", 106, 114], ["injuries", "OBSERVATION", 356, 364]]], ["The immense number of antipersonnel mines scattered throughout many parts of the world continues to plague civilization with horrible disabling injuries that, according to the International Committee of the Red Cross (ICRC), number 24,000 per year.", [["injuries", "DISEASE", 144, 152], ["antipersonnel mines", "TREATMENT", 22, 41], ["horrible disabling injuries", "PROBLEM", 125, 152], ["immense", "OBSERVATION_MODIFIER", 4, 11], ["number", "OBSERVATION_MODIFIER", 12, 18], ["scattered", "OBSERVATION_MODIFIER", 42, 51], ["disabling", "OBSERVATION_MODIFIER", 134, 143], ["injuries", "OBSERVATION", 144, 152]]], ["1 In this chapter we will address the myriad types of explosive weapons, how they work, and the resulting patterns of injury that threaten to present as mass casualties and to severely impact the health-care system clinically, logistically, and psychologically.ExplosionsAn explosive is a chemical compound or mixture that, when subjected to heat, shock, friction, or other impulse, leads to a rapid chemical reaction or combustion and an equally rapid generation of heat and gases.", [["shock", "DISEASE", 348, 353], ["injury", "PROBLEM", 118, 124], ["shock", "PROBLEM", 348, 353], ["friction", "PROBLEM", 355, 363], ["other impulse", "PROBLEM", 368, 381], ["a rapid chemical reaction", "PROBLEM", 392, 417], ["injury", "OBSERVATION", 118, 124], ["shock", "OBSERVATION", 348, 353]]], ["The consequent combined volume is much larger than the original substance.ExplosionsExplosives are classified as high or low, depending upon the rate at which this reaction takes place.", [["The consequent combined volume", "PROBLEM", 0, 30], ["ExplosionsExplosives", "TEST", 74, 94], ["this reaction", "PROBLEM", 159, 172], ["consequent", "OBSERVATION_MODIFIER", 4, 14], ["combined", "OBSERVATION_MODIFIER", 15, 23], ["volume", "OBSERVATION", 24, 30], ["much", "OBSERVATION_MODIFIER", 34, 38], ["larger", "OBSERVATION_MODIFIER", 39, 45]]], ["Gunpowder, the first explosive used in military ordnance, is an example of a low explosive.", [["Gunpowder", "CHEMICAL", 0, 9], ["Gunpowder", "TREATMENT", 0, 9], ["a low explosive", "PROBLEM", 75, 90]]], ["Low explosives change relatively slowly from a solid to a gaseous state, generally less than 2000 meters per second.ExplosionsBy comparison, high explosives (HE) react almost instantaneously, causing sudden increases in pressures and a detonation wave that moves at supersonic speed (1400-9000 meters per second).", [["Low explosives change", "PROBLEM", 0, 21], ["high explosives", "PROBLEM", 141, 156], ["sudden increases in pressures", "PROBLEM", 200, 229], ["a detonation wave", "PROBLEM", 234, 251], ["explosives", "OBSERVATION", 4, 14], ["gaseous", "OBSERVATION", 58, 65], ["sudden", "OBSERVATION_MODIFIER", 200, 206], ["increases", "OBSERVATION_MODIFIER", 207, 216], ["pressures", "OBSERVATION_MODIFIER", 220, 229], ["detonation wave", "OBSERVATION", 236, 251]]], ["Common examples are 2,4,6-trinitrotoluene (TNT) and the more recent polymer-bonded explosives, such as Semtex and Gelignite, which are 1.5 times the power of TNT.", [["2,4,6-trinitrotoluene", "CHEMICAL", 20, 41], ["TNT", "CHEMICAL", 43, 46], ["Gelignite", "CHEMICAL", 114, 123], ["2,4,6-trinitrotoluene", "CHEMICAL", 20, 41], ["TNT", "CHEMICAL", 43, 46], ["Gelignite", "CHEMICAL", 114, 123], ["2,4,6-trinitrotoluene", "SIMPLE_CHEMICAL", 20, 41], ["TNT", "SIMPLE_CHEMICAL", 43, 46], ["Semtex", "SIMPLE_CHEMICAL", 103, 109], ["Gelignite", "SIMPLE_CHEMICAL", 114, 123], ["TNT", "SIMPLE_CHEMICAL", 158, 161]]], ["High explosives are used commonly in military ordnance.ExplosionsA detonator is a type of explosive that reacts very rapidly and is used to set off other more inert explosives.", [["High explosives", "PROBLEM", 0, 15]]], ["Fulminate of Mercury mixed with potassium chlorate is the most commonly used detonator.", [["Mercury", "CHEMICAL", 13, 20], ["potassium chlorate", "CHEMICAL", 32, 50], ["Mercury", "CHEMICAL", 13, 20], ["potassium chlorate", "CHEMICAL", 32, 50], ["Mercury", "SIMPLE_CHEMICAL", 13, 20], ["potassium chlorate", "SIMPLE_CHEMICAL", 32, 50], ["potassium chlorate", "TREATMENT", 32, 50], ["Mercury", "OBSERVATION_MODIFIER", 13, 20]]], ["Detonators also can be equipment, which by flame, spark, percussion, friction, or pressure are used to set off a chemical detonator.", [["percussion", "TEST", 57, 67], ["pressure", "PROBLEM", 82, 90]]], ["Detonation refers to the chemical and exothermic reaction that creates a pressure wave propagating throughout the explosive, creating rapid production of heat and gases, resulting in a \"runaway\" process and producing the resulting explosion.ExplosionsThe rapid release of enormous amounts of energy in a high explosion results in a primary blast wave, propulsion of fragments and environmental material or debris, and often generates intense thermal radiation.", [["fragments", "ANATOMY", 366, 375], ["the chemical and exothermic reaction", "PROBLEM", 21, 57], ["a pressure wave", "PROBLEM", 71, 86], ["a \"runaway\" process", "PROBLEM", 183, 202], ["a high explosion", "PROBLEM", 302, 318], ["a primary blast wave", "PROBLEM", 330, 350], ["propulsion of fragments", "PROBLEM", 352, 375], ["environmental material", "PROBLEM", 380, 402], ["debris", "PROBLEM", 406, 412], ["intense thermal radiation", "TREATMENT", 434, 459], ["pressure", "OBSERVATION_MODIFIER", 73, 81], ["rapid", "OBSERVATION_MODIFIER", 134, 139], ["production", "OBSERVATION_MODIFIER", 140, 150], ["rapid", "OBSERVATION_MODIFIER", 255, 260], ["enormous", "OBSERVATION_MODIFIER", 272, 280], ["amounts", "OBSERVATION_MODIFIER", 281, 288], ["blast wave", "OBSERVATION", 340, 350], ["propulsion", "OBSERVATION_MODIFIER", 352, 362], ["fragments", "OBSERVATION_MODIFIER", 366, 375], ["environmental material", "OBSERVATION", 380, 402], ["debris", "OBSERVATION", 406, 412], ["intense", "OBSERVATION_MODIFIER", 434, 441], ["thermal", "OBSERVATION_MODIFIER", 442, 449], ["radiation", "OBSERVATION", 450, 459]]], ["The initial explosion creates an instantaneous rise in pressure, resulting in a shock wave that travels outward at supersonic speed.", [["shock", "DISEASE", 80, 85], ["an instantaneous rise in pressure", "PROBLEM", 30, 63], ["a shock wave", "PROBLEM", 78, 90], ["instantaneous", "OBSERVATION_MODIFIER", 33, 46], ["rise", "OBSERVATION_MODIFIER", 47, 51], ["pressure", "OBSERVATION_MODIFIER", 55, 63], ["shock", "OBSERVATION", 80, 85]]], ["The shock wave is the leading front and an integral component of the blast wave.", [["shock", "DISEASE", 4, 9], ["The shock wave", "PROBLEM", 0, 14], ["the blast wave", "PROBLEM", 65, 79], ["shock", "OBSERVATION", 4, 9], ["front", "OBSERVATION_MODIFIER", 30, 35], ["integral", "OBSERVATION_MODIFIER", 43, 51], ["component", "OBSERVATION_MODIFIER", 52, 61], ["blast wave", "OBSERVATION", 69, 79]]], ["The generation and propagation of blast waves are governed by nonlinear physics.ExplosionsThe response of structures, including human tissues, also may be nonlinear, as evidenced by the pathophysiology of blast injuries.ExplosionsThis sudden variation in air pressure creates a mass movement of air known as the dynamic overpressure or blast wave.", [["structures", "ANATOMY", 106, 116], ["tissues", "ANATOMY", 134, 141], ["blast injuries", "DISEASE", 205, 219], ["structures", "TISSUE", 106, 116], ["human", "ORGANISM", 128, 133], ["tissues", "TISSUE", 134, 141], ["human", "SPECIES", 128, 133], ["human", "SPECIES", 128, 133], ["blast waves", "PROBLEM", 34, 45], ["blast injuries", "PROBLEM", 205, 219], ["Explosions", "PROBLEM", 220, 230], ["air pressure", "TEST", 255, 267], ["a mass movement of air", "PROBLEM", 276, 298], ["propagation", "OBSERVATION_MODIFIER", 19, 30], ["blast waves", "OBSERVATION", 34, 45], ["human tissues", "ANATOMY", 128, 141], ["may be", "UNCERTAINTY", 148, 154], ["blast injuries", "OBSERVATION", 205, 219], ["variation", "OBSERVATION_MODIFIER", 242, 251], ["air pressure", "OBSERVATION", 255, 267], ["mass", "OBSERVATION", 278, 282], ["air", "OBSERVATION", 295, 298], ["blast wave", "OBSERVATION", 336, 346]]], ["The Friedlander Relationship (Figure 3-1) illustrates the physical properties of an ideal blast wave in open air.", [["air", "OBSERVATION", 109, 112]]], ["With the arrival of the shock wave, the pressure instantly increases to a peak overpressure, then rapidly falls and creates subatmospheric pressures before returning to normal ambient atmospheric pressure.ExplosionsIn reality, the reflection of the blast wave as it encounters environmental structures creates a very complex pattern of overpressures.", [["shock", "DISEASE", 24, 29], ["the shock wave", "TEST", 20, 34], ["the pressure", "TEST", 36, 48], ["a peak overpressure", "PROBLEM", 72, 91], ["subatmospheric pressures", "TEST", 124, 148], ["the blast wave", "PROBLEM", 245, 259], ["shock", "OBSERVATION", 24, 29], ["pressure", "OBSERVATION_MODIFIER", 40, 48], ["peak overpressure", "OBSERVATION", 74, 91], ["subatmospheric", "OBSERVATION_MODIFIER", 124, 138], ["pressures", "OBSERVATION_MODIFIER", 139, 148], ["normal", "OBSERVATION", 169, 175], ["ambient", "OBSERVATION_MODIFIER", 176, 183], ["atmospheric pressure", "OBSERVATION", 184, 204], ["blast wave", "OBSERVATION", 249, 259], ["very complex", "OBSERVATION_MODIFIER", 312, 324]]], ["These overpressures and an actual reversal of the blast wind in the negative phase may cause significant damage.", [["significant damage", "PROBLEM", 93, 111], ["blast wind", "OBSERVATION", 50, 60], ["negative phase", "OBSERVATION_MODIFIER", 68, 82], ["may cause", "UNCERTAINTY", 83, 92], ["significant", "OBSERVATION_MODIFIER", 93, 104], ["damage", "OBSERVATION", 105, 111]]], ["For an in-depth discussion of the creation and propagation of blast waves and how they interact with various structures, the reader is referred to an article by I.G. Cullis.", [["blast waves", "PROBLEM", 62, 73], ["blast waves", "OBSERVATION", 62, 73]]], ["2Enhanced-Blast WeaponsOngoing research in the ordnance industry and recent technological advances in explosives and material has propagated the development of enhanced-blast weapons (EBW).", [["blast weapons", "OBSERVATION", 169, 182]]], ["There are four known types of enhancedblast explosives:Enhanced-Blast Weapons1. metallized explosives, 2. reactive surround, 3. fuel-air, 4. thermobaric.Enhanced-Blast WeaponsOnce confined to fuel-air explosive (FAE) bombs, EBWs, recently proliferating the arms market, span the range of weapon systems from small grenades and hand-held weapons to large-caliber rockets (Table 3-1) .Enhanced-Blast WeaponsRelatively few primary blast injuries have been seen, as there are few survivors with primary blast injury from conventional HEs.", [["hand", "ANATOMY", 327, 331], ["primary blast injuries", "DISEASE", 420, 442], ["primary blast injury", "DISEASE", 491, 511], ["HEs", "DISEASE", 530, 533], ["thermobaric", "TREATMENT", 141, 152], ["small grenades and hand", "PROBLEM", 308, 331], ["primary blast injuries", "PROBLEM", 420, 442], ["primary blast injury", "PROBLEM", 491, 511], ["explosives", "OBSERVATION", 44, 54], ["Blast Weapons1", "OBSERVATION", 64, 78], ["explosives", "OBSERVATION", 91, 101], ["air", "OBSERVATION", 133, 136], ["air explosive", "OBSERVATION", 197, 210], ["arms", "ANATOMY", 257, 261], ["small", "OBSERVATION_MODIFIER", 308, 313], ["grenades", "OBSERVATION", 314, 322], ["hand", "ANATOMY", 327, 331], ["large", "OBSERVATION_MODIFIER", 348, 353], ["caliber", "OBSERVATION_MODIFIER", 354, 361], ["Blast", "OBSERVATION_MODIFIER", 392, 397], ["WeaponsRelatively", "OBSERVATION_MODIFIER", 398, 415], ["few", "OBSERVATION_MODIFIER", 416, 419], ["primary", "OBSERVATION_MODIFIER", 420, 427], ["blast injuries", "OBSERVATION", 428, 442], ["few", "OBSERVATION_MODIFIER", 472, 475], ["primary", "OBSERVATION_MODIFIER", 491, 498], ["blast injury", "OBSERVATION", 499, 511]]], ["Most die immediately, but this may change with the increase of EBW usage.", [["EBW", "SIMPLE_CHEMICAL", 63, 66], ["EBW usage", "TREATMENT", 63, 72]]], ["With conventional HEs, the blast wave decays very rapidly and is affected significantly by the environment.", [["blast wave", "OBSERVATION", 27, 37]]], ["Enhanced-blast weapons produce a lower overpressure than conventional HE, but the period of overpressure lasts longer and reaches farther, thereby increasing the lethality zone and producing blast casualties farther from the epicenter of the detonation ( Figure 3 -2).", [["overpressure", "PROBLEM", 92, 104], ["the lethality zone", "PROBLEM", 158, 176], ["blast weapons", "OBSERVATION", 9, 22], ["lower", "OBSERVATION_MODIFIER", 33, 38], ["overpressure", "OBSERVATION_MODIFIER", 39, 51], ["overpressure", "OBSERVATION", 92, 104], ["increasing", "OBSERVATION_MODIFIER", 147, 157], ["lethality", "OBSERVATION_MODIFIER", 162, 171], ["zone", "OBSERVATION_MODIFIER", 172, 176], ["blast casualties", "OBSERVATION", 191, 207]]], ["The classic EBW mechanism is illustrated best in the FAE, which has an initial small explosion that disperses a vapor cloud of ethylene oxide or other fuel.", [["ethylene oxide", "CHEMICAL", 127, 141], ["ethylene oxide", "CHEMICAL", 127, 141], ["FAE", "SIMPLE_CHEMICAL", 53, 56], ["ethylene oxide", "SIMPLE_CHEMICAL", 127, 141], ["an initial small explosion", "PROBLEM", 68, 94], ["ethylene oxide", "TREATMENT", 127, 141], ["FAE", "ANATOMY", 53, 56], ["initial", "OBSERVATION_MODIFIER", 71, 78], ["small", "OBSERVATION_MODIFIER", 79, 84], ["explosion", "OBSERVATION", 85, 94], ["ethylene oxide", "OBSERVATION", 127, 141]]], ["At a critical time and distance, the dispersed fuel is ignited by a second detonation, producing a uniform dynamic overpressure through the covered area.", [["a second detonation", "PROBLEM", 66, 85], ["overpressure", "OBSERVATION_MODIFIER", 115, 127]]], ["This may produce lethal overpressures as high as 2 Mpa, whereas a conventional HE would produce only 200 Kpa at a similar distance from the initiating explosion.", [["lethal overpressures", "PROBLEM", 17, 37], ["lethal", "OBSERVATION_MODIFIER", 17, 23]]], ["The EBW also produces a longer-lasting fireball and may produce more energy [area beneath the curve ( Figure 3 -2)], resulting in more casualties with primary blast injuries combined with burns, crush, and penetrating-fragment injuries.", [["primary blast injuries", "DISEASE", 151, 173], ["burns", "DISEASE", 188, 193], ["crush", "DISEASE", 195, 200], ["injuries", "DISEASE", 227, 235], ["The EBW", "TEST", 0, 7], ["a longer-lasting fireball", "PROBLEM", 22, 47], ["primary blast injuries", "PROBLEM", 151, 173], ["burns", "PROBLEM", 188, 193], ["crush", "TREATMENT", 195, 200], ["penetrating-fragment injuries", "PROBLEM", 206, 235], ["blast injuries", "OBSERVATION", 159, 173], ["penetrating", "OBSERVATION_MODIFIER", 206, 217], ["fragment injuries", "OBSERVATION", 218, 235]]], ["48 T.W. Baskin and J.B. Holcomb The blast wave from an EBW can diffract around corners, rapidly expanding and filling a structure, and is enhanced by reflection in enclosed spaces, making this an ideal weapon to defeat field defenses, soft unreinforced buildings, communication equipment, and low-flying aircraft.", [["The blast wave", "TEST", 32, 46], ["communication equipment", "TREATMENT", 264, 287], ["blast wave", "OBSERVATION", 36, 46], ["corners", "OBSERVATION_MODIFIER", 79, 86], ["rapidly", "OBSERVATION_MODIFIER", 88, 95], ["expanding", "OBSERVATION_MODIFIER", 96, 105], ["structure", "OBSERVATION_MODIFIER", 120, 129], ["enhanced", "OBSERVATION_MODIFIER", 138, 146], ["reflection", "OBSERVATION_MODIFIER", 150, 160]]], ["As an antipersonnel weapon, an EBW can be expected to rapidly produce large numbers of casualties with burns, blast injuries, fragment, translational injuries, and crush injuries from demolished buildings, placing a sudden and intense clinical and logistical strain on medical resources.Enhanced-Blast WeaponsSeveral foreign studies have suggested that body armor enhances the effects of primary blast, creating a \"behind armor blunt trauma\" (BABT).", [["body", "ANATOMY", 353, 357], ["primary blast", "ANATOMY", 388, 401], ["burns", "DISEASE", 103, 108], ["blast injuries", "DISEASE", 110, 124], ["injuries", "DISEASE", 150, 158], ["crush injuries", "DISEASE", 164, 178], ["primary blast", "DISEASE", 388, 401], ["blunt trauma", "DISEASE", 428, 440], ["body", "ORGANISM_SUBDIVISION", 353, 357], ["burns", "PROBLEM", 103, 108], ["blast injuries", "PROBLEM", 110, 124], ["fragment", "PROBLEM", 126, 134], ["translational injuries", "PROBLEM", 136, 158], ["crush injuries", "PROBLEM", 164, 178], ["medical resources", "TREATMENT", 269, 286], ["Blast WeaponsSeveral foreign studies", "TEST", 296, 332], ["primary blast", "PROBLEM", 388, 401], ["armor blunt trauma", "PROBLEM", 422, 440], ["large", "OBSERVATION_MODIFIER", 70, 75], ["blast injuries", "OBSERVATION", 110, 124], ["fragment", "OBSERVATION_MODIFIER", 126, 134]]], ["Although studies by the US Army Soldier Systems Command, Natick, MA, indicated that the Interceptor Body Armor in use by US forces does not enhance the blast effect-and may actually reduce effects-when the ceramic plates are included in the armor, it is safe to say that most body armor currently in use will protect only marginally against primary blast injury and offer little, if any, protection against an accompanying thermal injury.", [["body", "ANATOMY", 276, 280], ["primary blast injury", "DISEASE", 341, 361], ["body", "ORGANISM_SUBDIVISION", 276, 280], ["the Interceptor Body Armor", "TREATMENT", 84, 110], ["the ceramic plates", "TREATMENT", 202, 220], ["primary blast injury", "PROBLEM", 341, 361], ["an accompanying thermal injury", "PROBLEM", 407, 437], ["injury", "OBSERVATION", 431, 437]]], ["Armor-employing decouplers or layers of material with different acoustic and mechanical properties specifically designed to maximally attenuate the shock wave needs to be designed.", [["shock", "DISEASE", 148, 153], ["layers of material", "PROBLEM", 30, 48], ["different acoustic and mechanical properties", "PROBLEM", 54, 98], ["the shock wave", "PROBLEM", 144, 158], ["layers", "OBSERVATION_MODIFIER", 30, 36]]], ["It is the combination of the shock wave or leading edge, the dynamic overpressure, the secondary and tertiary effects, and the associated thermal energy that result in the characteristic injuries seen following detonation of an explosive device.", [["shock", "DISEASE", 29, 34], ["injuries", "DISEASE", 187, 195], ["the shock wave", "PROBLEM", 25, 39], ["the dynamic overpressure", "PROBLEM", 57, 81], ["the associated thermal energy", "PROBLEM", 123, 152], ["the characteristic injuries", "PROBLEM", 168, 195], ["an explosive device", "TREATMENT", 225, 244], ["shock", "OBSERVATION", 29, 34], ["edge", "OBSERVATION_MODIFIER", 51, 55], ["dynamic", "OBSERVATION_MODIFIER", 61, 68], ["overpressure", "OBSERVATION_MODIFIER", 69, 81], ["secondary", "OBSERVATION_MODIFIER", 87, 96], ["tertiary effects", "OBSERVATION", 101, 117], ["injuries", "OBSERVATION", 187, 195], ["explosive device", "OBSERVATION", 228, 244]]], ["These injuries may be classified according to the mechanism by which they are produced (Table 3-2) .Enhanced-Blast WeaponsBoth conventional and terrorist weapons are designed to produce multiple wounds with the maximum number of casualties.", [["wounds", "ANATOMY", 195, 201], ["injuries", "DISEASE", 6, 14], ["wounds", "PATHOLOGICAL_FORMATION", 195, 201], ["These injuries", "PROBLEM", 0, 14], ["multiple wounds", "PROBLEM", 186, 201], ["injuries", "OBSERVATION", 6, 14], ["multiple", "OBSERVATION_MODIFIER", 186, 194], ["wounds", "OBSERVATION", 195, 201]]], ["Indeed, on today's battlefield, up to 90% of casualties are secondary to fragmentation wounds, with wounding from small arms or bullets producing generally less than 15 to 20% of battlefield casualties.", [["wounds", "ANATOMY", 87, 93], ["wounds", "DISEASE", 87, 93], ["wounds", "PATHOLOGICAL_FORMATION", 87, 93], ["fragmentation wounds", "PROBLEM", 73, 93], ["wounding from small arms or bullets", "PROBLEM", 100, 135], ["fragmentation", "OBSERVATION_MODIFIER", 73, 86], ["wounds", "OBSERVATION", 87, 93], ["small", "OBSERVATION_MODIFIER", 114, 119], ["bullets", "OBSERVATION", 128, 135]]], ["Modern fragmentation weapons have a high casing-to-explosive ratio designed to produce preformed fragments, which significantly enhances the wounding radius and casualty probability.", [["fragments", "ANATOMY", 97, 106], ["Modern fragmentation weapons", "PROBLEM", 0, 28], ["preformed fragments", "PROBLEM", 87, 106], ["fragmentation", "OBSERVATION", 7, 20], ["high", "OBSERVATION_MODIFIER", 36, 40], ["fragments", "OBSERVATION", 97, 106], ["wounding", "OBSERVATION_MODIFIER", 141, 149], ["radius", "OBSERVATION_MODIFIER", 150, 156]]], ["50 T.W. Baskin and J.B. Holcomb Wounds produced by fragments from weapon, environmental projectiles, and debris, with penetrating injury predominating Tertiary Displacement of body (translational) and structural collapse with acceleration-deceleration, crush, and blunt injuries QuaternaryEnhanced-Blast WeaponsAll other mechanisms producing injury, burns, toxidromes from fuel, metals, septic syndromes from soil and environmental contamination (septic meliodosis)Pathophysiology of Primary Blast InjuryThe biological effects of the blast wave depend on the peak pressure and the duration of the dynamic overpressure and the effects of the secondary, tertiary, and quaternary mechanisms of injury.", [["fragments", "ANATOMY", 51, 60], ["body", "ANATOMY", 176, 180], ["penetrating injury", "DISEASE", 118, 136], ["crush", "DISEASE", 253, 258], ["blunt injuries", "DISEASE", 264, 278], ["burns", "DISEASE", 350, 355], ["toxidromes", "DISEASE", 357, 367], ["metals", "CHEMICAL", 379, 385], ["septic syndromes", "DISEASE", 387, 403], ["septic meliodosis", "DISEASE", 447, 464], ["Primary Blast Injury", "DISEASE", 484, 504], ["body", "ORGANISM_SUBDIVISION", 176, 180], ["Holcomb Wounds", "PROBLEM", 24, 38], ["debris", "PROBLEM", 105, 111], ["penetrating injury", "PROBLEM", 118, 136], ["Tertiary Displacement of body (translational)", "TREATMENT", 151, 196], ["structural collapse", "PROBLEM", 201, 220], ["deceleration", "PROBLEM", 239, 251], ["crush", "PROBLEM", 253, 258], ["blunt injuries", "PROBLEM", 264, 278], ["injury", "PROBLEM", 342, 348], ["burns", "PROBLEM", 350, 355], ["septic syndromes", "PROBLEM", 387, 403], ["environmental contamination (septic meliodosis)", "PROBLEM", 418, 465], ["Primary Blast Injury", "PROBLEM", 484, 504], ["the blast wave", "PROBLEM", 530, 544], ["the peak pressure", "TEST", 555, 572], ["the dynamic overpressure", "PROBLEM", 593, 617], ["injury", "PROBLEM", 691, 697], ["Wounds", "OBSERVATION", 32, 38], ["fragments", "OBSERVATION_MODIFIER", 51, 60], ["environmental projectiles", "OBSERVATION", 74, 99], ["debris", "OBSERVATION", 105, 111], ["penetrating", "OBSERVATION_MODIFIER", 118, 129], ["injury", "OBSERVATION", 130, 136], ["Tertiary Displacement", "OBSERVATION", 151, 172], ["body", "ANATOMY_MODIFIER", 176, 180], ["collapse", "OBSERVATION", 212, 220], ["acceleration", "OBSERVATION_MODIFIER", 226, 238], ["deceleration", "OBSERVATION_MODIFIER", 239, 251], ["injury", "OBSERVATION", 342, 348], ["septic syndromes", "OBSERVATION", 387, 403], ["septic meliodosis", "OBSERVATION", 447, 464], ["Primary", "OBSERVATION_MODIFIER", 484, 491], ["Blast Injury", "OBSERVATION", 492, 504], ["blast wave", "OBSERVATION", 534, 544], ["peak pressure", "OBSERVATION", 559, 572], ["injury", "OBSERVATION", 691, 697]]], ["Primary blast injury results from the interaction of the blast wave with the body or tissue, producing two types of energy: stress waves and shear waves.", [["body", "ANATOMY", 77, 81], ["tissue", "ANATOMY", 85, 91], ["blast injury", "DISEASE", 8, 20], ["body", "ORGANISM_SUBDIVISION", 77, 81], ["tissue", "TISSUE", 85, 91], ["Primary blast injury", "PROBLEM", 0, 20], ["stress waves", "PROBLEM", 124, 136], ["shear waves", "PROBLEM", 141, 152], ["blast injury", "OBSERVATION", 8, 20], ["body", "ANATOMY", 77, 81], ["tissue", "ANATOMY", 85, 91], ["stress waves", "OBSERVATION", 124, 136], ["shear waves", "OBSERVATION", 141, 152]]], ["Stress waves produced by the interaction of the blast wave and the body surface are supersonic longitudinal pressure waves that create high local forces with small, but very rapid distortions, producing microvascular injury; they are reinforced and reflected at tissue interfaces, thus enhancing the injury potential.Pathophysiology of Primary Blast InjuryOrgans with heightened differences in physical properties such as the lungs, auditory system, and the gas-filled intestine are most susceptible.Pathophysiology of Primary Blast InjuryInjuries from the stress waves are caused in several ways.Pathophysiology of Primary Blast InjuryPressure differentials across delicate structures such as alveoli; Rapid compression of and subsequent re-expansion of gas-filled structures; Reflection of a component of the compressive stress wave known as a tension wave at the interface of tissue and gas.Pathophysiology of Primary Blast InjuryThese myriad mechanisms result in damage originating in the mucosa and submucosa, but also reflect outward.", [["body surface", "ANATOMY", 67, 79], ["microvascular", "ANATOMY", 203, 216], ["tissue", "ANATOMY", 262, 268], ["lungs", "ANATOMY", 426, 431], ["auditory system", "ANATOMY", 433, 448], ["intestine", "ANATOMY", 469, 478], ["alveoli", "ANATOMY", 694, 701], ["tissue", "ANATOMY", 879, 885], ["mucosa", "ANATOMY", 993, 999], ["submucosa", "ANATOMY", 1004, 1013], ["microvascular injury", "DISEASE", 203, 223], ["Primary Blast Injury", "DISEASE", 616, 636], ["Primary Blast Injury", "DISEASE", 913, 933], ["body surface", "CELLULAR_COMPONENT", 67, 79], ["microvascular", "TISSUE", 203, 216], ["tissue", "TISSUE", 262, 268], ["lungs", "ORGAN", 426, 431], ["intestine", "ORGAN", 469, 478], ["alveoli", "MULTI-TISSUE_STRUCTURE", 694, 701], ["tissue", "TISSUE", 879, 885], ["mucosa", "MULTI-TISSUE_STRUCTURE", 993, 999], ["submucosa", "MULTI-TISSUE_STRUCTURE", 1004, 1013], ["Stress waves", "PROBLEM", 0, 12], ["the blast wave", "TEST", 44, 58], ["supersonic longitudinal pressure waves", "PROBLEM", 84, 122], ["high local forces", "PROBLEM", 135, 152], ["very rapid distortions", "PROBLEM", 169, 191], ["microvascular injury", "PROBLEM", 203, 223], ["Primary Blast InjuryOrgans", "PROBLEM", 336, 362], ["heightened differences in physical properties", "PROBLEM", 368, 413], ["the gas-filled intestine", "PROBLEM", 454, 478], ["Primary Blast InjuryInjuries", "PROBLEM", 519, 547], ["the stress waves", "PROBLEM", 553, 569], ["Primary Blast Injury", "PROBLEM", 616, 636], ["Pressure differentials", "TEST", 636, 658], ["alveoli", "PROBLEM", 694, 701], ["Rapid compression of and subsequent re-expansion of gas-filled structures", "PROBLEM", 703, 776], ["the compressive stress wave", "PROBLEM", 807, 834], ["a tension wave", "PROBLEM", 844, 858], ["Primary Blast Injury", "PROBLEM", 913, 933], ["damage originating in the mucosa and submucosa", "PROBLEM", 967, 1013], ["blast wave", "OBSERVATION", 48, 58], ["body", "ANATOMY_MODIFIER", 67, 71], ["surface", "ANATOMY_MODIFIER", 72, 79], ["supersonic", "OBSERVATION", 84, 94], ["longitudinal pressure", "OBSERVATION", 95, 116], ["high", "OBSERVATION_MODIFIER", 135, 139], ["local forces", "OBSERVATION", 140, 152], ["small", "OBSERVATION_MODIFIER", 158, 163], ["very", "OBSERVATION_MODIFIER", 169, 173], ["rapid distortions", "OBSERVATION", 174, 191], ["microvascular", "OBSERVATION_MODIFIER", 203, 216], ["injury", "OBSERVATION", 217, 223], ["enhancing", "OBSERVATION_MODIFIER", 286, 295], ["injury", "OBSERVATION", 300, 306], ["Primary", "OBSERVATION_MODIFIER", 336, 343], ["Blast InjuryOrgans", "OBSERVATION", 344, 362], ["heightened", "OBSERVATION_MODIFIER", 368, 378], ["differences", "OBSERVATION_MODIFIER", 379, 390], ["lungs", "ANATOMY", 426, 431], ["auditory system", "ANATOMY", 433, 448], ["gas", "OBSERVATION", 458, 461], ["filled", "OBSERVATION", 462, 468], ["intestine", "ANATOMY", 469, 478], ["Primary", "OBSERVATION_MODIFIER", 519, 526], ["Blast InjuryInjuries", "OBSERVATION", 527, 547], ["stress waves", "OBSERVATION", 557, 569], ["Primary", "OBSERVATION_MODIFIER", 616, 623], ["Blast Injury", "OBSERVATION", 624, 636], ["alveoli", "ANATOMY", 694, 701], ["Rapid", "OBSERVATION_MODIFIER", 703, 708], ["compression", "OBSERVATION", 709, 720], ["re-expansion", "OBSERVATION_MODIFIER", 739, 751], ["gas", "OBSERVATION_MODIFIER", 755, 758], ["filled structures", "OBSERVATION", 759, 776], ["component", "OBSERVATION_MODIFIER", 794, 803], ["compressive stress wave", "OBSERVATION", 811, 834], ["tension wave", "OBSERVATION", 846, 858], ["tissue", "ANATOMY", 879, 885], ["gas", "OBSERVATION_MODIFIER", 890, 893], ["Primary", "OBSERVATION_MODIFIER", 913, 920], ["Blast Injury", "OBSERVATION", 921, 933], ["damage", "OBSERVATION", 967, 973], ["mucosa", "ANATOMY", 993, 999], ["submucosa", "ANATOMY", 1004, 1013], ["outward", "OBSERVATION_MODIFIER", 1032, 1039]]], ["Therefore, evidence of serosal injury may well represent full thickness damage.", [["serosal", "ANATOMY", 23, 30], ["serosal", "MULTI-TISSUE_STRUCTURE", 23, 30], ["serosal injury", "PROBLEM", 23, 37], ["full thickness damage", "PROBLEM", 57, 78], ["evidence of", "UNCERTAINTY", 11, 22], ["serosal injury", "OBSERVATION", 23, 37], ["may well represent", "UNCERTAINTY", 38, 56], ["full thickness", "OBSERVATION_MODIFIER", 57, 71], ["damage", "OBSERVATION", 72, 78]]], ["The interaction of these forces at the tissue interface is also known as spalling, characterized by the \"boiling\" effect seen at the air-water interface following an underwater explosion.", [["tissue", "ANATOMY", 39, 45], ["tissue", "TISSUE", 39, 45], ["the \"boiling\" effect", "PROBLEM", 100, 120], ["forces", "OBSERVATION_MODIFIER", 25, 31], ["tissue", "ANATOMY", 39, 45], ["interface", "OBSERVATION", 46, 55]]], ["A similar phenomenon most likely occurs at tissue interfaces, with resultant microvascular damage.", [["tissue", "ANATOMY", 43, 49], ["microvascular", "ANATOMY", 77, 90], ["microvascular damage", "DISEASE", 77, 97], ["tissue", "TISSUE", 43, 49], ["microvascular", "TISSUE", 77, 90], ["A similar phenomenon", "PROBLEM", 0, 20], ["resultant microvascular damage", "PROBLEM", 67, 97], ["similar", "OBSERVATION_MODIFIER", 2, 9], ["phenomenon", "OBSERVATION", 10, 20], ["most likely", "UNCERTAINTY", 21, 32], ["tissue interfaces", "OBSERVATION", 43, 60], ["resultant", "OBSERVATION_MODIFIER", 67, 76], ["microvascular damage", "OBSERVATION", 77, 97]]], ["Shear waves are transverse waves with a lower velocity and longer duration that cause asynchronous movement of tissues.", [["tissues", "ANATOMY", 111, 118], ["tissues", "TISSUE", 111, 118], ["Shear waves", "PROBLEM", 0, 11], ["transverse waves", "PROBLEM", 16, 32], ["a lower velocity", "PROBLEM", 38, 54], ["asynchronous movement of tissues", "PROBLEM", 86, 118], ["waves", "OBSERVATION_MODIFIER", 6, 11], ["transverse", "OBSERVATION_MODIFIER", 16, 26], ["lower velocity", "OBSERVATION_MODIFIER", 40, 54], ["asynchronous movement", "OBSERVATION", 86, 107]]], ["Actual damage depends on the degree to which the asynchronous motions overcome the inherent tissue elasticity, resulting in tearing of tissue and possible disruption of attachments.", [["tissue", "ANATOMY", 92, 98], ["tissue", "ANATOMY", 135, 141], ["tissue", "TISSUE", 92, 98], ["tissue", "TISSUE", 135, 141], ["Actual damage", "PROBLEM", 0, 13], ["tearing of tissue", "PROBLEM", 124, 141], ["disruption of attachments", "PROBLEM", 155, 180], ["damage", "OBSERVATION", 7, 13], ["inherent tissue", "OBSERVATION_MODIFIER", 83, 98], ["elasticity", "OBSERVATION_MODIFIER", 99, 109], ["tearing", "OBSERVATION_MODIFIER", 124, 131], ["possible", "UNCERTAINTY", 146, 154], ["disruption", "OBSERVATION", 155, 165]]], ["However, muscle, bone, and solid-organ injury is far more likely to result from the tertiary and quaternary effects of the blast than from the blast wave alone.ThoracicBlasts producing overpressure of less than 40 pounds per square inch (psi) generally will not cause pulmonary injury, (40 psi being produced by 20 Kg TNT exploding 6 meters away).", [["muscle", "ANATOMY", 9, 15], ["bone", "ANATOMY", 17, 21], ["solid-organ", "ANATOMY", 27, 38], ["pulmonary", "ANATOMY", 268, 277], ["ThoracicBlasts", "CHEMICAL", 160, 174], ["pulmonary injury", "DISEASE", 268, 284], ["muscle", "TISSUE", 9, 15], ["bone", "TISSUE", 17, 21], ["organ", "ORGAN", 33, 38], ["ThoracicBlasts", "SIMPLE_CHEMICAL", 160, 174], ["pulmonary", "ORGAN", 268, 277], ["muscle, bone, and solid-organ injury", "PROBLEM", 9, 45], ["pulmonary injury", "PROBLEM", 268, 284], ["muscle", "ANATOMY", 9, 15], ["bone", "ANATOMY", 17, 21], ["organ", "ANATOMY", 33, 38], ["injury", "OBSERVATION", 39, 45], ["quaternary effects", "OBSERVATION", 97, 115], ["blast", "OBSERVATION", 123, 128], ["overpressure", "OBSERVATION_MODIFIER", 185, 197], ["pulmonary", "ANATOMY", 268, 277], ["injury", "OBSERVATION", 278, 284]]], ["Approximately 50% or more of casualties will sustain pulmonary damage with pressures of 80 psi or more, with overpressures of 200 psi being uniformly fatal in open-air blasts.ThoracicBlast injury to the lungs is the cause of the greatest morbidity and mortality from the blast effect alone.", [["pulmonary", "ANATOMY", 53, 62], ["lungs", "ANATOMY", 203, 208], ["pulmonary damage", "DISEASE", 53, 69], ["injury to the lungs", "DISEASE", 189, 208], ["pulmonary", "ORGAN", 53, 62], ["lungs", "ORGAN", 203, 208], ["open-air blasts", "CELL_TYPE", 159, 174], ["pulmonary damage", "PROBLEM", 53, 69], ["pressures", "TEST", 75, 84], ["overpressures", "TEST", 109, 122], ["ThoracicBlast injury to the lungs", "PROBLEM", 175, 208], ["the greatest morbidity", "PROBLEM", 225, 247], ["the blast effect", "PROBLEM", 267, 283], ["pulmonary", "ANATOMY", 53, 62], ["damage", "OBSERVATION", 63, 69], ["pressures", "OBSERVATION_MODIFIER", 75, 84], ["fatal", "OBSERVATION_MODIFIER", 150, 155], ["air blasts", "OBSERVATION", 164, 174], ["injury", "OBSERVATION", 189, 195], ["lungs", "ANATOMY", 203, 208], ["greatest", "OBSERVATION_MODIFIER", 229, 237], ["morbidity", "OBSERVATION", 238, 247], ["blast effect", "OBSERVATION", 271, 283]]], ["In the lungs, reflection of stress waves at more rigid interfaces account for the predilection of paramediastinal, peri-bronchial, and subpleural tissue disruption and hemorrhage.", [["lungs", "ANATOMY", 7, 12], ["paramediastinal", "ANATOMY", 98, 113], ["peri-bronchial", "ANATOMY", 115, 129], ["subpleural tissue", "ANATOMY", 135, 152], ["hemorrhage", "DISEASE", 168, 178], ["lungs", "ORGAN", 7, 12], ["paramediastinal", "CANCER", 98, 113], ["peri-bronchial", "CANCER", 115, 129], ["subpleural tissue", "TISSUE", 135, 152], ["stress waves at more rigid interfaces", "PROBLEM", 28, 65], ["paramediastinal, peri-bronchial, and subpleural tissue disruption", "PROBLEM", 98, 163], ["hemorrhage", "PROBLEM", 168, 178], ["lungs", "ANATOMY", 7, 12], ["stress waves", "OBSERVATION", 28, 40], ["rigid interfaces", "OBSERVATION", 49, 65], ["predilection", "OBSERVATION_MODIFIER", 82, 94], ["paramediastinal", "ANATOMY", 98, 113], ["peri-bronchial", "ANATOMY_MODIFIER", 115, 129], ["subpleural tissue", "ANATOMY", 135, 152], ["hemorrhage", "OBSERVATION", 168, 178]]], ["Propagation of the stress wave results in pulmonary contusions distant from the site of impact in air-filled tissues, with damage to alveolar septae.", [["pulmonary", "ANATOMY", 42, 51], ["tissues", "ANATOMY", 109, 116], ["alveolar septae", "ANATOMY", 133, 148], ["contusions", "DISEASE", 52, 62], ["pulmonary", "ORGAN", 42, 51], ["tissues", "TISSUE", 109, 116], ["alveolar septae", "TISSUE", 133, 148], ["the stress wave", "TEST", 15, 30], ["pulmonary contusions", "PROBLEM", 42, 62], ["impact in air-filled tissues", "PROBLEM", 88, 116], ["damage to alveolar septae", "PROBLEM", 123, 148], ["stress wave", "OBSERVATION", 19, 30], ["pulmonary", "ANATOMY", 42, 51], ["contusions", "OBSERVATION", 52, 62], ["site", "OBSERVATION_MODIFIER", 80, 84], ["impact", "OBSERVATION_MODIFIER", 88, 94], ["air", "OBSERVATION", 98, 101], ["filled tissues", "OBSERVATION", 102, 116], ["alveolar", "ANATOMY_MODIFIER", 133, 141], ["septae", "ANATOMY_MODIFIER", 142, 148]]], ["Type I and some Type II pneumocytes are disrupted structurally and dysfunctionally, with loss of surfactant production, which when combined with capillary endothelial damage and release of ecosinoids and TXA2 may lead to progressive hypoxic respiratory failure and a clinical picture resembling acute respiratory distress syndrome (ARDS).ThoracicPathologically, when the alveola septae are disrupted, hemorrhage occurs in three distinct patterns 1. pleural and subpleural, 2. multifocal and diffuse parenchymal and alveolar hemorrhage, 3. peribronchial and perivascular hemorrhage.ThoracicThese patterns of injury may range from isolated scattered petechiae to confluent, consolidated areas of hemorrhage.", [["Type II pneumocytes", "ANATOMY", 16, 35], ["capillary endothelial", "ANATOMY", 145, 166], ["respiratory", "ANATOMY", 241, 252], ["respiratory", "ANATOMY", 301, 312], ["alveola septae", "ANATOMY", 371, 385], ["pleural", "ANATOMY", 449, 456], ["subpleural", "ANATOMY", 461, 471], ["parenchymal", "ANATOMY", 499, 510], ["alveolar", "ANATOMY", 515, 523], ["peribronchial", "ANATOMY", 539, 552], ["perivascular", "ANATOMY", 557, 569], ["petechiae", "ANATOMY", 648, 657], ["TXA2", "CHEMICAL", 204, 208], ["hypoxic respiratory failure", "DISEASE", 233, 260], ["acute respiratory distress syndrome", "DISEASE", 295, 330], ["ARDS", "DISEASE", 332, 336], ["hemorrhage", "DISEASE", 401, 411], ["parenchymal and alveolar hemorrhage", "DISEASE", 499, 534], ["hemorrhage", "DISEASE", 570, 580], ["petechiae", "DISEASE", 648, 657], ["hemorrhage", "DISEASE", 694, 704], ["TXA2", "CHEMICAL", 204, 208], ["Type I", "GENE_OR_GENE_PRODUCT", 0, 6], ["Type II pneumocytes", "GENE_OR_GENE_PRODUCT", 16, 35], ["surfactant", "SIMPLE_CHEMICAL", 97, 107], ["capillary endothelial", "TISSUE", 145, 166], ["ecosinoids", "GENE_OR_GENE_PRODUCT", 189, 199], ["TXA2", "SIMPLE_CHEMICAL", 204, 208], ["alveola septae", "MULTI-TISSUE_STRUCTURE", 371, 385], ["pleural", "MULTI-TISSUE_STRUCTURE", 449, 456], ["parenchymal", "MULTI-TISSUE_STRUCTURE", 499, 510], ["alveolar", "MULTI-TISSUE_STRUCTURE", 515, 523], ["peribronchial", "MULTI-TISSUE_STRUCTURE", 539, 552], ["perivascular", "IMMATERIAL_ANATOMICAL_ENTITY", 557, 569], ["petechiae", "PATHOLOGICAL_FORMATION", 648, 657], ["Type II pneumocytes", "CELL_TYPE", 16, 35], ["Type I", "PROBLEM", 0, 6], ["some Type II pneumocytes", "PROBLEM", 11, 35], ["loss of surfactant production", "PROBLEM", 89, 118], ["capillary endothelial damage", "PROBLEM", 145, 173], ["ecosinoids", "PROBLEM", 189, 199], ["TXA2", "PROBLEM", 204, 208], ["progressive hypoxic respiratory failure", "PROBLEM", 221, 260], ["acute respiratory distress syndrome", "PROBLEM", 295, 330], ["ARDS", "PROBLEM", 332, 336], ["the alveola septae", "PROBLEM", 367, 385], ["hemorrhage", "PROBLEM", 401, 411], ["pleural and subpleural, 2", "PROBLEM", 449, 474], ["multifocal and diffuse parenchymal and alveolar hemorrhage", "PROBLEM", 476, 534], ["peribronchial and perivascular hemorrhage", "PROBLEM", 539, 580], ["injury", "PROBLEM", 607, 613], ["isolated scattered petechiae to confluent", "PROBLEM", 629, 670], ["hemorrhage", "PROBLEM", 694, 704], ["Type II", "OBSERVATION_MODIFIER", 16, 23], ["pneumocytes", "OBSERVATION", 24, 35], ["structurally", "OBSERVATION_MODIFIER", 50, 62], ["loss", "OBSERVATION_MODIFIER", 89, 93], ["surfactant production", "OBSERVATION", 97, 118], ["capillary", "ANATOMY_MODIFIER", 145, 154], ["endothelial", "ANATOMY", 155, 166], ["damage", "OBSERVATION", 167, 173], ["may lead to", "UNCERTAINTY", 209, 220], ["progressive", "OBSERVATION_MODIFIER", 221, 232], ["hypoxic", "OBSERVATION_MODIFIER", 233, 240], ["respiratory failure", "OBSERVATION", 241, 260], ["acute", "OBSERVATION_MODIFIER", 295, 300], ["respiratory distress syndrome", "OBSERVATION", 301, 330], ["alveola septae", "ANATOMY", 371, 385], ["hemorrhage", "OBSERVATION", 401, 411], ["three distinct", "OBSERVATION_MODIFIER", 422, 436], ["subpleural", "ANATOMY", 461, 471], ["diffuse", "OBSERVATION_MODIFIER", 491, 498], ["parenchymal", "ANATOMY_MODIFIER", 499, 510], ["alveolar", "ANATOMY_MODIFIER", 515, 523], ["hemorrhage", "OBSERVATION", 524, 534], ["perivascular", "ANATOMY_MODIFIER", 557, 569], ["hemorrhage", "OBSERVATION", 570, 580], ["injury", "OBSERVATION", 607, 613], ["scattered", "OBSERVATION_MODIFIER", 638, 647], ["petechiae", "OBSERVATION", 648, 657], ["confluent", "OBSERVATION_MODIFIER", 661, 670], ["consolidated", "OBSERVATION_MODIFIER", 672, 684], ["areas", "OBSERVATION_MODIFIER", 685, 690], ["hemorrhage", "OBSERVATION", 694, 704]]], ["Subpleural cysts and lacerations of pleura may lead to hemo-pneumothorax, pneumomediastinum, or tension pneumothorax.", [["Subpleural cysts", "ANATOMY", 0, 16], ["pleura", "ANATOMY", 36, 42], ["hemo", "ANATOMY", 55, 59], ["Subpleural cysts", "DISEASE", 0, 16], ["lacerations", "DISEASE", 21, 32], ["hemo-pneumothorax", "DISEASE", 55, 72], ["pneumomediastinum", "DISEASE", 74, 91], ["tension pneumothorax", "DISEASE", 96, 116], ["Subpleural cysts", "PATHOLOGICAL_FORMATION", 0, 16], ["pleura", "ORGAN", 36, 42], ["Subpleural cysts", "PROBLEM", 0, 16], ["lacerations of pleura", "PROBLEM", 21, 42], ["hemo-pneumothorax", "PROBLEM", 55, 72], ["pneumomediastinum", "PROBLEM", 74, 91], ["tension pneumothorax", "PROBLEM", 96, 116], ["cysts", "OBSERVATION", 11, 16], ["lacerations", "OBSERVATION", 21, 32], ["pleura", "ANATOMY", 36, 42], ["pneumomediastinum", "OBSERVATION", 74, 91], ["tension", "OBSERVATION_MODIFIER", 96, 103], ["pneumothorax", "OBSERVATION", 104, 116]]], ["A lethal primary blast injury potentially could present with no outward signs of trauma.", [["primary blast", "ANATOMY", 9, 22], ["primary blast injury", "DISEASE", 9, 29], ["trauma", "DISEASE", 81, 87], ["A lethal primary blast injury", "PROBLEM", 0, 29], ["trauma", "PROBLEM", 81, 87], ["lethal", "OBSERVATION_MODIFIER", 2, 8], ["primary", "OBSERVATION_MODIFIER", 9, 16], ["blast injury", "OBSERVATION", 17, 29], ["trauma", "OBSERVATION", 81, 87]]], ["In severe blast injury, immediate death may be attributed to a characteristic triad of physiologic responses of primary thoracic blast of bradycardia, apnea, and hypotension that is unrelated to hemorrhage.", [["thoracic blast", "ANATOMY", 120, 134], ["blast injury", "DISEASE", 10, 22], ["death", "DISEASE", 34, 39], ["primary thoracic blast", "DISEASE", 112, 134], ["bradycardia", "DISEASE", 138, 149], ["apnea", "DISEASE", 151, 156], ["hypotension", "DISEASE", 162, 173], ["hemorrhage", "DISEASE", 195, 205], ["severe blast injury", "PROBLEM", 3, 22], ["immediate death", "PROBLEM", 24, 39], ["primary thoracic blast of bradycardia", "PROBLEM", 112, 149], ["apnea", "PROBLEM", 151, 156], ["hypotension", "PROBLEM", 162, 173], ["hemorrhage", "PROBLEM", 195, 205], ["severe", "OBSERVATION_MODIFIER", 3, 9], ["blast injury", "OBSERVATION", 10, 22], ["thoracic", "ANATOMY", 120, 128], ["blast", "OBSERVATION", 129, 134], ["bradycardia", "OBSERVATION", 138, 149], ["apnea", "OBSERVATION", 151, 156], ["hypotension", "OBSERVATION", 162, 173], ["hemorrhage", "OBSERVATION", 195, 205]]], ["Immediate death also has been attributed to massive air embolism resulting from the disruption of the alveolar wall and adjacent pulmonary capillaries, with the air emboli primarily affecting cerebral and coronary vessels.ThoracicMultiple animal studies have demonstrated large alveolar-venous and broncho-venous fistulae following blast injuries.", [["alveolar wall", "ANATOMY", 102, 115], ["pulmonary capillaries", "ANATOMY", 129, 150], ["air emboli", "ANATOMY", 161, 171], ["cerebral", "ANATOMY", 192, 200], ["coronary vessels", "ANATOMY", 205, 221], ["alveolar", "ANATOMY", 278, 286], ["venous", "ANATOMY", 287, 293], ["broncho-venous fistulae", "ANATOMY", 298, 321], ["death", "DISEASE", 10, 15], ["air embolism", "DISEASE", 52, 64], ["fistulae", "DISEASE", 313, 321], ["blast injuries", "DISEASE", 332, 346], ["alveolar wall", "MULTI-TISSUE_STRUCTURE", 102, 115], ["pulmonary capillaries", "TISSUE", 129, 150], ["air emboli", "PATHOLOGICAL_FORMATION", 161, 171], ["cerebral", "MULTI-TISSUE_STRUCTURE", 192, 200], ["coronary vessels", "MULTI-TISSUE_STRUCTURE", 205, 221], ["alveolar-venous", "MULTI-TISSUE_STRUCTURE", 278, 293], ["broncho-venous fistulae", "PATHOLOGICAL_FORMATION", 298, 321], ["Immediate death", "PROBLEM", 0, 15], ["massive air embolism", "PROBLEM", 44, 64], ["the disruption of the alveolar wall and adjacent pulmonary capillaries", "PROBLEM", 80, 150], ["the air emboli", "PROBLEM", 157, 171], ["ThoracicMultiple animal studies", "TEST", 222, 253], ["large alveolar-venous and broncho-venous fistulae", "PROBLEM", 272, 321], ["blast injuries", "PROBLEM", 332, 346], ["attributed to", "UNCERTAINTY", 30, 43], ["massive", "OBSERVATION_MODIFIER", 44, 51], ["air embolism", "OBSERVATION", 52, 64], ["disruption", "OBSERVATION", 84, 94], ["alveolar", "ANATOMY_MODIFIER", 102, 110], ["wall", "ANATOMY_MODIFIER", 111, 115], ["adjacent", "ANATOMY_MODIFIER", 120, 128], ["pulmonary capillaries", "ANATOMY", 129, 150], ["air emboli", "OBSERVATION", 161, 171], ["cerebral", "ANATOMY_MODIFIER", 192, 200], ["coronary vessels", "ANATOMY", 205, 221], ["large", "OBSERVATION_MODIFIER", 272, 277], ["alveolar", "ANATOMY_MODIFIER", 278, 286], ["venous", "ANATOMY", 287, 293], ["broncho-venous fistulae", "OBSERVATION", 298, 321], ["blast injuries", "OBSERVATION", 332, 346]]], ["This occurs in both air and underwater blasts and is commonly found in both cerebral and coronary circulation at autopsy and in experimental animal studies.", [["blasts", "ANATOMY", 39, 45], ["cerebral", "ANATOMY", 76, 84], ["coronary", "ANATOMY", 89, 97], ["blasts", "CELL", 39, 45], ["cerebral", "MULTI-TISSUE_STRUCTURE", 76, 84], ["coronary circulation", "MULTI-TISSUE_STRUCTURE", 89, 109], ["underwater blasts", "CELL_TYPE", 28, 45], ["underwater blasts", "PROBLEM", 28, 45], ["experimental animal studies", "TEST", 128, 155], ["both", "OBSERVATION_MODIFIER", 15, 19], ["air", "OBSERVATION", 20, 23], ["underwater blasts", "OBSERVATION", 28, 45], ["both", "ANATOMY_MODIFIER", 71, 75], ["cerebral", "ANATOMY", 76, 84], ["coronary circulation", "ANATOMY", 89, 109]]], ["Dysrythmias, signs of neurologic injury, and retinal artery air emboli may be seen in immediate survivors.", [["neurologic", "ANATOMY", 22, 32], ["retinal artery air emboli", "ANATOMY", 45, 70], ["Dysrythmias", "DISEASE", 0, 11], ["neurologic injury", "DISEASE", 22, 39], ["retinal artery air emboli", "DISEASE", 45, 70], ["retinal artery", "MULTI-TISSUE_STRUCTURE", 45, 59], ["Dysrythmias", "PROBLEM", 0, 11], ["neurologic injury", "PROBLEM", 22, 39], ["retinal artery air emboli", "PROBLEM", 45, 70], ["signs of", "UNCERTAINTY", 13, 21], ["neurologic injury", "OBSERVATION", 22, 39], ["retinal artery", "ANATOMY", 45, 59], ["air emboli", "OBSERVATION", 60, 70], ["may be seen", "UNCERTAINTY", 71, 82]]], ["The Trendelenberg position is not advisable in these patients, as now it is thought to predispose patients to coronary air embolus.", [["coronary", "ANATOMY", 110, 118], ["coronary air embolus", "DISEASE", 110, 130], ["patients", "ORGANISM", 53, 61], ["patients", "ORGANISM", 98, 106], ["coronary air embolus", "PATHOLOGICAL_FORMATION", 110, 130], ["patients", "SPECIES", 53, 61], ["patients", "SPECIES", 98, 106], ["The Trendelenberg position", "TREATMENT", 0, 26], ["coronary air embolus", "PROBLEM", 110, 130], ["Trendelenberg", "OBSERVATION", 4, 17], ["not advisable", "UNCERTAINTY", 30, 43], ["coronary", "ANATOMY", 110, 118], ["air embolus", "OBSERVATION", 119, 130]]], ["The immediate therapy is supplemental oxygen, with Hyperbaric Oxygen being the definitive treatment of systemic air embolus, although not usually available or clinically practical.", [["oxygen", "CHEMICAL", 38, 44], ["Oxygen", "CHEMICAL", 62, 68], ["systemic air embolus", "DISEASE", 103, 123], ["oxygen", "CHEMICAL", 38, 44], ["Oxygen", "CHEMICAL", 62, 68], ["oxygen", "SIMPLE_CHEMICAL", 38, 44], ["Oxygen", "SIMPLE_CHEMICAL", 62, 68], ["The immediate therapy", "TREATMENT", 0, 21], ["supplemental oxygen", "TREATMENT", 25, 44], ["Hyperbaric Oxygen", "TREATMENT", 51, 68], ["the definitive treatment", "TREATMENT", 75, 99], ["systemic air embolus", "PROBLEM", 103, 123], ["immediate", "OBSERVATION_MODIFIER", 4, 13], ["therapy", "OBSERVATION", 14, 21], ["supplemental oxygen", "OBSERVATION", 25, 44], ["systemic", "OBSERVATION_MODIFIER", 103, 111], ["air embolus", "OBSERVATION", 112, 123]]], ["Alveolar-venous fistulae are thought to resolve in 24 hours, but must be considered a continuing risk in casualties that require positive pressure ventilation, especially with application of positive end expiratory pressure (PEEP), which is commonly used for hypoxic pathophysiology.ThoracicIn survivors, clinical manifestations of primary blast may be present immediately or may have a delayed onset of 24 to 48 hours.ThoracicIntrapulmonary hemorrhage and focal alveolar edema leading to ventilation perfusion (V/Q) mismatch, increased intrapulmonary shunting, and decreased compliance results in hypoxia and increased work of breathing that is pathophysiologically similar to pulmonary contusions induced by other mechanisms of nonpenetrating thoracic trauma.", [["Alveolar", "ANATOMY", 0, 8], ["venous", "ANATOMY", 9, 15], ["primary blast", "ANATOMY", 332, 345], ["alveolar", "ANATOMY", 463, 471], ["intrapulmonary", "ANATOMY", 537, 551], ["pulmonary", "ANATOMY", 678, 687], ["thoracic", "ANATOMY", 745, 753], ["Alveolar-venous fistulae", "DISEASE", 0, 24], ["ThoracicIn", "DISEASE", 283, 293], ["primary blast", "DISEASE", 332, 345], ["ThoracicIntrapulmonary hemorrhage", "DISEASE", 419, 452], ["alveolar edema", "DISEASE", 463, 477], ["hypoxia", "DISEASE", 598, 605], ["pulmonary contusions", "DISEASE", 678, 698], ["thoracic trauma", "DISEASE", 745, 760], ["Alveolar-venous fistulae", "PATHOLOGICAL_FORMATION", 0, 24], ["blast", "CANCER", 340, 345], ["alveolar edema", "PATHOLOGICAL_FORMATION", 463, 477], ["intrapulmonary", "MULTI-TISSUE_STRUCTURE", 537, 551], ["pulmonary", "ORGAN", 678, 687], ["thoracic", "ORGAN", 745, 753], ["Alveolar-venous fistulae", "PROBLEM", 0, 24], ["positive pressure ventilation", "TREATMENT", 129, 158], ["positive end expiratory pressure (PEEP", "TREATMENT", 191, 229], ["hypoxic pathophysiology", "PROBLEM", 259, 282], ["primary blast", "PROBLEM", 332, 345], ["ThoracicIntrapulmonary hemorrhage", "PROBLEM", 419, 452], ["focal alveolar edema", "PROBLEM", 457, 477], ["ventilation perfusion", "TEST", 489, 510], ["V/Q) mismatch", "PROBLEM", 512, 525], ["increased intrapulmonary shunting", "PROBLEM", 527, 560], ["hypoxia", "PROBLEM", 598, 605], ["increased work of breathing", "PROBLEM", 610, 637], ["pulmonary contusions", "PROBLEM", 678, 698], ["nonpenetrating thoracic trauma", "PROBLEM", 730, 760], ["venous", "ANATOMY", 9, 15], ["fistulae", "OBSERVATION", 16, 24], ["pressure ventilation", "OBSERVATION", 138, 158], ["hemorrhage", "OBSERVATION", 442, 452], ["focal", "OBSERVATION_MODIFIER", 457, 462], ["alveolar", "ANATOMY_MODIFIER", 463, 471], ["edema", "OBSERVATION", 472, 477], ["ventilation perfusion", "OBSERVATION", 489, 510], ["increased", "OBSERVATION_MODIFIER", 527, 536], ["intrapulmonary shunting", "OBSERVATION", 537, 560], ["decreased", "OBSERVATION_MODIFIER", 566, 575], ["compliance", "OBSERVATION_MODIFIER", 576, 586], ["hypoxia", "OBSERVATION", 598, 605], ["increased", "OBSERVATION_MODIFIER", 610, 619], ["work of breathing", "OBSERVATION", 620, 637], ["pulmonary", "ANATOMY", 678, 687], ["contusions", "OBSERVATION", 688, 698], ["nonpenetrating", "OBSERVATION_MODIFIER", 730, 744], ["thoracic", "ANATOMY", 745, 753], ["trauma", "OBSERVATION", 754, 760]]], ["Chest X-rays have revealed diffuse patchy infiltrates that present in a butterfly pattern.", [["Chest X-rays", "TEST", 0, 12], ["diffuse patchy infiltrates", "PROBLEM", 27, 53], ["diffuse", "OBSERVATION_MODIFIER", 27, 34], ["patchy", "OBSERVATION_MODIFIER", 35, 41], ["infiltrates", "OBSERVATION", 42, 53], ["butterfly pattern", "OBSERVATION", 72, 89]]], ["These become more extensive over the first 48 hours, but are usually nearly resolved in seven days.", [["more", "OBSERVATION_MODIFIER", 13, 17], ["extensive", "OBSERVATION_MODIFIER", 18, 27]]], ["Continued progression of the infiltrates after 48 hours should lead one to consider ARDS or superimposed pneumonia.", [["ARDS", "DISEASE", 84, 88], ["pneumonia", "DISEASE", 105, 114], ["the infiltrates", "PROBLEM", 25, 40], ["ARDS", "PROBLEM", 84, 88], ["superimposed pneumonia", "PROBLEM", 92, 114], ["progression", "OBSERVATION_MODIFIER", 10, 21], ["infiltrates", "OBSERVATION", 29, 40], ["ARDS", "OBSERVATION", 84, 88], ["superimposed", "OBSERVATION_MODIFIER", 92, 104], ["pneumonia", "OBSERVATION", 105, 114]]], ["Clinically, one also may see pneumothorax, hemothorax, subcutaneous and mediastinal emphysema, and even pneumoperitoneum or tension pneumoperitoneum, which may or may not be secondary to ruptured hollow viscous injury.", [["subcutaneous", "ANATOMY", 55, 67], ["mediastinal emphysema", "ANATOMY", 72, 93], ["pneumothorax", "DISEASE", 29, 41], ["hemothorax", "DISEASE", 43, 53], ["subcutaneous and mediastinal emphysema", "DISEASE", 55, 93], ["pneumothorax", "PROBLEM", 29, 41], ["hemothorax", "PROBLEM", 43, 53], ["subcutaneous and mediastinal emphysema", "PROBLEM", 55, 93], ["even pneumoperitoneum", "PROBLEM", 99, 120], ["tension pneumoperitoneum", "PROBLEM", 124, 148], ["ruptured hollow viscous injury", "PROBLEM", 187, 217], ["pneumothorax", "OBSERVATION", 29, 41], ["hemothorax", "OBSERVATION", 43, 53], ["subcutaneous", "ANATOMY", 55, 67], ["mediastinal", "ANATOMY", 72, 83], ["emphysema", "OBSERVATION", 84, 93], ["pneumoperitoneum", "OBSERVATION", 104, 120], ["tension", "OBSERVATION_MODIFIER", 124, 131], ["pneumoperitoneum", "OBSERVATION", 132, 148], ["may not be", "UNCERTAINTY", 163, 173], ["ruptured", "OBSERVATION_MODIFIER", 187, 195], ["hollow", "OBSERVATION_MODIFIER", 196, 202], ["viscous injury", "OBSERVATION", 203, 217]]], ["Rib fractures should always alert one to tertiary or quaternary injury to the thorax.ThoracicBlast Lung casualties are more susceptible to pulmonary barotrauma (pneumothorax, air embolism) than other pulmonary injuries, and although early positive-pressure mechanical ventilation with the application of positive-end expiratory pressure to maintain adequate oxygenation may be required, the risk of barotrauma may be enhanced by such therapeutic requirements.", [["thorax", "ANATOMY", 78, 84], ["Lung", "ANATOMY", 99, 103], ["pulmonary", "ANATOMY", 139, 148], ["pulmonary", "ANATOMY", 200, 209], ["fractures", "DISEASE", 4, 13], ["Lung casualties", "DISEASE", 99, 114], ["pulmonary barotrauma", "DISEASE", 139, 159], ["pneumothorax", "DISEASE", 161, 173], ["air embolism", "DISEASE", 175, 187], ["pulmonary injuries", "DISEASE", 200, 218], ["barotrauma", "DISEASE", 399, 409], ["thorax", "ORGAN", 78, 84], ["pulmonary", "ORGAN", 139, 148], ["pulmonary", "ORGAN", 200, 209], ["Rib fractures", "PROBLEM", 0, 13], ["quaternary injury to the thorax", "PROBLEM", 53, 84], ["pulmonary barotrauma", "PROBLEM", 139, 159], ["pneumothorax", "PROBLEM", 161, 173], ["air embolism", "PROBLEM", 175, 187], ["other pulmonary injuries", "PROBLEM", 194, 218], ["early positive-pressure mechanical ventilation", "TREATMENT", 233, 279], ["positive-end expiratory pressure", "TREATMENT", 304, 336], ["barotrauma", "PROBLEM", 399, 409], ["fractures", "OBSERVATION", 4, 13], ["quaternary", "OBSERVATION_MODIFIER", 53, 63], ["injury", "OBSERVATION", 64, 70], ["thorax", "ANATOMY", 78, 84], ["Lung", "ANATOMY", 99, 103], ["casualties", "OBSERVATION", 104, 114], ["pulmonary", "ANATOMY", 139, 148], ["barotrauma", "OBSERVATION", 149, 159], ["pneumothorax", "OBSERVATION", 161, 173], ["air embolism", "OBSERVATION", 175, 187], ["pulmonary", "ANATOMY", 200, 209], ["injuries", "OBSERVATION", 210, 218], ["early", "OBSERVATION_MODIFIER", 233, 238], ["positive", "OBSERVATION_MODIFIER", 239, 247], ["pressure", "OBSERVATION_MODIFIER", 248, 256], ["mechanical ventilation", "OBSERVATION", 257, 279], ["barotrauma", "OBSERVATION", 399, 409]]], ["Various ventilatory strategies have been proposed to lessen such risk, including Continuous Positive Airway Pressure (CPAP), Intermittent Mandatory Ventilation (IMV), and volume-controlled ventilation with low tidal volumes and permissive hypercapnia.", [["hypercapnia", "DISEASE", 239, 250], ["Various ventilatory strategies", "TREATMENT", 0, 30], ["Continuous Positive Airway Pressure (CPAP", "TREATMENT", 81, 122], ["Intermittent Mandatory Ventilation", "TREATMENT", 125, 159], ["IMV)", "TREATMENT", 161, 165], ["volume-controlled ventilation", "TREATMENT", 171, 200], ["low tidal volumes", "PROBLEM", 206, 223], ["permissive hypercapnia", "PROBLEM", 228, 250], ["ventilatory strategies", "OBSERVATION", 8, 30], ["Airway Pressure", "OBSERVATION", 101, 116], ["low", "OBSERVATION_MODIFIER", 206, 209], ["tidal volumes", "OBSERVATION", 210, 223], ["permissive hypercapnia", "OBSERVATION", 228, 250]]], ["Prophylactic tube thoracostomy should be considered if casualties must be evacuated by air or when close observation is impractical.ThoracicFluid resuscitation should be managed judiciously, and early monitoring of hemodynamic parameters should be considered.", [["tube", "ANATOMY", 13, 17], ["tube", "TISSUE", 13, 17], ["ThoracicFluid", "SIMPLE_CHEMICAL", 132, 145], ["Prophylactic tube thoracostomy", "TREATMENT", 0, 30], ["ThoracicFluid resuscitation", "TREATMENT", 132, 159], ["hemodynamic parameters", "TEST", 215, 237], ["tube thoracostomy", "OBSERVATION", 13, 30], ["air", "OBSERVATION", 87, 90]]], ["The ideal fluid for resuscitation in blast injury is not known; however, pre-load should be optimized without overload using crystalloid with or without colloid.", [["fluid", "ANATOMY", 10, 15], ["blast injury", "DISEASE", 37, 49], ["fluid", "ORGANISM_SUBSTANCE", 10, 15], ["resuscitation", "TREATMENT", 20, 33], ["blast injury", "PROBLEM", 37, 49], ["pre-load", "TEST", 73, 81], ["overload", "PROBLEM", 110, 118], ["crystalloid", "TREATMENT", 125, 136], ["colloid", "TREATMENT", 153, 160], ["fluid", "OBSERVATION", 10, 15], ["blast injury", "OBSERVATION", 37, 49]]], ["Patients probably should not be resuscitated to a mean arterial pressure (MAP) of greater than 60 millimeters mercury.", [["arterial", "ANATOMY", 55, 63], ["mercury", "CHEMICAL", 110, 117], ["mercury", "CHEMICAL", 110, 117], ["Patients", "ORGANISM", 0, 8], ["arterial", "MULTI-TISSUE_STRUCTURE", 55, 63], ["mercury", "SIMPLE_CHEMICAL", 110, 117], ["Patients", "SPECIES", 0, 8], ["a mean arterial pressure", "TEST", 48, 72], ["MAP", "TEST", 74, 77]]], ["In the absence of hemorrhage, many patients with thoracic blast manifest a prolonged hypotension for several days, with MAPs typically in the range of 50 to 60 millimeters Hg, with systolic pressure of 80 to 90 millimeters Hg and diastolic pressure of 40-50 millimeters Hg.", [["thoracic blast", "ANATOMY", 49, 63], ["hemorrhage", "DISEASE", 18, 28], ["thoracic blast", "DISEASE", 49, 63], ["hypotension", "DISEASE", 85, 96], ["Hg", "CHEMICAL", 223, 225], ["Hg", "CHEMICAL", 172, 174], ["Hg", "CHEMICAL", 223, 225], ["Hg", "CHEMICAL", 270, 272], ["patients", "ORGANISM", 35, 43], ["MAPs", "PROTEIN", 120, 124], ["patients", "SPECIES", 35, 43], ["hemorrhage", "PROBLEM", 18, 28], ["thoracic blast", "PROBLEM", 49, 63], ["a prolonged hypotension", "PROBLEM", 73, 96], ["MAPs", "TEST", 120, 124], ["systolic pressure", "TEST", 181, 198], ["Hg", "TEST", 223, 225], ["diastolic pressure", "TEST", 230, 248], ["hemorrhage", "OBSERVATION", 18, 28], ["thoracic", "ANATOMY", 49, 57], ["prolonged", "OBSERVATION_MODIFIER", 75, 84], ["hypotension", "OBSERVATION", 85, 96], ["pressure", "OBSERVATION_MODIFIER", 190, 198], ["diastolic", "OBSERVATION_MODIFIER", 230, 239], ["pressure", "OBSERVATION_MODIFIER", 240, 248]]], ["The mechanism of this hypotension is poorly understood and may complicate management in the face of ongoing blood loss.AuditoryThe auditory system is very susceptible to blast and is the most commonly observed blast injury.", [["blood", "ANATOMY", 108, 113], ["auditory system", "ANATOMY", 131, 146], ["hypotension", "DISEASE", 22, 33], ["blood loss", "DISEASE", 108, 118], ["blast injury", "DISEASE", 210, 222], ["blood", "ORGANISM_SUBSTANCE", 108, 113], ["this hypotension", "PROBLEM", 17, 33], ["management", "TREATMENT", 74, 84], ["ongoing blood loss", "PROBLEM", 100, 118], ["blast", "PROBLEM", 170, 175], ["blast injury", "PROBLEM", 210, 222], ["hypotension", "OBSERVATION", 22, 33], ["blood loss", "OBSERVATION", 108, 118], ["auditory system", "ANATOMY", 131, 146], ["blast", "OBSERVATION", 170, 175], ["most commonly", "OBSERVATION_MODIFIER", 187, 200], ["blast injury", "OBSERVATION", 210, 222]]], ["Perforation in the anteroinferior part of the pars tensa is the most common manifestation of injury.", [["anteroinferior part", "ANATOMY", 19, 38], ["pars tensa", "ANATOMY", 46, 56], ["anteroinferior part", "MULTI-TISSUE_STRUCTURE", 19, 38], ["pars tensa", "MULTI-TISSUE_STRUCTURE", 46, 56], ["Perforation", "PROBLEM", 0, 11], ["injury", "PROBLEM", 93, 99], ["anteroinferior", "ANATOMY_MODIFIER", 19, 33], ["pars tensa", "OBSERVATION", 46, 56], ["most common", "OBSERVATION_MODIFIER", 64, 75], ["injury", "OBSERVATION", 93, 99]]], ["Perforation occurs at 5 to 15 psi, and 33% of injuries are associated with ossicular injury, which does not occur in the absence of tympanic disruption.", [["ossicular", "ANATOMY", 75, 84], ["tympanic", "ANATOMY", 132, 140], ["Perforation", "DISEASE", 0, 11], ["injuries", "DISEASE", 46, 54], ["ossicular injury", "DISEASE", 75, 91], ["ossicular", "ORGAN", 75, 84], ["tympanic", "ORGAN", 132, 140], ["Perforation", "PROBLEM", 0, 11], ["injuries", "PROBLEM", 46, 54], ["ossicular injury", "PROBLEM", 75, 91], ["tympanic disruption", "PROBLEM", 132, 151], ["injuries", "OBSERVATION", 46, 54], ["ossicular", "ANATOMY", 75, 84], ["injury", "OBSERVATION", 85, 91], ["tympanic", "ANATOMY", 132, 140], ["disruption", "OBSERVATION", 141, 151]]], ["Cholesteatoma from embedded squamous debris is a long-term complication occurring in up to 12% of blast-perforated ears, dictating long-term follow up.", [["squamous debris", "ANATOMY", 28, 43], ["ears", "ANATOMY", 115, 119], ["Cholesteatoma", "DISEASE", 0, 13], ["squamous debris", "DISEASE", 28, 43], ["squamous debris", "TISSUE", 28, 43], ["ears", "ORGAN", 115, 119], ["Cholesteatoma", "PROBLEM", 0, 13], ["embedded squamous debris", "PROBLEM", 19, 43], ["a long-term complication", "PROBLEM", 47, 71], ["blast-perforated ears", "PROBLEM", 98, 119], ["embedded", "OBSERVATION_MODIFIER", 19, 27], ["squamous debris", "OBSERVATION", 28, 43], ["long-term complication", "OBSERVATION_MODIFIER", 49, 71], ["perforated ears", "OBSERVATION", 104, 119]]], ["Associated ossicular injury is a feature of more severe blast injury in as many as a third of reported cases.", [["ossicular", "ANATOMY", 11, 20], ["ossicular injury", "DISEASE", 11, 27], ["blast injury", "DISEASE", 56, 68], ["ossicular", "MULTI-TISSUE_STRUCTURE", 11, 20], ["ossicular injury", "PROBLEM", 11, 27], ["more severe blast injury", "PROBLEM", 44, 68], ["ossicular", "ANATOMY", 11, 20], ["injury", "OBSERVATION", 21, 27], ["severe", "OBSERVATION_MODIFIER", 49, 55], ["blast injury", "OBSERVATION", 56, 68]]], ["Sensorineural hearing loss associated with a high-pitched tinnitus frequently occurs immediately following a blast.", [["Sensorineural hearing loss", "DISEASE", 0, 26], ["tinnitus", "DISEASE", 58, 66], ["Sensorineural hearing loss", "PROBLEM", 0, 26], ["a high-pitched tinnitus", "PROBLEM", 43, 66], ["hearing loss", "OBSERVATION", 14, 26], ["tinnitus", "OBSERVATION", 58, 66]]], ["Hearing loss may resolve in hours or may become permanent in greater than 50% of patients, as has been reported in some series.", [["Hearing loss", "DISEASE", 0, 12], ["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["Hearing loss", "PROBLEM", 0, 12], ["loss", "OBSERVATION", 8, 12]]], ["Although not a priority for treatment, auditory injury should be addressed in 24 hours and auditory canal cleaned of all debris.", [["auditory canal", "ANATOMY", 91, 105], ["auditory injury", "DISEASE", 39, 54], ["auditory canal", "MULTI-TISSUE_STRUCTURE", 91, 105], ["treatment", "TREATMENT", 28, 37], ["auditory injury", "PROBLEM", 39, 54], ["all debris", "PROBLEM", 117, 127], ["auditory canal", "ANATOMY", 91, 105], ["debris", "OBSERVATION", 121, 127]]], ["Fifty to 80% of ruptured tympanic membranes will heal spontaneously without further treatment.AuditoryAlthough studies have not shown perforated tympanic membranes to be a marker for blast injury, traumatic loss of an ear or ear lobe secondary to primary blast is a marker of severe primary blast injury and associated morbidity and increased mortality.OphthalmicThe eyes are markedly resistant to primary blast injury and more often tend to suffer to secondary and tertiary mechanisms with resultant penetrating trauma.IntestinalWhile primary blast injury to the intestine may be overshadowed by the more immediate life-threatening pulmonary and cardiovascular manifestations, a review of US Army collective animal data indicates that gastrointestinal primary blast injury may be far more prevalent and occur with equal frequency in free-field blasts.", [["tympanic membranes", "ANATOMY", 25, 43], ["tympanic membranes", "ANATOMY", 145, 163], ["ear", "ANATOMY", 218, 221], ["ear lobe", "ANATOMY", 225, 233], ["primary blast", "ANATOMY", 247, 260], ["primary blast", "ANATOMY", 283, 296], ["eyes", "ANATOMY", 367, 371], ["primary blast", "ANATOMY", 398, 411], ["intestine", "ANATOMY", 564, 573], ["pulmonary", "ANATOMY", 633, 642], ["cardiovascular", "ANATOMY", 647, 661], ["gastrointestinal primary blast", "ANATOMY", 736, 766], ["blasts", "ANATOMY", 845, 851], ["blast injury", "DISEASE", 183, 195], ["traumatic loss of an ear or ear lobe", "DISEASE", 197, 233], ["primary blast", "DISEASE", 247, 260], ["primary blast injury", "DISEASE", 283, 303], ["primary blast injury", "DISEASE", 398, 418], ["trauma", "DISEASE", 513, 519], ["primary blast injury", "DISEASE", 536, 556], ["gastrointestinal primary blast injury", "DISEASE", 736, 773], ["tympanic membranes", "MULTI-TISSUE_STRUCTURE", 25, 43], ["tympanic membranes", "MULTI-TISSUE_STRUCTURE", 145, 163], ["ear", "ORGAN", 218, 221], ["ear lobe", "MULTI-TISSUE_STRUCTURE", 225, 233], ["eyes", "ORGAN", 367, 371], ["intestine", "ORGAN", 564, 573], ["pulmonary", "ORGAN", 633, 642], ["cardiovascular", "ANATOMICAL_SYSTEM", 647, 661], ["blasts", "CELL", 845, 851], ["free-field blasts", "CELL_TYPE", 834, 851], ["ruptured tympanic membranes", "PROBLEM", 16, 43], ["further treatment", "TREATMENT", 76, 93], ["AuditoryAlthough studies", "TEST", 94, 118], ["perforated tympanic membranes", "PROBLEM", 134, 163], ["blast injury", "PROBLEM", 183, 195], ["traumatic loss of an ear or ear lobe", "PROBLEM", 197, 233], ["severe primary blast injury", "PROBLEM", 276, 303], ["associated morbidity", "PROBLEM", 308, 328], ["increased mortality", "PROBLEM", 333, 352], ["primary blast injury", "PROBLEM", 398, 418], ["secondary and tertiary mechanisms", "PROBLEM", 452, 485], ["resultant penetrating trauma", "PROBLEM", 491, 519], ["IntestinalWhile primary blast injury to the intestine", "PROBLEM", 520, 573], ["gastrointestinal primary blast injury", "PROBLEM", 736, 773], ["ruptured", "OBSERVATION", 16, 24], ["tympanic", "ANATOMY", 25, 33], ["membranes", "OBSERVATION", 34, 43], ["tympanic", "ANATOMY", 145, 153], ["membranes", "OBSERVATION", 154, 163], ["traumatic", "OBSERVATION_MODIFIER", 197, 206], ["loss", "OBSERVATION", 207, 211], ["ear", "ANATOMY", 218, 221], ["ear lobe", "ANATOMY", 225, 233], ["severe", "OBSERVATION_MODIFIER", 276, 282], ["primary", "OBSERVATION_MODIFIER", 283, 290], ["blast injury", "OBSERVATION", 291, 303], ["morbidity", "OBSERVATION", 319, 328], ["increased", "OBSERVATION_MODIFIER", 333, 342], ["mortality", "OBSERVATION", 343, 352], ["eyes", "ANATOMY", 367, 371], ["markedly", "OBSERVATION_MODIFIER", 376, 384], ["resistant", "OBSERVATION_MODIFIER", 385, 394], ["primary", "OBSERVATION_MODIFIER", 398, 405], ["blast injury", "OBSERVATION", 406, 418], ["penetrating", "OBSERVATION_MODIFIER", 501, 512], ["trauma", "OBSERVATION", 513, 519], ["blast injury", "OBSERVATION", 544, 556], ["intestine", "ANATOMY", 564, 573], ["may be", "UNCERTAINTY", 574, 580], ["pulmonary", "ANATOMY", 633, 642], ["cardiovascular", "ANATOMY", 647, 661], ["gastrointestinal", "ANATOMY", 736, 752]]], ["In the case of immersion blast or in enclosed spaces, primary blast injury may occur even more frequently than pulmonary injury and at less intense exposure to dynamic overpressures.IntestinalThe lower gastrointestinal (GI) tract more often tends to be air filled, with the ileo-cecal area being the most susceptible to primary blast injury and the small intestine generally spared.", [["pulmonary", "ANATOMY", 111, 120], ["Intestinal", "ANATOMY", 182, 192], ["lower gastrointestinal (GI) tract", "ANATOMY", 196, 229], ["ileo-cecal area", "ANATOMY", 274, 289], ["primary blast", "ANATOMY", 320, 333], ["small intestine", "ANATOMY", 349, 364], ["blast injury", "DISEASE", 62, 74], ["pulmonary injury", "DISEASE", 111, 127], ["lower gastrointestinal (GI) tract", "DISEASE", 196, 229], ["primary blast injury", "DISEASE", 320, 340], ["pulmonary", "ORGAN", 111, 120], ["Intestinal", "ORGAN", 182, 192], ["lower gastrointestinal", "ORGANISM_SUBDIVISION", 196, 218], ["GI) tract", "PATHOLOGICAL_FORMATION", 220, 229], ["cecal area", "MULTI-TISSUE_STRUCTURE", 279, 289], ["small intestine", "ORGAN", 349, 364], ["immersion blast", "PROBLEM", 15, 30], ["primary blast injury", "PROBLEM", 54, 74], ["pulmonary injury", "PROBLEM", 111, 127], ["IntestinalThe lower gastrointestinal (GI) tract", "PROBLEM", 182, 229], ["air filled", "PROBLEM", 253, 263], ["the ileo-cecal area", "PROBLEM", 270, 289], ["primary blast injury", "PROBLEM", 320, 340], ["the small intestine", "PROBLEM", 345, 364], ["blast", "OBSERVATION", 25, 30], ["blast injury", "OBSERVATION", 62, 74], ["pulmonary", "ANATOMY", 111, 120], ["injury", "OBSERVATION", 121, 127], ["lower", "ANATOMY_MODIFIER", 196, 201], ["gastrointestinal", "ANATOMY", 202, 218], ["GI", "ANATOMY", 220, 222], ["air filled", "OBSERVATION", 253, 263], ["cecal", "ANATOMY", 279, 284], ["most susceptible", "OBSERVATION_MODIFIER", 300, 316], ["primary", "OBSERVATION_MODIFIER", 320, 327], ["blast injury", "OBSERVATION", 328, 340], ["small", "OBSERVATION_MODIFIER", 349, 354], ["intestine", "ANATOMY", 355, 364]]], ["The mechanism of injury, as discussed earlier, is varying degrees of rapid compression/decompression resulting in wall damage and immediate rupture leading to peritonitis and hemorrhage.", [["wall", "ANATOMY", 114, 118], ["rupture", "DISEASE", 140, 147], ["peritonitis", "DISEASE", 159, 170], ["hemorrhage", "DISEASE", 175, 185], ["wall", "TISSUE", 114, 118], ["injury", "PROBLEM", 17, 23], ["rapid compression/decompression", "TREATMENT", 69, 100], ["wall damage", "PROBLEM", 114, 125], ["immediate rupture", "PROBLEM", 130, 147], ["peritonitis", "PROBLEM", 159, 170], ["hemorrhage", "PROBLEM", 175, 185], ["injury", "OBSERVATION", 17, 23], ["rapid", "OBSERVATION_MODIFIER", 69, 74], ["compression", "OBSERVATION", 75, 86], ["decompression", "OBSERVATION", 87, 100], ["wall", "ANATOMY_MODIFIER", 114, 118], ["damage", "OBSERVATION", 119, 125], ["immediate", "OBSERVATION_MODIFIER", 130, 139], ["rupture", "OBSERVATION", 140, 147], ["peritonitis", "OBSERVATION", 159, 170], ["hemorrhage", "OBSERVATION", 175, 185]]], ["Displacement and tearing of mesenteric and peritoneal attachments with bleeding and devascularizing injury and the reflection of stress waves and spalling at the mucosal-gas interface, resulting in submucosal to transmural injury.", [["mesenteric", "ANATOMY", 28, 38], ["peritoneal", "ANATOMY", 43, 53], ["mucosal", "ANATOMY", 162, 169], ["submucosal", "ANATOMY", 198, 208], ["bleeding", "DISEASE", 71, 79], ["mesenteric", "MULTI-TISSUE_STRUCTURE", 28, 38], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 43, 53], ["mucosal", "MULTI-TISSUE_STRUCTURE", 162, 169], ["submucosal", "MULTI-TISSUE_STRUCTURE", 198, 208], ["Displacement", "PROBLEM", 0, 12], ["tearing of mesenteric and peritoneal attachments", "PROBLEM", 17, 65], ["bleeding", "PROBLEM", 71, 79], ["devascularizing injury", "PROBLEM", 84, 106], ["stress waves", "PROBLEM", 129, 141], ["spalling at the mucosal-gas interface", "PROBLEM", 146, 183], ["submucosal to transmural injury", "PROBLEM", 198, 229], ["tearing", "OBSERVATION_MODIFIER", 17, 24], ["mesenteric", "ANATOMY", 28, 38], ["peritoneal", "ANATOMY", 43, 53], ["bleeding", "OBSERVATION", 71, 79], ["injury", "OBSERVATION", 100, 106], ["stress waves", "OBSERVATION", 129, 141], ["mucosal", "ANATOMY", 162, 169], ["gas interface", "OBSERVATION", 170, 183], ["submucosal", "ANATOMY", 198, 208], ["transmural", "OBSERVATION_MODIFIER", 212, 222], ["injury", "OBSERVATION", 223, 229]]], ["The characteristic injury seen is a multifocal intramural hematoma beginning in the submucosa, extending with increasing severity to large transmural confluent hematoma and may involve the mesentery and vascular supply.", [["intramural hematoma", "ANATOMY", 47, 66], ["submucosa", "ANATOMY", 84, 93], ["mesentery", "ANATOMY", 189, 198], ["vascular", "ANATOMY", 203, 211], ["hematoma", "DISEASE", 58, 66], ["hematoma", "DISEASE", 160, 168], ["intramural hematoma", "PATHOLOGICAL_FORMATION", 47, 66], ["submucosa", "MULTI-TISSUE_STRUCTURE", 84, 93], ["mesentery", "MULTI-TISSUE_STRUCTURE", 189, 198], ["vascular", "MULTI-TISSUE_STRUCTURE", 203, 211], ["The characteristic injury", "PROBLEM", 0, 25], ["a multifocal intramural hematoma", "PROBLEM", 34, 66], ["large transmural confluent hematoma", "PROBLEM", 133, 168], ["characteristic", "OBSERVATION_MODIFIER", 4, 18], ["injury", "OBSERVATION", 19, 25], ["multifocal", "OBSERVATION_MODIFIER", 36, 46], ["intramural", "OBSERVATION_MODIFIER", 47, 57], ["hematoma", "OBSERVATION", 58, 66], ["submucosa", "ANATOMY", 84, 93], ["increasing", "OBSERVATION_MODIFIER", 110, 120], ["severity", "OBSERVATION_MODIFIER", 121, 129], ["large", "OBSERVATION_MODIFIER", 133, 138], ["transmural", "OBSERVATION_MODIFIER", 139, 149], ["confluent", "OBSERVATION_MODIFIER", 150, 159], ["hematoma", "OBSERVATION", 160, 168], ["mesentery", "ANATOMY", 189, 198], ["vascular", "ANATOMY", 203, 211], ["supply", "ANATOMY_MODIFIER", 212, 218]]], ["Serosal injury always should be considered indicative of transmural injury.", [["transmural", "ANATOMY", 57, 67], ["Serosal injury", "DISEASE", 0, 14], ["transmural", "MULTI-TISSUE_STRUCTURE", 57, 67], ["Serosal injury", "PROBLEM", 0, 14], ["transmural injury", "PROBLEM", 57, 74], ["injury", "OBSERVATION", 8, 14], ["should be considered indicative of", "UNCERTAINTY", 22, 56], ["transmural", "OBSERVATION_MODIFIER", 57, 67], ["injury", "OBSERVATION", 68, 74]]], ["Cripps identified those lesions at greater risk of perforation in experimental studies in pigs, suggesting that serosal lesions greater than 15 millimeters in the small intestine and greater than 20 millimeters in the large bowel are at higher risk of perforation and should be resected.", [["lesions", "ANATOMY", 24, 31], ["serosal lesions", "ANATOMY", 112, 127], ["small intestine", "ANATOMY", 163, 178], ["bowel", "ANATOMY", 224, 229], ["perforation", "DISEASE", 51, 62], ["perforation", "DISEASE", 252, 263], ["lesions", "PATHOLOGICAL_FORMATION", 24, 31], ["pigs", "ORGANISM", 90, 94], ["serosal lesions", "PATHOLOGICAL_FORMATION", 112, 127], ["small intestine", "ORGAN", 163, 178], ["bowel", "ORGAN", 224, 229], ["pigs", "SPECIES", 90, 94], ["pigs", "SPECIES", 90, 94], ["those lesions", "PROBLEM", 18, 31], ["perforation", "PROBLEM", 51, 62], ["experimental studies", "TEST", 66, 86], ["serosal lesions", "PROBLEM", 112, 127], ["perforation", "PROBLEM", 252, 263], ["lesions", "OBSERVATION", 24, 31], ["greater", "OBSERVATION_MODIFIER", 35, 42], ["perforation", "OBSERVATION", 51, 62], ["serosal", "ANATOMY", 112, 119], ["lesions", "OBSERVATION", 120, 127], ["small intestine", "ANATOMY", 163, 178], ["greater", "OBSERVATION_MODIFIER", 183, 190], ["large", "OBSERVATION_MODIFIER", 218, 223], ["bowel", "ANATOMY", 224, 229], ["perforation", "OBSERVATION", 252, 263], ["should be", "UNCERTAINTY", 268, 277], ["resected", "OBSERVATION", 278, 286]]], ["Delayed perforation up to 14 days post injury can occur and most likely is related to progressive ischemia and necrosis with transmural injury or adjacent mesenteric injury.IntestinalClinically, patients present with nausea, vomiting, abdominal pain, rectal and testicular pain, tenesmus, and rarely hemetemesis.", [["mesenteric", "ANATOMY", 155, 165], ["abdominal", "ANATOMY", 235, 244], ["rectal", "ANATOMY", 251, 257], ["testicular", "ANATOMY", 262, 272], ["Delayed perforation", "DISEASE", 0, 19], ["ischemia", "DISEASE", 98, 106], ["necrosis", "DISEASE", 111, 119], ["adjacent mesenteric injury", "DISEASE", 146, 172], ["nausea", "DISEASE", 217, 223], ["vomiting", "DISEASE", 225, 233], ["abdominal pain", "DISEASE", 235, 249], ["rectal and testicular pain", "DISEASE", 251, 277], ["tenesmus", "DISEASE", 279, 287], ["hemetemesis", "DISEASE", 300, 311], ["mesenteric", "MULTI-TISSUE_STRUCTURE", 155, 165], ["patients", "ORGANISM", 195, 203], ["abdominal", "ORGANISM_SUBDIVISION", 235, 244], ["rectal", "ORGANISM_SUBDIVISION", 251, 257], ["testicular", "ORGAN", 262, 272], ["patients", "SPECIES", 195, 203], ["Delayed perforation", "PROBLEM", 0, 19], ["injury", "PROBLEM", 39, 45], ["progressive ischemia", "PROBLEM", 86, 106], ["necrosis", "PROBLEM", 111, 119], ["transmural injury", "PROBLEM", 125, 142], ["adjacent mesenteric injury", "PROBLEM", 146, 172], ["nausea", "PROBLEM", 217, 223], ["vomiting", "PROBLEM", 225, 233], ["abdominal pain", "PROBLEM", 235, 249], ["rectal and testicular pain", "PROBLEM", 251, 277], ["tenesmus", "PROBLEM", 279, 287], ["rarely hemetemesis", "PROBLEM", 293, 311], ["perforation", "OBSERVATION", 8, 19], ["most likely is related to", "UNCERTAINTY", 60, 85], ["progressive", "OBSERVATION_MODIFIER", 86, 97], ["ischemia", "OBSERVATION", 98, 106], ["necrosis", "OBSERVATION", 111, 119], ["transmural", "OBSERVATION_MODIFIER", 125, 135], ["injury", "OBSERVATION", 136, 142], ["mesenteric", "ANATOMY", 155, 165], ["injury", "OBSERVATION", 166, 172], ["abdominal", "ANATOMY", 235, 244], ["pain", "OBSERVATION", 245, 249], ["rectal", "ANATOMY", 251, 257], ["testicular", "ANATOMY", 262, 272], ["pain", "OBSERVATION", 273, 277], ["tenesmus", "OBSERVATION", 279, 287]]], ["Treatment is guided best by clinical judgment, with selective use of diagnostic peritoneal lavage (DPL) being the most sensitive diagnostic test for early diagnosis of GI injury in the obtunded or intubated patient.", [["peritoneal lavage", "ANATOMY", 80, 97], ["GI", "ANATOMY", 168, 170], ["GI injury", "DISEASE", 168, 177], ["peritoneal lavage", "MULTI-TISSUE_STRUCTURE", 80, 97], ["GI", "ORGANISM_SUBDIVISION", 168, 170], ["patient", "ORGANISM", 207, 214], ["patient", "SPECIES", 207, 214], ["diagnostic peritoneal lavage", "TEST", 69, 97], ["diagnostic test", "TEST", 129, 144], ["GI injury", "PROBLEM", 168, 177], ["peritoneal", "ANATOMY", 80, 90], ["lavage", "OBSERVATION", 91, 97], ["GI", "ANATOMY", 168, 170], ["injury", "OBSERVATION", 171, 177]]], ["Diagnostic peritoneal lavage fluid should be examined for blood, fecal material, bile, food particles, Alkaline phosphatase >10 international units (IU), Amylase >175 IU, elevated lactate dehydrogeanse (LDH), aspartate aminotransferase (AST), and Phosphate all being suspicious for possible GI injury.", [["peritoneal lavage fluid", "ANATOMY", 11, 34], ["blood", "ANATOMY", 58, 63], ["fecal material", "ANATOMY", 65, 79], ["bile", "ANATOMY", 81, 85], ["GI", "ANATOMY", 291, 293], ["lactate", "CHEMICAL", 180, 187], ["aspartate", "CHEMICAL", 209, 218], ["Phosphate", "CHEMICAL", 247, 256], ["GI injury", "DISEASE", 291, 300], ["lactate", "CHEMICAL", 180, 187], ["aspartate", "CHEMICAL", 209, 218], ["Phosphate", "CHEMICAL", 247, 256], ["peritoneal lavage fluid", "ORGANISM_SUBSTANCE", 11, 34], ["blood", "ORGANISM_SUBSTANCE", 58, 63], ["fecal material", "MULTI-TISSUE_STRUCTURE", 65, 79], ["bile", "SIMPLE_CHEMICAL", 81, 85], ["Alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 103, 123], ["Amylase", "GENE_OR_GENE_PRODUCT", 154, 161], ["lactate dehydrogeanse", "SIMPLE_CHEMICAL", 180, 201], ["LDH", "SIMPLE_CHEMICAL", 203, 206], ["aspartate aminotransferase", "SIMPLE_CHEMICAL", 209, 235], ["AST", "SIMPLE_CHEMICAL", 237, 240], ["Phosphate", "SIMPLE_CHEMICAL", 247, 256], ["GI", "ORGANISM_SUBDIVISION", 291, 293], ["Alkaline phosphatase", "PROTEIN", 103, 123], ["Amylase", "PROTEIN", 154, 161], ["lactate dehydrogeanse", "PROTEIN", 180, 201], ["LDH", "PROTEIN", 203, 206], ["aspartate aminotransferase", "PROTEIN", 209, 235], ["AST", "PROTEIN", 237, 240], ["Diagnostic peritoneal lavage fluid", "TEST", 0, 34], ["blood", "TEST", 58, 63], ["Alkaline phosphatase", "TEST", 103, 123], ["Amylase", "TEST", 154, 161], ["elevated lactate dehydrogeanse", "PROBLEM", 171, 201], ["LDH", "TEST", 203, 206], ["aspartate aminotransferase", "TEST", 209, 235], ["AST", "TEST", 237, 240], ["Phosphate", "TEST", 247, 256], ["GI injury", "PROBLEM", 291, 300], ["peritoneal", "ANATOMY", 11, 21], ["lavage fluid", "OBSERVATION", 22, 34], ["fecal", "ANATOMY", 65, 70], ["bile", "ANATOMY", 81, 85], ["GI", "ANATOMY", 291, 293], ["injury", "OBSERVATION", 294, 300]]], ["Computed tomography (CT), which has not proven to be sensitive for intestinal injury, should only be used in selective cases (suspected solid organ hemorrhage) and should probably not be considered in the situation with multiple casualties.", [["intestinal", "ANATOMY", 67, 77], ["organ", "ANATOMY", 142, 147], ["intestinal injury", "DISEASE", 67, 84], ["solid organ hemorrhage", "DISEASE", 136, 158], ["intestinal", "ORGAN", 67, 77], ["organ", "ORGAN", 142, 147], ["Computed tomography (CT)", "TEST", 0, 24], ["intestinal injury", "PROBLEM", 67, 84], ["solid organ hemorrhage", "PROBLEM", 136, 158], ["intestinal", "ANATOMY", 67, 77], ["injury", "OBSERVATION", 78, 84], ["organ", "ANATOMY", 142, 147], ["hemorrhage", "OBSERVATION", 148, 158]]], ["Free air and excess free fluid not characteristic of blood, when seen on CT, are considered indications for laparotomy in blunt trauma patients; however, in primary blast with pulmonary injury, free-air and even tension pneumoperitoneum without intestinal injury has been reported and should be kept in mind.Solid Organ InjuryLiver, spleen, adrenal, kidney, and testicle injuries have all been reported in underwater blasts; solid organ injury is less common in air blasts.", [["blood", "ANATOMY", 53, 58], ["primary blast", "ANATOMY", 157, 170], ["pulmonary", "ANATOMY", 176, 185], ["intestinal", "ANATOMY", 245, 255], ["spleen", "ANATOMY", 333, 339], ["adrenal", "ANATOMY", 341, 348], ["kidney", "ANATOMY", 350, 356], ["testicle", "ANATOMY", 362, 370], ["blasts", "ANATOMY", 417, 423], ["organ", "ANATOMY", 431, 436], ["air blasts", "ANATOMY", 462, 472], ["trauma", "DISEASE", 128, 134], ["primary blast", "DISEASE", 157, 170], ["pulmonary injury", "DISEASE", 176, 192], ["intestinal injury", "DISEASE", 245, 262], ["testicle injuries", "DISEASE", 362, 379], ["organ injury", "DISEASE", 431, 443], ["blood", "ORGANISM_SUBSTANCE", 53, 58], ["patients", "ORGANISM", 135, 143], ["pulmonary", "ORGAN", 176, 185], ["intestinal", "ORGAN", 245, 255], ["spleen", "ORGAN", 333, 339], ["adrenal", "ORGAN", 341, 348], ["kidney", "ORGAN", 350, 356], ["testicle", "ORGAN", 362, 370], ["blasts", "CELL", 417, 423], ["solid", "MULTI-TISSUE_STRUCTURE", 425, 430], ["organ", "ORGAN", 431, 436], ["air blasts", "CELL", 462, 472], ["underwater blasts", "CELL_TYPE", 406, 423], ["air blasts", "CELL_TYPE", 462, 472], ["patients", "SPECIES", 135, 143], ["Free air", "PROBLEM", 0, 8], ["excess free fluid", "PROBLEM", 13, 30], ["blood", "PROBLEM", 53, 58], ["CT", "TEST", 73, 75], ["laparotomy", "TREATMENT", 108, 118], ["blunt trauma", "PROBLEM", 122, 134], ["pulmonary injury", "PROBLEM", 176, 192], ["free-air", "PROBLEM", 194, 202], ["tension pneumoperitoneum", "PROBLEM", 212, 236], ["intestinal injury", "PROBLEM", 245, 262], ["Solid Organ InjuryLiver, spleen, adrenal, kidney, and testicle injuries", "PROBLEM", 308, 379], ["underwater blasts", "PROBLEM", 406, 423], ["solid organ injury", "PROBLEM", 425, 443], ["air blasts", "PROBLEM", 462, 472], ["air", "OBSERVATION", 5, 8], ["excess", "OBSERVATION_MODIFIER", 13, 19], ["free", "OBSERVATION_MODIFIER", 20, 24], ["fluid", "OBSERVATION", 25, 30], ["blood", "OBSERVATION", 53, 58], ["laparotomy", "OBSERVATION", 108, 118], ["pulmonary", "ANATOMY", 176, 185], ["injury", "OBSERVATION", 186, 192], ["air", "OBSERVATION", 199, 202], ["tension", "OBSERVATION_MODIFIER", 212, 219], ["pneumoperitoneum", "OBSERVATION", 220, 236], ["without", "UNCERTAINTY", 237, 244], ["intestinal", "ANATOMY", 245, 255], ["injury", "OBSERVATION", 256, 262], ["Organ", "ANATOMY", 314, 319], ["InjuryLiver", "OBSERVATION", 320, 331], ["spleen", "ANATOMY", 333, 339], ["adrenal", "ANATOMY", 341, 348], ["kidney", "ANATOMY", 350, 356], ["testicle", "ANATOMY", 362, 370], ["injuries", "OBSERVATION", 371, 379], ["underwater blasts", "OBSERVATION", 406, 423], ["organ", "ANATOMY", 431, 436], ["injury", "OBSERVATION", 437, 443], ["less common", "OBSERVATION_MODIFIER", 447, 458], ["air blasts", "OBSERVATION", 462, 472]]], ["Such injuries are most likely the result of shear forces and present similarly to solid organ injury resulting from blunt trauma.", [["organ", "ANATOMY", 88, 93], ["injuries", "DISEASE", 5, 13], ["organ injury", "DISEASE", 88, 100], ["blunt trauma", "DISEASE", 116, 128], ["organ", "ORGAN", 88, 93], ["Such injuries", "PROBLEM", 0, 13], ["shear forces", "PROBLEM", 44, 56], ["solid organ injury", "PROBLEM", 82, 100], ["blunt trauma", "PROBLEM", 116, 128], ["injuries", "OBSERVATION", 5, 13], ["most likely", "UNCERTAINTY", 18, 29], ["shear forces", "OBSERVATION", 44, 56], ["solid", "ANATOMY_MODIFIER", 82, 87], ["organ", "ANATOMY", 88, 93], ["injury", "OBSERVATION", 94, 100], ["blunt trauma", "OBSERVATION", 116, 128]]], ["Gallbladder, renal pelvis, and bladder injury secondary to primary blast rarely have been recorded.Central Nervous SystemTraumatic brain injury (TBI) remains a major cause of death in bombing, accounting for 71% of early and 52% of later deaths.", [["Gallbladder", "ANATOMY", 0, 11], ["renal pelvis", "ANATOMY", 13, 25], ["bladder", "ANATOMY", 31, 38], ["primary blast", "ANATOMY", 59, 72], ["brain", "ANATOMY", 131, 136], ["Gallbladder, renal pelvis, and bladder injury", "DISEASE", 0, 45], ["Nervous SystemTraumatic brain injury", "DISEASE", 107, 143], ["TBI", "DISEASE", 145, 148], ["death", "DISEASE", 175, 180], ["deaths", "DISEASE", 238, 244], ["Gallbladder", "ORGAN", 0, 11], ["renal pelvis", "MULTI-TISSUE_STRUCTURE", 13, 25], ["bladder", "ORGAN", 31, 38], ["brain", "ORGAN", 131, 136], ["Gallbladder, renal pelvis, and bladder injury", "PROBLEM", 0, 45], ["primary blast", "PROBLEM", 59, 72], ["Central Nervous SystemTraumatic brain injury", "PROBLEM", 99, 143], ["TBI", "PROBLEM", 145, 148], ["death", "PROBLEM", 175, 180], ["renal pelvis", "ANATOMY", 13, 25], ["bladder", "ANATOMY", 31, 38], ["injury", "OBSERVATION", 39, 45], ["Nervous", "ANATOMY", 107, 114], ["SystemTraumatic", "ANATOMY_MODIFIER", 115, 130], ["brain", "ANATOMY", 131, 136], ["injury", "OBSERVATION", 137, 143]]], ["However, TBI and death usually is due to secondary and tertiary effects, not the primary blast.", [["primary blast", "ANATOMY", 81, 94], ["TBI", "DISEASE", 9, 12], ["death", "DISEASE", 17, 22], ["TBI", "PROBLEM", 9, 12], ["death", "PROBLEM", 17, 22], ["secondary and tertiary effects", "PROBLEM", 41, 71]]], ["Recent studies have shown that significant histologic damage and CNS dysfunction does occur with primary blast.", [["CNS", "ANATOMY", 65, 68], ["primary blast", "ANATOMY", 97, 110], ["CNS dysfunction", "DISEASE", 65, 80], ["primary blast", "DISEASE", 97, 110], ["CNS", "ANATOMICAL_SYSTEM", 65, 68], ["blast", "CANCER", 105, 110], ["Recent studies", "TEST", 0, 14], ["significant histologic damage", "PROBLEM", 31, 60], ["CNS dysfunction", "PROBLEM", 65, 80], ["significant", "OBSERVATION_MODIFIER", 31, 42], ["histologic", "OBSERVATION_MODIFIER", 43, 53], ["damage", "OBSERVATION", 54, 60], ["CNS dysfunction", "OBSERVATION", 65, 80]]], ["Patients may present with prolonged periods of loss of consciousness, agitation, excitability, and irrational behavior.", [["loss of consciousness", "DISEASE", 47, 68], ["agitation", "DISEASE", 70, 79], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["loss of consciousness", "PROBLEM", 47, 68], ["agitation", "PROBLEM", 70, 79], ["excitability", "PROBLEM", 81, 93], ["irrational behavior", "PROBLEM", 99, 118]]], ["Long-term sequelae such as posttraumatic stress syndrome also have been related to TBI from primary blast mechanisms.MusculoskeletalTraumatic amputation as a result of a primary blast is a marker of injury severity that has few survivors (1.5%), but relatively more common in nonsurvivors.", [["primary blast", "ANATOMY", 170, 183], ["posttraumatic stress syndrome", "DISEASE", 27, 56], ["TBI", "DISEASE", 83, 86], ["Traumatic amputation", "DISEASE", 132, 152], ["primary blast", "DISEASE", 170, 183], ["Long-term sequelae", "PROBLEM", 0, 18], ["posttraumatic stress syndrome", "PROBLEM", 27, 56], ["TBI", "PROBLEM", 83, 86], ["primary blast mechanisms", "PROBLEM", 92, 116], ["MusculoskeletalTraumatic amputation", "PROBLEM", 117, 152], ["injury severity", "PROBLEM", 199, 214], ["-term sequelae", "OBSERVATION_MODIFIER", 4, 18], ["posttraumatic stress syndrome", "OBSERVATION", 27, 56], ["blast mechanisms", "OBSERVATION", 100, 116], ["Traumatic", "OBSERVATION_MODIFIER", 132, 141], ["amputation", "OBSERVATION", 142, 152], ["few", "OBSERVATION_MODIFIER", 224, 227]]], ["Traumatic amputation is seen in 11% of immediate fatalities in suicide bombings.", [["Traumatic amputation", "DISEASE", 0, 20], ["fatalities", "DISEASE", 49, 59], ["Traumatic amputation", "PROBLEM", 0, 20], ["amputation", "OBSERVATION", 10, 20]]], ["Patients with traumatic amputation caused from the blast effect of a conventional bomb usually are within one meter of the detonated ordnance.", [["traumatic amputation", "DISEASE", 14, 34], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["traumatic amputation", "PROBLEM", 14, 34], ["traumatic", "OBSERVATION_MODIFIER", 14, 23], ["amputation", "OBSERVATION", 24, 34], ["blast effect", "OBSERVATION", 51, 63]]], ["Traumatic amputations of the ear lobe also should be con-sidered a marker of injury severity and mortality.", [["ear lobe", "ANATOMY", 29, 37], ["Traumatic amputations of the ear lobe", "DISEASE", 0, 37], ["ear", "ORGAN", 29, 32], ["lobe", "MULTI-TISSUE_STRUCTURE", 33, 37], ["Traumatic amputations of the ear lobe", "PROBLEM", 0, 37], ["injury severity", "PROBLEM", 77, 92], ["amputations", "OBSERVATION", 10, 21], ["ear lobe", "ANATOMY", 29, 37]]], ["Stein, reporting in 1999 on a series of suicide bombings in Israel, noted only one survivor among traumatic amputations of the ear lobe.", [["ear lobe", "ANATOMY", 127, 135], ["traumatic amputations of the ear lobe", "DISEASE", 98, 135], ["ear lobe", "MULTI-TISSUE_STRUCTURE", 127, 135], ["traumatic amputations of the ear lobe", "PROBLEM", 98, 135], ["traumatic", "OBSERVATION_MODIFIER", 98, 107], ["amputations", "OBSERVATION", 108, 119], ["ear lobe", "ANATOMY", 127, 135]]], ["9Thermal BlastThe flash (fireball) produced by the detonation of an explosion can reach temperatures greater than 3000 degrees centigrade.", [["flash", "OBSERVATION_MODIFIER", 18, 23]]], ["There is some controversy regarding the incidence of burns in surviving casualties, although Stein reported an incidence as high as 31%.", [["burns", "DISEASE", 53, 58], ["burns", "OBSERVATION", 53, 58], ["high", "OBSERVATION_MODIFIER", 124, 128]]], ["With the increasing prevalence of FAEs and thermobaric EBWs that have a larger and longer lasting fireball, the incidence of burns may increase.", [["FAEs", "DISEASE", 34, 38], ["burns", "DISEASE", 125, 130], ["FAEs", "SIMPLE_CHEMICAL", 34, 38], ["thermobaric EBWs", "TREATMENT", 43, 59], ["a larger and longer lasting fireball", "PROBLEM", 70, 106], ["burns", "PROBLEM", 125, 130], ["increasing", "OBSERVATION_MODIFIER", 9, 19], ["larger", "OBSERVATION_MODIFIER", 72, 78], ["burns", "OBSERVATION", 125, 130], ["increase", "OBSERVATION_MODIFIER", 135, 143]]], ["Flash burns, flame burns from secondary fires, and inhalation injury from toxic substances all may be seen, complicating an already severe mechanism of injury.Fragmentation InjuryThere are a myriad of weapon systems and missiles, ranging from grenades to aerial delivered bombs weighing several tons that depending on the size and design of the weapon may deliver several thousand fragments ranging in weight from a few milligrams to many grams with an initial velocity of greater than 1500 meters per second.", [["burns", "DISEASE", 6, 11], ["burns", "DISEASE", 19, 24], ["inhalation injury", "DISEASE", 51, 68], ["Injury", "DISEASE", 173, 179], ["Flash burns", "PROBLEM", 0, 11], ["flame burns", "PROBLEM", 13, 24], ["secondary fires", "PROBLEM", 30, 45], ["inhalation injury", "PROBLEM", 51, 68], ["toxic substances", "PROBLEM", 74, 90], ["injury", "PROBLEM", 152, 158], ["Fragmentation Injury", "PROBLEM", 159, 179], ["missiles", "PROBLEM", 220, 228], ["several thousand fragments", "PROBLEM", 364, 390], ["an initial velocity", "TEST", 450, 469], ["burns", "OBSERVATION", 6, 11], ["flame burns", "OBSERVATION", 13, 24], ["secondary fires", "OBSERVATION", 30, 45], ["inhalation injury", "OBSERVATION", 51, 68], ["toxic", "OBSERVATION_MODIFIER", 74, 79], ["severe", "OBSERVATION_MODIFIER", 132, 138], ["injury", "OBSERVATION", 152, 158], ["Injury", "OBSERVATION", 173, 179], ["myriad", "OBSERVATION_MODIFIER", 191, 197], ["missiles", "OBSERVATION_MODIFIER", 220, 228], ["size", "OBSERVATION_MODIFIER", 322, 326]]], ["These fragments decline in velocity rapidly generally producing multiple low velocity incapacitating wounds.", [["fragments", "ANATOMY", 6, 15], ["wounds", "ANATOMY", 101, 107], ["wounds", "PATHOLOGICAL_FORMATION", 101, 107], ["These fragments", "PROBLEM", 0, 15], ["multiple low velocity incapacitating wounds", "PROBLEM", 64, 107], ["fragments", "OBSERVATION_MODIFIER", 6, 15], ["decline", "OBSERVATION_MODIFIER", 16, 23], ["velocity", "OBSERVATION_MODIFIER", 27, 35], ["rapidly", "OBSERVATION_MODIFIER", 36, 43], ["multiple", "OBSERVATION_MODIFIER", 64, 72], ["low velocity", "OBSERVATION_MODIFIER", 73, 85], ["incapacitating", "OBSERVATION_MODIFIER", 86, 100], ["wounds", "OBSERVATION", 101, 107]]], ["Modern fragmentation weapons are designed with preformed fragments to optimize velocity, distance, and probability of hit producing multiple casualties with multiple wounds (Figure 3-3) .", [["fragments", "ANATOMY", 57, 66], ["wounds", "ANATOMY", 166, 172], ["wounds", "PATHOLOGICAL_FORMATION", 166, 172], ["Modern fragmentation weapons", "PROBLEM", 0, 28], ["preformed fragments", "PROBLEM", 47, 66], ["hit", "PROBLEM", 118, 121], ["multiple wounds", "PROBLEM", 157, 172], ["fragmentation", "OBSERVATION", 7, 20], ["fragments", "OBSERVATION", 57, 66], ["multiple", "OBSERVATION_MODIFIER", 132, 140], ["casualties", "OBSERVATION", 141, 151], ["multiple", "OBSERVATION_MODIFIER", 157, 165], ["wounds", "OBSERVATION", 166, 172]]], ["Body armor has altered the pattern of distribution of fragmentation injury so that the most common casualty seen on today's battlefield will have multiple extremity, head, and facial wounds (Table 3-4) .Fragmentation InjuryThe use of antipersonnel bomblets or submunitions effectively has increased the probability of a hit and increased the lethality and wounding area of the munition.", [["Body", "ANATOMY", 0, 4], ["extremity", "ANATOMY", 155, 164], ["head", "ANATOMY", 166, 170], ["facial wounds", "ANATOMY", 176, 189], ["Injury", "DISEASE", 217, 223], ["extremity", "ORGANISM_SUBDIVISION", 155, 164], ["head", "ORGANISM_SUBDIVISION", 166, 170], ["wounds", "PATHOLOGICAL_FORMATION", 183, 189], ["fragmentation injury", "PROBLEM", 54, 74], ["multiple extremity, head, and facial wounds", "PROBLEM", 146, 189], ["Fragmentation Injury", "PROBLEM", 203, 223], ["antipersonnel bomblets", "TREATMENT", 234, 256], ["submunitions", "TREATMENT", 260, 272], ["a hit and increased the lethality", "PROBLEM", 318, 351], ["altered", "OBSERVATION", 15, 22], ["pattern", "OBSERVATION_MODIFIER", 27, 34], ["distribution", "OBSERVATION_MODIFIER", 38, 50], ["fragmentation", "OBSERVATION_MODIFIER", 54, 67], ["injury", "OBSERVATION", 68, 74], ["extremity", "ANATOMY", 155, 164], ["head", "ANATOMY", 166, 170], ["facial", "ANATOMY", 176, 182], ["wounds", "OBSERVATION", 183, 189], ["Injury", "OBSERVATION", 217, 223], ["lethality", "OBSERVATION", 342, 351]]], ["In the Israeli-Egyptian October War of 1973, each antipersonnel canister released 600 Guava bomblets (named from an Egyptian fruit with large numbers of seeds), with each bomblet containing 300 pellets.", [["large numbers of seeds", "TREATMENT", 136, 158]]], ["Each bomblet is released at one-meter intervals and can travel 150 meters, with an explosive lethal radius of 5 to 8 meters.", [["an explosive lethal radius", "TREATMENT", 80, 106]]], ["Each pellet acts as a small missile of moderate velocity, striking from different angles within the lethal zone.", [["pellet", "ANATOMY", 5, 11], ["a small missile of moderate velocity", "PROBLEM", 20, 56], ["small", "OBSERVATION_MODIFIER", 22, 27], ["missile", "OBSERVATION_MODIFIER", 28, 35], ["moderate", "OBSERVATION_MODIFIER", 39, 47], ["velocity", "OBSERVATION_MODIFIER", 48, 56], ["different", "OBSERVATION_MODIFIER", 72, 81], ["angles", "OBSERVATION_MODIFIER", 82, 88], ["lethal zone", "ANATOMY_MODIFIER", 100, 111]]], ["This raised the incidence of multiple system injuries, with penetrating wounds of the extremities constituting 56% of injuries.", [["wounds", "ANATOMY", 72, 78], ["extremities", "ANATOMY", 86, 97], ["multiple system injuries", "DISEASE", 29, 53], ["penetrating wounds of the extremities", "DISEASE", 60, 97], ["injuries", "DISEASE", 118, 126], ["wounds", "PATHOLOGICAL_FORMATION", 72, 78], ["extremities", "ORGANISM_SUBDIVISION", 86, 97], ["multiple system injuries", "PROBLEM", 29, 53], ["penetrating wounds of the extremities", "PROBLEM", 60, 97], ["injuries", "PROBLEM", 118, 126], ["multiple", "OBSERVATION_MODIFIER", 29, 37], ["system", "ANATOMY", 38, 44], ["injuries", "OBSERVATION", 45, 53], ["penetrating", "OBSERVATION_MODIFIER", 60, 71], ["wounds", "OBSERVATION", 72, 78], ["extremities", "ANATOMY", 86, 97], ["injuries", "OBSERVATION", 118, 126]]], ["There also was a 15% increase in head and neck injuries, with 14% of injuries to the chest and abdomen.", [["head", "ANATOMY", 33, 37], ["neck", "ANATOMY", 42, 46], ["chest", "ANATOMY", 85, 90], ["abdomen", "ANATOMY", 95, 102], ["head and neck injuries", "DISEASE", 33, 55], ["injuries", "DISEASE", 69, 77], ["head", "ORGANISM_SUBDIVISION", 33, 37], ["neck", "ORGAN", 42, 46], ["chest", "ORGANISM_SUBDIVISION", 85, 90], ["abdomen", "ORGAN", 95, 102], ["a 15% increase in head and neck injuries", "PROBLEM", 15, 55], ["injuries to the chest and abdomen", "PROBLEM", 69, 102], ["increase", "OBSERVATION_MODIFIER", 21, 29], ["head", "ANATOMY", 33, 37], ["neck", "ANATOMY", 42, 46], ["injuries", "OBSERVATION", 47, 55], ["chest", "ANATOMY", 85, 90], ["abdomen", "ANATOMY", 95, 102]]], ["Pellet paraplegia was a characteristic injury seen with the Guava bomblet in the Israeli-Egyptian conflict.", [["paraplegia", "DISEASE", 7, 17], ["Pellet paraplegia", "PROBLEM", 0, 17], ["a characteristic injury", "PROBLEM", 22, 45], ["paraplegia", "OBSERVATION", 7, 17], ["characteristic", "OBSERVATION_MODIFIER", 24, 38], ["injury", "OBSERVATION", 39, 45]]], ["Penetrating abdominal wounds with visceral injury proved difficult, with frequently missed visceral injury due to the small pellet size (Figure 3-4) .Fragmentation InjuryImproved grenade launchers with preformed fragments, laser-sighted accuracy, and precision fusing such as the US Objective Infantry Combat Weapon, with a 5.56 barrel combined with a 20-millimeter grenade launcher, will increase firepower and extend the killing range to 1000 meters.", [["abdominal wounds", "ANATOMY", 12, 28], ["visceral", "ANATOMY", 34, 42], ["visceral", "ANATOMY", 91, 99], ["fragments", "ANATOMY", 212, 221], ["abdominal wounds", "DISEASE", 12, 28], ["visceral injury", "DISEASE", 34, 49], ["visceral injury", "DISEASE", 91, 106], ["abdominal wounds", "PATHOLOGICAL_FORMATION", 12, 28], ["visceral", "TISSUE", 34, 42], ["visceral", "TISSUE", 91, 99], ["Penetrating abdominal wounds", "PROBLEM", 0, 28], ["visceral injury", "PROBLEM", 34, 49], ["frequently missed visceral injury", "PROBLEM", 73, 106], ["the small pellet size", "PROBLEM", 114, 135], ["Fragmentation", "PROBLEM", 150, 163], ["preformed fragments", "PROBLEM", 202, 221], ["a 20-millimeter grenade launcher", "TREATMENT", 350, 382], ["abdominal", "ANATOMY", 12, 21], ["wounds", "OBSERVATION", 22, 28], ["visceral", "ANATOMY", 34, 42], ["injury", "OBSERVATION", 43, 49], ["visceral", "ANATOMY", 91, 99], ["injury", "OBSERVATION", 100, 106], ["small", "OBSERVATION_MODIFIER", 118, 123], ["pellet", "OBSERVATION_MODIFIER", 124, 130], ["size", "OBSERVATION_MODIFIER", 131, 135], ["preformed", "OBSERVATION_MODIFIER", 202, 211], ["fragments", "OBSERVATION_MODIFIER", 212, 221]]], ["The use of flechettes, depleted uranium, and tungsten missiles capable of penetrating body armor and conventional cover may further compound the complexity of wounding with toxicities that have yet to be defined, thus increasing the impact on the medical support system.", [["body", "ANATOMY", 86, 90], ["uranium", "CHEMICAL", 32, 39], ["tungsten", "CHEMICAL", 45, 53], ["toxicities", "DISEASE", 173, 183], ["uranium", "CHEMICAL", 32, 39], ["tungsten", "CHEMICAL", 45, 53], ["flechettes", "SIMPLE_CHEMICAL", 11, 21], ["uranium", "SIMPLE_CHEMICAL", 32, 39], ["body", "ORGANISM_SUBDIVISION", 86, 90], ["flechettes, depleted uranium", "TREATMENT", 11, 39], ["tungsten missiles", "TREATMENT", 45, 62], ["penetrating body armor", "TREATMENT", 74, 96], ["toxicities", "PROBLEM", 173, 183], ["depleted uranium", "OBSERVATION", 23, 39], ["penetrating", "OBSERVATION_MODIFIER", 74, 85]]], ["Many of the more modern fragment munitions are designed to produce multiple preformed fragments that weigh 100 to 200 milligrams and are 2 to 3 millimeters in diameter, whereas others may weigh as much as 20 grams.", [["fragments", "ANATOMY", 86, 95], ["the more modern fragment munitions", "PROBLEM", 8, 42], ["multiple preformed fragments", "PROBLEM", 67, 95], ["more", "OBSERVATION_MODIFIER", 12, 16], ["modern", "OBSERVATION_MODIFIER", 17, 23], ["fragment munitions", "OBSERVATION", 24, 42], ["multiple", "OBSERVATION_MODIFIER", 67, 75], ["preformed", "OBSERVATION_MODIFIER", 76, 85], ["fragments", "OBSERVATION", 86, 95], ["2 to 3 millimeters", "OBSERVATION_MODIFIER", 137, 155]]], ["Both have initial velocities of 1500 meters per second, which falls off rapidly, especially with the large, more irregular-shaped fragments.", [["fragments", "ANATOMY", 130, 139], ["initial velocities", "TEST", 10, 28], ["the large, more irregular-shaped fragments", "PROBLEM", 97, 139], ["initial", "OBSERVATION_MODIFIER", 10, 17], ["velocities", "OBSERVATION_MODIFIER", 18, 28], ["large", "OBSERVATION_MODIFIER", 101, 106], ["more", "OBSERVATION_MODIFIER", 108, 112], ["irregular", "OBSERVATION_MODIFIER", 113, 122], ["shaped", "OBSERVATION_MODIFIER", 123, 129], ["fragments", "OBSERVATION", 130, 139]]], ["The mechanism of injury is related as much to energy transfer as to the velocity of the projectile, and the magnitude of injury is thought to depend more upon the inherent tissue characteristics of the organ involved than upon the projectile itself.", [["tissue", "ANATOMY", 172, 178], ["organ", "ANATOMY", 202, 207], ["tissue", "TISSUE", 172, 178], ["organ", "ORGAN", 202, 207], ["injury", "PROBLEM", 17, 23], ["injury", "PROBLEM", 121, 127], ["injury", "OBSERVATION", 17, 23], ["projectile", "OBSERVATION_MODIFIER", 88, 98], ["magnitude", "OBSERVATION_MODIFIER", 108, 117], ["injury", "OBSERVATION", 121, 127], ["inherent tissue", "OBSERVATION_MODIFIER", 163, 178], ["organ", "ANATOMY", 202, 207]]], ["The clinical impact and priority of treatment depends on the tissue or organ involved.", [["tissue", "ANATOMY", 61, 67], ["organ", "ANATOMY", 71, 76], ["tissue", "TISSUE", 61, 67], ["organ", "ORGAN", 71, 76], ["treatment", "TREATMENT", 36, 45]]], ["Extremity wounds that may be innumerable usually are not life threatening and perhaps may not be immediately disabling.", [["Extremity wounds", "ANATOMY", 0, 16], ["Extremity wounds", "DISEASE", 0, 16], ["wounds", "PATHOLOGICAL_FORMATION", 10, 16], ["Extremity wounds", "PROBLEM", 0, 16], ["wounds", "OBSERVATION", 10, 16], ["may be", "UNCERTAINTY", 22, 28], ["innumerable", "OBSERVATION_MODIFIER", 29, 40], ["may not be", "UNCERTAINTY", 86, 96]]], ["In contrast, wounds of the eyes or thorax are far more likely to be immediately disabling or life threatening, respectively.Fragmentation InjuryEnvironmental debris such as glass, splinters, soil, and various structural particles are propelled with similar velocities by the blast wind and may well be the major cause of fragment wounding.", [["wounds", "ANATOMY", 13, 19], ["eyes", "ANATOMY", 27, 31], ["thorax", "ANATOMY", 35, 41], ["Injury", "DISEASE", 138, 144], ["wounds", "PATHOLOGICAL_FORMATION", 13, 19], ["eyes", "ORGAN", 27, 31], ["thorax", "ORGAN", 35, 41], ["wounds of the eyes or thorax", "PROBLEM", 13, 41], ["Fragmentation Injury", "PROBLEM", 124, 144], ["Environmental debris", "PROBLEM", 144, 164], ["fragment wounding", "PROBLEM", 321, 338], ["wounds", "OBSERVATION", 13, 19], ["eyes", "ANATOMY", 27, 31], ["thorax", "ANATOMY", 35, 41], ["debris", "OBSERVATION", 158, 164], ["structural particles", "OBSERVATION", 209, 229], ["velocities", "OBSERVATION_MODIFIER", 257, 267], ["blast wind", "OBSERVATION", 275, 285], ["fragment", "OBSERVATION", 321, 329], ["wounding", "OBSERVATION_MODIFIER", 330, 338]]], ["The advent of the human suicide bomber brings a new dimension to fragment wounding, with human body parts acting as missile fragments and projectiles that may carry with them the specter of human immunodeficiency virus (HIV), hepatitis, and other serious and yet to be identified threats of unknown clinical consequence, thus presenting a rather complex therapeutic dilemma for the clinician.Fragmentation InjuryPenetrating fragment wounds of the abdomen and thorax are no different than other penetrating wounds except that the number of pellets and the small size of visceral injuries demand meticulous attention to detail.", [["body parts", "ANATOMY", 95, 105], ["fragments", "ANATOMY", 124, 133], ["wounds", "ANATOMY", 433, 439], ["abdomen", "ANATOMY", 447, 454], ["thorax", "ANATOMY", 459, 465], ["wounds", "ANATOMY", 506, 512], ["visceral", "ANATOMY", 569, 577], ["human immunodeficiency virus (HIV), hepatitis", "DISEASE", 190, 235], ["visceral injuries", "DISEASE", 569, 586], ["human", "ORGANISM", 18, 23], ["human", "ORGANISM", 89, 94], ["body", "ORGANISM_SUBDIVISION", 95, 99], ["human immunodeficiency virus", "ORGANISM", 190, 218], ["HIV", "ORGANISM", 220, 223], ["wounds", "PATHOLOGICAL_FORMATION", 433, 439], ["abdomen", "ORGAN", 447, 454], ["thorax", "ORGAN", 459, 465], ["wounds", "PATHOLOGICAL_FORMATION", 506, 512], ["visceral", "ORGANISM_SUBDIVISION", 569, 577], ["human", "SPECIES", 18, 23], ["human", "SPECIES", 89, 94], ["human immunodeficiency virus (HIV", "SPECIES", 190, 223], ["human", "SPECIES", 18, 23], ["human", "SPECIES", 89, 94], ["human immunodeficiency virus", "SPECIES", 190, 218], ["HIV", "SPECIES", 220, 223], ["the human suicide bomber", "TREATMENT", 14, 38], ["fragment wounding", "PROBLEM", 65, 82], ["human body parts", "TREATMENT", 89, 105], ["missile fragments and projectiles", "PROBLEM", 116, 149], ["human immunodeficiency virus", "PROBLEM", 190, 218], ["HIV", "PROBLEM", 220, 223], ["hepatitis", "PROBLEM", 226, 235], ["Fragmentation InjuryPenetrating fragment wounds of the abdomen and thorax", "PROBLEM", 392, 465], ["other penetrating wounds", "PROBLEM", 488, 512], ["visceral injuries", "PROBLEM", 569, 586], ["new", "OBSERVATION_MODIFIER", 48, 51], ["fragment", "OBSERVATION_MODIFIER", 65, 73], ["wounding", "OBSERVATION_MODIFIER", 74, 82], ["missile fragments", "OBSERVATION", 116, 133], ["fragment", "OBSERVATION_MODIFIER", 424, 432], ["wounds", "OBSERVATION", 433, 439], ["abdomen", "ANATOMY", 447, 454], ["thorax", "ANATOMY", 459, 465], ["no", "UNCERTAINTY", 470, 472], ["different", "OBSERVATION_MODIFIER", 473, 482], ["penetrating", "OBSERVATION_MODIFIER", 494, 505], ["wounds", "OBSERVATION", 506, 512], ["small", "OBSERVATION_MODIFIER", 555, 560], ["size", "OBSERVATION_MODIFIER", 561, 565], ["visceral", "ANATOMY", 569, 577], ["injuries", "OBSERVATION", 578, 586]]], ["Almost all penetrating fragment wounds of the abdomen can be closed primarily and 85% of penetrating thoracic wounds can be managed successfully by tube thoracostomy.", [["wounds", "ANATOMY", 32, 38], ["abdomen", "ANATOMY", 46, 53], ["thoracic wounds", "ANATOMY", 101, 116], ["tube", "ANATOMY", 148, 152], ["thoracic wounds", "DISEASE", 101, 116], ["wounds", "PATHOLOGICAL_FORMATION", 32, 38], ["abdomen", "ORGAN", 46, 53], ["thoracic wounds", "PATHOLOGICAL_FORMATION", 101, 116], ["tube", "TISSUE", 148, 152], ["all penetrating fragment wounds of the abdomen", "PROBLEM", 7, 53], ["penetrating thoracic wounds", "PROBLEM", 89, 116], ["tube thoracostomy", "TREATMENT", 148, 165], ["penetrating", "OBSERVATION_MODIFIER", 11, 22], ["fragment", "OBSERVATION_MODIFIER", 23, 31], ["wounds", "OBSERVATION", 32, 38], ["abdomen", "ANATOMY", 46, 53], ["closed", "OBSERVATION", 61, 67], ["thoracic", "ANATOMY", 101, 109], ["wounds", "OBSERVATION", 110, 116], ["tube thoracostomy", "OBSERVATION", 148, 165]]], ["Animal studies examining multiple colonic injuries found that colotomies closed by either one-layer interrupted absorbable suture or stainless steel skin staples were equivalent, except that the stapled anastomosis histologically healed more quickly than the sutured anastomosis, supporting definitive repair of intestinal low-velocity wounds.Fragmentation InjuryAll war wounds are contaminated by soil, clothing, and skin.", [["colonic", "ANATOMY", 34, 41], ["colotomies", "ANATOMY", 62, 72], ["skin", "ANATOMY", 149, 153], ["intestinal", "ANATOMY", 312, 322], ["wounds", "ANATOMY", 336, 342], ["wounds", "ANATOMY", 371, 377], ["skin", "ANATOMY", 418, 422], ["colonic injuries", "DISEASE", 34, 50], ["low-velocity wounds", "DISEASE", 323, 342], ["Injury", "DISEASE", 357, 363], ["colonic", "MULTI-TISSUE_STRUCTURE", 34, 41], ["skin", "ORGAN", 149, 153], ["intestinal", "ORGAN", 312, 322], ["wounds", "PATHOLOGICAL_FORMATION", 336, 342], ["wounds", "PATHOLOGICAL_FORMATION", 371, 377], ["skin", "ORGAN", 418, 422], ["Animal studies", "TEST", 0, 14], ["multiple colonic injuries", "PROBLEM", 25, 50], ["colotomies", "TREATMENT", 62, 72], ["one-layer interrupted absorbable suture", "TREATMENT", 90, 129], ["stainless steel skin staples", "TREATMENT", 133, 161], ["the stapled anastomosis", "TREATMENT", 191, 214], ["the sutured anastomosis", "TREATMENT", 255, 278], ["definitive repair", "TREATMENT", 291, 308], ["intestinal low-velocity wounds", "PROBLEM", 312, 342], ["Fragmentation Injury", "PROBLEM", 343, 363], ["All war wounds", "PROBLEM", 363, 377], ["multiple", "OBSERVATION_MODIFIER", 25, 33], ["colonic", "ANATOMY", 34, 41], ["injuries", "OBSERVATION", 42, 50], ["layer", "OBSERVATION_MODIFIER", 94, 99], ["absorbable suture", "OBSERVATION", 112, 129], ["stainless", "OBSERVATION_MODIFIER", 133, 142], ["steel", "OBSERVATION_MODIFIER", 143, 148], ["skin", "ANATOMY", 149, 153], ["staples", "OBSERVATION", 154, 161], ["stapled", "OBSERVATION_MODIFIER", 195, 202], ["anastomosis", "OBSERVATION_MODIFIER", 203, 214], ["histologically", "OBSERVATION_MODIFIER", 215, 229], ["healed", "OBSERVATION", 230, 236], ["sutured anastomosis", "OBSERVATION", 259, 278], ["definitive", "OBSERVATION_MODIFIER", 291, 301], ["repair", "OBSERVATION", 302, 308], ["intestinal", "ANATOMY", 312, 322], ["low", "OBSERVATION_MODIFIER", 323, 326], ["velocity", "OBSERVATION_MODIFIER", 327, 335], ["wounds", "OBSERVATION", 336, 342], ["Injury", "OBSERVATION", 357, 363], ["war", "OBSERVATION_MODIFIER", 367, 370], ["wounds", "OBSERVATION", 371, 377], ["contaminated", "OBSERVATION_MODIFIER", 382, 394], ["skin", "ANATOMY", 418, 422]]], ["Highvelocity missiles have been shown to widely contaminate a wound track, 3 whereas low-velocity fragmentation wounds are minimally contaminated with debris.", [["wound", "ANATOMY", 62, 67], ["wounds", "ANATOMY", 112, 118], ["wound", "PATHOLOGICAL_FORMATION", 62, 67], ["wounds", "PATHOLOGICAL_FORMATION", 112, 118], ["Highvelocity missiles", "PROBLEM", 0, 21], ["a wound track", "PROBLEM", 60, 73], ["low-velocity fragmentation wounds", "PROBLEM", 85, 118], ["debris", "PROBLEM", 151, 157], ["widely", "OBSERVATION_MODIFIER", 41, 47], ["wound", "OBSERVATION", 62, 67], ["velocity", "OBSERVATION_MODIFIER", 89, 97], ["fragmentation", "OBSERVATION_MODIFIER", 98, 111], ["wounds", "OBSERVATION", 112, 118], ["minimally", "OBSERVATION_MODIFIER", 123, 132], ["contaminated", "OBSERVATION_MODIFIER", 133, 145], ["debris", "OBSERVATION", 151, 157]]], ["Bacterial contamination is ubiquitous in fragmentation wounds, with soil and skin organisms, Clostridia, Streptococcus, Staphylococcus, Proteus, E Coli, and Enterococcus, 4 although infection is uncommon in small low-velocity wounds of the extremity.Fragmentation InjuryAlthough somewhat controversial, some reports in the literature support early antibiotics and nonoperative treatment of extremity wounds less than a centimeter in size in patients who show no evidence of neurovascular injury or compartment syndrome and also have a stable fracture pattern.", [["wounds", "ANATOMY", 55, 61], ["skin", "ANATOMY", 77, 81], ["wounds", "ANATOMY", 226, 232], ["extremity", "ANATOMY", 240, 249], ["wounds", "ANATOMY", 400, 406], ["neurovascular", "ANATOMY", 474, 487], ["infection", "DISEASE", 182, 191], ["neurovascular injury", "DISEASE", 474, 494], ["compartment syndrome", "DISEASE", 498, 518], ["fracture", "DISEASE", 542, 550], ["wounds", "PATHOLOGICAL_FORMATION", 55, 61], ["skin", "ORGAN", 77, 81], ["E Coli", "GENE_OR_GENE_PRODUCT", 145, 151], ["wounds", "PATHOLOGICAL_FORMATION", 226, 232], ["extremity", "ORGANISM_SUBDIVISION", 240, 249], ["wounds", "PATHOLOGICAL_FORMATION", 400, 406], ["patients", "ORGANISM", 441, 449], ["neurovascular", "MULTI-TISSUE_STRUCTURE", 474, 487], ["E Coli", "SPECIES", 145, 151], ["patients", "SPECIES", 441, 449], ["E Coli", "SPECIES", 145, 151], ["Bacterial contamination", "PROBLEM", 0, 23], ["fragmentation wounds", "PROBLEM", 41, 61], ["soil and skin organisms", "PROBLEM", 68, 91], ["Clostridia", "PROBLEM", 93, 103], ["Streptococcus", "PROBLEM", 105, 118], ["Staphylococcus", "PROBLEM", 120, 134], ["Proteus", "PROBLEM", 136, 143], ["E Coli", "PROBLEM", 145, 151], ["Enterococcus", "PROBLEM", 157, 169], ["infection", "PROBLEM", 182, 191], ["small low-velocity wounds of the extremity", "PROBLEM", 207, 249], ["Fragmentation InjuryAlthough", "PROBLEM", 250, 278], ["early antibiotics", "TREATMENT", 342, 359], ["nonoperative treatment", "TREATMENT", 364, 386], ["extremity wounds", "PROBLEM", 390, 406], ["neurovascular injury", "PROBLEM", 474, 494], ["compartment syndrome", "PROBLEM", 498, 518], ["a stable fracture pattern", "PROBLEM", 533, 558], ["contamination", "OBSERVATION", 10, 23], ["ubiquitous", "OBSERVATION_MODIFIER", 27, 37], ["fragmentation", "OBSERVATION_MODIFIER", 41, 54], ["wounds", "OBSERVATION", 55, 61], ["skin", "ANATOMY", 77, 81], ["Enterococcus", "OBSERVATION", 157, 169], ["infection", "OBSERVATION", 182, 191], ["uncommon", "OBSERVATION_MODIFIER", 195, 203], ["small", "OBSERVATION_MODIFIER", 207, 212], ["low-velocity", "OBSERVATION_MODIFIER", 213, 225], ["wounds", "OBSERVATION", 226, 232], ["extremity", "ANATOMY", 240, 249], ["extremity", "ANATOMY", 390, 399], ["wounds", "OBSERVATION", 400, 406], ["size", "OBSERVATION_MODIFIER", 433, 437], ["no evidence of", "UNCERTAINTY", 459, 473], ["neurovascular", "ANATOMY", 474, 487], ["injury", "OBSERVATION", 488, 494], ["compartment syndrome", "OBSERVATION", 498, 518], ["stable", "OBSERVATION_MODIFIER", 535, 541], ["fracture", "OBSERVATION", 542, 550]]], ["5 Operative debridement of these numerous wounds can lead to increased morbidity and, in general, is unnecessary.", [["wounds", "ANATOMY", 42, 48], ["wounds", "PATHOLOGICAL_FORMATION", 42, 48], ["Operative debridement", "TREATMENT", 2, 23], ["these numerous wounds", "PROBLEM", 27, 48], ["increased morbidity", "PROBLEM", 61, 80], ["debridement", "OBSERVATION", 12, 23], ["numerous", "OBSERVATION_MODIFIER", 33, 41], ["wounds", "OBSERVATION", 42, 48], ["increased", "OBSERVATION_MODIFIER", 61, 70], ["morbidity", "OBSERVATION", 71, 80]]], ["6 However, in the authors' experience, small low-velocity wounds involving a major joint resulted in a higher incidence of infection when treated with early antibiotics and delayed operative treatment of more than 6 hours (Operation Just Cause).Fragmentation InjurySmall (less than one centimeter) low-velocity wounds with no evidence of contamination that can be cleaned and dressed with early administration of appropriate broad-spectrum antibiotics may be treated nonoperatively.", [["wounds", "ANATOMY", 58, 64], ["joint", "ANATOMY", 83, 88], ["wounds", "ANATOMY", 311, 317], ["low-velocity wounds", "DISEASE", 45, 64], ["infection", "DISEASE", 123, 132], ["wounds", "PATHOLOGICAL_FORMATION", 58, 64], ["joint", "MULTI-TISSUE_STRUCTURE", 83, 88], ["wounds", "PATHOLOGICAL_FORMATION", 311, 317], ["small low-velocity wounds", "PROBLEM", 39, 64], ["infection", "PROBLEM", 123, 132], ["early antibiotics", "TREATMENT", 151, 168], ["delayed operative treatment", "TREATMENT", 173, 200], ["Fragmentation InjurySmall", "PROBLEM", 245, 270], ["low-velocity wounds", "PROBLEM", 298, 317], ["contamination", "PROBLEM", 338, 351], ["appropriate broad-spectrum antibiotics", "TREATMENT", 413, 451], ["small", "OBSERVATION_MODIFIER", 39, 44], ["low-velocity", "OBSERVATION_MODIFIER", 45, 57], ["wounds", "OBSERVATION", 58, 64], ["joint", "ANATOMY", 83, 88], ["higher", "OBSERVATION_MODIFIER", 103, 109], ["infection", "OBSERVATION", 123, 132], ["less", "OBSERVATION_MODIFIER", 272, 276], ["low", "OBSERVATION_MODIFIER", 298, 301], ["-velocity", "OBSERVATION_MODIFIER", 301, 310], ["wounds", "OBSERVATION", 311, 317], ["no evidence of", "UNCERTAINTY", 323, 337], ["contamination", "OBSERVATION", 338, 351]]], ["However, when there is question, delay in treatment greater than 6 hours, or evidence of cavitation and contamination in wounds greater than one centimeter, operative debridement should be the standard.Land MineLand mines currently are deployed in 64 countries around the world and number between 84 to 100 million.", [["wounds", "ANATOMY", 121, 127], ["cavitation", "DISEASE", 89, 99], ["wounds", "PATHOLOGICAL_FORMATION", 121, 127], ["treatment", "TREATMENT", 42, 51], ["cavitation", "PROBLEM", 89, 99], ["contamination in wounds", "PROBLEM", 104, 127], ["operative debridement", "TREATMENT", 157, 178], ["Land MineLand mines", "TREATMENT", 202, 221], ["evidence of", "UNCERTAINTY", 77, 88], ["cavitation", "OBSERVATION", 89, 99], ["contamination", "OBSERVATION_MODIFIER", 104, 117], ["wounds", "OBSERVATION_MODIFIER", 121, 127], ["greater", "OBSERVATION_MODIFIER", 128, 135], ["debridement", "OBSERVATION", 167, 178]]], ["It is estimated that in countries with existing mine fields such as Cambodia, Angola, and Somalia, one in every 450 persons undergoes traumatic amputation compared to United States, where amputations only number one per 22 000.", [["traumatic amputation", "DISEASE", 134, 154], ["amputations", "DISEASE", 188, 199], ["persons", "ORGANISM", 116, 123], ["persons", "SPECIES", 116, 123], ["traumatic amputation", "TREATMENT", 134, 154], ["amputations", "TREATMENT", 188, 199], ["traumatic", "OBSERVATION_MODIFIER", 134, 143], ["amputation", "OBSERVATION", 144, 154]]], ["It is estimated that only half of these noncombatant victims even live to reach a hospital and undergo treatment for these devastating injuries.", [["injuries", "DISEASE", 135, 143], ["treatment", "TREATMENT", 103, 112], ["these devastating injuries", "PROBLEM", 117, 143], ["devastating", "OBSERVATION_MODIFIER", 123, 134], ["injuries", "OBSERVATION", 135, 143]]], ["7 Mines can cost no more than $3.00 apiece and can be distributed by a plethora of weapon systems to include aerial delivery and Multiple Launch Rocket Systems (MLRS) that can deliver 8000 bomblets and hundreds of mines in a matter of minutes.", [["weapon systems", "TREATMENT", 83, 97], ["aerial delivery", "TREATMENT", 109, 124]]], ["The American Gator mines (72 antitank and 22 antipersonnel) are delivered aerially in containers with one fighter aircraft able to deliver 600 mines in a single sortie.", [["The American Gator mines", "TREATMENT", 0, 24]]], ["There is no reason to expect that the use of antipersonnel mines will cease or that the incidence of landmine injuries will decline.", [["injuries", "DISEASE", 110, 118], ["antipersonnel mines", "TREATMENT", 45, 64], ["landmine injuries", "PROBLEM", 101, 118], ["no reason to expect", "UNCERTAINTY", 9, 28]]], ["Mines with increased blast radius and lethality, and with fuel-air-enhanced blast technology already are in development.", [["increased blast radius", "PROBLEM", 11, 33], ["lethality", "PROBLEM", 38, 47], ["increased", "OBSERVATION_MODIFIER", 11, 20], ["blast radius", "OBSERVATION", 21, 33], ["lethality", "OBSERVATION_MODIFIER", 38, 47], ["air", "OBSERVATION", 63, 66]]], ["8 There are essentially three classes of conventional antipersonnel land mines based on mechanism of action-static, bounding, and horizontalspray mines.Land MineStatic mines are implanted in the ground and vary from 5 to 15 centimeters in diameter, contain 20 to 200 grams of explosive, and most commonly are detonated by direct contact, although newer mines that detonate on motion and proximity motion are being developed.Land MineBounding mines, known as \"Bouncing Betty,\" have the highest mortality.", [["conventional antipersonnel land mines", "TREATMENT", 41, 78], ["Land MineStatic mines", "TREATMENT", 152, 173], ["essentially", "OBSERVATION_MODIFIER", 12, 23], ["three", "OBSERVATION_MODIFIER", 24, 29], ["classes", "OBSERVATION_MODIFIER", 30, 37], ["implanted", "OBSERVATION_MODIFIER", 178, 187], ["ground", "ANATOMY_MODIFIER", 195, 201], ["vary", "OBSERVATION_MODIFIER", 206, 210], ["5 to 15 centimeters", "OBSERVATION_MODIFIER", 216, 235], ["20 to 200 grams of explosive", "OBSERVATION_MODIFIER", 257, 285], ["proximity motion", "OBSERVATION", 387, 403]]], ["These mines propel a small explosive device 1 to 2 meters above ground then explode, dispersing multiple small preformed fragments.Land MineHorizontal-spray or directional fragmentation mines, of which the US M18A1 Claymore AP munition mine is the best known, can be command detonated or victim detonated by means of trip wires.", [["fragments", "ANATOMY", 121, 130], ["a small explosive device", "TREATMENT", 19, 43], ["multiple small preformed fragments", "PROBLEM", 96, 130], ["Land MineHorizontal-spray", "TREATMENT", 131, 156], ["directional fragmentation mines", "TREATMENT", 160, 191], ["the US", "TEST", 202, 208], ["trip wires", "TREATMENT", 317, 327], ["small", "OBSERVATION_MODIFIER", 21, 26], ["explosive", "OBSERVATION_MODIFIER", 27, 36], ["multiple", "OBSERVATION_MODIFIER", 96, 104], ["small", "OBSERVATION_MODIFIER", 105, 110], ["preformed fragments", "OBSERVATION", 111, 130]]], ["The Claymore fires 700 steel spheres, each weighing 0.75 grams in a 60 degree arc, resulting in multiple penetrating wounds dispersed throughout the body, creating multiple system injuries and multiple casualties.", [["wounds", "ANATOMY", 117, 123], ["body", "ANATOMY", 149, 153], ["injuries", "DISEASE", 180, 188], ["wounds", "PATHOLOGICAL_FORMATION", 117, 123], ["body", "ORGANISM_SUBDIVISION", 149, 153], ["The Claymore fires 700 steel spheres", "TREATMENT", 0, 36], ["multiple penetrating wounds", "PROBLEM", 96, 123], ["creating multiple system injuries", "PROBLEM", 155, 188], ["multiple", "OBSERVATION_MODIFIER", 96, 104], ["penetrating", "OBSERVATION_MODIFIER", 105, 116], ["wounds", "OBSERVATION", 117, 123], ["body", "ANATOMY", 149, 153], ["multiple", "OBSERVATION_MODIFIER", 164, 172], ["system", "ANATOMY", 173, 179], ["injuries", "OBSERVATION", 180, 188], ["multiple", "OBSERVATION_MODIFIER", 193, 201], ["casualties", "OBSERVATION", 202, 212]]], ["The horizontal spray and bounding mines essentially produce multiple penetrating injuries of both high and low velocity, depending on the range of the target, with a very high mortality.", [["injuries", "DISEASE", 81, 89], ["The horizontal spray", "TREATMENT", 0, 20], ["multiple penetrating injuries", "PROBLEM", 60, 89], ["both high and low velocity", "PROBLEM", 93, 119], ["a very high mortality", "PROBLEM", 164, 185], ["multiple", "OBSERVATION_MODIFIER", 60, 68], ["penetrating", "OBSERVATION_MODIFIER", 69, 80], ["injuries", "OBSERVATION", 81, 89], ["both", "OBSERVATION_MODIFIER", 93, 97], ["high", "OBSERVATION_MODIFIER", 98, 102], ["low velocity", "OBSERVATION_MODIFIER", 107, 119]]], ["Thus, the mechanism of injury is no different than any other penetrating wound and surviving casualties are treated as such.Land MineThe static mine is most common throughout the world, and its mechanism of injury is unique to this weapon system.", [["wound", "ANATOMY", 73, 78], ["wound", "PATHOLOGICAL_FORMATION", 73, 78], ["injury", "PROBLEM", 23, 29], ["any other penetrating wound", "PROBLEM", 51, 78], ["injury", "PROBLEM", 207, 213], ["injury", "OBSERVATION", 23, 29], ["no", "UNCERTAINTY", 33, 35], ["different", "OBSERVATION_MODIFIER", 36, 45], ["penetrating", "OBSERVATION_MODIFIER", 61, 72], ["wound", "OBSERVATION", 73, 78], ["most common", "OBSERVATION_MODIFIER", 152, 163], ["injury", "OBSERVATION", 207, 213]]], ["Upon contact and detonation, an instantaneous rise in pressure or shock wave is produced, which along with the products and heated air produce a blast wave or dynamic overpressure.", [["shock", "DISEASE", 66, 71], ["shock wave", "PROBLEM", 66, 76], ["heated air", "PROBLEM", 124, 134], ["dynamic overpressure", "PROBLEM", 159, 179], ["rise", "OBSERVATION_MODIFIER", 46, 50], ["pressure", "OBSERVATION_MODIFIER", 54, 62], ["shock", "OBSERVATION", 66, 71], ["blast wave", "OBSERVATION", 145, 155], ["overpressure", "OBSERVATION_MODIFIER", 167, 179]]], ["Contact with the body produces stress waves that propagate proximally along with shear waves produced by the blast effect.", [["body", "ANATOMY", 17, 21], ["body", "ORGANISM_SUBDIVISION", 17, 21], ["stress waves", "PROBLEM", 31, 43], ["shear waves", "PROBLEM", 81, 92], ["the blast effect", "PROBLEM", 105, 121], ["proximally", "ANATOMY_MODIFIER", 59, 69], ["blast effect", "OBSERVATION", 109, 121]]], ["These stress waves can propagate as far as the middle thigh with demyelination of nerves occurring 30 centimeters above the most proximal area of tissue injury.", [["middle thigh", "ANATOMY", 47, 59], ["nerves", "ANATOMY", 82, 88], ["tissue", "ANATOMY", 146, 152], ["demyelination", "DISEASE", 65, 78], ["thigh", "ORGANISM_SUBDIVISION", 54, 59], ["nerves", "MULTI-TISSUE_STRUCTURE", 82, 88], ["tissue", "TISSUE", 146, 152], ["These stress waves", "PROBLEM", 0, 18], ["demyelination of nerves", "PROBLEM", 65, 88], ["tissue injury", "PROBLEM", 146, 159], ["stress waves", "OBSERVATION", 6, 18], ["middle thigh", "ANATOMY", 47, 59], ["demyelination", "OBSERVATION", 65, 78], ["nerves", "ANATOMY", 82, 88], ["30 centimeters", "OBSERVATION_MODIFIER", 99, 113], ["most", "OBSERVATION_MODIFIER", 124, 128], ["proximal", "OBSERVATION_MODIFIER", 129, 137], ["area", "OBSERVATION_MODIFIER", 138, 142], ["tissue", "ANATOMY", 146, 152], ["injury", "OBSERVATION", 153, 159]]], ["This, combined with fragments from the device, soil, and footwear, produces the classic land-mine injury of complete tissue destruction, distally associated with traumatic amputation at the midfoot or distal tibia (Figures 3-5 and 3-6).", [["fragments", "ANATOMY", 20, 29], ["tissue", "ANATOMY", 117, 123], ["midfoot", "ANATOMY", 190, 197], ["distal tibia", "ANATOMY", 201, 213], ["traumatic amputation", "DISEASE", 162, 182], ["tissue", "TISSUE", 117, 123], ["midfoot", "ORGANISM_SUBDIVISION", 190, 197], ["tibia", "ORGAN", 208, 213], ["fragments from the device", "TREATMENT", 20, 45], ["the classic land-mine injury", "PROBLEM", 76, 104], ["complete tissue destruction", "PROBLEM", 108, 135], ["traumatic amputation at the midfoot", "PROBLEM", 162, 197], ["Figures", "TEST", 215, 222], ["fragments", "OBSERVATION", 20, 29], ["device", "OBSERVATION_MODIFIER", 39, 45], ["soil", "OBSERVATION_MODIFIER", 47, 51], ["mine injury", "OBSERVATION", 93, 104], ["complete tissue", "OBSERVATION_MODIFIER", 108, 123], ["destruction", "OBSERVATION", 124, 135], ["distally", "OBSERVATION_MODIFIER", 137, 145], ["traumatic", "OBSERVATION_MODIFIER", 162, 171], ["amputation", "OBSERVATION", 172, 182], ["midfoot", "ANATOMY", 190, 197], ["distal", "ANATOMY_MODIFIER", 201, 207], ["tibia", "ANATOMY", 208, 213]]], ["Proximal to the variable level of amputation there is complete stripping of tissue from the bony structures and separation of fascial planes contaminated with soil debris, microorganisms, pieces of the device, footwear, and clothing.", [["tissue", "ANATOMY", 76, 82], ["bony structures", "ANATOMY", 92, 107], ["fascial planes", "ANATOMY", 126, 140], ["amputation", "DISEASE", 34, 44], ["tissue", "TISSUE", 76, 82], ["bony structures", "TISSUE", 92, 107], ["amputation", "TREATMENT", 34, 44], ["fascial planes", "PROBLEM", 126, 140], ["soil debris", "PROBLEM", 159, 170], ["microorganisms", "PROBLEM", 172, 186], ["the device", "TREATMENT", 198, 208], ["variable", "OBSERVATION_MODIFIER", 16, 24], ["amputation", "OBSERVATION", 34, 44], ["complete", "OBSERVATION_MODIFIER", 54, 62], ["stripping", "OBSERVATION", 63, 72], ["tissue", "OBSERVATION", 76, 82], ["bony", "ANATOMY", 92, 96], ["separation", "OBSERVATION_MODIFIER", 112, 122], ["fascial planes", "ANATOMY", 126, 140], ["soil debris", "OBSERVATION", 159, 170], ["microorganisms", "OBSERVATION_MODIFIER", 172, 186]]], ["Associated penetrating injury to contralateral limb and perineum are common.Land MineInjuries occur in three distinct patterns.", [["contralateral limb", "ANATOMY", 33, 51], ["perineum", "ANATOMY", 56, 64], ["injury to contralateral limb and perineum", "DISEASE", 23, 64], ["limb", "ORGANISM_SUBDIVISION", 47, 51], ["perineum", "ORGAN", 56, 64], ["Associated penetrating injury to contralateral limb and perineum", "PROBLEM", 0, 64], ["Land MineInjuries", "TREATMENT", 76, 93], ["penetrating", "OBSERVATION_MODIFIER", 11, 22], ["injury", "OBSERVATION", 23, 29], ["contralateral", "ANATOMY_MODIFIER", 33, 46], ["limb", "ANATOMY", 47, 51], ["perineum", "ANATOMY", 56, 64], ["common", "OBSERVATION", 69, 75], ["three distinct", "OBSERVATION_MODIFIER", 103, 117]]], ["Pattern 1 injuries occur with contact of a buried mine that produces severe lower-extremity, perineal, and genital injury.", [["lower-extremity", "ANATOMY", 76, 91], ["perineal", "ANATOMY", 93, 101], ["genital", "ANATOMY", 107, 114], ["injuries", "DISEASE", 10, 18], ["genital injury", "DISEASE", 107, 121], ["lower-", "ORGANISM_SUBDIVISION", 76, 82], ["extremity", "ORGANISM_SUBDIVISION", 82, 91], ["perineal", "ORGANISM_SUBDIVISION", 93, 101], ["genital", "ORGANISM_SUBDIVISION", 107, 114], ["Pattern 1 injuries", "PROBLEM", 0, 18], ["a buried mine", "PROBLEM", 41, 54], ["severe lower-extremity, perineal, and genital injury", "PROBLEM", 69, 121], ["injuries", "OBSERVATION", 10, 18], ["severe", "OBSERVATION_MODIFIER", 69, 75], ["lower", "ANATOMY_MODIFIER", 76, 81], ["extremity", "ANATOMY", 82, 91], ["perineal", "ANATOMY", 93, 101], ["genital", "ANATOMY", 107, 114], ["injury", "OBSERVATION", 115, 121]]], ["Pattern 2 injuries occur with a proximity device explosion that produces less severe lower-extremity injury with less traumatic amputation.", [["lower-extremity", "ANATOMY", 85, 100], ["injuries", "DISEASE", 10, 18], ["lower-extremity injury", "DISEASE", 85, 107], ["traumatic amputation", "DISEASE", 118, 138], ["lower-extremity", "ORGANISM_SUBDIVISION", 85, 100], ["Pattern 2 injuries", "PROBLEM", 0, 18], ["a proximity device explosion", "PROBLEM", 30, 58], ["less severe lower-extremity injury", "PROBLEM", 73, 107], ["less traumatic amputation", "PROBLEM", 113, 138], ["injuries", "OBSERVATION", 10, 18], ["less", "OBSERVATION_MODIFIER", 73, 77], ["severe", "OBSERVATION_MODIFIER", 78, 84], ["lower", "ANATOMY_MODIFIER", 85, 90], ["extremity", "ANATOMY", 91, 100], ["injury", "OBSERVATION", 101, 107], ["less", "OBSERVATION_MODIFIER", 113, 117], ["traumatic", "OBSERVATION_MODIFIER", 118, 127], ["amputation", "OBSERVATION", 128, 138]]], ["Head, thoracic, and abdominal injuries are common.", [["thoracic", "ANATOMY", 6, 14], ["abdominal", "ANATOMY", 20, 29], ["Head, thoracic, and abdominal injuries", "DISEASE", 0, 38], ["Head", "ORGANISM_SUBDIVISION", 0, 4], ["thoracic", "ORGAN", 6, 14], ["abdominal", "ORGAN", 20, 29], ["Head, thoracic, and abdominal injuries", "PROBLEM", 0, 38], ["thoracic", "ANATOMY", 6, 14], ["abdominal", "ANATOMY", 20, 29], ["injuries", "OBSERVATION", 30, 38]]], ["Pattern 3 injuries occur with handling or clearing that produce severe head, face, and upper-extremity injury.Land MineOcular injuries are not uncommon with all categories of mines.", [["head", "ANATOMY", 71, 75], ["face", "ANATOMY", 77, 81], ["injuries", "DISEASE", 10, 18], ["upper-extremity injury", "DISEASE", 87, 109], ["injuries", "DISEASE", 126, 134], ["head", "ORGANISM_SUBDIVISION", 71, 75], ["Pattern 3 injuries", "PROBLEM", 0, 18], ["severe head, face, and upper-extremity injury", "PROBLEM", 64, 109], ["Land MineOcular injuries", "PROBLEM", 110, 134], ["injuries", "OBSERVATION", 10, 18], ["severe", "OBSERVATION_MODIFIER", 64, 70], ["head", "ANATOMY", 71, 75], ["face", "ANATOMY", 77, 81], ["upper-extremity", "ANATOMY", 87, 102], ["injury", "OBSERVATION", 103, 109], ["MineOcular injuries", "OBSERVATION", 115, 134]]], ["The products of detonation and environmental fragments and debris producing penetrating ocular wounds are the primary mechanism and were seen in 4.5% of all antipersonnel mine injuries in Afghanistan.", [["fragments", "ANATOMY", 45, 54], ["ocular wounds", "ANATOMY", 88, 101], ["ocular wounds", "DISEASE", 88, 101], ["injuries", "DISEASE", 176, 184], ["ocular wounds", "PATHOLOGICAL_FORMATION", 88, 101], ["detonation and environmental fragments", "PROBLEM", 16, 54], ["debris", "PROBLEM", 59, 65], ["penetrating ocular wounds", "PROBLEM", 76, 101], ["detonation", "OBSERVATION_MODIFIER", 16, 26], ["environmental fragments", "OBSERVATION", 31, 54], ["debris", "OBSERVATION_MODIFIER", 59, 65], ["penetrating", "OBSERVATION_MODIFIER", 76, 87], ["ocular wounds", "OBSERVATION", 88, 101], ["injuries", "OBSERVATION", 176, 184]]], ["62 T.W. Baskin and J.B. Holcomb All lower-extremity injuries need debridement or completion of amputation and many may require laparotomy, with all wounds of perineum, buttocks, back, and abdomen having a low threshold for laparotomy.", [["lower-extremity", "ANATOMY", 36, 51], ["wounds", "ANATOMY", 148, 154], ["perineum", "ANATOMY", 158, 166], ["buttocks", "ANATOMY", 168, 176], ["back", "ANATOMY", 178, 182], ["abdomen", "ANATOMY", 188, 195], ["lower-extremity injuries", "DISEASE", 36, 60], ["wounds", "PATHOLOGICAL_FORMATION", 148, 154], ["perineum", "ORGANISM_SUBDIVISION", 158, 166], ["buttocks", "ORGANISM_SUBDIVISION", 168, 176], ["abdomen", "ORGAN", 188, 195], ["All lower-extremity injuries", "PROBLEM", 32, 60], ["debridement", "TREATMENT", 66, 77], ["amputation", "TREATMENT", 95, 105], ["laparotomy", "TREATMENT", 127, 137], ["all wounds of perineum, buttocks, back, and abdomen", "PROBLEM", 144, 195], ["laparotomy", "TREATMENT", 223, 233], ["lower", "OBSERVATION_MODIFIER", 36, 41], ["extremity", "ANATOMY", 42, 51], ["injuries", "OBSERVATION", 52, 60], ["debridement", "OBSERVATION", 66, 77], ["amputation", "OBSERVATION", 95, 105], ["laparotomy", "OBSERVATION", 127, 137], ["wounds", "OBSERVATION", 148, 154], ["perineum", "ANATOMY", 158, 166], ["buttocks", "ANATOMY", 168, 176], ["back", "ANATOMY", 178, 182], ["abdomen", "ANATOMY", 188, 195], ["low threshold", "OBSERVATION_MODIFIER", 205, 218], ["laparotomy", "OBSERVATION", 223, 233]]], ["Every effort should be made to conserve the contralateral limb.The primary injury is treated with excision, lavage, and exploration and lavage of fascial planes with delayed closure.", [["limb", "ANATOMY", 58, 62], ["fascial", "ANATOMY", 146, 153], ["primary injury", "DISEASE", 67, 81], ["contralateral limb", "ORGANISM_SUBDIVISION", 44, 62], ["The primary injury", "PROBLEM", 63, 81], ["excision", "TREATMENT", 98, 106], ["lavage", "TREATMENT", 108, 114], ["exploration", "TEST", 120, 131], ["lavage of fascial planes", "TREATMENT", 136, 160], ["delayed closure", "TREATMENT", 166, 181], ["contralateral", "ANATOMY_MODIFIER", 44, 57], ["limb", "ANATOMY", 58, 62], ["primary", "OBSERVATION_MODIFIER", 67, 74], ["injury", "OBSERVATION", 75, 81], ["excision", "OBSERVATION", 98, 106], ["lavage", "OBSERVATION", 108, 114], ["fascial", "ANATOMY", 146, 153], ["closure", "OBSERVATION", 174, 181]]], ["All casualties should receive broad-spectrum antibiotics to cover indigenous soil spore-forming microorganisms.Combined InjuryCombined injuries, including primary blast injury, penetrating fragment wounds, crush, burn, and inhalation injuries, are to be expected, especially in urban-warfare environments or urban terrorist bombings.", [["primary blast", "ANATOMY", 155, 168], ["wounds", "ANATOMY", 198, 204], ["InjuryCombined injuries", "DISEASE", 120, 143], ["primary blast injury", "DISEASE", 155, 175], ["wounds", "DISEASE", 198, 204], ["crush", "DISEASE", 206, 211], ["burn", "DISEASE", 213, 217], ["inhalation injuries", "DISEASE", 223, 242], ["wounds", "PATHOLOGICAL_FORMATION", 198, 204], ["broad-spectrum antibiotics", "TREATMENT", 30, 56], ["indigenous soil spore", "PROBLEM", 66, 87], ["microorganisms", "PROBLEM", 96, 110], ["Combined InjuryCombined injuries", "PROBLEM", 111, 143], ["primary blast injury", "PROBLEM", 155, 175], ["penetrating fragment wounds", "PROBLEM", 177, 204], ["crush", "PROBLEM", 206, 211], ["burn", "PROBLEM", 213, 217], ["inhalation injuries", "PROBLEM", 223, 242], ["injuries", "OBSERVATION", 135, 143], ["primary", "OBSERVATION_MODIFIER", 155, 162], ["blast injury", "OBSERVATION", 163, 175], ["penetrating", "OBSERVATION_MODIFIER", 177, 188], ["fragment", "OBSERVATION_MODIFIER", 189, 197], ["wounds", "OBSERVATION", 198, 204], ["crush", "OBSERVATION_MODIFIER", 206, 211], ["burn", "OBSERVATION_MODIFIER", 213, 217], ["inhalation injuries", "OBSERVATION", 223, 242]]], ["With the advent of EBWs and handheld thermobaric weapons, these combined injuries are likely to become even more common, placing extreme stress on medical support systems, be they military or civilian.", [["injuries", "DISEASE", 73, 81], ["handheld thermobaric weapons", "TREATMENT", 28, 56], ["these combined injuries", "PROBLEM", 58, 81], ["extreme stress on medical support systems", "PROBLEM", 129, 170]]], ["Triage and appropriate patient distribution may be the most critical piece of patient management.", [["patient", "ORGANISM", 23, 30], ["patient", "ORGANISM", 78, 85], ["patient", "SPECIES", 23, 30], ["patient", "SPECIES", 78, 85], ["patient management", "TREATMENT", 78, 96]]], ["Combined blast and penetrating injuries are almost always the most life threatening and the basic principles of the ABCs should always be adhered to.", [["penetrating injuries", "DISEASE", 19, 39], ["Combined blast and penetrating injuries", "PROBLEM", 0, 39], ["blast", "OBSERVATION", 9, 14], ["penetrating", "OBSERVATION_MODIFIER", 19, 30], ["injuries", "OBSERVATION", 31, 39]]], ["Blast lung may not present for 24 to 48 hours; therefore, all patients requiring early mechanical ventilation or those going immediately to the operating room should be managed with low tidal volumes of 5 to 6 milliliters per kilogram of ideal body weight, peak inspiratory pressures of less than 25 centimeters H 2 O, allowing for permissive hypercapnia.", [["lung", "ANATOMY", 6, 10], ["body", "ANATOMY", 244, 248], ["hypercapnia", "DISEASE", 343, 354], ["H 2 O", "CHEMICAL", 312, 317], ["lung", "ORGAN", 6, 10], ["patients", "ORGANISM", 62, 70], ["body", "ORGANISM_SUBDIVISION", 244, 248], ["patients", "SPECIES", 62, 70], ["early mechanical ventilation", "TREATMENT", 81, 109], ["low tidal volumes", "TREATMENT", 182, 199], ["ideal body weight", "TEST", 238, 255], ["peak inspiratory pressures", "TEST", 257, 283], ["permissive hypercapnia", "PROBLEM", 332, 354], ["lung", "ANATOMY", 6, 10], ["mechanical ventilation", "OBSERVATION", 87, 109], ["inspiratory pressures", "OBSERVATION", 262, 283], ["hypercapnia", "OBSERVATION", 343, 354]]], ["If associated TBI is present, hypercapnia should be avoided or minimized, if possible, due to the deleterious effects on intracranial hypertension.", [["intracranial", "ANATOMY", 121, 133], ["TBI", "DISEASE", 14, 17], ["hypercapnia", "DISEASE", 30, 41], ["intracranial hypertension", "DISEASE", 121, 146], ["TBI", "PROBLEM", 14, 17], ["hypercapnia", "PROBLEM", 30, 41], ["the deleterious effects", "PROBLEM", 94, 117], ["intracranial hypertension", "PROBLEM", 121, 146], ["TBI", "OBSERVATION", 14, 17], ["hypercapnia", "OBSERVATION", 30, 41], ["intracranial", "ANATOMY", 121, 133], ["hypertension", "OBSERVATION", 134, 146]]], ["For a patient undergoing anesthesia with obvious signs of blast lung injury, there is an increased risk of barotrauma with resultant tension pneumothorax.", [["lung", "ANATOMY", 64, 68], ["blast lung injury", "DISEASE", 58, 75], ["barotrauma", "DISEASE", 107, 117], ["pneumothorax", "DISEASE", 141, 153], ["patient", "ORGANISM", 6, 13], ["lung", "ORGAN", 64, 68], ["patient", "SPECIES", 6, 13], ["anesthesia", "TREATMENT", 25, 35], ["blast lung injury", "PROBLEM", 58, 75], ["barotrauma", "PROBLEM", 107, 117], ["resultant tension pneumothorax", "PROBLEM", 123, 153], ["blast", "OBSERVATION", 58, 63], ["lung", "ANATOMY", 64, 68], ["injury", "OBSERVATION", 69, 75], ["increased", "OBSERVATION_MODIFIER", 89, 98], ["barotrauma", "OBSERVATION", 107, 117], ["resultant", "OBSERVATION_MODIFIER", 123, 132], ["tension", "OBSERVATION_MODIFIER", 133, 140], ["pneumothorax", "OBSERVATION", 141, 153]]], ["The authors recommend consideration of bilateral prophylactic tube thoracostomy.Combined InjuryPatients without vascular compromise or evidence of compartment syndrome who have penetrating injuries of the extremities of one centimeter or less may be managed conservatively with early antibiotics and cleansing with frequent observation.Combined InjuryPenetrating injuries of the trunk associated with hemodynamic instability should undergo immediate operation.", [["tube", "ANATOMY", 62, 66], ["vascular", "ANATOMY", 112, 120], ["extremities", "ANATOMY", 205, 216], ["trunk", "ANATOMY", 379, 384], ["compartment syndrome", "DISEASE", 147, 167], ["penetrating injuries", "DISEASE", 177, 197], ["injuries of the trunk", "DISEASE", 363, 384], ["hemodynamic instability", "DISEASE", 401, 424], ["tube", "TISSUE", 62, 66], ["vascular", "MULTI-TISSUE_STRUCTURE", 112, 120], ["extremities", "ORGANISM_SUBDIVISION", 205, 216], ["trunk", "ORGANISM_SUBDIVISION", 379, 384], ["bilateral prophylactic tube thoracostomy", "TREATMENT", 39, 79], ["vascular compromise", "PROBLEM", 112, 131], ["compartment syndrome", "PROBLEM", 147, 167], ["penetrating injuries of the extremities", "PROBLEM", 177, 216], ["early antibiotics", "TREATMENT", 278, 295], ["cleansing", "TREATMENT", 300, 309], ["frequent observation", "TEST", 315, 335], ["Combined InjuryPenetrating injuries of the trunk", "PROBLEM", 336, 384], ["hemodynamic instability", "PROBLEM", 401, 424], ["immediate operation", "TREATMENT", 440, 459], ["bilateral", "ANATOMY_MODIFIER", 39, 48], ["tube thoracostomy", "OBSERVATION", 62, 79], ["without", "UNCERTAINTY", 104, 111], ["vascular", "ANATOMY", 112, 120], ["compromise", "OBSERVATION", 121, 131], ["compartment syndrome", "OBSERVATION", 147, 167], ["penetrating", "OBSERVATION_MODIFIER", 177, 188], ["injuries", "OBSERVATION", 189, 197], ["extremities", "ANATOMY", 205, 216], ["one centimeter", "OBSERVATION_MODIFIER", 220, 234], ["injuries", "OBSERVATION", 363, 371], ["trunk", "ANATOMY", 379, 384], ["hemodynamic instability", "OBSERVATION", 401, 424]]], ["Most thoracic injuries can be managed with tube thoracostomy, and thoracotomy is rarely indicated in combined injury.", [["thoracic", "ANATOMY", 5, 13], ["tube", "ANATOMY", 43, 47], ["thoracic injuries", "DISEASE", 5, 22], ["thoracic", "ORGAN", 5, 13], ["tube", "TISSUE", 43, 47], ["Most thoracic injuries", "PROBLEM", 0, 22], ["tube thoracostomy", "TREATMENT", 43, 60], ["thoracotomy", "TREATMENT", 66, 77], ["combined injury", "PROBLEM", 101, 116], ["thoracic", "ANATOMY", 5, 13], ["injuries", "OBSERVATION", 14, 22], ["tube thoracostomy", "OBSERVATION", 43, 60], ["thoracotomy", "OBSERVATION", 66, 77], ["injury", "OBSERVATION", 110, 116]]], ["Emergent thoracotomy for penetrating thoracic injury in the presence of primary blast should be considered futile and be abandoned.Combined InjuryAbdominal wounds with associated hemodynamic instability require immediate laparotomy once the airway is controlled.Combined InjuryManagement of truncal penetrating injuries combined with blast should undergo, at minimum, a focused abdominal sonogram for trauma (FAST) exam if available, but the decision to operate frequently must be based on clinical judgment and a high index of suspicion.", [["thoracic", "ANATOMY", 37, 45], ["primary blast", "ANATOMY", 72, 85], ["wounds", "ANATOMY", 156, 162], ["airway", "ANATOMY", 241, 247], ["abdominal", "ANATOMY", 378, 387], ["thoracic injury", "DISEASE", 37, 52], ["primary blast", "DISEASE", 72, 85], ["hemodynamic instability", "DISEASE", 179, 202], ["Injury", "DISEASE", 271, 277], ["truncal penetrating injuries", "DISEASE", 291, 319], ["trauma", "DISEASE", 401, 407], ["thoracic", "ORGAN", 37, 45], ["wounds", "PATHOLOGICAL_FORMATION", 156, 162], ["airway", "MULTI-TISSUE_STRUCTURE", 241, 247], ["abdominal", "ORGAN", 378, 387], ["Emergent thoracotomy", "TREATMENT", 0, 20], ["penetrating thoracic injury", "PROBLEM", 25, 52], ["primary blast", "PROBLEM", 72, 85], ["Combined InjuryAbdominal wounds", "PROBLEM", 131, 162], ["associated hemodynamic instability", "PROBLEM", 168, 202], ["immediate laparotomy", "TREATMENT", 211, 231], ["Combined Injury", "PROBLEM", 262, 277], ["truncal penetrating injuries", "PROBLEM", 291, 319], ["a focused abdominal sonogram", "TEST", 368, 396], ["trauma (FAST) exam", "TEST", 401, 419], ["clinical judgment", "TEST", 490, 507], ["thoracotomy", "OBSERVATION", 9, 20], ["penetrating", "OBSERVATION_MODIFIER", 25, 36], ["thoracic", "ANATOMY", 37, 45], ["injury", "OBSERVATION", 46, 52], ["wounds", "OBSERVATION", 156, 162], ["hemodynamic instability", "OBSERVATION", 179, 202], ["laparotomy", "OBSERVATION", 221, 231], ["airway", "ANATOMY", 241, 247], ["Injury", "OBSERVATION", 271, 277], ["truncal", "OBSERVATION_MODIFIER", 291, 298], ["penetrating", "OBSERVATION_MODIFIER", 299, 310], ["injuries", "OBSERVATION", 311, 319], ["abdominal", "ANATOMY", 378, 387]]], ["Patients with blast injury and associated blunt abdominal trauma from tertiary and quaternary mechanisms who are hemodynamically unstable should undergo immediate laparotomy, as conservative management in this scenario is not indicated at this time.", [["abdominal", "ANATOMY", 48, 57], ["blast injury", "DISEASE", 14, 26], ["blunt abdominal trauma", "DISEASE", 42, 64], ["Patients", "ORGANISM", 0, 8], ["abdominal", "ORGANISM_SUBDIVISION", 48, 57], ["Patients", "SPECIES", 0, 8], ["blast injury", "PROBLEM", 14, 26], ["blunt abdominal trauma", "PROBLEM", 42, 64], ["hemodynamically unstable", "PROBLEM", 113, 137], ["immediate laparotomy", "TREATMENT", 153, 173], ["conservative management", "TREATMENT", 178, 201], ["blast injury", "OBSERVATION", 14, 26], ["blunt", "OBSERVATION_MODIFIER", 42, 47], ["abdominal", "ANATOMY", 48, 57], ["trauma", "OBSERVATION", 58, 64], ["laparotomy", "OBSERVATION", 163, 173]]], ["However, the use of Recombinant factor VIIa and other nonoperative hemorrhage control methods may alter the clinical management of some categories of blast-injured casualties in the near future.Retained OrdnanceAn injury that is truly unique to the military is the casualty presenting with retained and unexploded ordnance.", [["hemorrhage", "DISEASE", 67, 77], ["OrdnanceAn injury", "DISEASE", 203, 220], ["factor VIIa", "GENE_OR_GENE_PRODUCT", 32, 43], ["Recombinant factor VIIa", "PROTEIN", 20, 43], ["Recombinant factor VIIa", "TREATMENT", 20, 43], ["other nonoperative hemorrhage control methods", "TREATMENT", 48, 93], ["Retained OrdnanceAn injury", "PROBLEM", 194, 220], ["hemorrhage", "OBSERVATION", 67, 77], ["OrdnanceAn", "OBSERVATION_MODIFIER", 203, 213], ["injury", "OBSERVATION", 214, 220]]], ["Since World War II there have been 36 documented cases with only four deaths.", [["deaths", "DISEASE", 70, 76]]], ["The deaths occurred not from the detonation of the missile, but from the moribund condition of the casualty, usually due to hemorrhage.", [["deaths", "DISEASE", 4, 10], ["hemorrhage", "DISEASE", 124, 134], ["The deaths", "PROBLEM", 0, 10], ["hemorrhage", "PROBLEM", 124, 134], ["missile", "OBSERVATION_MODIFIER", 51, 58], ["hemorrhage", "OBSERVATION", 124, 134]]], ["The M79 grenade launcher (40 mm), mortars, and RPG missiles have been the most commonly reported cause of retained ordnance.", [["mortars", "TEST", 34, 41], ["retained ordnance", "PROBLEM", 106, 123], ["retained", "OBSERVATION", 106, 114]]], ["There is often a safety built into the device requiring a defined number of revolutions or a required distance and time before the missile is armed to explode.", [["the device", "TREATMENT", 35, 45]]], ["The RPG round must travel a proscribed distance before the fuse is armed to trigger on impact.", [["round", "OBSERVATION_MODIFIER", 8, 13]]], ["All missiles that have been fired must be considered armed, and a defined and predetermined algorithm for the care of the casualty and the safety of the medical personnel should be followed.Retained OrdnanceA casualty with unexploded ordnance should be transported in the position found so as not to change the missile orientation and should always be grounded to the airframe if evacuated by air.", [["unexploded ordnance", "TREATMENT", 223, 242], ["missiles", "OBSERVATION", 4, 12], ["air", "OBSERVATION", 393, 396]]], ["These patients should be isolated and, in a mass casualty situation, should be treated last as the removal of ordnance is time consuming and the surgeon must attend to other casualties before placing his or herself at risk.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["the removal of ordnance", "TREATMENT", 95, 118]]], ["Closed chest massage or defibrillation should never be attempted, and during removal, any equipment emanating electrical energy, heat, vibration, or sonic waves, such as the electrocautery, ultrasound, blood warmers, or power instruments, should be avoided.", [["chest", "ANATOMY", 7, 12], ["blood", "ANATOMY", 202, 207], ["chest", "ORGAN", 7, 12], ["blood", "ORGANISM_SUBSTANCE", 202, 207], ["Closed chest massage", "TREATMENT", 0, 20], ["defibrillation", "TREATMENT", 24, 38], ["removal", "TREATMENT", 77, 84], ["heat, vibration, or sonic waves", "PROBLEM", 129, 160], ["the electrocautery", "TEST", 170, 188], ["ultrasound", "TEST", 190, 200], ["blood warmers", "TEST", 202, 215], ["power instruments", "TREATMENT", 220, 237], ["chest", "ANATOMY", 7, 12]]], ["The patient should be placed in a protected area away from the main hospital, and all personnel in the immediate area should employ body armor or explosive ordnance disposal (EOD) equipment.", [["body", "ANATOMY", 132, 136], ["patient", "ORGANISM", 4, 11], ["body", "ORGANISM_SUBDIVISION", 132, 136], ["patient", "SPECIES", 4, 11]]], ["Explosive ordnance disposal personnel should be involved prior to removal to help with identifying the round and fuse; a plain radiograph will help in planning the operative removal and will not cause the round to explode.", [["removal", "TREATMENT", 66, 73], ["a plain radiograph", "TEST", 119, 137], ["the operative removal", "TREATMENT", 160, 181]]], ["The minimum anesthesia required should be used and in such a manner that the anesthesia provider need not be present during actual removal.", [["The minimum anesthesia", "TREATMENT", 0, 22], ["the anesthesia provider", "TREATMENT", 73, 96], ["actual removal", "TREATMENT", 124, 138]]], ["The round should be removed en bloc without touching the missile with metal instruments.", [["en bloc", "TREATMENT", 28, 35], ["metal instruments", "TREATMENT", 70, 87]]], ["The basic guidelines for removal of ordnance are outlined in Table 3 -5.TriageTriage of overwhelming numbers of casualties with multisystem injury from terrorist explosive munitions, once the sole province of the battlefield hospital, now threaten the urban hospital, the civilian trauma surgeon, and health systems throughout the populated world.", [["multisystem injury", "DISEASE", 128, 146], ["trauma", "DISEASE", 281, 287], ["removal of ordnance", "TREATMENT", 25, 44], ["multisystem injury", "PROBLEM", 128, 146], ["multisystem", "OBSERVATION_MODIFIER", 128, 139], ["injury", "OBSERVATION", 140, 146]]], ["All medical providers must bear the burden of preparing for the eventuality of casualties in overwhelming numbers, sustaining primary blast, penetrating wounds, burns, and crush injuries.", [["primary blast", "ANATOMY", 126, 139], ["wounds", "ANATOMY", 153, 159], ["crush", "ANATOMY", 172, 177], ["primary blast", "DISEASE", 126, 139], ["penetrating wounds", "DISEASE", 141, 159], ["burns", "DISEASE", 161, 166], ["crush injuries", "DISEASE", 172, 186], ["wounds", "PATHOLOGICAL_FORMATION", 153, 159], ["penetrating wounds", "PROBLEM", 141, 159], ["burns", "PROBLEM", 161, 166], ["crush injuries", "PROBLEM", 172, 186], ["primary blast", "OBSERVATION", 126, 139], ["penetrating", "OBSERVATION_MODIFIER", 141, 152], ["wounds", "OBSERVATION", 153, 159], ["burns", "OBSERVATION", 161, 166], ["crush injuries", "OBSERVATION", 172, 186]]]], "725f88f863cfb160f89c5127ab9ed59bd9ea5a5b": [["IntroductionSince the start of the outbreak of SARS-CoV-2 in December 2019, in the Hubei province in China, the virus has quickly spread across the world.", [["SARS", "DISEASE", 47, 51], ["SARS-CoV", "SPECIES", 47, 55], ["the virus", "PROBLEM", 108, 117], ["virus", "OBSERVATION", 112, 117]]], ["[1] [2] [3] As the virus spread, so did the COVID-19 disease that it causes.", [["the virus spread", "PROBLEM", 15, 31], ["the COVID-19 disease", "PROBLEM", 40, 60]]], ["To curb the surge in COVID-19 related mortality, different governments enforced different measures for the containment of the epidemic.", [["different measures", "TREATMENT", 80, 98]]], ["Now, as the epidemic claims more lives worldwide, the accumulation of mortality can be compared between countries, [6, 7] to obtain some insight into the effectiveness of the different containment measures.", [["the different containment measures", "TREATMENT", 171, 205]]], ["Here, we propose methods to enable a comparison and present the results of this comparison.DataReported numbers of cases and deaths per country were obtained from the European Union Open Data Portal, where data on worldwide numbers of reported cases and numbers of reported deaths, for the COVID-19 epidemic are updated daily.", [["deaths", "DISEASE", 125, 131], ["deaths", "DISEASE", 274, 280], ["the COVID", "TEST", 286, 295], ["Portal", "ANATOMY", 192, 198]]], ["[6] Numbers of reported cases and deaths between January 1 st and April 17 th 2020 were compared between countries.Comparability of data between countriesThe comparability of data between countries was increased in two distinct ways.", [["deaths", "DISEASE", 34, 40], ["two distinct", "OBSERVATION_MODIFIER", 215, 227]]], ["First, the start of the epidemic was synchronized between countries, by using the date of the first reported COVID-19 case or COVID-19 related death as the index date.", [["death", "DISEASE", 143, 148]]], ["Second, the size and susceptibility of the population, and the probability of a COVID-19 case or a COVID-19 related death being reported as such, were all corrected for in a single procedure.", [["death", "DISEASE", 116, 121], ["a COVID-19 related death", "PROBLEM", 97, 121], ["a single procedure", "TREATMENT", 172, 190], ["size", "OBSERVATION_MODIFIER", 12, 16], ["susceptibility", "OBSERVATION_MODIFIER", 21, 35], ["population", "OBSERVATION_MODIFIER", 43, 53]]], ["All cumulative numbers of cases or deaths were normalized to a reference number.", [["deaths", "DISEASE", 35, 41], ["deaths", "PROBLEM", 35, 41]]], ["As a reference we took the cumulative number of cases or deaths at day 25 of the synchronized epidemic (i.e. day 25 after the index date for each country).Sensitivity analysesWe chose day 25 as the reference day because, in most countries, by day 25 after the first case or death, the epidemic has stably established itself and the number of cases or deaths has increased to a level where random fluctuations are reduced to an acceptable level.", [["deaths", "DISEASE", 57, 63], ["death", "DISEASE", 274, 279], ["deaths", "DISEASE", 351, 357], ["death", "PROBLEM", 274, 279], ["deaths", "PROBLEM", 351, 357], ["increased", "OBSERVATION_MODIFIER", 362, 371]]], ["To assess the potential influence of choosing day 25 as a reference, sensitivity analyses were performed repeating all analyses, while taking days 20 and 30 as the references.Visual representation and categorization of countriesAfter synchronizing countries by the date of the first death in each country, cumulative numbers of deaths were expressed as percentages of the cumulative number of deaths on day 25, for each country.", [["death", "DISEASE", 283, 288], ["deaths", "DISEASE", 328, 334], ["deaths", "DISEASE", 393, 399], ["sensitivity analyses", "TEST", 69, 89]]], ["Resulting percentages were expressed in graphs, plotted against synchronized time.Visual representation and categorization of countriesTemporal trends in cumulative numbers of deaths were compared to those for China, where the epidemic started, and where the temporal trends have therefore developed the farthest.Visual representation and categorization of countriesFor comparison to China, countries were divided into three categories.", [["deaths", "DISEASE", 176, 182], ["Visual representation", "TEST", 82, 103]]], ["These are the European countries, where governments waited for the epidemic to establish itself, but not for substantial numbers of COVID-19 related deaths to occur, before taking preventive measures.", [["deaths", "DISEASE", 149, 155], ["preventive measures", "TREATMENT", 180, 199]]], ["Germany, Italy, the Netherlands, Spain, and Sweden (alphabetic order) were used as examples, but graph shapes for other European countries were rather similar.Visual representation and categorization of countriesSecond, in South Korea, strict preventive measures were put into place even before the virus spread substantially in the population.", [["strict preventive measures", "TREATMENT", 236, 262], ["the virus spread", "PROBLEM", 295, 311]]], ["Third, a comparison was made with the United States of America (USA), where preventive measures were not put into place until large numbers of deaths had already occurred.ResultsAs shown in figure 1 , the temporal development of the epidemic appears very different between different countries in panels A through C, but not in panel D. When comparing the number of cases To appreciate our results, it is important to note that data from different countries are not directly comparable, for at least five distinct reasons.", [["deaths", "DISEASE", 143, 149], ["preventive measures", "TREATMENT", 76, 95], ["ResultsAs", "TEST", 171, 180], ["temporal", "OBSERVATION_MODIFIER", 205, 213], ["very", "OBSERVATION_MODIFIER", 250, 254], ["different", "OBSERVATION_MODIFIER", 255, 264]]], ["First, the virus did not arrive in all countries simultaneously, causing a desynchronized development of the epidemic in different countries.ResultsSecond, absolute numbers are incomparable due to different population sizes.", [["the virus", "PROBLEM", 7, 16], ["absolute numbers", "TEST", 156, 172], ["virus", "OBSERVATION", 11, 16], ["epidemic", "OBSERVATION_MODIFIER", 109, 117], ["absolute numbers", "OBSERVATION", 156, 172], ["different", "OBSERVATION_MODIFIER", 197, 206], ["population", "OBSERVATION_MODIFIER", 207, 217], ["sizes", "OBSERVATION_MODIFIER", 218, 223]]], ["Third, rates per 100,000 of the population are incomparable, because not all countries are affected homogeneously.J o u r n a l P r e -p r o o fEspecially in the larger countries, like China and the United States, epidemics can be (temporarily) focused on a localized level.", [["fEspecially", "PROBLEM", 143, 154], ["epidemics", "PROBLEM", 214, 223]]], ["For example, in China, the province of Hubei was severely affected, while the rest of the country was not.", [["severely affected", "PROBLEM", 49, 66], ["severely", "OBSERVATION_MODIFIER", 49, 57], ["affected", "OBSERVATION", 58, 66]]], ["Therefore, correction for the total size of the Chinese population would not provide a representative figure.", [["the Chinese population", "TREATMENT", 44, 66], ["size", "OBSERVATION_MODIFIER", 36, 40]]], ["Of particular note, in panels A and B of figure 1 , the numbers of cases and deaths in China disappear almost completely, due to this false inflation of the denominator.", [["deaths", "DISEASE", 77, 83], ["false inflation", "OBSERVATION", 134, 149]]], ["Fourth, susceptibility to death by COVID-19 can differ between populations, depending on the demographic composition of a country's population.", [["death", "DISEASE", 26, 31], ["COVID-19", "CHEMICAL", 35, 43], ["COVID", "TEST", 35, 40]]], ["For example, in Italy, older people are known to be relatively overrepresented in the population, and to be more likely to be in a single household with relatives from a younger generation, causing increased numbers of elderly to be infected and therefore relatively more COVID-19 mortality.", [["people", "ORGANISM", 29, 35], ["people", "SPECIES", 29, 35], ["increased numbers", "PROBLEM", 198, 215], ["known to be", "UNCERTAINTY", 40, 51], ["relatively", "OBSERVATION_MODIFIER", 52, 62], ["overrepresented", "OBSERVATION", 63, 78], ["increased", "OBSERVATION_MODIFIER", 198, 207], ["numbers", "OBSERVATION_MODIFIER", 208, 215], ["infected", "OBSERVATION", 233, 241]]], ["Fifth, a death during the COVID-19 epidemic will only be reported as a COVID-19 related death if the patient was diagnosed with SARS-CoV-2 infection.", [["death", "DISEASE", 9, 14], ["death", "DISEASE", 88, 93], ["SARS-CoV-2 infection", "DISEASE", 128, 148], ["patient", "ORGANISM", 101, 108], ["SARS-CoV-2", "ORGANISM", 128, 138], ["patient", "SPECIES", 101, 108], ["a death", "PROBLEM", 7, 14], ["the COVID", "TEST", 22, 31], ["SARS", "PROBLEM", 128, 132], ["CoV", "PROBLEM", 133, 136], ["2 infection", "PROBLEM", 137, 148], ["infection", "OBSERVATION", 139, 148]]], ["Therefore, differences in testing policy and guidelines for clinical diagnosis (i.e. in the absence of laboratory testing), will also cause differences in estimated numbers of COVID-19 related deaths.J o u r n a l P r e -p r o o fThe first problem was addressed by choosing an appropriate index date for each country and setting this date to day 1, for the start of the epidemic in that country.", [["deaths", "DISEASE", 193, 199], ["laboratory testing", "TEST", 103, 121], ["COVID", "TEST", 176, 181]]], ["As an index date, we choose the date of the first reported COVID-19 related case or death in each country, depending on whether cases or deaths were being synchronized.", [["death", "DISEASE", 84, 89], ["deaths", "DISEASE", 137, 143]]], ["Synchronization of the development of deaths by the date of the first death was much better ( figure 1 panels B and D) .", [["deaths", "DISEASE", 38, 44], ["death", "DISEASE", 70, 75], ["the first death", "PROBLEM", 60, 75]]], ["The remaining four problems all pertain to the size and the susceptibility of the population, or the probability of a COVID-19 case or COVID-19 related death being reported as such.", [["death", "DISEASE", 152, 157], ["a COVID", "TEST", 116, 123], ["COVID-19 related death", "PROBLEM", 135, 157], ["remaining", "OBSERVATION_MODIFIER", 4, 13], ["four", "OBSERVATION_MODIFIER", 14, 18], ["problems", "OBSERVATION", 19, 27], ["size", "OBSERVATION_MODIFIER", 47, 51]]], ["Therefore, we choose to normalize the cumulative number of deaths, by a reference number of deaths.", [["deaths", "DISEASE", 59, 65], ["deaths", "DISEASE", 92, 98]]], ["The number of actually reported COVID-19 related deaths is clearly a direct function of the size and susceptibility of the population and the probability of a COVID-19 J o u r n a l P r e -p r o o f related death being reported as such.", [["deaths", "DISEASE", 49, 55], ["death", "DISEASE", 207, 212], ["a COVID", "TEST", 157, 164], ["death", "PROBLEM", 207, 212], ["size", "OBSERVATION_MODIFIER", 92, 96]]], ["Therefore, taking the reported number of COVID-19 related deaths on a synchronized reference date as a standard will correct results for all these factors simultaneously.J o u r n a l P r e -p r o o fIn conclusion, although the future development of the epidemic remains difficult to predict accurately, due to changing containment policies, changing seasonal influences, [8] and the possibility of a depletion of susceptibles, or the development of herd immunity, [9, 10] current data suggest the USA should expect an explosive increase in cumulative mortality due to COVID-19, with containment policies still lagging behind, while most European countries seem well on the way to containing the epidemic.Author contributions:RAM conceptualised, designed, and executed the research, wrote the manuscript, and affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as originally planned have been explained.Author contributions:FRR conceptualised the research and revised the manuscript.Declaration of interests\u2612 The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.Competing interests:None of the authors report any competing interest relevant to this paper.Role of funding source:There was no funding for this research.", [["deaths", "DISEASE", 58, 64], ["a l P r e -p r o o fIn conclusion", "TREATMENT", 180, 213], ["the epidemic", "PROBLEM", 250, 262], ["a depletion of susceptibles", "PROBLEM", 399, 426], ["COVID", "TEST", 569, 574], ["containment policies", "TREATMENT", 584, 604], ["the study", "TEST", 888, 897], ["the study", "TEST", 943, 952], ["the study", "TEST", 1004, 1013], ["depletion", "OBSERVATION", 401, 410], ["explosive", "OBSERVATION_MODIFIER", 519, 528], ["increase", "OBSERVATION_MODIFIER", 529, 537]]], ["Since only publicly available data was used, no ethical approval was required.", [["ethical approval", "TREATMENT", 48, 64]]]], "PMC7415411": [], "894676819b105b56f30438858631fce2958592e0": [["BackgroundHuman adenovirus (HAdV) type 55 (HAdV-55)is an intertypic recombinant virus described originally as genome type 11a and identified from an outbreak of acute respiratory tract infection (ALRTI) in Shanxi Province, China, in 2006 [1] .", [["respiratory", "ANATOMY", 167, 178], ["acute respiratory tract infection", "DISEASE", 161, 194], ["ALRTI", "DISEASE", 196, 201], ["BackgroundHuman adenovirus (HAdV) type 55", "ORGANISM", 0, 41], ["HAdV-55", "ORGANISM", 43, 50], ["BackgroundHuman adenovirus (HAdV) type 55 (HAdV-55", "SPECIES", 0, 50], ["BackgroundHuman adenovirus (HAdV) type 55 (HAdV", "PROBLEM", 0, 47], ["an intertypic recombinant virus", "PROBLEM", 54, 85], ["acute respiratory tract infection", "PROBLEM", 161, 194], ["virus", "OBSERVATION", 80, 85], ["outbreak", "OBSERVATION_MODIFIER", 149, 157], ["acute", "OBSERVATION_MODIFIER", 161, 166], ["respiratory tract", "ANATOMY", 167, 184], ["infection", "OBSERVATION", 185, 194]]], ["In 2011, this pathogen apparently re-emerged and caused several cases of severe community-acquired pneumonia in adults in Beijing, China [2] .", [["pneumonia", "DISEASE", 99, 108], ["severe community-acquired pneumonia", "PROBLEM", 73, 108], ["severe", "OBSERVATION_MODIFIER", 73, 79], ["pneumonia", "OBSERVATION", 99, 108]]], ["Research demonstrated that HAdV-55 showed the pathogenic properties of HAdV-14 but exhibited a neutralizing antigen epitope of HAdV-11 [3] .", [["HAdV-55", "CHEMICAL", 27, 34], ["HAdV-55", "ORGANISM", 27, 34], ["HAdV-14", "ORGANISM", 71, 78], ["HAdV-55", "SPECIES", 27, 34], ["HAdV-14", "SPECIES", 71, 78], ["HAdV-11", "SPECIES", 127, 134], ["HAdV", "TEST", 27, 31], ["HAdV", "TEST", 71, 75], ["a neutralizing antigen epitope of HAdV", "PROBLEM", 93, 131]]], ["Further whole-genome sequencing verified that HAdV-55 had a HAdV-14 backbone and partial HAdV-11 hexon gene [4] ; therefore, this pathogen was renamed HAdV-55 [5] .", [["HAdV-55", "ORGANISM", 46, 53], ["HAdV-14", "ORGANISM", 60, 67], ["HAdV-55", "ORGANISM", 151, 158], ["HAdV-14 backbone", "DNA", 60, 76], ["HAdV-11 hexon gene", "DNA", 89, 107], ["HAdV-55", "SPECIES", 46, 53], ["HAdV-55", "SPECIES", 151, 158], ["HAdV", "TEST", 46, 50], ["a HAdV", "TEST", 58, 64], ["partial HAdV", "PROBLEM", 81, 93]]], ["Comparative studies have shown that the ability of HAdV to cause severe disease may relate to HAdV serotypes.", [["HAdV", "ORGANISM", 51, 55], ["HAdV", "ORGANISM", 94, 98], ["Comparative studies", "TEST", 0, 19], ["HAdV", "PROBLEM", 51, 55], ["severe disease", "PROBLEM", 65, 79], ["HAdV serotypes", "PROBLEM", 94, 108], ["severe", "OBSERVATION_MODIFIER", 65, 71], ["disease", "OBSERVATION", 72, 79], ["may relate to", "UNCERTAINTY", 80, 93], ["HAdV serotypes", "OBSERVATION", 94, 108]]], ["In adults, the emerging HAdV-55 has been reported to cause more severe cases of adenoviral pneumonia compared to other HAdV serotypes (HAdV-3, HAdV-7, HAdV-14) [6, 7] .", [["HAdV-55", "CHEMICAL", 24, 31], ["adenoviral pneumonia", "DISEASE", 80, 100], ["HAdV-55", "ORGANISM", 24, 31], ["adenoviral", "ORGANISM", 80, 90], ["HAdV", "ORGANISM", 119, 123], ["HAdV-3", "ORGANISM", 135, 141], ["HAdV-7", "ORGANISM", 143, 149], ["HAdV-14", "ORGANISM", 151, 158], ["HAdV-55", "SPECIES", 24, 31], ["adenoviral", "SPECIES", 80, 90], ["adenoviral pneumonia", "PROBLEM", 80, 100], ["other HAdV serotypes", "PROBLEM", 113, 133], ["HAdV", "TEST", 135, 139], ["HAdV", "TEST", 143, 147], ["HAdV", "TEST", 151, 155], ["adenoviral", "ANATOMY", 80, 90], ["pneumonia", "OBSERVATION", 91, 100]]], ["However, there is a dearth of comparative studies, particularly in children, that address differences in clinical epidemiological features between HAdV-55 and other HAdV serotypes that can also induce severe infection (such as HAdV-7).", [["HAdV-55", "CHEMICAL", 147, 154], ["infection", "DISEASE", 208, 217], ["children", "ORGANISM", 67, 75], ["HAdV-55", "ORGANISM", 147, 154], ["HAdV", "ORGANISM", 165, 169], ["HAdV-7", "ORGANISM", 227, 233], ["children", "SPECIES", 67, 75], ["HAdV-55", "SPECIES", 147, 154], ["comparative studies", "TEST", 30, 49], ["HAdV", "PROBLEM", 147, 151], ["other HAdV serotypes", "PROBLEM", 159, 179], ["severe infection", "PROBLEM", 201, 217], ["severe", "OBSERVATION_MODIFIER", 201, 207], ["infection", "OBSERVATION", 208, 217]]], ["In this study, we investigated whether HAdV-55 and HAdV-7(the most common adenovirus circulating in China that can cause severe or acute infection) have different epidemiological and clinical profiles in children, to assess if HAdV-55 virus can cause more severe infection than HAdV-7 as observed in adults.Patient enrollmentWe retrospectively enrolled pediatric patients with ALR-TIs who were admitted to Beijing Children's Hospital from April 2008 to December 2013.", [["infection", "DISEASE", 137, 146], ["HAdV-55 virus", "CHEMICAL", 227, 240], ["infection", "DISEASE", 263, 272], ["ALR-TIs", "DISEASE", 377, 384], ["HAdV-55", "ORGANISM", 39, 46], ["HAdV-7", "ORGANISM", 51, 57], ["adenovirus", "ORGANISM", 74, 84], ["children", "ORGANISM", 204, 212], ["HAdV-55 virus", "ORGANISM", 227, 240], ["HAdV-7", "ORGANISM", 278, 284], ["patients", "ORGANISM", 363, 371], ["children", "SPECIES", 204, 212], ["Patient", "SPECIES", 307, 314], ["patients", "SPECIES", 363, 371], ["HAdV-55", "SPECIES", 39, 46], ["HAdV-7", "SPECIES", 51, 57], ["HAdV-55 virus", "SPECIES", 227, 240], ["HAdV-7", "SPECIES", 278, 284], ["this study", "TEST", 3, 13], ["HAdV", "TEST", 39, 43], ["HAdV", "PROBLEM", 51, 55], ["acute infection", "PROBLEM", 131, 146], ["HAdV", "PROBLEM", 227, 231], ["severe infection", "PROBLEM", 256, 272], ["severe", "OBSERVATION_MODIFIER", 121, 127], ["acute", "OBSERVATION_MODIFIER", 131, 136], ["infection", "OBSERVATION", 137, 146], ["severe", "OBSERVATION_MODIFIER", 256, 262], ["infection", "OBSERVATION", 263, 272]]], ["Patients with signs and symptoms of respiratory tract infection (such as fever, coughing, expectoration), and lower respiratory signs (tachypnea, dyspnea, retractions, or wheezing/rales upon auscultation etc.) were defined as ALRTIs.", [["respiratory tract", "ANATOMY", 36, 53], ["respiratory", "ANATOMY", 116, 127], ["respiratory tract infection", "DISEASE", 36, 63], ["fever", "DISEASE", 73, 78], ["coughing", "DISEASE", 80, 88], ["expectoration", "DISEASE", 90, 103], ["respiratory signs", "DISEASE", 116, 133], ["tachypnea", "DISEASE", 135, 144], ["dyspnea", "DISEASE", 146, 153], ["retractions", "DISEASE", 155, 166], ["wheezing", "DISEASE", 171, 179], ["ALRTIs", "DISEASE", 226, 232], ["Patients", "ORGANISM", 0, 8], ["respiratory tract", "ORGANISM_SUBDIVISION", 36, 53], ["Patients", "SPECIES", 0, 8], ["signs and symptoms", "PROBLEM", 14, 32], ["respiratory tract infection", "PROBLEM", 36, 63], ["fever", "PROBLEM", 73, 78], ["coughing", "PROBLEM", 80, 88], ["expectoration", "PROBLEM", 90, 103], ["lower respiratory signs", "PROBLEM", 110, 133], ["tachypnea", "PROBLEM", 135, 144], ["dyspnea", "PROBLEM", 146, 153], ["retractions", "PROBLEM", 155, 166], ["wheezing", "PROBLEM", 171, 179], ["rales", "PROBLEM", 180, 185], ["auscultation", "TEST", 191, 203], ["respiratory tract", "ANATOMY", 36, 53], ["infection", "OBSERVATION", 54, 63], ["lower", "ANATOMY_MODIFIER", 110, 115], ["respiratory", "ANATOMY", 116, 127]]], ["Chest X-rays were taken for all patients.", [["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["Chest X-rays", "TEST", 0, 12]]], ["Nasopharyngeal aspirate or throat swab specimens were collected from each patient in virus transport media and stored at \u2212 80\u00b0C prior to use.", [["Nasopharyngeal aspirate", "ANATOMY", 0, 23], ["throat swab specimens", "ANATOMY", 27, 48], ["Nasopharyngeal aspirate", "ORGANISM_SUBSTANCE", 0, 23], ["throat swab specimens", "ORGANISM_SUBSTANCE", 27, 48], ["patient", "ORGANISM", 74, 81], ["patient", "SPECIES", 74, 81], ["Nasopharyngeal aspirate", "TEST", 0, 23], ["throat swab specimens", "TEST", 27, 48], ["virus transport media", "TREATMENT", 85, 106], ["aspirate", "OBSERVATION", 15, 23], ["throat", "ANATOMY", 27, 33]]], ["No repeated samples were collected from any patient.Patient enrollmentFor each patient with HAdV-55 infection, we matched four neighbours with HAdV-7 infection as controls.", [["samples", "ANATOMY", 12, 19], ["HAdV-55 infection", "DISEASE", 92, 109], ["HAdV-7 infection", "DISEASE", 143, 159], ["patient", "ORGANISM", 44, 51], ["patient", "ORGANISM", 79, 86], ["HAdV-55", "ORGANISM", 92, 99], ["HAdV-7", "ORGANISM", 143, 149], ["patient", "SPECIES", 44, 51], ["Patient", "SPECIES", 52, 59], ["patient", "SPECIES", 79, 86], ["HAdV-55", "SPECIES", 92, 99], ["HAdV-7", "SPECIES", 143, 149], ["repeated samples", "TEST", 3, 19], ["HAdV", "PROBLEM", 92, 96], ["55 infection", "PROBLEM", 97, 109], ["HAdV", "PROBLEM", 143, 147], ["infection", "OBSERVATION", 100, 109], ["infection", "OBSERVATION", 150, 159]]], ["Control subjects were collected within two months before and two months after the HAdV-55 cases.", [["subjects", "ORGANISM", 8, 16], ["the HAdV", "TEST", 78, 86]]], ["A clinical scoring system for ALRTIs, which related with hospitalization time, pediatric intensive care unit (PICU) admitted time, oxygen supplemented time, maximal FIO 2 , was used to assess severity of illness [8] .Clinical information collectionThe score values ranged from 0 to 14.", [["ALRTIs", "DISEASE", 30, 36], ["oxygen", "CHEMICAL", 131, 137], ["illness", "DISEASE", 204, 211], ["oxygen", "CHEMICAL", 131, 137], ["oxygen", "SIMPLE_CHEMICAL", 131, 137], ["illness", "PROBLEM", 204, 211], ["The score values", "TEST", 248, 264]]], ["The median score value of 7 or greater was used to define severe ALRTIs infection and scores less than 7 were considered as mild or moderate disease.Preparation of nucleic acids and detection of pathogensNucliSens easyMAG system (bioM\u00e9rieux, Marcy-l'Etoile, France) was used to extract viral nucleic acids in accordance with the manufacturer's instructions. cDNA was reverse transcribed from RNA using random primers and a SuperScript II reverse transcriptase (Invitrogen).", [["ALRTIs infection", "DISEASE", 65, 81], ["nucleic acids", "CHEMICAL", 164, 177], ["nucleic acids", "CHEMICAL", 292, 305], ["nucleic acids", "SIMPLE_CHEMICAL", 164, 177], ["SuperScript II reverse transcriptase", "GENE_OR_GENE_PRODUCT", 423, 459], ["cDNA", "DNA", 358, 362], ["SuperScript II reverse transcriptase", "PROTEIN", 423, 459], ["The median score value", "TEST", 0, 22], ["severe ALRTIs infection", "PROBLEM", 58, 81], ["mild or moderate disease", "PROBLEM", 124, 148], ["nucleic acids", "TREATMENT", 164, 177], ["pathogens", "PROBLEM", 195, 204], ["viral nucleic acids", "TREATMENT", 286, 305], ["random primers", "TREATMENT", 402, 416], ["a SuperScript II reverse transcriptase (Invitrogen)", "TREATMENT", 421, 472], ["severe", "OBSERVATION_MODIFIER", 58, 64], ["ALRTIs", "OBSERVATION_MODIFIER", 65, 71], ["infection", "OBSERVATION", 72, 81], ["mild", "OBSERVATION_MODIFIER", 124, 128], ["moderate", "OBSERVATION_MODIFIER", 132, 140], ["disease", "OBSERVATION", 141, 148], ["nucleic acids", "OBSERVATION", 164, 177]]], ["Nineteen common respiratory viral pathogens and subtypes (influenza A (IFA); IFA subtype H1; IFA subtype H3; 2009 H1N1; influenza B (IFB); HAdV; human parainfluenza virus (HPIV) 1-4; respiratory syncytial virus (RSV) A and B; human metapneumovirus (HMPV); enteroviruses and rhinoviruses (EV/RhV); human coronavirus (HCoV) HKU1, 229E, NL63 and OC43; and human bocavirus (HBoV)) were detected by using the Luminex xTAG respiratory viral panel assay and a Luminex 200 instrument (Luminex, Austin, TX).", [["respiratory viral pathogens", "DISEASE", 16, 43], ["influenza A", "DISEASE", 58, 69], ["influenza B", "DISEASE", 120, 131], ["human parainfluenza virus", "DISEASE", 145, 170], ["respiratory syncytial virus (RSV) A and B", "DISEASE", 183, 224], ["human metapneumovirus (HMPV); enteroviruses and rhinoviruses (EV/RhV)", "DISEASE", 226, 295], ["influenza A", "ORGANISM", 58, 69], ["IFA", "GENE_OR_GENE_PRODUCT", 71, 74], ["IFA subtype H1", "ORGANISM", 77, 91], ["IFA subtype H3", "GENE_OR_GENE_PRODUCT", 93, 107], ["2009 H1N1; influenza B (IFB); HAdV", "ORGANISM", 109, 143], ["human parainfluenza virus (HPIV) 1-4; respiratory syncytial virus", "ORGANISM", 145, 210], ["RSV", "ORGANISM", 212, 215], ["human metapneumovirus", "ORGANISM", 226, 247], ["HMPV", "ORGANISM", 249, 253], ["enteroviruses", "ORGANISM", 256, 269], ["rhinoviruses", "ORGANISM", 274, 286], ["EV/RhV", "ORGANISM", 288, 294], ["human coronavirus", "ORGANISM", 297, 314], ["HCoV", "GENE_OR_GENE_PRODUCT", 316, 320], ["HKU1", "GENE_OR_GENE_PRODUCT", 322, 326], ["229E", "GENE_OR_GENE_PRODUCT", 328, 332], ["NL63", "GENE_OR_GENE_PRODUCT", 334, 338], ["OC43", "GENE_OR_GENE_PRODUCT", 343, 347], ["human", "ORGANISM", 353, 358], ["bocavirus", "GENE_OR_GENE_PRODUCT", 359, 368], ["HBoV", "ORGANISM", 370, 374], ["OC43", "PROTEIN", 343, 347], ["influenza B", "SPECIES", 120, 131], ["human", "SPECIES", 145, 150], ["parainfluenza virus", "SPECIES", 151, 170], ["respiratory syncytial virus", "SPECIES", 183, 210], ["human", "SPECIES", 226, 231], ["metapneumovirus", "SPECIES", 232, 247], ["human", "SPECIES", 297, 302], ["coronavirus", "SPECIES", 303, 314], ["human", "SPECIES", 353, 358], ["human parainfluenza virus", "SPECIES", 145, 170], ["HPIV", "SPECIES", 172, 176], ["respiratory syncytial virus", "SPECIES", 183, 210], ["RSV", "SPECIES", 212, 215], ["human metapneumovirus", "SPECIES", 226, 247], ["HMPV", "SPECIES", 249, 253], ["RhV", "SPECIES", 291, 294], ["human coronavirus", "SPECIES", 297, 314], ["HCoV", "SPECIES", 316, 320], ["human", "SPECIES", 353, 358], ["HBoV", "SPECIES", 370, 374], ["Nineteen common respiratory viral pathogens", "PROBLEM", 0, 43], ["influenza", "TEST", 58, 67], ["IFA", "TEST", 71, 74], ["IFA", "TEST", 77, 80], ["subtype H1", "PROBLEM", 81, 91], ["IFA", "TEST", 93, 96], ["subtype H3", "PROBLEM", 97, 107], ["H1N1", "PROBLEM", 114, 118], ["influenza B", "TEST", 120, 131], ["IFB", "TEST", 133, 136], ["HAdV", "PROBLEM", 139, 143], ["human parainfluenza virus (HPIV)", "TEST", 145, 177], ["respiratory syncytial virus", "PROBLEM", 183, 210], ["human metapneumovirus (HMPV", "PROBLEM", 226, 253], ["enteroviruses", "PROBLEM", 256, 269], ["rhinoviruses", "PROBLEM", 274, 286], ["EV/RhV", "TEST", 288, 294], ["human coronavirus", "TEST", 297, 314], ["HKU1", "TEST", 322, 326], ["NL63", "TEST", 334, 338], ["OC43", "TEST", 343, 347], ["human bocavirus (HBoV)", "PROBLEM", 353, 375], ["the Luminex xTAG respiratory viral panel", "TEST", 400, 440], ["a Luminex", "TREATMENT", 451, 460], ["respiratory", "ANATOMY", 16, 27], ["viral pathogens", "OBSERVATION", 28, 43], ["respiratory syncytial", "ANATOMY", 183, 204]]], ["HAdV-positive samples were further amplified using a nested PCR procedure that targeted hypervariable regions 1-6 of the hexon gene, as described previously [9] .", [["samples", "ANATOMY", 14, 21], ["HAdV", "ORGANISM", 0, 4], ["hexon", "GENE_OR_GENE_PRODUCT", 121, 126], ["hypervariable regions 1-6", "DNA", 88, 113], ["hexon gene", "DNA", 121, 131], ["HAdV", "PROBLEM", 0, 4], ["positive samples", "PROBLEM", 5, 21], ["a nested PCR procedure", "TREATMENT", 51, 73], ["targeted hypervariable regions", "PROBLEM", 79, 109]]], ["PCR products were purified and sequenced for further confirmation.", [["PCR products", "DNA", 0, 12], ["PCR products", "TREATMENT", 0, 12], ["further confirmation", "TEST", 45, 65]]], ["Meanwhile, bronchial alveolar lavage fluids (if available), blood, and cerebrospinal fluid (if available) from HAdV-55 and HAdV-7 infected patients during the entire hospital admission were plated onto selective agar plates to identify any bacteria or fungi.Statistical analysisData analyses were performed using SPSS 19.0.", [["bronchial alveolar lavage fluids", "ANATOMY", 11, 43], ["blood", "ANATOMY", 60, 65], ["cerebrospinal fluid", "ANATOMY", 71, 90], ["bronchial alveolar lavage fluids", "ORGANISM_SUBSTANCE", 11, 43], ["blood", "ORGANISM_SUBSTANCE", 60, 65], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 71, 90], ["HAdV-55", "ORGANISM", 111, 118], ["HAdV-7", "ORGANISM", 123, 129], ["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 139, 147], ["HAdV-55", "SPECIES", 111, 118], ["HAdV-7", "SPECIES", 123, 129], ["bronchial alveolar lavage fluids", "TEST", 11, 43], ["blood", "TEST", 60, 65], ["cerebrospinal fluid", "TEST", 71, 90], ["HAdV", "TEST", 111, 115], ["HAdV", "PROBLEM", 123, 127], ["selective agar plates", "TEST", 202, 223], ["any bacteria", "PROBLEM", 236, 248], ["fungi", "PROBLEM", 252, 257], ["Statistical analysisData analyses", "TEST", 258, 291], ["SPSS", "TEST", 313, 317], ["bronchial", "ANATOMY", 11, 20], ["alveolar", "ANATOMY_MODIFIER", 21, 29], ["cerebrospinal", "ANATOMY", 71, 84], ["fluid", "OBSERVATION", 85, 90], ["bacteria", "OBSERVATION", 240, 248], ["fungi", "OBSERVATION", 252, 257]]], ["A two-tailed independent-samples t-test method was used to compare continuous variables between two groups.", [["samples t-test method", "TEST", 25, 46]]], ["Univariate analysis was conducted using \u03c7 2 tests or Fisher's exact test for categorical data.", [["Univariate analysis", "TEST", 0, 19], ["Fisher's exact test", "TEST", 53, 72], ["categorical data", "TEST", 77, 93]]], ["Probability < 0.05 was considered to be statistically significant.ResultsFrom April 2008 to December 2013, 3428 pediatric patients with ALRTIs were identified.", [["ALRTIs", "DISEASE", 136, 142], ["patients", "ORGANISM", 122, 130], ["ALRTIs", "CANCER", 136, 142], ["patients", "SPECIES", 122, 130], ["ALRTIs", "TEST", 136, 142]]], ["A total of 194 HAdV-positive cases were detected using the Luminex xTAG respiratory viral panel assay; the most prevalent HAdV serotype was HAdV-7 (102/194, 53%), followed by HAdV-3 (51/194, 26%).", [["HAdV", "ORGANISM", 15, 19], ["HAdV", "ORGANISM", 122, 126], ["HAdV-7", "ORGANISM", 140, 146], ["HAdV-3", "ORGANISM", 175, 181], ["HAdV-7", "SPECIES", 140, 146], ["HAdV-3", "SPECIES", 175, 181], ["the Luminex xTAG respiratory viral panel assay", "TEST", 55, 101], ["HAdV", "TEST", 140, 144], ["HAdV", "TEST", 175, 179]]], ["Eight cases (8/194 , 4%) of HAdV-55 infection were detected.", [["HAdV-55 infection", "DISEASE", 28, 45], ["HAdV-55", "ORGANISM", 28, 35], ["HAdV-55", "SPECIES", 28, 35], ["Eight cases", "TEST", 0, 11], ["HAdV", "PROBLEM", 28, 32], ["infection", "PROBLEM", 36, 45], ["infection", "OBSERVATION", 36, 45]]], ["Other newly emerging and re-emergent serotypes or variants, such as HAdV-57 (3/194, 2%) and HAdV-14 (3/194, 2%), were also identified (Fig. 1) .ResultsAmong the 8 HAdV-55 positive cases, 5 (63%) cases were detected in April, 2 (25%) cases were detected in March, and 1 (13%) case was detected in October.", [["HAdV-57", "ORGANISM", 68, 75], ["HAdV-14", "ORGANISM", 92, 99], ["HAdV-55", "ORGANISM", 163, 170], ["HAdV-57", "SPECIES", 68, 75], ["HAdV-14", "SPECIES", 92, 99], ["HAdV", "TEST", 68, 72], ["HAdV", "TEST", 92, 96], ["HAdV", "TEST", 163, 167], ["cases", "TEST", 195, 200]]], ["In contrast, HAdV-7 infections occurred throughout the year, although such infections were also most frequent in April (19%) (Fig. 2) .ResultsAmong the 8 HAdV-55 infected patients, one child was an outpatient, and we only knew her age and sex.", [["infections", "DISEASE", 20, 30], ["infections", "DISEASE", 75, 85], ["HAdV-55 infected", "DISEASE", 154, 170], ["HAdV-7", "ORGANISM", 13, 19], ["HAdV-55", "ORGANISM", 154, 161], ["patients", "ORGANISM", 171, 179], ["child", "ORGANISM", 185, 190], ["patients", "SPECIES", 171, 179], ["child", "SPECIES", 185, 190], ["HAdV-7", "SPECIES", 13, 19], ["HAdV-55", "SPECIES", 154, 161], ["HAdV", "PROBLEM", 13, 17], ["7 infections", "PROBLEM", 18, 30], ["such infections", "PROBLEM", 70, 85], ["infections", "OBSERVATION", 20, 30], ["infections", "OBSERVATION", 75, 85]]], ["Another patient left hospital in advance and without recovery, and her clinical features (except for the first blood test after admission to hospital) could not be documented.", [["blood", "ANATOMY", 111, 116], ["patient", "ORGANISM", 8, 15], ["blood", "ORGANISM_SUBSTANCE", 111, 116], ["patient", "SPECIES", 8, 15], ["the first blood test", "TEST", 101, 121], ["left", "ANATOMY_MODIFIER", 16, 20]]], ["All 32 matched control subjects were inpatients.", [["subjects", "ORGANISM", 23, 31]]], ["Table 1 shows clinical characteristics of the patients with HAdV-55 infection and the control subjects with HAdV-7 infection.", [["HAdV-55 infection", "DISEASE", 60, 77], ["HAdV-7 infection", "DISEASE", 108, 124], ["patients", "ORGANISM", 46, 54], ["HAdV-55", "ORGANISM", 60, 67], ["HAdV-7", "ORGANISM", 108, 114], ["patients", "SPECIES", 46, 54], ["HAdV-55", "SPECIES", 60, 67], ["HAdV-7", "SPECIES", 108, 114], ["HAdV", "PROBLEM", 60, 64], ["55 infection", "PROBLEM", 65, 77], ["HAdV", "PROBLEM", 108, 112], ["7 infection", "PROBLEM", 113, 124], ["infection", "OBSERVATION", 68, 77], ["infection", "OBSERVATION", 115, 124]]], ["There were no cases of mortality in either group.", [["no", "UNCERTAINTY", 11, 13]]], ["Most clinical symptoms and signs, and blood parameters did not significantly differ between the two groups, with the exception of wheezing, which was observed in 17% of HAdV-55-infected patients and 63% of HAdV-7-infected patients (P = 0.038).ResultsFurthermore, no patient infected with HAdV-55 exhibited vomiting or had any underlying disease; however, 3 (9%) patients vomited during the course of HAdV-7 infection, and 2 HAdV-7-infected patients had underlying disease (congenital heart disease and wheezing).", [["blood", "ANATOMY", 38, 43], ["heart", "ANATOMY", 484, 489], ["wheezing", "DISEASE", 130, 138], ["HAdV-55-infected", "DISEASE", 169, 185], ["HAdV-7-infected", "DISEASE", 206, 221], ["vomiting", "DISEASE", 306, 314], ["HAdV-7 infection", "DISEASE", 400, 416], ["HAdV-7-infected", "DISEASE", 424, 439], ["congenital heart disease", "DISEASE", 473, 497], ["wheezing", "DISEASE", 502, 510], ["blood", "ORGANISM_SUBSTANCE", 38, 43], ["HAdV-55", "ORGANISM", 169, 176], ["patients", "ORGANISM", 186, 194], ["HAdV-7", "ORGANISM", 206, 212], ["patients", "ORGANISM", 222, 230], ["patient", "ORGANISM", 266, 273], ["HAdV-55", "ORGANISM", 288, 295], ["patients", "ORGANISM", 362, 370], ["HAdV-7", "ORGANISM", 400, 406], ["HAdV-7", "ORGANISM", 424, 430], ["patients", "ORGANISM", 440, 448], ["heart", "ORGAN", 484, 489], ["patients", "SPECIES", 186, 194], ["patients", "SPECIES", 222, 230], ["patient", "SPECIES", 266, 273], ["patients", "SPECIES", 362, 370], ["patients", "SPECIES", 440, 448], ["HAdV-55", "SPECIES", 169, 176], ["HAdV-7", "SPECIES", 206, 212], ["HAdV-55", "SPECIES", 288, 295], ["HAdV-7", "SPECIES", 400, 406], ["Most clinical symptoms", "PROBLEM", 0, 22], ["blood parameters", "TEST", 38, 54], ["wheezing", "PROBLEM", 130, 138], ["HAdV", "TEST", 169, 173], ["HAdV", "TEST", 206, 210], ["HAdV", "PROBLEM", 288, 292], ["vomiting", "PROBLEM", 306, 314], ["any underlying disease", "PROBLEM", 322, 344], ["HAdV", "PROBLEM", 400, 404], ["7 infection", "PROBLEM", 405, 416], ["underlying disease", "PROBLEM", 453, 471], ["congenital heart disease", "PROBLEM", 473, 497], ["wheezing", "PROBLEM", 502, 510], ["wheezing", "OBSERVATION", 130, 138], ["no", "UNCERTAINTY", 263, 265], ["infected", "OBSERVATION", 274, 282], ["disease", "OBSERVATION", 337, 344], ["infection", "OBSERVATION", 407, 416], ["disease", "OBSERVATION", 464, 471], ["congenital", "OBSERVATION_MODIFIER", 473, 483], ["heart", "ANATOMY", 484, 489], ["disease", "OBSERVATION", 490, 497]]], ["Meanwhile, only 29% (2/7) of HAdV-55 infected patients developed respiratory failure, cardiac damage, or liver function damage, whereas in HAdV-7 infected group, the above mentioned complications arosed in more than half of the patients (56%, 18/32); however, this was not statistically significant (P = 0.184).", [["respiratory", "ANATOMY", 65, 76], ["cardiac", "ANATOMY", 86, 93], ["liver", "ANATOMY", 105, 110], ["HAdV-55 infected", "DISEASE", 29, 45], ["respiratory failure", "DISEASE", 65, 84], ["cardiac damage", "DISEASE", 86, 100], ["liver function damage", "DISEASE", 105, 126], ["HAdV-55", "ORGANISM", 29, 36], ["patients", "ORGANISM", 46, 54], ["cardiac", "ORGAN", 86, 93], ["liver", "ORGAN", 105, 110], ["HAdV-7", "ORGANISM", 139, 145], ["patients", "ORGANISM", 228, 236], ["patients", "SPECIES", 46, 54], ["patients", "SPECIES", 228, 236], ["HAdV-55", "SPECIES", 29, 36], ["HAdV-7", "SPECIES", 139, 145], ["HAdV", "PROBLEM", 29, 33], ["respiratory failure", "PROBLEM", 65, 84], ["cardiac damage", "PROBLEM", 86, 100], ["liver function damage", "PROBLEM", 105, 126], ["HAdV", "PROBLEM", 139, 143], ["the above mentioned complications", "PROBLEM", 162, 195], ["P", "TEST", 300, 301], ["respiratory failure", "OBSERVATION", 65, 84], ["cardiac", "ANATOMY", 86, 93], ["damage", "OBSERVATION", 94, 100], ["liver", "ANATOMY", 105, 110], ["function damage", "OBSERVATION", 111, 126], ["complications", "OBSERVATION", 182, 195]]], ["Co-infections were observed in 75 and 94% of cases of HAdV-55 and HAdV-7 infections, respectively.", [["infections", "DISEASE", 73, 83], ["HAdV-55", "ORGANISM", 54, 61], ["HAdV-7", "ORGANISM", 66, 72], ["HAdV-55", "SPECIES", 54, 61], ["HAdV-7", "SPECIES", 66, 72], ["Co-infections", "PROBLEM", 0, 13], ["HAdV", "TEST", 54, 58], ["HAdV", "PROBLEM", 66, 70], ["infections", "PROBLEM", 73, 83]]], ["HAdV-55 patients were most frequently coinfected with HPIV (25%); Streptococcus pneumoniae (17%), RhV (8%), IFA (8%), HCoV (8%), HBoV (8%), HMPV (8%), Escherichia coli (8%), and Haemophilus influenzae (8%) were also detected in cases involving multiple infection in the HAdV-55 group, in which the percentages of double, triple, and quadruple infection were each 33%.", [["HPIV", "DISEASE", 54, 58], ["Streptococcus pneumoniae", "DISEASE", 66, 90], ["HBoV", "DISEASE", 129, 133], ["HMPV", "DISEASE", 140, 144], ["Escherichia coli", "DISEASE", 151, 167], ["Haemophilus influenzae", "DISEASE", 178, 200], ["infection", "DISEASE", 253, 262], ["infection", "DISEASE", 343, 352], ["HAdV-55", "ORGANISM", 0, 7], ["patients", "ORGANISM", 8, 16], ["Streptococcus pneumoniae", "ORGANISM", 66, 90], ["RhV", "GENE_OR_GENE_PRODUCT", 98, 101], ["HBoV", "ORGANISM", 129, 133], ["Escherichia coli", "ORGANISM", 151, 167], ["Haemophilus influenzae", "ORGANISM", 178, 200], ["HAdV-55", "ORGANISM", 270, 277], ["patients", "SPECIES", 8, 16], ["Streptococcus pneumoniae", "SPECIES", 66, 90], ["Escherichia coli", "SPECIES", 151, 167], ["Haemophilus influenzae", "SPECIES", 178, 200], ["HAdV-55", "SPECIES", 0, 7], ["HPIV", "SPECIES", 54, 58], ["Streptococcus pneumoniae", "SPECIES", 66, 90], ["RhV", "SPECIES", 98, 101], ["HCoV", "SPECIES", 118, 122], ["HBoV", "SPECIES", 129, 133], ["HMPV", "SPECIES", 140, 144], ["Escherichia coli", "SPECIES", 151, 167], ["Haemophilus influenzae", "SPECIES", 178, 200], ["HAdV-55", "SPECIES", 270, 277], ["HAdV", "TEST", 0, 4], ["HPIV", "TEST", 54, 58], ["Streptococcus pneumoniae", "PROBLEM", 66, 90], ["RhV", "TEST", 98, 101], ["IFA", "TEST", 108, 111], ["HCoV", "TEST", 118, 122], ["HBoV", "TEST", 129, 133], ["HMPV", "TEST", 140, 144], ["Escherichia coli", "TEST", 151, 167], ["Haemophilus influenzae", "PROBLEM", 178, 200], ["multiple infection", "PROBLEM", 244, 262], ["the HAdV", "TEST", 266, 274], ["double, triple", "TREATMENT", 313, 327], ["quadruple infection", "PROBLEM", 333, 352], ["Escherichia coli", "OBSERVATION", 151, 167], ["Haemophilus influenzae", "OBSERVATION", 178, 200], ["multiple", "OBSERVATION_MODIFIER", 244, 252], ["infection", "OBSERVATION", 253, 262], ["infection", "OBSERVATION", 343, 352]]], ["HAdV-7-infected patients were also most commonly coinfected with HPIV (40%); in the HAdV-7 group, multiple infections involving Mycoplasma pneumoniae (27%), RhV (23%), RSV (20%), viridans group Streptococci (17%), HBoV (10%), Streptococcus pneumoniae (10%), Klebsiella pneumoniae (10%), HCoV (7%), fungus (7%), IFA (3%), EBV (3%), Acinetobacter baumannii (3%), and Haemophilus influenzae (3%) were also detected.", [["HPIV", "DISEASE", 65, 69], ["infections", "DISEASE", 107, 117], ["Mycoplasma pneumoniae", "DISEASE", 128, 149], ["viridans group Streptococci", "DISEASE", 179, 206], ["Streptococcus pneumoniae", "DISEASE", 226, 250], ["Klebsiella pneumoniae", "DISEASE", 258, 279], ["Acinetobacter baumannii", "DISEASE", 331, 354], ["Haemophilus influenzae", "DISEASE", 365, 387], ["HAdV-7", "ORGANISM", 0, 6], ["patients", "ORGANISM", 16, 24], ["HPIV", "CANCER", 65, 69], ["HAdV-7", "ORGANISM", 84, 90], ["Mycoplasma pneumoniae", "ORGANISM", 128, 149], ["RSV", "ORGANISM", 168, 171], ["viridans group Streptococci", "ORGANISM", 179, 206], ["HBoV", "ORGANISM", 214, 218], ["Streptococcus pneumoniae", "ORGANISM", 226, 250], ["Klebsiella pneumoniae", "ORGANISM", 258, 279], ["HCoV", "GENE_OR_GENE_PRODUCT", 287, 291], ["IFA", "GENE_OR_GENE_PRODUCT", 311, 314], ["EBV", "ORGANISM", 321, 324], ["Acinetobacter baumannii", "ORGANISM", 331, 354], ["Haemophilus influenzae", "ORGANISM", 365, 387], ["patients", "SPECIES", 16, 24], ["Mycoplasma pneumoniae", "SPECIES", 128, 149], ["RSV", "SPECIES", 168, 171], ["viridans group Streptococci", "SPECIES", 179, 206], ["Streptococcus pneumoniae", "SPECIES", 226, 250], ["Klebsiella pneumoniae", "SPECIES", 258, 279], ["Acinetobacter baumannii", "SPECIES", 331, 354], ["Haemophilus influenzae", "SPECIES", 365, 387], ["HAdV-7", "SPECIES", 0, 6], ["HPIV", "SPECIES", 65, 69], ["HAdV-7", "SPECIES", 84, 90], ["Mycoplasma pneumoniae", "SPECIES", 128, 149], ["RhV", "SPECIES", 157, 160], ["RSV", "SPECIES", 168, 171], ["HBoV", "SPECIES", 214, 218], ["Streptococcus pneumoniae", "SPECIES", 226, 250], ["Klebsiella pneumoniae", "SPECIES", 258, 279], ["HCoV", "SPECIES", 287, 291], ["EBV", "SPECIES", 321, 324], ["Acinetobacter baumannii", "SPECIES", 331, 354], ["Haemophilus influenzae", "SPECIES", 365, 387], ["HAdV", "PROBLEM", 0, 4], ["HPIV", "TREATMENT", 65, 69], ["multiple infections", "PROBLEM", 98, 117], ["Mycoplasma pneumoniae", "PROBLEM", 128, 149], ["RhV", "TEST", 157, 160], ["RSV", "TEST", 168, 171], ["viridans group Streptococci", "TEST", 179, 206], ["HBoV", "TEST", 214, 218], ["Streptococcus pneumoniae", "PROBLEM", 226, 250], ["Klebsiella pneumoniae", "PROBLEM", 258, 279], ["HCoV", "TEST", 287, 291], ["fungus", "TEST", 298, 304], ["IFA", "TEST", 311, 314], ["EBV", "TEST", 321, 324], ["Acinetobacter baumannii", "PROBLEM", 331, 354], ["Haemophilus influenzae", "PROBLEM", 365, 387], ["multiple", "OBSERVATION_MODIFIER", 98, 106], ["infections", "OBSERVATION", 107, 117], ["Mycoplasma pneumoniae", "OBSERVATION", 128, 149], ["Streptococcus pneumoniae", "OBSERVATION", 226, 250], ["Klebsiella pneumoniae", "OBSERVATION", 258, 279]]], ["In that group, the percentages of double, triple, quadruple, quintuple, and sextuple infections were 56, 13, 13, 9, and 3%, respectively (Fig. 3 ).DiscussionEpidemiological results in this study showed that in children, HAdV-55 infection was observed much less frequently than HAdV-7 infection.", [["infections", "DISEASE", 85, 95], ["HAdV-55", "CHEMICAL", 220, 227], ["infection", "DISEASE", 228, 237], ["infection", "DISEASE", 284, 293], ["children", "ORGANISM", 210, 218], ["HAdV-55", "ORGANISM", 220, 227], ["HAdV-7", "ORGANISM", 277, 283], ["children", "SPECIES", 210, 218], ["HAdV-55", "SPECIES", 220, 227], ["HAdV-7", "SPECIES", 277, 283], ["double, triple, quadruple, quintuple, and sextuple infections", "PROBLEM", 34, 95], ["this study", "TEST", 184, 194], ["HAdV", "PROBLEM", 220, 224], ["55 infection", "PROBLEM", 225, 237], ["HAdV", "PROBLEM", 277, 281], ["7 infection", "PROBLEM", 282, 293], ["double", "OBSERVATION_MODIFIER", 34, 40], ["infection", "OBSERVATION", 228, 237], ["infection", "OBSERVATION", 284, 293]]], ["Most cases of HAdV-55 There was a patient (other than the aforementioned outpatient) who left hospital in advance and without recovery, and her clinical features (except for the first blood test after admission to hospital) could not be documented c Statistically significant (P < 0.05) d Complications include respiratory failure, cardiac damage, or liver function damage e A clinical scoring system for ALRTIs was used to assess severity of illness on the day of enrollment infection were identified during March and April, whereas HAdV-7 infection occurred throughout the year.", [["blood", "ANATOMY", 184, 189], ["respiratory", "ANATOMY", 311, 322], ["cardiac", "ANATOMY", 332, 339], ["liver", "ANATOMY", 351, 356], ["respiratory failure", "DISEASE", 311, 330], ["cardiac damage", "DISEASE", 332, 346], ["liver function damage", "DISEASE", 351, 372], ["illness", "DISEASE", 443, 450], ["infection", "DISEASE", 476, 485], ["infection", "DISEASE", 541, 550], ["HAdV-55", "ORGANISM", 14, 21], ["patient", "ORGANISM", 34, 41], ["blood", "ORGANISM_SUBSTANCE", 184, 189], ["cardiac", "ORGAN", 332, 339], ["liver", "ORGAN", 351, 356], ["HAdV-7", "ORGANISM", 534, 540], ["patient", "SPECIES", 34, 41], ["HAdV-7", "SPECIES", 534, 540], ["HAdV", "PROBLEM", 14, 18], ["the first blood test", "TEST", 174, 194], ["respiratory failure", "PROBLEM", 311, 330], ["cardiac damage", "PROBLEM", 332, 346], ["liver function damage", "PROBLEM", 351, 372], ["ALRTIs", "TEST", 405, 411], ["illness", "PROBLEM", 443, 450], ["enrollment infection", "PROBLEM", 465, 485], ["HAdV", "PROBLEM", 534, 538], ["7 infection", "PROBLEM", 539, 550], ["respiratory failure", "OBSERVATION", 311, 330], ["cardiac", "ANATOMY", 332, 339], ["damage", "OBSERVATION", 340, 346], ["liver", "ANATOMY", 351, 356], ["infection", "OBSERVATION", 476, 485], ["infection", "OBSERVATION", 541, 550]]], ["These results were in accordance with previous reports about the typical adenoviruses season months [6, 10, 11] .", [["adenoviruses", "ORGANISM", 73, 85]]], ["A comparative study involving adult patients was conducted by Cao et al to discern epidemiological and clinical differences between HAdV-55 and other HAdV serotypes (HAdV-7, HAdV-3, HAdV-14, HAdV-50, and HAdV-C) [6] .", [["patients", "ORGANISM", 36, 44], ["HAdV-55", "ORGANISM", 132, 139], ["HAdV", "ORGANISM", 150, 154], ["HAdV-7", "ORGANISM", 166, 172], ["HAdV-3", "ORGANISM", 174, 180], ["HAdV-14", "ORGANISM", 182, 189], ["HAdV-50", "ORGANISM", 191, 198], ["HAdV-C", "ORGANISM", 204, 210], ["patients", "SPECIES", 36, 44], ["HAdV-55", "SPECIES", 132, 139], ["A comparative study", "TEST", 0, 19], ["HAdV", "TEST", 132, 136], ["other HAdV serotypes", "PROBLEM", 144, 164], ["HAdV", "TEST", 166, 170], ["HAdV", "TEST", 174, 178], ["HAdV", "TEST", 182, 186], ["HAdV", "TEST", 191, 195]]], ["Their results showed that most HAdV-55 cases were identified during February and March.", [["HAdV-55", "ORGANISM", 31, 38], ["most HAdV", "PROBLEM", 26, 35]]], ["They also found that patients with HAdV-55 infection had higher pneumonia severity index scores (P = 0.030) than patients infected with another HAdV serotype (HAdV-7, HAdV-3, HAdV-14, HAdV-50, or HAdV-C).", [["HAdV-55 infection", "DISEASE", 35, 52], ["pneumonia", "DISEASE", 64, 73], ["patients", "ORGANISM", 21, 29], ["HAdV-55", "ORGANISM", 35, 42], ["patients", "ORGANISM", 113, 121], ["HAdV", "ORGANISM", 144, 148], ["HAdV-7", "ORGANISM", 159, 165], ["HAdV-3", "ORGANISM", 167, 173], ["HAdV-14", "ORGANISM", 175, 182], ["HAdV-50", "ORGANISM", 184, 191], ["HAdV-C", "ORGANISM", 196, 202], ["patients", "SPECIES", 21, 29], ["patients", "SPECIES", 113, 121], ["HAdV-55", "SPECIES", 35, 42], ["HAdV", "PROBLEM", 35, 39], ["55 infection", "PROBLEM", 40, 52], ["higher pneumonia severity index scores", "PROBLEM", 57, 95], ["another HAdV serotype", "PROBLEM", 136, 157], ["HAdV", "TEST", 159, 163], ["HAdV", "TEST", 167, 171], ["HAdV", "TEST", 175, 179], ["HAdV", "TEST", 184, 188], ["HAdV", "PROBLEM", 196, 200], ["infection", "OBSERVATION", 43, 52], ["higher", "OBSERVATION_MODIFIER", 57, 63], ["pneumonia", "OBSERVATION", 64, 73]]], ["Sun et al also found that HAdV-55 may cause severe acute respiratory distress syndrome (ARDS) in immunocompetent young men.", [["respiratory", "ANATOMY", 57, 68], ["HAdV-55", "CHEMICAL", 26, 33], ["acute respiratory distress syndrome", "DISEASE", 51, 86], ["ARDS", "DISEASE", 88, 92], ["HAdV-55", "ORGANISM", 26, 33], ["men", "ORGANISM", 119, 122], ["men", "SPECIES", 119, 122], ["HAdV-55", "SPECIES", 26, 33], ["HAdV", "PROBLEM", 26, 30], ["severe acute respiratory distress syndrome", "PROBLEM", 44, 86], ["ARDS", "PROBLEM", 88, 92], ["may cause", "UNCERTAINTY", 34, 43], ["severe", "OBSERVATION_MODIFIER", 44, 50], ["acute", "OBSERVATION_MODIFIER", 51, 56], ["respiratory distress", "OBSERVATION", 57, 77], ["ARDS", "OBSERVATION", 88, 92]]], ["They conducted a prospective, single-center observational study of pneumonia with ARDS with confirmed HAdV-55 infection in immunocompetent adults, and four (80%) of the five patients died despite receiving appropriate respiratory support [7] .", [["respiratory", "ANATOMY", 218, 229], ["pneumonia", "DISEASE", 67, 76], ["ARDS", "DISEASE", 82, 86], ["HAdV-55 infection", "DISEASE", 102, 119], ["HAdV-55", "ORGANISM", 102, 109], ["patients", "ORGANISM", 174, 182], ["patients", "SPECIES", 174, 182], ["HAdV-55", "SPECIES", 102, 109], ["observational study", "TEST", 44, 63], ["pneumonia", "PROBLEM", 67, 76], ["ARDS", "PROBLEM", 82, 86], ["HAdV", "PROBLEM", 102, 106], ["55 infection", "PROBLEM", 107, 119], ["appropriate respiratory support", "TREATMENT", 206, 237], ["pneumonia", "OBSERVATION", 67, 76], ["ARDS", "OBSERVATION", 82, 86], ["infection", "OBSERVATION", 110, 119]]], ["However, our data showed that the HAdV-55 group had lower ALRTI clinical scores than the HAdV-7 group, although this difference was not significant.DiscussionCao and Lu separately reported the presence of underlying diseases in 19.1 and 50% of HAdV-55 patients, respectively [6, 12] .", [["HAdV-55", "ORGANISM", 34, 41], ["HAdV-7", "ORGANISM", 89, 95], ["HAdV", "ORGANISM", 244, 248], ["patients", "ORGANISM", 252, 260], ["patients", "SPECIES", 252, 260], ["HAdV-7", "SPECIES", 89, 95], ["HAdV-55", "SPECIES", 244, 251], ["our data", "TEST", 9, 17], ["the HAdV", "TEST", 30, 38], ["lower ALRTI clinical scores", "PROBLEM", 52, 79], ["the HAdV", "TEST", 85, 93], ["underlying diseases", "PROBLEM", 205, 224], ["HAdV", "TEST", 244, 248], ["diseases", "OBSERVATION", 216, 224]]], ["We could not exclude the possibility that vomiting and underlying disease may be observed if our study is enlarged to include additional cases of HAdV-55 infection.", [["vomiting", "DISEASE", 42, 50], ["HAdV-55", "CHEMICAL", 146, 153], ["infection", "DISEASE", 154, 163], ["HAdV-55", "ORGANISM", 146, 153], ["HAdV-55", "SPECIES", 146, 153], ["vomiting", "PROBLEM", 42, 50], ["underlying disease", "PROBLEM", 55, 73], ["our study", "TEST", 93, 102], ["HAdV", "PROBLEM", 146, 150], ["infection", "PROBLEM", 154, 163], ["could not exclude the possibility", "UNCERTAINTY", 3, 36], ["disease", "OBSERVATION", 66, 73], ["infection", "OBSERVATION", 154, 163]]], ["One potential weakness of our data is that there were only 8 patients with HAdV-55 infection.", [["HAdV-55 infection", "DISEASE", 75, 92], ["patients", "ORGANISM", 61, 69], ["HAdV-55", "ORGANISM", 75, 82], ["patients", "SPECIES", 61, 69], ["HAdV-55", "SPECIES", 75, 82], ["One potential weakness", "PROBLEM", 0, 22], ["HAdV", "PROBLEM", 75, 79], ["55 infection", "PROBLEM", 80, 92], ["weakness", "OBSERVATION", 14, 22], ["infection", "OBSERVATION", 83, 92]]], ["However, these patients represented all positive cases of HAdV-55 infection in our hospital from April 2008 to December 2013.", [["HAdV-55 infection", "DISEASE", 58, 75], ["patients", "ORGANISM", 15, 23], ["HAdV-55", "ORGANISM", 58, 65], ["patients", "SPECIES", 15, 23], ["HAdV-55", "SPECIES", 58, 65], ["HAdV", "PROBLEM", 58, 62], ["infection", "OBSERVATION", 66, 75]]], ["This result also indicated that HAdV-55 infection was less common than HAdV-7 infection in children.DiscussionOur results were consistent with those reported by Lu, who found that coinfections were frequent and observed coinfection in 83.3% of hospitalized children infected with HAdV-55 [12] .", [["HAdV-55", "CHEMICAL", 32, 39], ["infection", "DISEASE", 40, 49], ["infection", "DISEASE", 78, 87], ["coinfections", "DISEASE", 180, 192], ["coinfection", "DISEASE", 220, 231], ["HAdV-55", "CHEMICAL", 280, 287], ["HAdV-55", "ORGANISM", 32, 39], ["HAdV-7", "ORGANISM", 71, 77], ["children", "ORGANISM", 91, 99], ["children", "ORGANISM", 257, 265], ["HAdV-55", "ORGANISM", 280, 287], ["children", "SPECIES", 91, 99], ["children", "SPECIES", 257, 265], ["HAdV-55", "SPECIES", 32, 39], ["HAdV-7", "SPECIES", 71, 77], ["HAdV-55", "SPECIES", 280, 287], ["HAdV", "PROBLEM", 32, 36], ["55 infection", "PROBLEM", 37, 49], ["HAdV", "PROBLEM", 71, 75], ["coinfections", "PROBLEM", 180, 192], ["HAdV", "TEST", 280, 284], ["infection", "OBSERVATION", 40, 49], ["infection", "OBSERVATION", 78, 87], ["coinfections", "OBSERVATION", 180, 192]]], ["However, our data differed from Cao's data in certain respects.", [["Cao's data", "TEST", 32, 42]]], ["Their results showed that only 4 (19.1%) HAdV-55-infected patients were coinfected with other pathogens, with Mycoplasma pneumoniae detected in three patients and HPIV and IFB detected in one patient, and that only 1 HAdV-7-infected patient exhibited coinfection (with Mycoplasma pneumoniae) [6] .", [["HAdV-55-infected", "DISEASE", 41, 57], ["Mycoplasma pneumoniae", "DISEASE", 110, 131], ["HAdV-7-infected", "DISEASE", 217, 232], ["coinfection", "DISEASE", 251, 262], ["Mycoplasma pneumoniae", "DISEASE", 269, 290], ["HAdV-55", "ORGANISM", 41, 48], ["patients", "ORGANISM", 58, 66], ["Mycoplasma pneumoniae", "ORGANISM", 110, 131], ["patients", "ORGANISM", 150, 158], ["HPIV", "CANCER", 163, 167], ["IFB", "CANCER", 172, 175], ["patient", "ORGANISM", 192, 199], ["HAdV-7", "ORGANISM", 217, 223], ["patient", "ORGANISM", 233, 240], ["Mycoplasma pneumoniae", "ORGANISM", 269, 290], ["patients", "SPECIES", 58, 66], ["Mycoplasma pneumoniae", "SPECIES", 110, 131], ["patients", "SPECIES", 150, 158], ["patient", "SPECIES", 192, 199], ["patient", "SPECIES", 233, 240], ["Mycoplasma pneumoniae", "SPECIES", 269, 290], ["HAdV-55", "SPECIES", 41, 48], ["Mycoplasma pneumoniae", "SPECIES", 110, 131], ["HPIV", "SPECIES", 163, 167], ["Mycoplasma pneumoniae", "SPECIES", 269, 290], ["HAdV", "TEST", 41, 45], ["other pathogens", "PROBLEM", 88, 103], ["Mycoplasma pneumoniae", "PROBLEM", 110, 131], ["HPIV", "PROBLEM", 163, 167], ["IFB", "PROBLEM", 172, 175], ["1 HAdV", "PROBLEM", 215, 221], ["coinfection", "PROBLEM", 251, 262], ["Mycoplasma pneumoniae)", "PROBLEM", 269, 291], ["Mycoplasma pneumoniae", "OBSERVATION", 110, 131], ["coinfection", "OBSERVATION", 251, 262]]], ["These inconsistent findings may be attributable to different pathogen detection methods.", [["different pathogen detection methods", "PROBLEM", 51, 87], ["may be attributable to", "UNCERTAINTY", 28, 50], ["different", "OBSERVATION_MODIFIER", 51, 60], ["pathogen", "OBSERVATION", 61, 69]]], ["The Luminex xTAG respiratory viral panel assay is more sensitive and comprehensive than the approach used by Cao et al. Meanwhile, in our study, a nasopharyngeal aspirate or throat swab specimen was considered to be co-infected with one pathogen when either the Luminex xTAG respiratory viral panel assay or the selective agar plate culture showed positive result.", [["nasopharyngeal aspirate", "ANATOMY", 147, 170], ["throat swab specimen", "ANATOMY", 174, 194], ["nasopharyngeal aspirate", "MULTI-TISSUE_STRUCTURE", 147, 170], ["throat swab specimen", "ORGANISM_SUBSTANCE", 174, 194], ["The Luminex xTAG respiratory viral panel assay", "TEST", 0, 46], ["our study", "TEST", 134, 143], ["a nasopharyngeal aspirate", "TEST", 145, 170], ["throat swab specimen", "TEST", 174, 194], ["the Luminex xTAG respiratory viral panel assay", "TEST", 258, 304], ["the selective agar plate culture", "TEST", 308, 340], ["nasopharyngeal", "ANATOMY", 147, 161]]], ["Furthermore, respiratory tract specimens, blood, and cerebrospinal fluid collected during the entire hospital admission from patients were cultured to identify any bacteria or fungi.", [["respiratory tract specimens", "ANATOMY", 13, 40], ["blood", "ANATOMY", 42, 47], ["cerebrospinal fluid", "ANATOMY", 53, 72], ["blood", "ORGANISM_SUBSTANCE", 42, 47], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 53, 72], ["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 125, 133], ["respiratory tract specimens", "TEST", 13, 40], ["blood", "TEST", 42, 47], ["cerebrospinal fluid", "TEST", 53, 72], ["any bacteria", "PROBLEM", 160, 172], ["fungi", "PROBLEM", 176, 181], ["respiratory tract", "ANATOMY", 13, 30], ["cerebrospinal", "ANATOMY", 53, 66], ["fluid", "OBSERVATION", 67, 72], ["fungi", "OBSERVATION", 176, 181]]], ["For these reasons, our study may have identified more co-infections than previous studies.ConclusionTo our knowledge, our investigation is the only case-control study to date involving pediatric patients with HAdV-55 or HAdV-7 infection and comparisons of epidemiological and clinical features of HAdV-55-infected subjects and HAdV-7-infected subjects.", [["infection", "DISEASE", 227, 236], ["HAdV-55-infected", "DISEASE", 297, 313], ["HAdV-7-infected", "DISEASE", 327, 342], ["patients", "ORGANISM", 195, 203], ["HAdV-55", "ORGANISM", 209, 216], ["HAdV-7", "ORGANISM", 220, 226], ["HAdV-55", "ORGANISM", 297, 304], ["subjects", "ORGANISM", 314, 322], ["HAdV-7", "ORGANISM", 327, 333], ["subjects", "ORGANISM", 343, 351], ["patients", "SPECIES", 195, 203], ["HAdV-55", "SPECIES", 209, 216], ["HAdV-7", "SPECIES", 220, 226], ["HAdV-55", "SPECIES", 297, 304], ["HAdV-7", "SPECIES", 327, 333], ["our study", "TEST", 19, 28], ["more co-infections", "PROBLEM", 49, 67], ["previous studies", "TEST", 73, 89], ["HAdV", "PROBLEM", 209, 213], ["HAdV", "PROBLEM", 220, 224], ["7 infection", "PROBLEM", 225, 236], ["HAdV", "TEST", 297, 301], ["HAdV", "PROBLEM", 327, 331], ["co-infections", "OBSERVATION", 54, 67], ["infection", "OBSERVATION", 227, 236]]], ["We concluded that HAdV-55 circulated in Beijing during spring and appeared to cause pediatric respiratory infections that were as severe as HAdV-7 infections.", [["respiratory", "ANATOMY", 94, 105], ["HAdV-55", "CHEMICAL", 18, 25], ["respiratory infections", "DISEASE", 94, 116], ["infections", "DISEASE", 147, 157], ["HAdV-55", "ORGANISM", 18, 25], ["HAdV-7", "ORGANISM", 140, 146], ["HAdV-55", "SPECIES", 18, 25], ["HAdV-7", "SPECIES", 140, 146], ["HAdV", "PROBLEM", 18, 22], ["pediatric respiratory infections", "PROBLEM", 84, 116], ["HAdV", "PROBLEM", 140, 144], ["7 infections", "PROBLEM", 145, 157], ["respiratory", "ANATOMY", 94, 105], ["infections", "OBSERVATION", 106, 116]]], ["Our data provide new insight into the epidemiology of HAdV-55 infection in pediatric ALRTIs patients.", [["HAdV-55", "CHEMICAL", 54, 61], ["infection", "DISEASE", 62, 71], ["ALRTIs", "DISEASE", 85, 91], ["HAdV-55", "ORGANISM", 54, 61], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["HAdV-55", "SPECIES", 54, 61], ["HAdV", "PROBLEM", 54, 58], ["infection", "OBSERVATION", 62, 71]]], ["A wider or longer surveillance studies are needed to evaluate the spectrum of disease caused by this emerging pathogen in China.", [["longer surveillance studies", "TEST", 11, 38], ["disease", "PROBLEM", 78, 85], ["disease", "OBSERVATION", 78, 85]]]]}